WorldWideScience

Sample records for antigen psa isoforms

  1. Prostate-specific antigen (PSA) blood test

    Science.gov (United States)

    ... for prostate cancer, such as ethnicity and family history Men at high risk may need to have more tests. These may include: Repeating your PSA test, most often sometime within 3 months A prostate biopsy A follow-up test called a free PSA ( ...

  2. Proteolytic activity of prostate-specific antigen (PSA towards protein substrates and effect of peptides stimulating PSA activity.

    Directory of Open Access Journals (Sweden)

    Johanna M Mattsson

    Full Text Available Prostate-specific antigen (PSA or kallikrein-related peptidase-3, KLK3 exerts chymotrypsin-like proteolytic activity. The main biological function of PSA is the liquefaction of the clot formed after ejaculation by cleavage of semenogelins I and II in seminal fluid. PSA also cleaves several other substrates, which may explain its putative functions in prostate cancer and its antiangiogenic activity. We compared the proteolytic efficiency of PSA towards several protein and peptide substrates and studied the effect of peptides stimulating the activity of PSA with these substrates. An endothelial cell tube formation model was used to analyze the effect of PSA-degraded protein fragments on angiogenesis. We showed that PSA degrades semenogelins I and II much more efficiently than other previously identified protein substrates, e.g., fibronectin, galectin-3 and IGFBP-3. We identified nidogen-1 as a new substrate for PSA. Peptides B2 and C4 that stimulate the activity of PSA towards small peptide substrates also enhanced the proteolytic activity of PSA towards protein substrates. Nidogen-1, galectin-3 or their fragments produced by PSA did not have any effect on endothelial cell tube formation. Although PSA cleaves several other protein substrates, in addition to semenogelins, the physiological importance of this activity remains speculative. The PSA levels in prostate are very high, but several other highly active proteases, such as hK2 and trypsin, are also expressed in the prostate and may cleave protein substrates that are weakly cleaved by PSA.

  3. Molecular Form Differences Between Prostate-Specific Antigen (PSA) Standards Create Quantitative Discordances in PSA ELISA Measurements

    Science.gov (United States)

    McJimpsey, Erica L.

    2016-02-01

    The prostate-specific antigen (PSA) assays currently employed for the detection of prostate cancer (PCa) lack the specificity needed to differentiate PCa from benign prostatic hyperplasia and have high false positive rates. The PSA calibrants used to create calibration curves in these assays are typically purified from seminal plasma and contain many molecular forms (intact PSA and cleaved subforms). The purpose of this study was to determine if the composition of the PSA molecular forms found in these PSA standards contribute to the lack of PSA test reliability. To this end, seminal plasma purified PSA standards from different commercial sources were investigated by western blot (WB) and in multiple research grade PSA ELISAs. The WB results revealed that all of the PSA standards contained different mass concentrations of intact and cleaved molecular forms. Increased mass concentrations of intact PSA yielded higher immunoassay absorbance values, even between lots from the same manufacturer. Standardization of seminal plasma derived PSA calibrant molecular form mass concentrations and purification methods will assist in closing the gaps in PCa testing measurements that require the use of PSA values, such as the % free PSA and Prostate Health Index by increasing the accuracy of the calibration curves.

  4. Generation of monoclonal antibodies against prostate specific antigen (PSA) for the detection of PSA and its purification

    International Nuclear Information System (INIS)

    The prostate cancer in Cuba is a problem of health (2672 diagnosed cases and 2769 deaths in 2007). Various diagnostic methods have been implemented for the detection and management of this disease, emphasizing among them (PSA) prostate-specific antigen serological determination. At this work was generated and characterized a panel of 11 antibodies (AcMs) monoclonal IgG1 detected with high affinity described major epitopes of the PSA, both in solution and attached to the test plate. From the panel obtained AcMs was the standardization of an essay type ELISA for the detection of serum total PSA (associated and free) equimolar, based on antibody monoclonal CB-PSA.4 in the coating and the CB-PSA.9 coupled with biotin as liner, with a detection limit of 0.15 ng/mL. Similarly, standardized system for detection in serum free PSA, based on the AcMs CB-PSA.4 (coating) and CB-PSA.2 coupled with biotin (liner), with a detection limit of 0.5 ng/mL. Finally, with the purpose of using PSA as standard in trials type ELISA, developed a simple method of inmunopurificación based on the AcM, CB-PSA.2, which was obtained the PSA with a purity exceeding 90%. Immunoassay Centre on the basis of the AcMs panel and the results of this study, developed and recorded two diagnostic systems for the detection of PSA in human serum. (author)

  5. Arraying prostate specific antigen PSA and Fab anti-PSA using light-assisted molecular immobilization technology

    Science.gov (United States)

    Parracino, Antonietta; Neves-Petersen, Maria Teresa; di Gennaro, Ane Kold; Pettersson, Kim; Lövgren, Timo; Petersen, Steffen B

    2010-01-01

    We here report for the first time the creation of prostate specific antigen (PSA) and Fab anti-PSA biosensor arrays using UV light-assisted molecular immobilization (LAMI), aiming at the detection and quantification of PSA, a cancer marker. The technology involves formation of free, reactive thiol groups upon UV excitation of protein aromatic residues located in spatial proximity of disulphide bridges, a conserved structural feature in both PSA and Fab molecules. The created thiol groups bind onto thiol reactive surfaces leading to oriented covalent protein immobilization. Protein activity was confirmed carrying out immunoassays: immobilized PSA was recognized by Fab anti-PSA in solution and immobilized Fab anti-PSA cross-reacted with PSA in solution. LAMI technology proved successful in immobilizing biomedically relevant molecules while preserving their activity, highlighting that insight into how light interacts with biomolecules may lead to new biophotonic technologies. Our work focused on the application of our new engineering principles to the design, analysis, construction, and manipulation of biological systems, and on the discovery and application of new engineering principles inspired by the properties of biological systems. PMID:20665692

  6. A portable chemiluminescence imaging immunoassay for simultaneous detection of different isoforms of prostate specific antigen in serum.

    Science.gov (United States)

    Liu, Anran; Zhao, Fang; Zhao, Yuewu; Shangguan, Li; Liu, Songqin

    2016-07-15

    A multianalyte chemiluminescence (CL) imaging immunoassay strategy for sensitive detection of different isoforms of prostate specific antigen (PSA) was developed. The microtiter plates were fabricated by simultaneously immobilizing of free-PSA (f-PSA) and total-PSA (t-PSA) capture antibody on nitrocellulose (NC) membrane. Each of the array were spotted in replicates of six spots within a spacing of 2mm. 16 or 48 detection wells were integrated on a single NC membrane and each well could be used as a microreactor and microanalysis chamber. Under a sandwiched immunoassay, the CL signals on each sensing site were collected by a charge-coupled device (CCD), presenting an array-based chemiluminescence imaging. Soybean peroxidase (SBP) was used to label f-PSA or t-PSA monoclonal antibody. With the amplification effects of two enhancers, 3-(10'-phenothiazinyl) propane-1-sulfonate (SPTZ) and 4-morpholinopyridine (MORP), the CL intensity could significantly enhanced, which improved the sensing sensitivity and detection limit. Under the optimal conditions, the linear response to the analyte concentration ranged from 0.01-36.7ng/mL and 0.02-125ng/mL for f-PSA and t-PSA, respectively. The results for the detection of forty serum samples from prostate cancer patients and cancer-free patients showed good agreement with the clinical data, suggesting that the proposed assay had acceptable accuracy. The proposed CL imaging immunoassay possess high throughput and acceptable reproducibility, stability and accuracy, which made it great potential to available to distinguish different isoforms of PSA in serum samples. PMID:26922048

  7. Impact of capillary conditioning and background electrolyte composition on capillary electrophoresis analysis of prostate specific antigen isoforms.

    Science.gov (United States)

    Farina-Gomez, Noemi; Puerta, Angel; Gonzalez, Monica; Diez-Masa, Jose Carlos; de Frutos, Mercedes

    2016-04-22

    Glycoproteins expressed in the human body can experience modifications as result of pathological situations. Detection of those changes can be useful as disease biomarkers. As a result of these modifications, size and/or electrical charge of the glycoprotein can be altered. Migration in capillary zone electrophoresis (CZE) is governed by the size to charge ratio of the analyte and therefore this separation technique can be used to monitor those modifications. At its turn, the alteration of the electrophoretical pattern of a given glycoprotein could be used as disease biomarker. To this aim, high repeatability for separation of a large number of peaks for a given glycoprotein is desirable. For prostate cancer, new markers are needed to decrease the high number of false positive results provided by the biomarkers currently used in clinics. In this sense, CZE methods for analysis of the several prostate specific antigen (PSA) peaks which this glycoprotein exhibit, called isoforms and containing one or more glycoforms, could be useful to study the PSA pattern as prostate cancer marker. In this study two complementary strategies to achieve both lot-to-lot capillary repeatability and high resolution of a large number of PSA isoforms are developed. Better performance and precision have been obtained for capillaries conditioned with HCl than for those conditioned with NaOH. Optimization of the background electrolyte (BGE) pH value to 8.0 and inclusion of 3M urea on its composition were the two factors of highest impact for enhancing resolution of the highest number of PSA peaks. Under the optimized conditions for capillary conditioning and BGE pH and composition, long-term resolution of 10 isoforms of PSA was achieved. Inter-day (n=3) %RSD was 0.55 for the ratio tm/tEOF, 1.15 for μeff, and 5.02 for % Acorr of the PSA peaks. PMID:27018191

  8. Postoperative monitoring of prostate-specific antigen (PSA after treatment with high-intensive focused ultrasound (HIFU

    Directory of Open Access Journals (Sweden)

    Blyumberg B.I.

    2012-12-01

    Full Text Available Research objective: to estimate efficiency of treatment of prostate cancer using high-intensive focused ultrasound on the basis of laboratory analysis of postoperative level prostate-specific antigen (PSA. Objects of research. Objects of research consisted of 110 patients treated in urological clinic of Hospital n.a. S. R. Mirotvortsev (Saratov State Medical University during the period February, 2009 — March, 2012. Patients took 110 sessions of primary operative treatment of prostate cancer by HIFU therapy method. Technique and research methods. Concentration of PSA in blood changed in all patients every 1,5 month within 6 months after operation, irrespective of its kind (including after repeated HIFU, further — after every 3 month till one year, and later on after 6 months. We were guided by references of the International Consensus, which considers PSA level more than 0,5 ng/ml in blood after 3 months of treatment to be unsatisfactory result. We also headed for PSA level before treatment and oncological risk degree. Results. Median nadir formed 0,5 ng/ml PSA by 3 months after treatment. Patients demonstrated different indicators of PSA dynamics depending on oncological risk, stage and hormonal therapy management. Patients with low oncological risk had initially lower PSA concentration, further PSA concentration reached nadir level faster. At patients with widespread forms of prostate cancer accurate dependence of PSA concentration according to prevalence of process was traced. Time of PSA nadir amount did not differ and was marked as 12-14 weeks on average. At patients received hormonal therapy, lower value of PSA nadir was marked. The conclusion. Monitoring of PSA concentration (PSA nadir by 3 months, dynamics of PSA concentration change is of great importance in early revealing of relapse after prostate HIFU therapy. High level of PSA nadir and PSA growth according to time period are important prognostic factors.

  9. Applying strategies from libertarian paternalism to decision making for prostate specific antigen (PSA screening

    Directory of Open Access Journals (Sweden)

    Black Amanda

    2011-04-01

    Full Text Available Abstract Background Despite the recent publication of results from two randomized clinical trials, prostate specific antigen (PSA screening for prostate cancer remains a controversial issue. There is lack of agreement across studies that PSA screening significantly reduces prostate cancer mortality. In spite of these facts, the widespread use of PSA testing in the United States leads to overdetection and overtreatment of clinically indolent prostate cancer, and its associated harms of incontinence and impotence. Discussion Given the inconclusive results from clinical trials and incongruent PSA screening guidelines, the decision to screen for prostate cancer with PSA testing is an uncertain one for patients and health care providers. Screening guidelines from some health organizations recommend an informed decision making (IDM or shared decision making (SDM approach for deciding on PSA screening. These approaches aim to empower patients to choose among the available options by making them active participants in the decision making process. By increasing involvement of patients in the clinical decision-making process, IDM/SDM places more of the responsibility for a complex decision on the patient. Research suggests, however, that patients are not well-informed of the harms and benefits associated with prostate cancer screening and are also subject to an assortment of biases, emotion, fears, and irrational thought that interferes with making an informed decision. In response, the IDM/SDM approaches can be augmented with strategies from the philosophy of libertarian paternalism (LP to improve decision making. LP uses the insights of behavioural economics to help people better make better choices. Some of the main strategies of LP applicable to PSA decision making are a default decision rule, framing of decision aids, and timing of the decision. In this paper, we propose that applying strategies from libertarian paternalism can help with PSA

  10. 3D label-free prostate specific antigen (PSA) immunosensor based on graphene-gold composites.

    Science.gov (United States)

    Jang, Hee Dong; Kim, Sun Kyung; Chang, Hankwon; Choi, Jeong-Woo

    2015-01-15

    Highly sensitive and label-free detection of the prostate specific antigen (PSA) remains a challenge in the diagnosis of prostate cancer. Here, a novel three-dimensional (3D) electrochemical immunosensor capable of sensitive and label-free detection of PSA is reported. This unique immunosensor is equipped with a highly conductive graphene (GR)-based gold (Au) composite modified electrode. The GR-based Au composite is prepared using aerosol spray pyrolysis and the morphology of the composite is the shape of a crumpled GR ball decorated with Au nanoparticles. Unlike the previous research, this novel 3D immunosensor functions very well over a broad linear range of 0-10 ng/mL with a low detection limit of 0.59 ng/mL; furthermore, it exhibits a significantly increased electron transfer and high sensitivity toward PSA. The highest rate of current change with respect to the PSA concentration is 5 μA/(ng/mL). Satisfactory selectivity, reproducibility, and stability of the 3D immunosensor are also exhibited. PMID:25150936

  11. Prostate-specific antigen (PSA) screening: has the pendulum swung too far?

    Institute of Scientific and Technical Information of China (English)

    Jason M Phillips; E David Crawford

    2011-01-01

    @@ Prostate-specific antigen (PSA) along with digital rectal exam has been the standard for prostate cancer screening in the United States for the past 20 years.1 During this time period,the improved detection of prostate cancer decreased related mortality more than 30%? In fact,metastases and their comorbidities have decreased more than 75% since the early 1990s,resulting in a higher incidence of early organ-confined disease.While it is clear that prostate cancer mortality statistics have improved,it is unclear whether men are overscreened.

  12. Prostate-specific antigen (PSA/hK3): a further player in the field of breast cancer diagnostics?

    OpenAIRE

    Mannello, Ferdinando; Gazzanelli, Giancarlo

    2001-01-01

    Since its identification, much information has been obtained about prostate-specific antigen (PSA, or human glandular kallikrein 3 [hK3]), a kallikrein-like serine protease that is the most valuable tumour marker for the screening, diagnosis and management of human prostate carcinoma. Recently, it has become widely accepted that PSA is also present in many nonprostatic sources, casting doubts about the specificity of its tissue expression. Here we summarize the findings on the biomolecular ex...

  13. Recombinant Forms of Leishmania amazonensis Excreted/Secreted Promastigote Surface Antigen (PSA Induce Protective Immune Responses in Dogs.

    Directory of Open Access Journals (Sweden)

    Elodie Petitdidier

    2016-05-01

    Full Text Available Preventive vaccination is a highly promising strategy for interrupting leishmaniasis transmission that can, additionally, contribute to elimination. A vaccine formulation based on naturally excreted secreted (ES antigens was prepared from L. infantum promastigote culture supernatant. This vaccine achieved successful results in Phase III trials and was licensed and marketed as CaniLeish. We recently showed that newly identified ES promastigote surface antigen (PSA, from both viable promastigotes and axenically-grown amastigotes, represented the major constituent and the highly immunogenic antigen of L. infantum and L. amazonensis ES products. We report here that three immunizations with either the recombinant ES LaPSA-38S (rPSA or its carboxy terminal part LaPSA-12S (Cter-rPSA, combined with QA-21 as adjuvant, confer high levels of protection in naive L. infantum-infected Beagle dogs, as checked by bone marrow parasite absence in respectively 78.8% and 80% of vaccinated dogs at 6 months post-challenge. The parasite burden in infected vaccinated dogs was significantly reduced compared to placebo group, as measured by q-PCR. Moreover, our results reveal humoral and cellular immune response clear-cut differences between vaccinated and control dogs. An early increase in specific IgG2 antibodies was observed in rPSA/QA-21- and Cter-rPSA/QA-21-immunized dogs only. They were found functionally active in vitro and were highly correlated with vaccine protection. In vaccinated protected dogs, IFN-γ and NO productions, as well as anti-leishmanial macrophage activity, were increased. These data strongly suggest that ES PSA or its carboxy-terminal part, in recombinant forms, induce protection in a canine model of zoonotic visceral leishmaniasis by inducing a Th1-dominant immune response and an appropriate specific antibody response. These data suggest that they could be considered as important active components in vaccine candidates.

  14. Raising cut-off value of prostate specific antigen (PSA) for biopsy in symptomatic men in India to reduce unnecessary biopsy

    OpenAIRE

    Shalini Agnihotri; Mittal, R. D.; Kapoor, R; Anil Mandhani

    2014-01-01

    Background & objectives: The characteristics of prostate specific antigen (PSA) for trans-rectal ultrasonography guided prostate biopsy in men with lower urinary tract symptoms (LUTS) are not well defined. This study was carried out to analyse the threshold of PSA for biopsy in symptomatic men in India. Methods: From January 2000 to June 2011, consecutive patients who had digital rectal examination (DRE) and PSA testing done for LUTS were included in this study. PSA was done with ELISA te...

  15. The Leishmania promastigote surface antigen-2 (PSA-2) is specifically recognised by Th1 cells in humans with naturally acquired immunity to L. major

    DEFF Research Database (Denmark)

    Kemp, M; Handman, E; Kemp, K;

    1998-01-01

    The promastigote surface antigen-2 (PSA-2) is a Leishmania parasite antigen, which can induce Th1-mediated protection against murine leishmaniasis when used as a vaccine. To evaluate PSA-2 as a human vaccine candidate the specific T-cell response to PSA-2 was characterised in individuals immune...... to cutaneous leishmaniasis. Peripheral blood mononuclear cells from Sudanese individuals with a past history of self-healing cutaneous leishmaniasis proliferated vigorously in response to PSA-2 isolated from Leishmania major, whereas the antigen did not activate cells from presumably unexposed Danes...

  16. Proposal for the development of IRMA kits for prostate specific antigen, PSA

    International Nuclear Information System (INIS)

    The following are the major objectives of this research proposal: (1) To establish a protocol for biotinylation of monoclonal antibody, mabs or polyclonal antibody against the antigen, PSA. This shall include the purifying procedure using size exclusion chromatography on HPLC for use in binding assays to determine its binding capacity with PSA. (2) To establish an immunoassay protocol for IRMAs, using the technique of immobilizing the capture mabs on solid phase (surfaces of polystyrene) and the radioiodine labeled streptavidin-biotinylated bridge system. This will include optimization of the assay design and a Quality Control Assessment with the inclusion of standards derived from the Agency and subsequent work to determine its sensitivity (Minimum Detection Limit) and working range (the phenomenon of Hooke's Effect). An in-house quality control would also be useful to determine the assay's suitability for screening the tumour marker from patient samples obtained from neighboring hospitals (such as the Science University of Malaysia Hospital and the National University Hospital) and private clinical pathology laboratory (such as the Pantai Medical Centre) which compare concurrently the results with existing commercial immunoassay kits (RIA/IRMA). These work and that described earlier in (1) shall be done entirely at MINT. (3) To perform an external coordinated external Quality Control Assurance Programme with other research institutes (such as the Department of Immunology, Medical faculty, Science University of Malaysia and government hospitals) in Malaysia on several batches of the IRMA kits (produced at MINT and proven to be suitable for screening PSA in human serum from in-house Quality Control data, as mentioned earlier in (2)). This coordinated work shall include analyzing and documenting all values obtained from a group of patient's sample in clinical conditions such as batch to batch variation, inter and intra-assay variations and mean values for negative

  17. The validity of rapid test to detect prostate-specific antigen (PSA in seminal fluid

    Directory of Open Access Journals (Sweden)

    Henky Henky

    2011-11-01

    Full Text Available Background: This study was conducted to determine whether the rapid test device can be used to detect PSA in seminal fluid specifically, for solving sexual assault cases.Methods: A cross sectional study has been conducted. A total of 45 samples were taken consecutively. Semen was diluted in serially up to 1:5.000.000 and male urin up to 1:200 using distilled water, whereas female urin was not diluted. Samples were analyzed using rapid test PSA.Results: The proportion of positive results of PSA in seminal fluid, male urin and female urin respectively was 100%, 6.67%, and 0%. Statistically, these differences are highly significant. The analysis revealed that the PSA rapid test device was 100% sensitive and 96.67% specific to detect seminal fluid. The test also have PPV 93.75%, NPV 100%, LR(+ 33.33, LR(- 0, and AUC 0.983.Conclusion: PSA Rapid Test is very specific and sensitive to detect PSA in seminal fluid. Therefore, this device is suggested for forensic use in sexual assault cases. (Med J Indones 2011; 20:278-82Keywords: PSA, rapid test, sexual assault

  18. Development of simple immunoradiometric assay kits for measurement of Prostate Specific Antigen (PSA)

    International Nuclear Information System (INIS)

    The report summarizes our results obtained in the field of PSA IRMA kits development. In these experiments, we used Avidin-Biotin technology for coating of antibodies on beads/tubes and studied various parameters, such as investigation of different types of tubes, incubation time, volume of samples etc., as well as comparing two types of Mabs of PSA (free and total) for coating on the surface of bead/tube and obtaining optimized requirements to achieve reliable and simplified assays of PSA (free and total) in serum. (author)

  19. Prostate-specific antigen (PSA) rate of decline post external beam radiotherapy predicts prostate cancer death

    International Nuclear Information System (INIS)

    Background and purpose: To assess the association between PSA velocity (PSAV) in the first 24 months after external beam radiotherapy (EBRT) and prostate cancer-specific mortality (PCSM) and all cause mortality. Materials and methods: All eligible patients in the South Australian (SA) Prostate Cancer Clinical Outcomes registry were followed. 848 Patients treated by definitive EBRT with more than one PSA recorded in the two year post-treatment were included. We calculated PSAV by linear regression. Results: The mean number of PSA measurements in the 2 year period was 4.4 (SD1.9). The median PSAVs across quartiles (Q1–Q4) were −4.17, −1.29, −0.38 and 0.20 ng/ml/yr. In multivariable analysis, a U-shaped relationship was seen between PSAV and PCSM with Q1–Q4 hazard ratios (HR) being 3.82 (1.46–10.00), 3.07 (1.10–8.58), 1, 5.15 (1.99–13.30) respectively. HR for all cause mortality in a similar model were 1.79 (1.07–2.98), 1.55 (0.93–2.59), 1.00 and 1.74 (1.04–2.90) for Q1 to Q4 respectively. A rapid PSA decline in the first year was a strong predictor of PCSM. However, in the second year PSA increase was positively associated with PCSM. Conclusion: A rapid decline in PSA in the first year following EBRT is positively associated with PCSM. This may be a useful early indicator of the need for additional therapies

  20. Contribution of genetic variation rs266882 to prostate-specific antigen levels in healthy controls with serum PSA below 2.0 ng/ml.

    Science.gov (United States)

    Song, Jaeman; Park, Heeyoon; Lee, Gilho

    2013-04-01

    We evaluated the impact of genetic variation in the prostate-specific antigen (PSA) gene (rs266882) on serum PSA levels in healthy men as well as risk factors for benign prostate hypertrophy (BPH) and prostate cancer. The study population comprised 91 men with PSA levels below 2.0 ng/ml as healthy controls, 78 men with PSA 2-10 ng/ml as a BPH group, and 128 prostate cancer patients, all in Korea. DNA was amplified by polymerase chain reaction and the product was sequenced. We found that PSA levels were associated with a G/A polymorphism only in healthy controls. The transition, however, was not associated with PSA levels of BPH and cancer patients, nor was it a risk factor. In conclusion, this genetic factor is important for determining serum PSA levels in the naive group, whereas the disruption of prostatic architecture in BPH or prostate cancer may be a major determining factor for PSA levels. PMID:23315126

  1. Impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC) on prostate-specific antigen (PSA) testing by Dutch general practitioners

    NARCIS (Netherlands)

    Van der Meer, Saskia; Kollen, Boudewijn J.; Hirdes, Willem H.; Steffens, Martijn G.; Hoekstra-Weebers, Josette E. H. M.; Nijman, Rien M.; Blanker, Marco H.

    2013-01-01

    Objective To determine the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC) publication in 2009 on prostate-specific antigen (PSA) level testing by Dutch general practitioners (GPs) in men aged 40 years. Materials and Methods Retrospective study with a Dutch insurance

  2. Importance of prostate-specific antigen (PSA as a predictive factor for concordance between the Gleason scores of prostate biopsies and RADICAL prostatectomy specimens

    Directory of Open Access Journals (Sweden)

    Nelson Gianni de Lima

    2013-06-01

    Full Text Available OBJECTIVE: To evaluate the concordance between the Gleason scores of prostate biopsies and radical prostatectomy specimens, thereby highlighting the importance of the prostate-specific antigen (PSA level as a predictive factor of concordance. METHODS: We retrospectively analyzed 253 radical prostatectomy cases performed between 2006 and 2011. The patients were divided into 4 groups for the data analysis and dichotomized according to the preoperative PSA, <10 ng/mL and ≥10 ng/mL. A p-score <0.05 was considered significant. RESULTS: The average patient age was 63.3±7.8 years. The median PSA level was 9.3±4.9 ng/mL. The overall concordance between the Gleason scores was 52%. Patients presented preoperative PSA levels <10 ng/mL in 153 of 235 cases (65% and ≥10 ng/mL in 82 of 235 cases (35%. The Gleason scores were identical in 86 of 153 cases (56% in the <10 ng/mL group and 36 of 82 (44% cases in the ≥10 ng/mL group (p = 0.017. The biopsy underestimated the Gleason score in 45 (30% patients in the <10 ng/mL group and 38 (46% patients in the ≥10 ng/mL (p = 0.243. Specifically, the patients with Gleason 3 + 3 scores according to the biopsies demonstrated global concordance in 56 of 110 cases (51%. In this group, the patients with preoperative PSA levels <10 ng/dL had higher concordance than those with preoperative PSA levels ≥10 ng/dL (61% x 23%, p = 0.023, which resulted in 77% upgrading after surgery in those patients with PSA levels ≥10 ng/dl. CONCLUSION: The Gleason scores of needle prostate biopsies and those of the surgical specimens were concordant in approximately half of the global sample. The preoperative PSA level was a strong predictor of discrepancy and might improve the identification of those patients who tended to be upgraded after surgery, particularly in patients with Gleason scores of 3 + 3 in the prostate biopsy and preoperative PSA levels ≥10 ng/mL.

  3. Quality PSA for PSA applications

    International Nuclear Information System (INIS)

    The safety guideline defines with more precision Nuclear Regulatory Authority of the Slovak Republic requirements of the quality of probabilistic safety assessment (PSA) for PSA application. Term of quality of PSA is explained in detail. Procedure for determining the quality of PSA is provided. The categorization of PSA study according the quality of PSA is suggested. A comprehensive list of PSA applications for nuclear facilities is provided. What technical features of a PSA should be satisfied to support the PSA applications of interest is stated. (authors)

  4. Técnica para obtenção do aparelho geniturinário e dosagem do PSA (Prostate Specific Antigen) no hamster sírio, Mesocricetus auratus Technique for collecting blood for PSA (Prostate Specific Antigen) dosing and genitourinary system obtaining in syrian hamster, Mesocricetus auratus

    OpenAIRE

    Dimas José Araújo Vidigal; Alcino Lázaro da Silva; Luiz Mauro Andrade da Fonseca; Dilermando Fazito de Rezende

    2004-01-01

    Objetivo: Expor a técnica utilizada na colheita de sangue para dosagem do PSA ( Prostate Specific Antigen ) e retirada do aparelho geniturinário no hamster sírio, Mesocricetus auratus, e correlacionar os achados do PSA com as alterações histológicas dos anexos sexuais desse roedor. Métodos: Foram usados no experimento trinta (n= 30) Hamsters: dez (n=10) animais considerados jovens com idade média no momento da morte de 47,5 dias e vinte (n=20) animais considerados adultos com idade superior à...

  5. Técnica para obtenção do aparelho geniturinário e dosagem do PSA (Prostate Specific Antigen no hamster sírio, Mesocricetus auratus Technique for collecting blood for PSA (Prostate Specific Antigen dosing and genitourinary system obtaining in syrian hamster, Mesocricetus auratus

    Directory of Open Access Journals (Sweden)

    Dimas José Araújo Vidigal

    2004-12-01

    Full Text Available Objetivo: Expor a técnica utilizada na colheita de sangue para dosagem do PSA ( Prostate Specific Antigen e retirada do aparelho geniturinário no hamster sírio, Mesocricetus auratus, e correlacionar os achados do PSA com as alterações histológicas dos anexos sexuais desse roedor. Métodos: Foram usados no experimento trinta (n= 30 Hamsters: dez (n=10 animais considerados jovens com idade média no momento da morte de 47,5 dias e vinte (n=20 animais considerados adultos com idade superior à um ano. Após serem anestesiados com cloridrato de quetamina e diazepam, foi colhido diretamente da veia cava, em nível de abdome superior, cerca de 1,5mL a 2,0mL de sangue para dosagem do PSA totalpelo método ELISA, com antígeno humano. Morriam após colheita do sangue. Constatado a morte do animal, fazia-se a laparotomia retirando-se em monobloco todo aparelho geniturinário para estudo histológico dos anexos sexuais. Correlacionou-se o PSA com as alterações histológicas encontradas. Resultados: Os animais após serem anestesiados com cloridrato de quetamina e diazepam intraperitonealmente, obteve-se um excelente plano anestésico, que possibilitou colher via trans-dérmica da veia cava inferior em abdome superior sangue para dosagem do PSA. O animal morria após colheita do sangue. Fazia-se a laparotomia, com retirada em monobloco do aparelho geniturinário para estudo histológico e comparação das alterações encontradas nos anexos sexuais com o PSA dosado. Entre os Hamsters Jovens a média do PSA encontrado foi de 0,252ng/mL. Desvio Padrão (DP = 0,36. Entre os Hamsters adultos esta média foi de 0,325 ng/mL, DP= 0,12 . Quando comparou-se as médias do PSA entre os dois grupos de jovens e adultos obteve-se p= 0,0427. Dentre os Hamsters jovens, três apresentaram PSA não detectado. A análise histológica mostrou que, entre os animais jovens, não foi identificada qualquer alteração das estruturas microscópicas da próstata, ves

  6. Permanent 125I-seed prostate brachytherapy: early prostate specific antigen value as a predictor of PSA bounce occurrence

    Directory of Open Access Journals (Sweden)

    Mazeron Renaud

    2012-03-01

    Full Text Available Abstract Purpose To evaluate predictive factors for PSA bounce after 125I permanent seed prostate brachytherapy and identify criteria that distinguish between benign bounces and biochemical relapses. Materials and methods Men treated with exclusive permanent 125I seed brachytherapy from November 1999, with at least a 36 months follow-up were included. Bounce was defined as an increase ≥ 0.2 ng/ml above the nadir, followed by a spontaneous return to the nadir. Biochemical failure (BF was defined using the criteria of the Phoenix conference: nadir +2 ng/ml. Results 198 men were included. After a median follow-up of 63.9 months, 21 patients experienced a BF, and 35.9% had at least one bounce which occurred after a median period of 17 months after implantation (4-50. Bounce amplitude was 0.6 ng/ml (0.2-5.1, and duration was 13.6 months (4.0-44.9. In 12.5%, bounce magnitude exceeded the threshold defining BF. Age at the time of treatment and high PSA level assessed at 6 weeks were significantly correlated with bounce but not with BF. Bounce patients had a higher BF free survival than the others (100% versus 92%, p = 0,007. In case of PSA increase, PSA doubling time and velocity were not significantly different between bounce and BF patients. Bounces occurred significantly earlier than relapses and than nadir + 0.2 ng/ml in BF patients (17 vs 27.8 months, p Conclusion High PSA value assessed 6 weeks after brachytherapy and young age were significantly associated to a higher risk of bounces but not to BF. Long delays between brachytherapy and PSA increase are more indicative of BF.

  7. Permanent 125I-seed prostate brachytherapy: early prostate specific antigen value as a predictor of PSA bounce occurrence

    International Nuclear Information System (INIS)

    To evaluate predictive factors for PSA bounce after 125I permanent seed prostate brachytherapy and identify criteria that distinguish between benign bounces and biochemical relapses. Men treated with exclusive permanent 125I seed brachytherapy from November 1999, with at least a 36 months follow-up were included. Bounce was defined as an increase ≥ 0.2 ng/ml above the nadir, followed by a spontaneous return to the nadir. Biochemical failure (BF) was defined using the criteria of the Phoenix conference: nadir +2 ng/ml. 198 men were included. After a median follow-up of 63.9 months, 21 patients experienced a BF, and 35.9% had at least one bounce which occurred after a median period of 17 months after implantation (4-50). Bounce amplitude was 0.6 ng/ml (0.2-5.1), and duration was 13.6 months (4.0-44.9). In 12.5%, bounce magnitude exceeded the threshold defining BF. Age at the time of treatment and high PSA level assessed at 6 weeks were significantly correlated with bounce but not with BF. Bounce patients had a higher BF free survival than the others (100% versus 92%, p = 0,007). In case of PSA increase, PSA doubling time and velocity were not significantly different between bounce and BF patients. Bounces occurred significantly earlier than relapses and than nadir + 0.2 ng/ml in BF patients (17 vs 27.8 months, p < 0.0001). High PSA value assessed 6 weeks after brachytherapy and young age were significantly associated to a higher risk of bounces but not to BF. Long delays between brachytherapy and PSA increase are more indicative of BF

  8. Prostate Health Index (Phi and Prostate Cancer Antigen 3 (PCA3 significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml.

    Directory of Open Access Journals (Sweden)

    Matteo Ferro

    Full Text Available Many efforts to reduce prostate specific antigen (PSA overdiagnosis and overtreatment have been made. To this aim, Prostate Health Index (Phi and Prostate Cancer Antigen 3 (PCA3 have been proposed as new more specific biomarkers. We evaluated the ability of phi and PCA3 to identify prostate cancer (PCa at initial prostate biopsy in men with total PSA range of 2-10 ng/ml. The performance of phi and PCA3 were evaluated in 300 patients undergoing first prostate biopsy. ROC curve analyses tested the accuracy (AUC of phi and PCA3 in predicting PCa. Decision curve analyses (DCA were used to compare the clinical benefit of the two biomarkers. We found that the AUC value of phi (0.77 was comparable to those of %p2PSA (0.76 and PCA3 (0.73 with no significant differences in pairwise comparison (%p2PSA vs phi p = 0.673, %p2PSA vs. PCA3 p = 0.417 and phi vs. PCA3 p = 0.247. These three biomarkers significantly outperformed fPSA (AUC = 0.60, % fPSA (AUC = 0.62 and p2PSA (AUC = 0.63. At DCA, phi and PCA3 exhibited a very close net benefit profile until the threshold probability of 25%, then phi index showed higher net benefit than PCA3. Multivariable analysis showed that the addition of phi and PCA3 to the base multivariable model (age, PSA, %fPSA, DRE, prostate volume increased predictive accuracy, whereas no model improved single biomarker performance. Finally we showed that subjects with active surveillance (AS compatible cancer had significantly lower phi and PCA3 values (p<0.001 and p = 0.01, respectively. In conclusion, both phi and PCA3 comparably increase the accuracy in predicting the presence of PCa in total PSA range 2-10 ng/ml at initial biopsy, outperforming currently used %fPSA.

  9. Cytochemical localization of ATP diphosphohydrolase from Leishmania (Viannia) braziliensis promastigotes and identification of an antigenic and catalytically active isoform.

    Science.gov (United States)

    Rezende-Soares, F A; Carvalho-Campos, C; Marques, M J; Porcino, G N; Giarola, N L L; Costa, B L S; Taunay-Rodrigues, A; Faria-Pinto, P; Souza, M A; Diniz, V A; Corte-Real, S; Juliano, M A; Juliano, L; Vasconcelos, E G

    2010-04-01

    An ATP diphosphohydrolase (EC 3.6.1.5) activity was identified in a Leishmania (Viannia) braziliensis promastigotes preparation (Lb). Ultrastructural cytochemical microscopy showed this protein on the parasite surface and also stained a possible similar protein at the mitochondrial membrane. Isolation of an active ATP diphosphohydrolase isoform from Lb was obtained by cross-immunoreactivity with polyclonal anti-potato apyrase antibodies. These antibodies, immobilized on Protein A-Sepharose, immunoprecipitated a polypeptide of approximately 48 kDa and, in lower amount, a polypeptide of approximately 43 kDa, and depleted 83% ATPase and 87% of the ADPase activities from detergent-homogenized Lb. Potato apyrase was recognized in Western blots by IgG antibody from American cutaneous leishmaniasis (ACL) patients, suggesting that the parasite and vegetable proteins share antigenic conserved epitopes. Significant IgG seropositivity in serum samples diluted 1:50 from ACL patients (n=20) for Lb (65%) and potato apyrase (90%) was observed by ELISA technique. Significant IgG antibody reactivity was also observed against synthetic peptides belonging to a conserved domain from L. braziliensis NDPase (80% seropositivity) and its potato apyrase counterpart (50% seropositivity), in accordance with the existence of shared antigenic epitopes and demonstrating that in leishmaniasis infection the domain r82-103 from L. braziliensis NDPase is a target for the human immune response. PMID:19961654

  10. Long-Term Follow-Up of HLA-A2+ Patients with High-Risk, Hormone-Sensitive Prostate Cancer Vaccinated with the Prostate Specific Antigen Peptide Homologue (PSA146-154)

    OpenAIRE

    Perambakam, Supriya; Xie, Hui; Edassery, Seby; Peace, David J.

    2011-01-01

    Twenty-eight HLA-A2+ patients with high-risk, locally advanced or metastatic, hormone-sensitive prostate cancer were immunized with a peptide homologue of prostate-specific antigen, PSA146-154, between July 2002 and September 2004 and monitored for clinical and immune responses. Fifty percent of the patients developed strong PSA146-154-peptide-specific delayed-type hypersensitivity skin responses, tetramer and/or IFN-γ responses within one year. Thirteen patients had stable or declining serum...

  11. Long-Term Follow-Up of HLA-A2+ Patients with High-Risk, Hormone-Sensitive Prostate Cancer Vaccinated with the Prostate Specific Antigen Peptide Homologue (PSA146-154)

    OpenAIRE

    Perambakam, Supriya; Xie, Hui; Edassery, Seby; Peace, David J.

    2010-01-01

    Twenty-eight HLA-A2+ patients with high-risk, locally advanced or metastatic, hormone-sensitive prostate cancer were immunized with a peptide homologue of prostate-specific antigen, PSA146-154, between July 2002 and September 2004 and monitored for clinical and immune responses. Fifty percent of the patients developed strong PSA146-154-peptide-specific delayed-type hypersensitivity skin responses, tetramer and/or IFN-γ responses within one year. Thirteen patients had stable or declining serum...

  12. Crystallization and preliminary X-ray diffraction analysis of PsaA, the adhesive pilin subunit that forms the pH 6 antigen on the surface of Yersinia pestis

    International Nuclear Information System (INIS)

    The pH 6 antigen Psa displayed on the surface of Yersinia pestis, the bacterium that causes plague in humans, consists of polymers of a single protein subunit termed PsaA. Donor-strand complemented PsaA was purified and crystallized. Yersinia pestis has been responsible for a number of high-mortality epidemics throughout human history. Like all other bacterial infections, the pathogenesis of Y. pestis begins with the attachment of bacteria to the surface of host cells. At least five surface proteins from Y. pestis have been shown to interact with host cells. Psa, the pH 6 antigen, is one of them and is deployed on the surface of bacteria as thin flexible fibrils that are the result of the polymerization of a single PsaA pilin subunit. Here, the crystallization of recombinant donor-strand complemented PsaA by the hanging-drop vapor-diffusion method is reported. X-ray diffraction data sets were collected to 1.9 Å resolution from a native crystal and to 1.5 Å resolution from a bromide-derivatized crystal. These crystals displayed the symmetry of the orthorhombic space group P2221, with unit-cell parameters a = 26.3, b = 54.6, c = 102.1 Å. Initial phases were derived from single isomorphous replacement with anomalous scattering experiments, resulting in an electron-density map that showed a single molecule in the crystallographic asymmetric unit. Sequence assignment was aided by residues binding to bromide ions of the heavy-atom derivative

  13. Soluble human leukocyte antigen-G isoforms in maternal plasma in early and late pregnancy

    DEFF Research Database (Denmark)

    Rizzo, Roberta; Andersen, Anita Sylvest; Lassen, Michael Rud;

    2009-01-01

    of women with premature birth (<37 GW) compared with that of the control group (P = 0.028, P(C) = 0.17; Mann-Whitney). On the contrary, HLA-G5 was lower in the control group compared with that in the premature group (P = 0.004, P(C) = 0.02; Mann-Whitney). CONCLUSION: This study shows in line with......PROBLEM: Human Leukocyte Antigen (HLA)-G is a class Ib gene located in the human major histocompatibility complex (MHC). Several lines of investigation indicate that the HLA-G molecule is involved in the maternal acceptance of the semi-allogenic fetus during pregnancy and in the development of...... with severe pre-eclampsia compared with controls with uncomplicated pregnancies (P = 0.029, P(C) = 0.09; Mann-Whitney; Logistic regression analysis: P = 0.024, OR = 0.920, 95% CI: 0.855-0.989). However, this was not the case with HLA-G5, and significantly more of the cases with severe pre-eclampsia had...

  14. Lassen Veränderungen des Prostata-spezifischen Antigen- (PSA- Spiegels nach Prostatastanzbiopsie Rückschlüsse auf das pathologische Ergebnis zu?

    Directory of Open Access Journals (Sweden)

    Volkmer BG

    2004-01-01

    Full Text Available Einleitung: Die diagnostische Biopsie der Prostata führt bekanntermaßen zum Anstieg des Serum-PSA-Spiegels. Diese prospektive Untersuchung sollte die Frage klären, ob die Änderungen des Serum-PSA-Spiegels nach Stanzbiopsie Rückschlüsse auf das histologische Ergebnis zulassen und so als Entscheidungshilfe bei der Frage der Rebiopsie dienen können. Patienten und Methoden: Insgesamt 79 konsekutive Patienten mit klinischem Verdacht auf das Vorliegen eines Prostatakarzinoms (PCA und einem Gesamt-PSA 50 ng/ml wurden in die Studie eingeschlossen. Ausschlußkriterien waren klinische Hinweise für eine Prostatitis und Prostatabiopsie innerhalb der letzten 3 Monate. Die Serum-PSA-Werte wurden mit einem ultrasensitiven Enzymimmunoassay bestimmt. Die Bestimmung des Gesamt-PSA und des freien PSA im Serum erfolgte unmittelbar vor und 60 Minuten nach der Biopsie. Die Spiegel des Gesamt-PSA und freien PSA, sowie die f/t-PSA-Ratio vor und nach Biopsie wurden in Korrelation zum histologischen Ergebnis gesetzt. Ergebnisse: 86 Biopsieserien wurden bei 79 Patienten durchgeführt. 38 Biopsieserien diagnostizierten ein PCA, 48 eine benigne Prostatahyperplasie (BPH. Die abschließende Histologie nach wiederholter Biopsie war PCA und BPH in je 43 Fällen. Insgesamt fand sich ein Anstieg des durchschnittlichen Gesamt-PSA von 18,39 ng/ml auf 107,8 ng/ml, des durchschnittlichen freien PSA von 3,43 ng/ml auf 33,7 ng/ml und der durchschnittlichen f/t PSA-Ratio von 18,1 % auf 52,0 %. Es fand sich keine Korrelation zwischen dem Anstieg dieser Parameter und der Anzahl der Biopsiezylinder (4–51. Bezüglich des histologischen Befundes ergaben sich statistisch signifikante Unterschiede für das Gesamt-PSA vor und die f/t PSA-Ratio vor und nach Stanzbiopsie. Schlußfolgerung: Die Analyse der PSA-Parameter nach Stanzbiopsie bietet keine zusätzliche Information über die konventionellen PSA-Parameter vor der Biopsie hinaus. Sie korrelieren vor allem nicht mit falsch

  15. PSA methodology

    International Nuclear Information System (INIS)

    The purpose of this text is first to ask a certain number of questions on the methods related to PSAs. Notably we will explore the positioning of the French methodological approach - as applied in the EPS 13001 and EPS 9002 PSAs - compared to other approaches (Part One). This reflection leads to more general reflection: what contents, for what PSA? This is why, in Part Two, we will try to offer a framework for definition of the criteria a PSA should satisfy to meet the clearly identified needs. Finally, Part Three will quickly summarize the questions approached in the first two parts, as an introduction to the debate. 15 refs

  16. Prostate-specific antigen: does the current evidence support its use in prostate cancer screening?

    LENUS (Irish Health Repository)

    Duffy, Michael J

    2012-02-01

    Although widely used, the value of prostate-specific antigen (PSA) in screening asymptomatic men for prostate cancer is controversial. Reasons for the controversy relate to PSA being less than an ideal marker in detecting early prostate cancer, the possibility that screening for prostate cancer may result in the overdetection and thus overtreatment of indolent disease and the lack of clarity as to the definitive or best treatment for men diagnosed with localized prostate cancer. Although the results from some randomized prospective trials suggest that screening with PSA reduces mortality from prostate cancer, the overall benefit was modest. It is thus currently unclear as to whether the modest benefit of reduced mortality outweighs the harms of overdetection and overtreatment. Thus, prior to undergoing screening for prostate cancer, men should be informed of the risks and benefits of early detection. Newly emerging markers that may complement PSA in the early detection of prostate cancer include specific isoforms of PSA and PCA3.

  17. Long-Term Follow-Up of HLA-A2+ Patients with High-Risk, Hormone-Sensitive Prostate Cancer Vaccinated with the Prostate Specific Antigen Peptide Homologue (PSA146-154

    Directory of Open Access Journals (Sweden)

    Supriya Perambakam

    2010-01-01

    Full Text Available Twenty-eight HLA-A2+ patients with high-risk, locally advanced or metastatic, hormone-sensitive prostate cancer were immunized with a peptide homologue of prostate-specific antigen, PSA146-154, between July 2002 and September 2004 and monitored for clinical and immune responses. Fifty percent of the patients developed strong PSA146-154-peptide-specific delayed-type hypersensitivity skin responses, tetramer and/or IFN-γ responses within one year. Thirteen patients had stable or declining serum levels of PSA one year post-vaccination. A decreased risk of biochemical progression was observed in patients who developed augmented tetramer responses at six months compared to pre-vaccination levels (P=.02. Thirteen patients have died while 15 patients remain alive with a mean overall survival of 60 months (95% CI, 51 to 68 months per Kaplan-Meier analysis. A trend towards greater overall survival was detected in men with high-risk, hormone-sensitive CaP who developed specific T-cell immunity following vaccination with PSA146-154 peptide.

  18. PSA applications

    International Nuclear Information System (INIS)

    The IAEA now defines three types of PSA applications: Validation of design and of operation procedures; optimization of plant operation; and regulatory applications. The applications of PSA are manifold: only a few are dealt with here (precursor analysis is dealt with in session 3, topic 4). For each of them, we will do the utmost to demonstrate the main difficulties encountered, EDF's viewpoint on the matter, and the points remaining to be solved. In what follows, unless explicitly stated otherwise, we have made every effort to represent the different applications as they are practiced by all concerned in the international community, and to describe the inherent difficulties the international community has encountered with these applications with all objectivity. It goes without saying that the comments below are simply those of the ESF department, and are submitted here for discussion by the experts. 13 refs

  19. Determination of the Normal Prostate Specific Antigen (PSA) Value in Iraqi Society and its Relation to Bacterial Urinary Tract Infection (UTI)

    International Nuclear Information System (INIS)

    The study was carried out by radioimmunoassay and immuno radiographic analysis in the Iraqi Ministry of Health, within the research plan of Kurdistan institution for strategic study and scientific research. A total of 793 serum samples were collected in which 50 patient samples have biopsy with positive bacterial UTI. The other 743 samples were obtained from normal healthy volunteers all were over 45 years old. The samples were gathered randomly from three regions in Iraq namely, from north (Sulaymaniyah, Erbil and Dohuk), from the middle (Baghdad and Diyala) and from south (Basra, Missan and Najaf). The total PSA was measured and the results were subjected to statistical analysis based on statistical package social science (SPSS) method. The obtained data showed that the normal PSA values are function of the age of the donors. The results were grouped and clarified that PSA was less than 3.8 ng/ml for the age 45-55 years, while it was less than 4.8 ng/ml for the volunteers from 56-65 years old and the values lower than 5.9 ng/ml for group aged 66-75 years old. On the other hand, the obtained data illustrated that there were non-significant variations in PSA values as a function of the geographic regions. The PSA values for the 50 male positive bacterial UTI samples were within the same grouping previously stated for the normal healthy volunteers. Seven cases of the 743 samples showed abnormal high PSA values (i.e. greater than 9 ng/ml) which represent 0.93% of the healthy collected samples. It could be concluded that the PSA has non-significance relation to the bacterial UTI. In addition, the radioimmunoassay has a sensitivity of about 99.04% for the normal cases and specificity of 0.96% for prostate cancer.

  20. [5ARI and PSA: open questions.

    Science.gov (United States)

    Tubaro, Andrea; Puccini, Federica; De Nunzio, Cosimo

    2014-09-23

    No consensus has ever been reached on the predictive value of serum prostate specific antigen(PSA) for the diagnosis of prostate cancer. Limitations of PSA testing in clinical practice have beenoften discussed in the peer-reviewed literature following data derived from clinical trials such as theProstate Cancer Prevention Trial (PCPT) and the Reduction by Dutasteride of Prostate Cancer Events(REDUCE) study that showed a linear rise in the risk of prostate cancer with increasing PSA levels.Benign prostatic hyperplasia is a known confounding factor for the use of PSA as a marker of prostatecancer. Increased prostate volume observed with ageing, urinary retention, acute and chronicinflammatory conditions of the prostate, sexual activity and digital rectal examination may all cause anincrease of PSA values. Both finasteride and dutasteride, 5-alpha reductase inhibitors (5ARI) used inthe treatment of BPH, are known to induce a significant decrease of serum PSA levels close to 50%.The observed change in PSA values following 5ARI treatment has raised questions about the accuracyof PSA testing for the early diagnosis of prostate cancer in patients on finasteride/dutasteride treatment.Careful analysis of data from various clinical trials on pharmacological treatment of LUTS due toBPH suggested that the accuracy of PSA testing is not just maintained but rather increased following5ARI use. Then, the question of PSA accuracy during 5ARI treatment can be considered closed. PMID:25350562

  1. African-American (AA) men with local-regional prostate cancer (PC) present with higher prostate specific antigen (PSA) levels than whites: results of RTOG 94-12

    International Nuclear Information System (INIS)

    Purpose/Objective: To use pretreatment serum PSA levels as an20), gleason score (2-5,6-7,7-10), race (whites and AAs), and two interactions viz (a) PSA by race (p=0.0012) and (b) PSA by total gleason score (p=0.0001). When race was replaced by educational status, or income, or both, the fits (0.8246,0.8197, and 0.7815, respectively) were not as good as the fit with race in the model. Conclusion: The findings of this nation-wide prospective registration study with a high percentage of AA patient participation confirms previous, smaller, geographically-limited studies (1,2,3) results that AA patients with non-metastatic PC present with a higher mean PSA values than whites. The multivariate findings imply that, for each level of total gleason score, there is a higher percentage of whites with PSA levels 20. Education and/or income as surrogates of sociological status could not completely explain the racial differences. Other reasons for health-care barriers among AAs need to be identified

  2. Time to second prostate specific antigen (PSA) failure is a surrogate endpoint for prostate cancer death in prospective trials of therapy for localized disease

    International Nuclear Information System (INIS)

    Purpose In assessing the efficacy of the competing curative therapies for prostate cancer the most relevant endpoint is cancer specific death. Due to the long natural history of the disease and the use of salvage androgen suppression prospective trials need to mature for at least a decade to provide meaningful results. An endpoint that predicted for cancer death with high probability would allow more rapid completion of prospective studies, hopefully before the tested therapies become outdated. Materials and methods 202 patients entered into a single institution prospective randomized study for T3-4 prostate cancer between 1982 and 1992 were evaluated. All received radical irradiation to either a standard dose of 67.2Gy or a higher dose of 75.6Gy (the latter employing a proton beam boost). 76 men have received androgen suppression or orchiectomy for salvage following relapse (median follow-up 6.9 years). Of this group 35 experienced a second relapse heralded by a rise in the serum PSA. Second failure was scored on the date that the serum PSA rose to greater than 10% above the post-androgen suppression nadir. Kaplan-Meier analysis was made of survival from the time of second PSA failure and the cause of death established in all patients who subsequently died. Results The median duration of response to hormone therapy following first failure was 27.2 months. The actuarial survival from the time of second biochemical relapse was 93%, 66%, 35%, and 0% at 1, 2, 3, and 4 years respectively (50% at 32 months). 16 patients have so far died after second failure all from causes related to their prostate cancer. Conclusion Second PSA failure appears to be a secure surrogate for impending prostate cancer death. Its use as an endpoint in prospective studies should allow earlier reporting by 2 - 3 years

  3. Antigen

    Science.gov (United States)

    An antigen is any substance that causes your immune system to produce antibodies against it. This means your immune ... and is trying to fight it off. An antigen may be a substance from the environment, such ...

  4. Putting PSA to work

    International Nuclear Information System (INIS)

    The IAEA has, during the last three years, been working intensively on PSA applications. The draft TECDOC prepared during these activities, ''PSA Applications'' is summarized in this paper. Actual events at nuclear facilities provide an important basis to compare PSAs with reality. PSA based operational event analysis therefore can be used to evaluate the importance of operational events from a risk perspective but also can contribute to validating and enhancing PSAs and to continuously check whether or not the PSA models are adequate, appropriate and complete. The work of the IAEA in this area is therefore summarized as well. In a companion paper, titled ''Towards a credible PSA fit for applications'', two specific aspects regarding the quality of the PSA to be used are discussed in detail, namely the Living PSA concept, which ensures that the PSA reflects actual design and operational features and Quality Assurance for PSA. (author)

  5. Fire PSA methodology

    International Nuclear Information System (INIS)

    The fire PSA methodology, which NUPEC has introduced from one of US IPEEE fire PSA methodologies, was applied to a Japanese typical 1,100 Mwe class four loop PWR to confirm the applicability. Through this application, some consideration is given on some key parameters, such as fire frequencies and severity factor, in the fire PSA methodology to develop the fire PSA models specific to Japanese plants. (author)

  6. Antigenic characterization of an abnormal isoform of prion protein using a new diverse panel of monoclonal antibodies

    International Nuclear Information System (INIS)

    We established a panel of monoclonal antibodies (mAbs) against prion protein (PrP) by immunizing PrP gene-ablated mice with the pathogenic isoform of prion protein (PrPSc) or recombinant prion protein (rPrP). The mAbs could be divided into at least 10 groups by fine epitope analyses using mutant rPrPs and pepspot analysis. Seven linear epitopes, lying within residues 56-90, 119-127, 137-143, 143-149, 147-151, 163-169, and 219-229, were defined by seven groups of mAbs, although the remaining three groups of mAbs recognized discontinuous epitopes. We attempted to examine whether any of these epitopes are located on the accessible surface of PrPSc. However, no mAbs reacted with protease-treated PrPSc purified from scrapie-affected mice, even when PrPSc was dispersed into a detergent-lipid protein complex, to reduce the size of PrPSc aggregates. In contrast, denaturation of PrPSc by guanidine hydrochloride efficiently exposed all of the epitopes. This suggests that any epitope recognized by this panel of mAbs is buried within the PrPSc aggregates. Alternatively, if the corresponding region(s) are on the surface of PrPSc, the region(s) may be folded into conformations to which the mAbs cannot bind. The reactivity of a panel of mAb also showed that the state of PrPSc aggregation influenced the denaturation process, and the sensitivity to denaturation appeared to vary between epitopes. Our results demonstrate that this new panel of well-characterized mAbs will be valuable for studying the biochemistry and biophysics of PrP molecules as well as for the immuno-diagnosis of prion diseases

  7. PSA Velocity Does Not Improve Prostate Cancer Detection

    Science.gov (United States)

    A rapid increase in prostate-specific antigen (PSA) levels is not grounds for automatically recommending a prostate biopsy, according to a study published online February 24, 2011, in the Journal of the National Cancer Institute.

  8. Murine polyomavirus virus-like particles carrying full-length human PSA protect BALB/c mice from outgrowth of a PSA expressing tumor.

    Directory of Open Access Journals (Sweden)

    Mathilda Eriksson

    Full Text Available Virus-like particles (VLPs consist of capsid proteins from viruses and have been shown to be usable as carriers of protein and peptide antigens for immune therapy. In this study, we have produced and assayed murine polyomavirus (MPyV VLPs carrying the entire human Prostate Specific Antigen (PSA (PSA-MPyVLPs for their potential use for immune therapy in a mouse model system. BALB/c mice immunized with PSA-MPyVLPs were only marginally protected against outgrowth of a PSA-expressing tumor. To improve protection, PSA-MPyVLPs were co-injected with adjuvant CpG, either alone or loaded onto murine dendritic cells (DCs. Immunization with PSA-MPyVLPs loaded onto DCs in the presence of CpG was shown to efficiently protect mice from tumor outgrowth. In addition, cellular and humoral immune responses after immunization were examined. PSA-specific CD4(+ and CD8(+ cells were demonstrated, but no PSA-specific IgG antibodies. Vaccination with DCs loaded with PSA-MPyVLPs induced an eight-fold lower titre of anti-VLP antibodies than vaccination with PSA-MPyVLPs alone. In conclusion, immunization of BALB/c mice with PSA-MPyVLPs, loaded onto DCs and co-injected with CpG, induces an efficient PSA-specific tumor protective immune response, including both CD4(+ and CD8(+ cells with a low induction of anti-VLP antibodies.

  9. What is living PSA?

    International Nuclear Information System (INIS)

    The paper describes the pioneering work into living probabilistic safety analysis (PSA) within Nuclear Electric plc as part of its strategic development programme. This programme is targeted to provide risk management tools to assist in optimizing the testing and maintenance arrangements for the essential safety systems within the company's nuclear power plants. Three broad categories of living PSA development are described with their advantages. The first is a Stage 1 living PSA which is an off-line PSA which can be upgraded on a regular basis. Then a Stage 2 living PSA which is an on-line time-independent PSA, in which standby component failure probabilities are modelled at the end of their inspection period, and is updated by the plant operator as and when changes in plant configuration (i.e. opening/closing sectioning valves) or plant availability occur. Finally a Stage 3 living PSA which is an on-line dynamic PSA, in which all standby components are modelled with respect to their last inspection time, and is updated by the plant operator as and when changes in plant configuration and plant availability occur and when testing takes place. (author)

  10. Fire PSA for MAPS

    International Nuclear Information System (INIS)

    Full text: Fire hazard has been identified as one of the major contributors to a plant's operational risk. As a result of several fire incidences at nuclear power plants, internal fire is included in level 1 probabilistic safety assessment (PSA) studies of nuclear power plants (NPPs). This activity is termed as fire risk analysis or fire PSA. In this context, fire PSA studies were initiated for Madras Atomic Power Station (MAPS). Fire PSA extends the consequence analysis of a fire event towards core damage, in case of nuclear power plants. The paper summarises and gives an overview of the fire PSA procedure performed for MAPS. It highlights the issues associated with the collection of data and information needed for fire modelling. An estimate of the contribution of fire to core damage frequency (CDF) has been obtained

  11. DIAGNOSTIC AND PROGNOSTIC UTILITY OF SERUM PSA IN BREAST CANCER

    Institute of Scientific and Technical Information of China (English)

    张淑群; 强水云; 李妙羡; 纪宗正

    2004-01-01

    Objective To investigate the diagnostic and prognostic value of total and free prostate-specific antigen (PSA) in breast cancer women. Methods Using the microparticle enzyme immunoassay system, we measured the concentrations of these markers in the sera of 85 women with breast cancer and in 30 healthy women.Results Free PSA levels were significantly higher in women with breast cancer than healthy women (P <0. 05 ).The percentage of free PSA predominant subjects was 37. 6% in breast cancer patients and 3. 3% in healthy women.In women with breast cancer,total PSA positivity was 23.5% and free PSA positivity was 27. 1%. When compared to negatives,total PSA positive patients had a higher percentage of lymph node involvement tamours ( P >0. 05).However, patients with predominant free PSA had a higher percentage of early stage than patients with predominant PSA-ACT. Conclusion This study indicate clinical significance of preoperative measurement of serum total and free PSA in diagnosis and prognosis of women with breast cancer. The expression of KLKs is correlated with carcinogenesis of breast cancer.

  12. Prostate-specific antigen (Pasa) bounce and other fluctuations: Which biochemical relapse definition is least prone to PSA false calls? An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapy

    International Nuclear Information System (INIS)

    Purpose: To determine the false call (FC) rate for prostate-specific antigen (PSA) relapse according to nine different PSA relapse definitions after a PSA fluctuation (bounce) has occurred after external beam radiation therapy (EBRT) or brachytherapy, with or without adjuvant androgen deprivation therapy. Methods and Materials: An analysis of a prospective database of 2030 patients was conducted. Prostate-specific antigen relapse was scored according to the American Society for Therapeutic Radiology and Oncology (ASTRO), Vancouver, threshold + n, and nadir + n definitions for the complete data set and then compared against a truncated data set, with data subsequent to the height of the bounce deleted. The FC rate was calculated for each definition. Results: The bounce rate, with this very liberal definition of bounce, was 58% with EBRT and 84% with brachytherapy. The FC rate was lowest with nadir + 2 and + 3 definitions (2.2% and 1.6%, respectively) and greatest with low-threshold and ASTRO definitions (32% and 18%, respectively). The ASTRO definition was particularly susceptible to FC when androgen deprivation therapy was used with radiation (24%). Discussion: New definitions of biochemical non-evidence of disease that are more robust than the ASTRO definition have been identified. Those with the least FC rates are the nadir + 2 and nadir + 3 definitions, both of which are being considered to replace the ASTRO definition by the 2005 meeting of the Radiation Therapy Oncology Group-ASTRO consensus panel

  13. Prostate-Specific Antigen (PSA) Test

    Science.gov (United States)

    ... Understanding Laboratory Tests Prostate Cancer—Patient Version Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Tumor Markers Understanding Prostate Changes: A Health Guide for Men ...

  14. Temelin PSA level 2

    International Nuclear Information System (INIS)

    In this paper a brief overview of the performed PSA at Temelin NPP is given. The activities dealing with PSA level 2 update (2002-2003) are listed and the main results are discussed. Based on the obtained results the following conclusions have been made: containment failures 'moved' from 'early' to 'late' categories thanks to SAMG measures (penetration plugs, corium barriers); low frequency of overpressure failures; hydrogen recombiners important both for early and late containment failures; uncertainty of source terms due to insufficient and inconsistent analyses data; one early failure and two bypass scenarios found to be most important from frequency/radiological consequences viewpoint

  15. UV/EB curable psa's

    International Nuclear Information System (INIS)

    The author describe both water-based and 100% solids UV/EB curable PSA's (Pressure Sensitive Adhesives) and their properties. A new acrylate monomer, ethoxylated nonyl phenol acrylate, has great utility in the formulation of water-based PSA's

  16. Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer

    DEFF Research Database (Denmark)

    See, W; Iversen, P; Wirth, M;

    2003-01-01

    To evaluate the effect of bicalutamide ('Casodex') 150mg (in addition to standard care), on the risk of prostate-specific antigen (PSA) progression, in patients with early prostate cancer.......To evaluate the effect of bicalutamide ('Casodex') 150mg (in addition to standard care), on the risk of prostate-specific antigen (PSA) progression, in patients with early prostate cancer....

  17. Development of an MHC class I Ld-restricted PSA peptide-loaded tetramer for detection of PSA-specific CD8+ T cells in the mouse

    OpenAIRE

    Lemke, Caitlin D.; Graham, Jessica B.; Lubaroff, David M.; Salem, Aliasger K.

    2011-01-01

    Objectives We set out to develop a prostate specific antigen (PSA) peptide-loaded tetramer for enumeration of PSA-specific CD8+ T cells in the Balb/c mouse model. Methods A candidate MHC class I PSA peptide (HPQKVTKFML188–197) was selected based on its ability to restimulate PSA-specific CD8+ T cells to secrete IFN-γ in our assays. Next, H-2Ld-restricted peptide-loaded and fluorescently labeled tetramers were produced in conjunction with the NIH Tetramer Core Facility. This tetramer was then ...

  18. Evaluation of the effect of PSA inter-assay variability on nomograms for prostate cancer prediction

    OpenAIRE

    Siemßen, Kerstin

    2012-01-01

    Purpose: To evaluate the suitability of published nomograms for prostate cancer (PCa) risk prediction, in particular considering the prostate specific antigen (PSA) inter-assay variability. Patients and Methods: Total (tPSA) and free PSA were determined with five different assays in 780 biopsy-referred men. Together with age, prostate volume and digital rectal examination (DRE) status these data were applied to five published nomograms for PCa detection. The criteria discrimina...

  19. Babesiosis PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2012-04-25

    This 60 second PSA describes babesiosis, a preventable and treatable tickborne disease, including the signs and symptoms of infection and ways to prevent it.  Created: 4/25/2012 by Center for Global Health, Division of Parasitic Diseases and Malaria.   Date Released: 4/26/2012.

  20. Guideline level-3 PSA

    International Nuclear Information System (INIS)

    For several applications of radioactive materials calculations must be executed to determine the radiation risk for the population. A guideline for the risk calculation method of two main sources: nuclear power plants, and other intended and unintended activities with radioactive materials, is given. The standards, recommendations and regulations in this report concern mainly the analysis of the radiological (external) consequences of nuclear power plant accidents, classified as level-3 PSA (Probabilistic Safety Analysis). Level-3 PSA falls within the scales 5-7 of the International Nuclear Event Scale (INES). The standards, etc., focus on the risks for groups of people and the so-called maximum individual risk. In chapter two the standards and regulations are formulated for each part of level-3 PSA: the source term spectrum, atmospheric distribution and deposition, exposure to radiation doses and calculation of radiation doses, dose-response relationships, measures to reduce the effect of radiation doses, design basis accidents, and finally uncertainty analysis. In chapter four, modelled descriptions are given of the standards and regulations, which could or should be used in a calculation program in case of level-3 PSA. In chapter three the practical execution of a probabilistic consequences analysis, the collection of input data and the presentation of the results are dealt with. 2 figs., 14 tabs., 64 refs

  1. Probabilistic safety analyses (PSA)

    International Nuclear Information System (INIS)

    The guide shows how the probabilistic safety analyses (PSA) are used in the design, construction and operation of light water reactor plants in order for their part to ensure that the safety of the plant is good enough in all plant operational states

  2. PSA in operator training

    International Nuclear Information System (INIS)

    The systematic approach to training is internationally accepted as the best method to achieve and maintain the qualification and competence of power plant personnel and to guarantee the quality of their training. Following the recommendations and guidelines of international organisations competent in the field, TECNATOM SA has developed projects based on the systematic approach to training for all Spanish nuclear power plants. One of the latest projects was the systematic approach to training developed for the operation personnel of ASCO Nuclear Power Plant. In this case, certain results of the Probabilistic Safety Analysis (PSA) which complement the systematic safety and reliability criteria of the systematic approach to training process have been incorporated in the traditional processes of work and task analysis and training plan design. This incorporation provides the training manager with additional criteria based not only on safety aspects obtained through the statistical treatment of considerations of skilled technical personnel (operators, operation chief supervisors, etc), but also on the independent criterion of the PSA. The inclusion of this approach basically affects all systematics in two of its stages: During the selection process of operating practices in SMR or SGI, the possible scenarios have been associated with all those situations where human actions which lead to an initiating event or human actions to mitigate an initiating event, may take place, as defined in the PSA. During the scenario development process, the instruments involved in the performance of human actions which originate or mitigate an event taking place have been identified. This pakes it possible to reconcile the scenario event sequence with the sequence considered in the PSA study, as the most likely to provoke a more serious accident. The incorporation of these PSA results contributes to the strengthening of safety aspects in training in an objective way, and confirms that

  3. Point-of-care PSA testing: an evaluation of PSAwatch.

    Science.gov (United States)

    Karim, O; Rao, A; Emberton, M; Cochrane, D; Partridge, M; Edwards, P; Walker, I; Davidson, I

    2007-01-01

    We present a new quantitative prostate-specific antigen (PSA) assay using a portable, point-of-care test (PSAwatch) and reader system (BioScan) for measuring PSA concentrations in the range from 0.5 to BioScan system. PSA concentrations in 188 men were < or =25 microg/l and studied. Correlation between the two methods was good (R(2)=0.88) with a standard error of 1.588. The regression line had a bias of -0.02 at the concentration of 4.00 microg/l. This is the first report of a quantitative, portable, point-of-care PSA test and reader system. PSAwatch may reduce the number of hospital visits for patients with prostate disease. PMID:17353914

  4. Whooping Cough PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2015-01-22

    This 30 second PSA encourages pregnant women to get the whooping cough vaccine, called Tdap, during the third trimester of each pregnancy in order to pass antibodies to their babies so they are born with protection against this serious disease.  Created: 1/22/2015 by National Center for Immunization and Respiratory Diseases (NCIRD), Division of Bacterial Diseases (DBD), Meningitis and Vaccine Preventable Diseases Branch (MVPDB).   Date Released: 1/22/2015.

  5. Binge Drinking PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2010-10-05

    This PSA is based on the October, 2010 CDC Vital Signs report which indicates that drinking too much, including binge drinking, causes more than 79,000 deaths in the U.S. each year and is the third leading preventable cause of death.  Created: 10/5/2010 by Centers for Disease Control and Prevention (CDC).   Date Released: 10/5/2010.

  6. PSA Screening Has Led to Overtreatment of Many Prostate Cancers

    Science.gov (United States)

    Screening for prostate cancer with the prostate-specific antigen (PSA) test has led to overtreatment of many prostate cancers, including aggressive treatments in older men considered to be at low risk for progression of the disease according to a study published in the July 26, 2010 Archives of Internal Medicine.

  7. Early decrease of PSA, a prognosis factor independent from biochemical control in case of remedial radiotherapy after prostatectomy; Baisse precoce du PSA, un facteur pronostique independant de controle biochimique en cas de radiotherapie de rattrapage apres prostatectomie

    Energy Technology Data Exchange (ETDEWEB)

    Blanchard, P.; Bakkour, M.; Chaurin, P.; Negretti, L.; Wibault, P.; Bossi, A. [Institut de cancerologie Gustave-Roussy, Villejuif (France); Crevoisier, R. de [Centre Eugene-Marquis, Rennes (France)

    2011-10-15

    The authors report the analysis of the predictive value of PSA (prostate specific antigen) decrease during a remedial external radiotherapy performed to increase the PSA after a radical prostatectomy. During four years, 136 patients have been treated by external irradiation to obtain a PSA increase after prostatectomy. Different parameters are noticed: initial pathological stage, initial Gleason score, mean time between prostatectomy and external radiotherapy, values of PSA before and after prostatectomy and after radiotherapy. The evolution of PSA could be used for an early identification of patients presenting a pejorative prognosis. Short communication

  8. PSA data development for Novovoronezh unit 5 level 1 PSA

    International Nuclear Information System (INIS)

    This paper presents the approach used in developing data for the level-1 Probabilistic Safety Analysis (PSA) of the Novovoronezh Unit 5 nuclear power plant (NVNPP-5), the first Russian VVER-1000 reactor. The NVNPP-5 PSA is being carried out within the framework of the joint Russian-Swiss project (i.e., SWISRUS). This paper describes briefly approaches and results of PSA data analysis done in respect to various PSA data required for the PSA model quantification including: Initiating event frequencies; Component reliability parameters; Component unavailabilities due to maintenance and common cause failures; Human error probabilities. Specifically, both generic and plant-specific data on initiating event frequencies and reliability parameters for system components (pumps, valves, diesel generators, etc.) were developed on the basis of available initial statistical data ('raw' data) with usage of the Bayesian updating methodology. Samples of final data are provided. The problems and insights dealt with processing the statistical data and parameters definition are identified in the paper. The insights obtained from Human Reliability Analysis (HRA) and component Common Cause Failure (CCF) analysis, as well as the effect of various types of PSA data on PSA results are discussed. Also, plans and procedures for PSA data updating for Living PSA purposes are discussed in this paper. (authors)

  9. PSA results and trends for Spain's NPPs

    International Nuclear Information System (INIS)

    The Spain regulatory authority CSN demanded performance of PSA for all Spain nuclear power plants. The specific data analysis carried out as a part of the PSA has contributed to the realistic view on the results which could be achieved by the PSA. The main characteristics of the PSA in Spain and PSA trends in the development are presented in the paper

  10. PSA Update Procedures, an Ultimate Need for Living PSA

    International Nuclear Information System (INIS)

    Nuclear facilities by their complex nature, change with time. These changes can be both physical (plant modification, etc.), operational (enhanced procedures, etc.) and organizational. In addition, there are also changes in our understanding of the plant, due to operational experience, data collection, technology enhancements, etc. Therefore, it is imperative that PSA model must be frequently up-dated or modified to reflect these changes. Over the last ten years. these has been a remarkable growth of the use of Probabilistic Safety Assessments (PSAs). The most rapidly growing area of the PSA Applications is their use to support operational decision-making. Many of these applications are characterized by the potential for not only improving the safety level but also for providing guidance on the optimal use of resources and reducing regulatory burden. To enable a wider use of the PSA model as a tool for safety activities it is essential to maintain the model in a controlled state. Moreover, to fulfill requirements for Living PSA, the PSA model has to be constantly updated and/or monitored to reflect the current plant configuration. It should be noted that the PSA model should not only represent the plant design but should also represent the operational and emergency procedures. To keep the PSA model up-to-date several issues should be clearly defined including: - Responsibility should be divided among the PSA group, - Procedures for implementing changes should be established, and - QA requirements/program should be established to assure documentation and reporting. (author)

  11. Prostate Cancer Screening: the role of biopsy, PSA, PSA dynamics and isoforms

    NARCIS (Netherlands)

    P.F.J. Raaijmakers (René)

    2009-01-01

    textabstractIn the beginning of the past century, A. Astraldi urologist from Buenos Aires, Argentina, recognized the importance of early detection of prostate cancer and was unsatisfied with the available diagnostic tools he had to his disposal. The only diagnostic means for the urologist at that ti

  12. Nonprostatic sources of prostate-specific antigen.

    Science.gov (United States)

    Diamandis, E P; Yu, H

    1997-05-01

    The name prostate-specific antigen has been given to a protein that now is known not to be prostate-specific; however, prostatic tissue does produces extremely high levels of PSA and secrets it into the seminal plasma. Seminal plasma contains about 1 million micrograms/L of PSA and is the richest source of PSA reported. The biologic fluid with the second highest PSA concentration, however, is nipple aspirate fluid from the female breast (up to about 5000 micrograms/L), and the third is milk from lactating women (up to 300 micrograms/L). Male serum PSA is usually less than 4 micrograms/L. In nonprostatic tissues, PSA exists mainly in its free molecular form, but PSA-ACT complex is also present in most of the fluids that contain PSA, such as breast secretions and amniotic fluid. The gene expression and protein production of PSA in nonprostatic tissues are under the regulation of steroid hormones via their receptors. Androgens, glucocorticoids, and progestins up-regulate the PSA gene expression, resulting in an increase of protein production. Estrogen by itself seems to have no effect on PSA regulation, but it can impair PSA production induced by androgen. It remains unknown whether PSA is enzymatically active and what is the physiologic role of PSA in nonprostatic tissues. It is speculated that PSA may be involved in the regulation of growth factors. Measuring PSA in breast cancer cytosol, breast-nipple aspirate fluid, and female serum may have potential clinical utilities, including breast cancer prognosis, breast cancer risk assessment, and evaluation of androgen excess. Further studies are needed to identify the exact function and regulation of PSA in nonprostatic tissues and to explore the clinical application of this protein. PMID:9126224

  13. Early detection, PSA screening, and management of overdiagnosis.

    Science.gov (United States)

    Borza, Tudor; Konijeti, Ramdev; Kibel, Adam S

    2013-12-01

    Prostate cancer diagnosis and treatment rates have increased significantly since the introduction of prostate-specific antigen (PSA) screening. Although it was initially thought that most prostate cancers would lead to death or significant morbidity, recent randomized trials have demonstrated that many patients with screening-detected cancer will not die of their disease. Modifications to PSA screening, screening guideline statements, and novel screening markers have been developed to minimize the risk and morbidity associated with overdiagnosis and overtreatment. Less aggressive management strategies such as active surveillance may lead to lower treatment rates in men who are unlikely to benefit while maintaining cure rates. PMID:24188254

  14. EVALUATION OF FREE-TO-TOTAL PROSTATE SPECIFIC ANTIGEN RATIO IN THE DIAGNOSIS OF PROSTATE CANCER

    Institute of Scientific and Technical Information of China (English)

    2000-01-01

    @@ It's reported that free to total prostate specific antigen ration (f/tPSA) can provide more benefit than the single use of prostate specific antigen (PSA) in the diagnosis of prostate cancer (PCa). We measured serum PSA and fPSA levels in 62 cases of benign prostatic hyperplasia (BPH) and 40 cases of PCa using radioimmunoassay, with patients' age range 59y~ 89y.

  15. Evaluation of Soluble Human Leukocyte Antigen-G (sHLA-G) Isoforms and Regulatory T Cells in Relapsing-Remitting Multiple Sclerosis.

    Science.gov (United States)

    Alsahebfosoul, Fereshteh; Zavaran Hosseini, Ahmad; Salehi, Rasoul; Etemadifar, Masood; Esmaeil, Nafiseh; Jamshidian, Azam

    2015-06-01

    Soluble forms of nonclassical human leukocyte antigen (HLA)-G have recently been suggested as immunomodulatory factors in multiple sclerosis (MS). HLA-G inhibits the effecter function of T cells and natural killer (NK) cells. Also regulatory T cells (Treg) are considered as pivotal players in MS pathogenesis. Thus, we aimed to evaluate the presence of HLA-G molecules and Treg cells in Relapsing-Remitting Multiple Sclerosis (RRMS) patients and compare it to healthy controls. Patients with RRMS (n=205, mean age=31.32±8.53) and healthy subjects (n=205, mean age=32.2±7.48) were studied. The patients subgrouped to untreated and treated with Interferon beta. Then sHLA-G levels (sHLA-G1 and sHLA-G5) were measured using ELISA method. Treg (CD4+ CD25+ Foxp3+) cells in patients who had sHLA-G>10 U/ml were characterized by using flow cytometry. Our data showed that there was no significant differences between RRMS patients and healthy controls in sHLA-G concentration (p>0.05). Treg cell frequencies were higher in the patients who had sHLA-G >10 U/ml compared to healthy subjects (pTreg cells in treated RRMS patients and healthy individuals. It seems that high level sHLA-G has been instrumental in raising frequency of Treg cells in treated patients and could be associated with remission of MS disease. PMID:26546899

  16. Evaluation of Soluble Human Leukocyte Antigen-G (sHLA-G Isoforms and Regulatory T Cells in Relapsing-Remitting Multiple Sclerosis

    Directory of Open Access Journals (Sweden)

    Fereshteh Alsahebfosoul

    2015-10-01

    Full Text Available Soluble forms of nonclassical human leukocyte antigen (HLA-G have recently been suggested as immunomodulatory factors in multiple sclerosis (MS. HLA-G inhibits the effecter function of T cells and natural killer (NK cells. Also regulatory T cells (Treg are considered as pivotal players in MS pathogenesis. Thus, we aimed to evaluate the presence of HLA-G molecules and Treg cells in Relapsing-Remitting Multiple Sclerosis (RRMS patients and compare it to healthy controls.Patients with RRMS (n=205, mean age=31.32±8.53 and healthy subjects (n=205, mean age=32.2±7.48 were studied. The patients subgrouped to untreated and treated with Interferon  beta.  Then  sHLA-G  levels  (sHLA-G1  and  sHLA-G5  were measured  using ELISA method. Treg (CD4+CD25+  Foxp3+ cells in patients who had sHLA-G>10 U/ml were characterized by using flow cytometry.Our data showed that there was no significant differences between RRMS patients and healthy controls in  sHLA-G concentration (p>0.05. Treg cell frequencies were higher in the patients who had sHLA-G >10 U/ml compared to healthy subjects (p<0.05.Collectively, there was significant correlation between sHLA-G and frequency of Treg cells in treated RRMS patients and healthy individuals. It seems that high level sHLA-G has been  instrumental  in  raising  frequency  of  Treg  cells  in  treated  patients  and  could  be associated with remission of MS disease.

  17. Determining if pretreatment PSA doubling time predicts PSA trajectories after radiation therapy for localized prostate cancer

    International Nuclear Information System (INIS)

    Introduction: To determine if pretreatment PSA doubling time (PSA-DT) can predict post-radiation therapy (RT) PSA trajectories for localized prostate cancer. Materials and methods: Three hundred and seventy-five prostate cancer patients treated with external beam RT without androgen deprivation therapy (ADT) were identified with an adequate number of PSA values. We utilized a linear mixed model (LMM) analysis to model longitudinal PSA data sets after definitive treatment. Post-treatment PSA trajectories were allowed to depend on the pre-RT PSA-DT, pre-RT PSA (iPSA), Gleason score (GS), and T-stage. Results: Pre-RT PSA-DT had a borderline impact on predicting the rate of PSA rise after nadir (p = 0.08). For a typical low risk patient (T1, GS ≤ 6, iPSA 10), the predicted PSA-DT post-nadir was 21% shorter for pre-RT PSA-DT 24 month (19 month vs. 24 month). Additional significant predictors of post-RT PSA rate of rise included GS (p < 0.0001), iPSA (p < 0.0001), and T-stage (p = 0.02). Conclusions: We observed a trend between rapidly rising pre-RT PSA and the post-RT post-nadir PSA rise. This effect appeared to be independent of iPSA, GS, or T-stage. The results presented suggest that pretreatment PSA-DT may help predict post-RT PSA trajectories

  18. Activities toward PSA quality improvement in Japan

    International Nuclear Information System (INIS)

    PSA of adequate quality is indispensable for expanding the field of risk-informed plant management. Activities to construct framework of improving PSA quality in Japan, such as arrangement of PSA standard, adopting parameters based on operational experience of Japanese NPPs, and implementation of PSA peer review, are in progress. (author)

  19. Human behaviour in PSA

    International Nuclear Information System (INIS)

    Based on the current international state of the art of methodology for evaluation of human errors for PSA, many research projects have been initiated by the competent departments of the BMU and the BfS (Federal Min. of the Environment and Reactor Safety, Federal Radiation Protection Office). Three major areas of the research activities are discussed: Database: - Specific investigations into the applicability of generic data (THERP) to other than the original cases, possibly elaboration of approaches for application-specific modification, further evaluation of operating results; - general enhancement of insight into human performance and errors, e.g. with respect to causes of error and application areas (influence of organisation, cognitive performance); interviews with experts as a supplementary approach for data verification and database enhancement. Sensitivity analysis: - Identification of information describing human errors essentially contributing to frequency of occurrence of incidents and system non-availability; - establishment of relevance rating system, methodology for uncertainty analysis. Further development of methodology: - Modelling of repair activities and knowledge-based behaviour. (orig./CB)

  20. Result of salvage radiotherapy for post-operative PSA failure of prostate cancer. Evaluation of predictive factors

    International Nuclear Information System (INIS)

    Fifty-five patients with prostate specific antigen (PSA) failure were treated with salvage radiotherapy. Post-operative and post-radiotherapy PSA failure was defined as the PSA elevation (nadir +0.2 ng/ml) or the initiation of hormone therapy. The median follow-up period after salvage radiotherapy was 32 months (range; 1-67 months). The 3-yrs biochemical free survival and overall survival rate was 66.7% and 100%. Result of salvage radiotherapy for post-operation PSA failure is good and only the dose was significant predictive factor (60 Gy vs > 64 Gy; 53.9% vs 86.2%). (author)

  1. DETERMINATION OF PSA REFERENCE LEVEL FOR COMMON PROSTATIC DISEASE PATIENTS IN SUDAN

    OpenAIRE

    Yousef, Mohamed; ALIOMER, MOHAMMED A.

    2013-01-01

    This study aimed to determine the reference prostate specific antigen (PSA) range for different types prostatic disease patients in Sudanese men,A total of 50 patients, age ranged from 46-96 years with various types of prostatic disorders were enrolled into this study. The analyses included patients referred to RIA lab at RICK ,a biopsy was taken in those to exclude prostate cancer. The collected data included: PSA amount, diagnosis, habits, Age, residence and Races (tribe). The collected dat...

  2. Cancer of the prostate - role of PSA

    International Nuclear Information System (INIS)

    Since 1979 when prostate specific antigen (PSA), found in the cytoplasm of benign and malignant prostatic cells, was first purified, it has attained world wide popularity in prostate cancer detection. It is also a sensitive test for skeletal meta states from carcinoma of the prostate. Prostate cancer has become the number one cancer in men and constitutes 11% of all cancers. Approximately 50% of men over 50 years have symptoms referable to the lower urinary tract. 50% or more of patients at Ibadan present an advanced stage of the disease and are therefore not curable. Thus, lacking the skill to manage advanced manifestations, early detection and screening programs are the best means to reduce mortality due to prostate cancer

  3. Survey of Dynamic PSA Methodologies

    Energy Technology Data Exchange (ETDEWEB)

    Lee, Hansul; Kim, Hyeonmin; Heo, Gyunyoung [Kyung Hee University, Yongin (Korea, Republic of); Kim, Taewan [KEPCO International Nuclear Graduate School, Ulsan (Korea, Republic of)

    2015-05-15

    Event Tree(ET)/Fault Tree(FT) are significant methodology in Probabilistic Safety Assessment(PSA) for Nuclear Power Plants(NPPs). ET/FT methodology has the advantage for users to be able to easily learn and model. It enables better communication between engineers engaged in the same field. However, conventional methodologies are difficult to cope with the dynamic behavior (e.g. operation mode changes or sequence-dependent failure) and integrated situation of mechanical failure and human errors. Meanwhile, new possibilities are coming for the improved PSA by virtue of the dramatic development on digital hardware, software, information technology, and data analysis.. More specifically, the computing environment has been greatly improved with being compared to the past, so we are able to conduct risk analysis with the large amount of data actually available. One method which can take the technological advantages aforementioned should be the dynamic PSA such that conventional ET/FT can have time- and condition-dependent behaviors in accident scenarios. In this paper, we investigated the various enabling techniques for the dynamic PSA. Even though its history and academic achievement was great, it seems less interesting from industrial and regulatory viewpoint. Authors expect this can contribute to better understanding of dynamic PSA in terms of algorithm, practice, and applicability. In paper, the overview for the dynamic PSA was conducted. Most of methodologies share similar concepts. Among them, DDET seems a backbone for most of methodologies since it can be applied to large problems. The common characteristics sharing the concept of DDET are as follows: • Both deterministic and stochastic approaches • Improves the identification of PSA success criteria • Helps to limit detrimental effects of sequence binning (normally adopted in PSA) • Helps to avoid defining non-optimal success criteria that may distort the risk • Framework for comprehensively considering

  4. Survey of Dynamic PSA Methodologies

    International Nuclear Information System (INIS)

    Event Tree(ET)/Fault Tree(FT) are significant methodology in Probabilistic Safety Assessment(PSA) for Nuclear Power Plants(NPPs). ET/FT methodology has the advantage for users to be able to easily learn and model. It enables better communication between engineers engaged in the same field. However, conventional methodologies are difficult to cope with the dynamic behavior (e.g. operation mode changes or sequence-dependent failure) and integrated situation of mechanical failure and human errors. Meanwhile, new possibilities are coming for the improved PSA by virtue of the dramatic development on digital hardware, software, information technology, and data analysis.. More specifically, the computing environment has been greatly improved with being compared to the past, so we are able to conduct risk analysis with the large amount of data actually available. One method which can take the technological advantages aforementioned should be the dynamic PSA such that conventional ET/FT can have time- and condition-dependent behaviors in accident scenarios. In this paper, we investigated the various enabling techniques for the dynamic PSA. Even though its history and academic achievement was great, it seems less interesting from industrial and regulatory viewpoint. Authors expect this can contribute to better understanding of dynamic PSA in terms of algorithm, practice, and applicability. In paper, the overview for the dynamic PSA was conducted. Most of methodologies share similar concepts. Among them, DDET seems a backbone for most of methodologies since it can be applied to large problems. The common characteristics sharing the concept of DDET are as follows: • Both deterministic and stochastic approaches • Improves the identification of PSA success criteria • Helps to limit detrimental effects of sequence binning (normally adopted in PSA) • Helps to avoid defining non-optimal success criteria that may distort the risk • Framework for comprehensively considering

  5. A Databank for PSA Data

    International Nuclear Information System (INIS)

    The Swiss Regulatory (HSK) is developing a living PSA model of each Swiss nuclear power plant. This project includes a significant amount of work with data. A databank was developed to support data collection, processing and quality assurance. The databank consists of three modules. In the data collection module, plant-specific components (pumps, diesel generators, etc.) are described. This information is used to class the components into different statistical groups and to select appropriate generic data. The plant-specific component failures and demands are also documented in this module. In the reliability database, the results of the quantification are summarised. Finally, in the PSA event generator, the basic events, super-components and common cause failure (CCF) events are defined, checked for consistency and exported into the PSA code. The databank was successfully applied to the full-scope PSA for a Siemens KWU plant. The databank was particularly helpful for case studies and whenever updates needed to be performed quickly and consistently. Currently, the use of the databank is extended to other PSA studies. (authors)

  6. Vergleichende Einschätzung der diagnostischen Aussagekraft der Kenngrößen freies PSA, Alpha1-Antichymotrypsin-PSA und komplexiertes PSA in der Diagnostik des Prostatakarzinoms

    Directory of Open Access Journals (Sweden)

    Baumgart E

    2001-01-01

    Full Text Available Ziel der Studie war die vergleichende Einschätzung der diagnostischen Aussagekraft von Gesamt-PSA (tPSA, freiem PSA (fPSA, alpha1-Antichymotrypsin-PSA (ACT-PSA und komplexiertem PSA (cPSA sowie der entsprechenden Quotienten zur Differenzierung zwischen einem Prostatakarzinom (PCa und einer Benignen Prostatahyperplasie (BPH. Die Bestimmung erfolgte bei insgesamt 324 Männern (PCa: n = 144; BPH: n = 89; Kontrollen: n = 91. Die tPSA- und cPSA-Konzentrationen wurden mit dem Bayer Immuno 1 System (Bayer Diagnostics, Tarrytown, USA durchgeführt; die tPSA- und fPSA-Bestimmungen erfolgten mit dem Elecsys System (Roche Diagnostics, Mannheim, Deutschland. Der ACT-PSA-Test ist ein Prototyp für klinische Untersuchungen auf dem ES-System (Roche Diagnostics. Die medianen Konzentrationen von tPSA, ACT-PSA, cPSA und die Quotienten fPSA/tPSA, ACT-PSA/tPSA, cPSA/tPSA waren zwischen PCa- und BPH-Patienten signifikant unterschiedlich. Zur Objektivierung der Diskriminierungsfähigkeit wurde das "Receiver Operating Characteristics Analysis" Verfahren (tPSA 20µg/l eingesetzt. Die Quotienten fPSA/tPSA, ACT-PSA/tPSA und cPSA/tPSA unterschieden sich signifikant vom tPSA. ACT-PSA und cPSA waren nicht signifikant unterschiedlich von tPSA. Signifikante Unterschiede zwischen den Quotienten fPSA/tPSA, ACT-PSA/tPSA und cPSA/tPSA wurden nicht festgestellt. Die Bestimmung von ACT-PSA oder cPSA sowie der entsprechenden Quotienten verbessert nicht die PCa-Diagnostik im Vergleich zum Quotienten fPSA/tPSA. Die Quotienten ACT-PSA/tPSA und cPSA/tPSA können als Alternative zum fPSA/tPSA in Betracht gezogen werden.

  7. Prostate-Specific Antigen Nadir and Time to Prostate-Specific Antigen Nadir Following Maximal Androgen Blockade Independently Predict Prognosis in Patients with Metastatic Prostate Cancer

    OpenAIRE

    Hong, Seok Young; Cho, Dae Sung; Kim, Sun Il; Ahn, Hyun Soo; Kim, Se Joong

    2012-01-01

    Purpose To evaluate the influence of prostate-specific antigen (PSA) kinetics following maximal androgen blockade (MAB) on disease progression and cancer-specific survival in patients with metastatic, hormone-sensitive prostate cancer. Materials and Methods One hundred thirty-one patients with metastatic, hormone-sensitive prostate cancer treated with MAB at our institution were included in this study. Patients' characteristics, PSA at MAB initiation, PSA nadir, time to PSA nadir (TTN), and P...

  8. Determining Interactions in PSA models: Application to a Space PSA

    Energy Technology Data Exchange (ETDEWEB)

    C. Smith; E. Borgonovo

    2010-06-01

    This paper addresses use of an importance measure interaction study of a probabilistic risk analysis (PSA) performed for a hypothetical aerospace lunar mission. The PSA methods used in this study follow the general guidance provided in the NASA Probabilistic Risk Assessment Procedures Guide for NASA Managers and Practitioners. For the PSA portion, we used phased-based event tree and fault tree logic structures are used to model a lunar mission, including multiple phases (from launch to return to the Earth surface) and multiple critical systems. Details of the analysis results are not provided in this paper – instead specific basic events are denoted by number (e.g., the first event is 1, the second is 2, and so on). However, in the model, we used approximately 150 fault trees and over 800 basic events. Following analysis and truncation of cut sets, we were left with about 400 basic events to evaluate. We used this model to explore interactions between different basic events and systems. These sensitivity studies provide high-level insights into features of the PSA for the hypothetical lunar mission.

  9. fPSA、tPSA、 PAP、fPSA/tPSA值联合99m Tc-MDP骨扫描在前列腺癌诊断中的价值%The value of combination serum tumor marker measurement fPSA,tPSA, PAP, the ratio of fPSA/tPSA with 99mTC-MDP bone scanning in the patients with prostate cancer

    Institute of Scientific and Technical Information of China (English)

    王婵; 冯雪凤; 刘万红

    2013-01-01

    Objective: To study the value of combination"mTc- MDP bone scanning with serum tumor marker free prostate specific antigen (fPSA ) , total prostate specific antigen (tPSA) , prostatic acid phosphatase ( PAP) , the ratio of fPSA/tPSA measurement in the patients with prostate cancer. Methods: 99mTc-MDP whole-body bone scanning was performed in 175 patients with prostate cancer,the serum fPSA,tPSA and PAP were measured,and calculating the ratio of fPSA/tPSA. Results: In 175 patients with prostate cancer, the average value of fPSA,tPSA and PAP were significantly higher than the control group (P 50 ng·ml-1 ,it was 58. 97%. Conclusion; Combining fPSA,tPSA,PAP and fPSA/tPSA <0. 20 could increase the sensitivity of diagnosis prostate cancer. 99mTc-MDP whole-body bone scanning is considerable screening method in diagnosis osseous metastasis in the patients with prostate cancer, when tPSA increasing, the positive ratio of bone scanning in the patients with prostate cancer is higher and higher.%目的:研究肿瘤标记物fPSA、tPSA、PAP、fPSA/tPSA值联合99mTc-MDP骨扫描在前列腺癌中的诊断价值.方法:对175例初诊前列腺癌患者行99mTc-MDP骨扫描,检测fPSA、tPSA和PAP,并计算出fPSA/tPSA值.结果:在175例前列腺癌患者中,fPSA、tPSA、PAP均高于正常人,fPSA/tPSA值低于正常人,差异有统计学意义(P <0.01);fPSA、tPSA、PAP和fPSA/tPSA<0.20诊断前列腺癌的灵敏度分别为57.71%、69.14%、38.29%和66.29%,fPSA、tPSA和fPSA/tPSA<0.20三项联合检测灵敏性可达87.50%.99mTc-MDP骨扫描阳性病例占36.57% (64/175),阴性病例占63.43%(111/175).骨扫描阳生病例组的fPSA、tPSA和PAP均高于骨扫描阴性病例组(P<0.01).当tPSA< 10 ng·ml-1时,骨扫描阳性病例数占29.87%,当tPSA> 50 ng·ml-1,骨扫描阳性病例数高达58.97%.结论:fPSA、tPSA、PAP和fPSA/tPSA<0.20联合检测可提高诊断前列腺癌的灵敏性.99mTc-MDP核素骨扫描可作为前列腺癌骨

  10. The role of PSA in safety management

    International Nuclear Information System (INIS)

    The presentation discusses the following issues: defence in depth principle (the role of the barriers, how does PSA represents the barriers?); the safety management and nuclear power plants; the probabilistic and deterministic approaches; the PSA applications and safety management

  11. FATORES DEMOGRÁFICOS ASSOCIADOS À REALIZAÇÃO DO ANTÍGENO PROSTÁTICO ESPECÍFICO (PSA EM MUNICÍPIO SUL BRASILEIRO

    Directory of Open Access Journals (Sweden)

    Willian Augusto Melo

    2012-12-01

    Full Text Available The Prostate Specific Antigen (PSA is considered the most important marker to detect, monitor and internship prostate cancer. This study aimed to characterize the men who were examined for measurement of PSA in 2009 in a basic health unit of Maringá-PR. Were collected information about age, race, PSA test result and place of residence. The independent variable was PSA values (normal or abnormal. Were used descriptive statistics of the variables through the frequencies and bivariate analysis by Fisher's Exact Test. Was reached that 53.5% of men who underwent PSA testing were younger than 60 years, where these, 1.2% had their PSA level abnormal or above 4.01 Ng-mL. Being over 70 years was statistically significant PSA changes. It is concluded that age is a triggering factor for benign and malignant prostatic abnormalities.

  12. Sequential versus staggered testing towards dynamic PSA

    International Nuclear Information System (INIS)

    One of aspects of progression from off-line time independent Probabilistic Safety Assessment (PSA) towards on-line time dependent PSA or dynamic PSA, which is needed step leading to the Living PSA, is shown in the paper. It is the comparison of both testing strategies applied to the redundant components or systems. They are sequential and staggered testing strategies using subsystem mean unavailabilities which are the roots for the mean values, are shown and compared for the both cases. (author)

  13. Development of a PSA information management system

    International Nuclear Information System (INIS)

    In general, Probabilistic Safety Agreement (PSA) is a very complicated work that uses and generates a lot of resources such as reports, procedures, drawings, assumptions, calculation sheets, PSA model, and so on. In many PSAs, however, the data, materials and knowledge considered and generated during performing PSA are scattered in many documents so that overall structure of PSA and information relationship between documents and models cannot easily be understood. To organize and manage all documents related to PSA, to capture knowledge of analysts, and finally to improve the quality of PSA, a PSA information management system (PIMS) was developed. The PIMS can manage all the documents of a PSA in a database and connect the causal relation between one information to another in the scattered documents via link. The PIMS can manage all the assumptions and technical basis used in PSA, and it can keep the record of the design changes the revision of PSA model. It can also control the review results of PSA models. The link of the PIMS can explicitly describe and reveal the expertise of the PSA analysts, and it enables the users to capture the knowledge and to understand the structure and contents of a PSA with ease. We are planning to apply the PIMS to the PSA of Shin Kori Units 1 and 2 as feasibility study and then to all the PSAs of the nuclear power plants in Korea. The PIMS is expected to contribute to enhancing the quality and confidence of PSA and reducing the efforts and costs of maintenance and update of PSA. (authors)

  14. Development of a PSA information management system

    Energy Technology Data Exchange (ETDEWEB)

    Ho, Seok; Dong Kyu, Kim; Sun Koo, Kang [Korea Power Engineering Company, Inc (Korea, Republic of)

    2007-07-01

    In general, Probabilistic Safety Agreement (PSA) is a very complicated work that uses and generates a lot of resources such as reports, procedures, drawings, assumptions, calculation sheets, PSA model, and so on. In many PSAs, however, the data, materials and knowledge considered and generated during performing PSA are scattered in many documents so that overall structure of PSA and information relationship between documents and models cannot easily be understood. To organize and manage all documents related to PSA, to capture knowledge of analysts, and finally to improve the quality of PSA, a PSA information management system (PIMS) was developed. The PIMS can manage all the documents of a PSA in a database and connect the causal relation between one information to another in the scattered documents via link. The PIMS can manage all the assumptions and technical basis used in PSA, and it can keep the record of the design changes the revision of PSA model. It can also control the review results of PSA models. The link of the PIMS can explicitly describe and reveal the expertise of the PSA analysts, and it enables the users to capture the knowledge and to understand the structure and contents of a PSA with ease. We are planning to apply the PIMS to the PSA of Shin Kori Units 1 and 2 as feasibility study and then to all the PSAs of the nuclear power plants in Korea. The PIMS is expected to contribute to enhancing the quality and confidence of PSA and reducing the efforts and costs of maintenance and update of PSA. (authors)

  15. World AIDS Day PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2011-11-16

    December 1 is World AIDS Day. In this PSA, communities are encouraged to get tested for HIV.  Created: 11/16/2011 by National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP).   Date Released: 11/16/2011.

  16. Hepatitis Awareness Month PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2011-05-11

    May is National Hepatitis Awareness Month. This 30 second PSA discusses hepatitis and encourages listners to talk to their health care professional about getting tested.  Created: 5/11/2011 by National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention.   Date Released: 5/11/2011.

  17. Raccoon Roundworm Infection PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2012-08-27

    This 60 second PSA describes the signs and symptoms of and ways to prevent Baylisascaris infection, a parasitic roundworm infection that is spread through raccoon feces.  Created: 8/27/2012 by Centers for Disease Control and Prevention (CDC).   Date Released: 8/28/2012.

  18. Prostate-Specific Antigen Velocity Before and After Elimination of Factors That Can Confound the Prostate-Specific Antigen Level

    Energy Technology Data Exchange (ETDEWEB)

    Park, Jessica J., E-mail: park16@fas.harvard.edu [Department of Radiation Oncology, Brigham and Women' s Hospital and Dana-Farber Cancer Institute, Boston, MA (United States); Chen, Ming-Hui [Department of Statistics, University of Connecticut, Storrs, CT (United States); Loffredo, Marian; D' Amico, Anthony V. [Department of Radiation Oncology, Brigham and Women' s Hospital and Dana-Farber Cancer Institute, Boston, MA (United States)

    2012-03-01

    Purpose: Prostate-specific antigen (PSA) velocity, like PSA level, can be confounded. In this study, we estimated the impact that confounding factors could have on correctly identifying a patient with a PSA velocity >2 ng/ml/y. Methods and Materials: Between 2006 and 2010, a total of 50 men with newly diagnosed PC comprised the study cohort. We calculated and compared the false-positive and false-negative PSA velocity >2 ng/ml/y rates for all men and those with low-risk disease using two approaches to calculate PSA velocity. First, we used PSA values obtained within 18 months of diagnosis; second, we used values within 18 months of diagnosis, substituting the prebiopsy PSA for a repeat, nonconfounded PSA that was obtained using the same assay and without confounders. Results: Using PSA levels pre-biopsy, 46% of all men had a PSA velocity >2 ng/ml/y; whereas this value declined to 32% when substituting the last prebiopsy PSA for a repeat, nonconfounded PSA using the same assay and without confounders. The false-positive rate for PSA velocity >2 ng/ml/y was 43% as compared with a false-negative rate of PSA velocity >2 ng/ml/y of 11% (p = 0.0008) in the overall cohort. These respective values in the low-risk subgroup were 60% and 16.7% (p = 0.09). Conclusion: This study provides evidence to explain the discordance in cancer-specific outcomes among groups investigating the prognostic significance of PSA velocity >2 ng/ml/y, and highlights the importance of patient education on potential confounders of the PSA test before obtaining PSA levels.

  19. The PSA: Planetary Science Archive

    Science.gov (United States)

    Barthelemy, M.; Martinez, S.; Heather, D.; Vazquez, J. L.; Arviset, C.; Osuna, P.; PSA development Team

    2012-04-01

    Scientific and engineering data from ESA's planetary missions are made accessible to the world-wide scientific community via the Planetary Science Archive (PSA). The PSA consists of online services incorporating search, preview, download, notification and delivery basket functionality. Besides data from the GIOTTO spacecraft and several ground-based cometary observations, the PSA contains data from the Mars Express, Venus Express, Rosetta, SMART-1 and Huygens missions. The focus of the PSA activities is on the long-term preservation of data and knowledge from ESA's planetary missions. Scientific users can access the data online using several interfaces: - The Advanced Search Interface allows complex parameter based queries, providing the end user with a facility to complete very specific searches on meta-data and geometrical parameters. By nature, this interface requires careful use and heavy interaction with the end-user to input and control the relevant search parameters. - The Map-based Interface is currently operational only for Mars Express HRCS and OMEGA data. This interface allows an end-user to specify a region-of-interest by dragging a box onto a base map of Mars. From this interface, it is possible to directly visualize query results. The Map-based and Advanced interfaces are linked and cross-compatible. If a user defines a region-of-interest in the Map-based interface, the results can be refined by entering more detailed search parameters in the Advanced interface. - The FTP Browser Interface is designed for more experienced users, and allows for direct browsing and access of the data set content through ftp-tree search. Each dataset contains documentation and calibration information in addition to the scientific or engineering data. All data are prepared by the corresponding instrument teams, mostly located in Europe. PSA supports the instrument teams in the full archiving process, from the definition of the data products, meta-data and product labels

  20. PKC Isoform Expression in Modeled Microgravity

    Science.gov (United States)

    Risin, Diana; Sundaresan, Alamelu; Pellis, Neal R.; Dawson, David L. (Technical Monitor)

    1999-01-01

    Our previous studies showed that modeled (MMG) and true (USA Space Shuttle Missions STS-54 and STS-56) microgravity (MG) inhibit human lymphocyte locomotion, Modeled MG also suppressed polyclonal and antigen-specific lymphocyte activation. Activation of PKC by phorbol myristate acetate (PMA) restored the microgravity-inhibited lymphocyte locomotion as well as activation by phytohaemagglutinin (PHA), whereas calcium ionophore (ionomycin) was unable to restore these functions. Based on these results we hypothesized that MG-induced changes in lymphocyte functions are caused by a fundamental defect in signal transduction mechanism. This defect may be localized either at the PKC level or upstream of PKC, most likely, at the cell membrane level. In this study we examined the expression of PKC isoforms alpha, epsilon and delta in PBMC cultured in rotating wall vessel bioreactor, developed at NASA JSC, which models microgravity by sustaining cells in continuous free fall. The assessment of the isoforms was performed by FACS analysis following cell permeabilization. A decrease in the expression of isoforms epsilon and delta, but not isoform a, was observed in PBMC cultured in microgravity conditions. These data suggest that MMG might selectively affect the expression of Ca2+ independent isoforms of PKC Molecular analysis confirm selective suppression of Ca2+ independent isoforms of PKC.

  1. PSA bounce after {sup 125}I-brachytherapy for prostate cancer as a favorable prognosticator

    Energy Technology Data Exchange (ETDEWEB)

    Engeler, Daniel S.; Schwab, Christoph; Schmid, Hans-Peter [Cantonal Hospital St. Gallen, Department of Urology, St. Gallen (Switzerland); Thoeni, Armin F. [Lindenhofspital Berne, Department of Radiation Oncology, Berne (Switzerland); Hochreiter, Werner [Hirslanden Klinik Aarau, Department of Urology, Aarau (Switzerland); Prikler, Ladislav [Klinik Uroviva Buelach, Department of Urology, Buelach (Switzerland); Suter, Stefan [Cantonal Hospital Zug, Department of Urology, Zug (Switzerland); Stucki, Patrick [Cantonal Hospital Lucerne, Department of Urology, Lucerne (Switzerland); Schiefer, Johann; Plasswilm, Ludwig; Putora, Paul Martin [Cantonal Hospital St. Gallen, Department of Radiation Oncology, St. Gallen (Switzerland)

    2015-10-15

    Permanent low-dose-rate brachytherapy (BT) with iodine 125 is an established curative treatment for localized prostate cancer. After treatment, prostate-specific antigen (PSA) kinetics may show a transient rise (PSA bounce). Our aim was to investigate the association of PSA bounce with biochemical control. Patients treated with BT in Switzerland were registered in a prospective database. Only patients with a follow-up of at least 2 years were included in our analysis. Clinical follow-up and PSA measurements were assessed after 1.5, 3, 6, and 12 months, and annually thereafter. If PSA increased, additional follow-up visits were scheduled. Cases of PSA bounce were defined as a rise of at least 0.2 ng/ml above the initial PSA nadir with a subsequent decline to or below the initial nadir without treatment. Biochemical failure was defined as a rise to nadir + 2 ng/ml. Between March 2001 and November 2010, 713 patients with prostate cancer undergoing BT with at least 2 years of follow-up were registered. Median follow-up time was 41 months. Biochemical failure occurred in 28 patients (3.9 %). PSA bounce occurred in 173 (24.3 %) patients; only three (1.7 %) patients with PSA bounce developed biochemical failure, in contrast to 25 (4.6 %) patients without previous bounce (p < 0.05). The median time to bounce was 12 months, the median time to biochemical failure was 30 months. The median bounce increase was 0.78 ng/ml. Twenty-eight patients with bounce (16.5 %) had a transient PSA rise of + 2 ng/ml above the nadir. In most cases, an early increase in PSA after BT indicates PSA bounce and is associated with a lower risk of biochemical failure. (orig.) [German] Die permanente Low-dose-rate-Brachytherapie (BT) mit {sup 125}I ist ein etabliertes kuratives Verfahren bei lokalisiertem Prostatakarzinom. Posttherapeutisch koennen die PSA-Konzentrationen einen voruebergehenden Anstieg zeigen (Bounce-Phaenomen). Untersucht werden sollte ein moeglicher Zusammenhang mit der

  2. Chikungunya Virus Infection and Acute Elevation of Serum Prostate-Specific Antigen

    OpenAIRE

    William Derval Aiken; Anzinger, Joshua J.

    2015-01-01

    A man with prostate cancer on a regime of active surveillance had a laboratory-confirmed acute Chikungunya virus infection. The patient experienced a sudden increase in serum Prostate-Specific Antigen (PSA) during the acute illness that caused him anxiety and confounded interpretation of the PSA test. Six weeks after the onset of Chikungunya Fever symptoms, the elevated serum PSA returned to baseline. The association of Chikungunya Fever and elevated serum PSA may result in misinterpretation ...

  3. State of living PSA and further development

    International Nuclear Information System (INIS)

    In October 1985 OECD-Principal Working Group (PWG 5) - Risk Assessment has initiated the Task Force 7 'Use of PSA in Nuclear Power Plant Management' to explore and report on the principles, characteristics, requirements and status of PSA oriented safety management. During this study, it became apparent that the utilisation of PSA techniques in nuclear plant safety management requires the development of supporting programmes to ensure that PSA models are being updated to reflect plant changes, and to direct their use towards the evaluation and determination of plant changes. These requirements also influence the software and hardware characteristics necessary to support the programme. This overall process is known as Living PSA. In this context OECD-PWG 5 has arranged international workshops on Living PSA application to support this development, to facilitate exchange of international experience and to summarise the state-of-the-art of L-PSA methodology. These activities were accompanied by following Task Groups of OECD-PWG 5 and the work results were published in state-of-the-art reports. According to the increasing development of Living PSA in the international field and its capacity to support plant safety management in a broad sense, OECD PWG 5 continues its work in setting up the Task Group 96-1 'State of Living PSA and Further Development' to clarify specific aspects of Living PSA. This report summarises the state of Living PSA in the international field based on the four Living PSA Workshops from 1988 to 1994 (Chapter 2) and the state of Reliability Data Collection based on the results of Task Group 12 'Reliability Data Collection and Analysis to Support PSA' and the two Data-Workshops from 1995 and 1998 (Chapter 3). The specific items of further development of Living PSA application as mentioned above are treated in Chapter 4. Chapter 5 gives a summary of the current state of Living PSA as well as outlook and recommendations of further development

  4. Improvement of Prostate Cancer Diagnosis by Detecting PSA Glycosylation-Specific Changes

    Science.gov (United States)

    Llop, Esther; Ferrer-Batallé, Montserrat; Barrabés, Sílvia; Guerrero, Pedro Enrique; Ramírez, Manel; Saldova, Radka; Rudd, Pauline M.; Aleixandre, Rosa N.; Comet, Josep; de Llorens, Rafael; Peracaula, Rosa

    2016-01-01

    New markers based on PSA isoforms have recently been developed to improve prostate cancer (PCa) diagnosis. However, novel approaches are still required to differentiate aggressive from non-aggressive PCa to improve decision making for patients. PSA glycoforms have been shown to be differentially expressed in PCa. In particular, changes in the extent of core fucosylation and sialylation of PSA N-glycans in PCa patients compared to healthy controls or BPH patients have been reported. The objective of this study was to determine these specific glycan structures in serum PSA to analyze their potential value as markers for discriminating between BPH and PCa of different aggressiveness. In the present work, we have established two methodologies to analyze the core fucosylation and the sialic acid linkage of PSA N-glycans in serum samples from BPH (29) and PCa (44) patients with different degrees of aggressiveness. We detected a significant decrease in the core fucose and an increase in the α2,3-sialic acid percentage of PSA in high-risk PCa that differentiated BPH and low-risk PCa from high-risk PCa patients. In particular, a cut-off value of 0.86 of the PSA core fucose ratio, could distinguish high-risk PCa patients from BPH with 90% sensitivity and 95% specificity, with an AUC of 0.94. In the case of the α2,3-sialic acid percentage of PSA, the cut-off value of 30% discriminated between high-risk PCa and the group of BPH, low-, and intermediate-risk PCa with a sensitivity and specificity of 85.7% and 95.5%, respectively, with an AUC of 0.97. The latter marker exhibited high performance in differentiating between aggressive and non-aggressive PCa and has the potential for translational application in the clinic. PMID:27279911

  5. Improvement of Prostate Cancer Diagnosis by Detecting PSA Glycosylation-Specific Changes.

    Science.gov (United States)

    Llop, Esther; Ferrer-Batallé, Montserrat; Barrabés, Sílvia; Guerrero, Pedro Enrique; Ramírez, Manel; Saldova, Radka; Rudd, Pauline M; Aleixandre, Rosa N; Comet, Josep; de Llorens, Rafael; Peracaula, Rosa

    2016-01-01

    New markers based on PSA isoforms have recently been developed to improve prostate cancer (PCa) diagnosis. However, novel approaches are still required to differentiate aggressive from non-aggressive PCa to improve decision making for patients. PSA glycoforms have been shown to be differentially expressed in PCa. In particular, changes in the extent of core fucosylation and sialylation of PSA N-glycans in PCa patients compared to healthy controls or BPH patients have been reported. The objective of this study was to determine these specific glycan structures in serum PSA to analyze their potential value as markers for discriminating between BPH and PCa of different aggressiveness. In the present work, we have established two methodologies to analyze the core fucosylation and the sialic acid linkage of PSA N-glycans in serum samples from BPH (29) and PCa (44) patients with different degrees of aggressiveness. We detected a significant decrease in the core fucose and an increase in the α2,3-sialic acid percentage of PSA in high-risk PCa that differentiated BPH and low-risk PCa from high-risk PCa patients. In particular, a cut-off value of 0.86 of the PSA core fucose ratio, could distinguish high-risk PCa patients from BPH with 90% sensitivity and 95% specificity, with an AUC of 0.94. In the case of the α2,3-sialic acid percentage of PSA, the cut-off value of 30% discriminated between high-risk PCa and the group of BPH, low-, and intermediate-risk PCa with a sensitivity and specificity of 85.7% and 95.5%, respectively, with an AUC of 0.97. The latter marker exhibited high performance in differentiating between aggressive and non-aggressive PCa and has the potential for translational application in the clinic. PMID:27279911

  6. Predictors of mortality after prostate-specific antigen failure

    International Nuclear Information System (INIS)

    Purpose: We identified factors associated with the length of survival after prostate-specific antigen (PSA) failure. Methods and Materials: The study cohort comprised 81 of 206 men enrolled on a randomized trial evaluating external-beam radiation therapy (RT) with or without androgen suppression therapy (AST) and who experienced PSA failure. Salvage AST was administered at a PSA level of ∼10 ng/mL as per protocol. Cox regression was used to determine factors associated with length of survival after PSA failure. Results: A PSA DT (doubling time) 12, 6-12, or <6 months, respectively. Conclusions: Advanced age and a PSA DT <6 months at the time of PSA failure are associated with a significantly shorter survival

  7. Towards a credible PSA fit for applications

    International Nuclear Information System (INIS)

    Probabilistic Safety Assessment (PSA) is an effective tool to enhance plant safety, and to operate nuclear facilities in the most efficient manner. However, a PSA that is to be used as a day to day tool for decision making at NPPs has to reflect the actual design and operational features of the plant as accurate as possible and it must be of high quality. The first requirement can best be fulfilled with the Living PSA Concept, while the latter considerably depends on the Quality Assurance for the PSA project. The IAEA has made a considerable effort to support the development of technical capabilities for PSA in Member States and in writing technical oriented procedures for carrying out PSA. However, PSA reviews show that there are still some aspects, such as quality assurance, that need to be stressed further. With his background in mind, the IAEA has, during the last two years, been working on Living PSA and Quality Assurance for PSA. The draft TECDOCs prepared during these activities, ''Requirements for Living PSA'' and ''A framework for a Quality Assurance programme for PSA'' are summarized in this paper. (author)

  8. Prostate-Specific Antigen fluctuation: what does it mean in diagnosis of prostate cancer?

    Directory of Open Access Journals (Sweden)

    Jun Seok Kim

    2015-04-01

    Full Text Available Objective To investigate whether prostate-specific antigen (PSA fluctuation correlates with a prostate cancer and to assess whether PSA fluctuation could be used for diagnosis of prostate cancer. Materials and Methods Our study included 229 patients who were performed a prostate biopsy (non-cancer group, 177; prostate cancer group, 52. Enrolled patients were provided twice PSA tests within 6 months. PSA fluctuation (%/month was defined as a change rate of PSA per a month. Independent t test was used to compare between two groups. Receiver operator characteristic curve was used to assess the availability as a differential diagnostic tool and the correlation. Simple linear regression was performed to analyze a correlation between PSA fluctuation and other factors such as age, PSA, PSA density, and prostate volume. Results There were significant differences in PSA, PSA density, percentage of free PSA, and PSA fluctuation between two groups. PSA fluctuation was significantly greater in non-cancer group than prostate cancer group (19.95±23.34%/month vs 9.63±8.57%/month, P=0.004. The most optimal cut-off value of PSA fluctuation was defined as 8.48%/month (sensitivity, 61.6%; specificity, 59.6%; AUC, 0.633; P=0.004. In a simple linear regression model, only PSA level was significantly correlated with PSA fluctuation. Conclusion Patients with wide PSA fluctuations, although baseline PSA levels are high, might have a low risk of diagnosis with prostate cancer. Thus, serial PSA measurements could be an option in patients with an elevated PSA level.

  9. Programmable automation systems in PSA

    International Nuclear Information System (INIS)

    The Finnish safety authority (STUK) requires plant specific PSAs, and quantitative safety goals are set on different levels. The reliability analysis is more problematic when critical safety functions are realized by applying programmable automation systems. Conventional modeling techniques do not necessarily apply to the analysis of these systems, and the quantification seems to be impossible. However, it is important to analyze contribution of programmable automation systems to the plant safety and PSA is the only method with system analytical view over the safety. This report discusses the applicability of PSA methodology (fault tree analyses, failure modes and effects analyses) in the analysis of programmable automation systems. The problem of how to decompose programmable automation systems for reliability modeling purposes is discussed. In addition to the qualitative analysis and structural reliability modeling issues, the possibility to evaluate failure probabilities of programmable automation systems is considered. One solution to the quantification issue is the use of expert judgements, and the principles to apply expert judgements is discussed in the paper. A framework to apply expert judgements is outlined. Further, the impacts of subjective estimates on the interpretation of PSA results are discussed. (orig.) (13 refs.)

  10. PSA Velocity Does Not Improve Prostate Cancer Detection | Division of Cancer Prevention

    Science.gov (United States)

    A rapid increase in prostate-specific antigen (PSA) levels is not grounds for automatically recommending a prostate biopsy, according to a study published online February 24 in the Journal of the National Cancer Institute. |

  11. Infographic: Benefits and Harms of PSA Screening for Prostate Cancer | Division of Cancer Prevention

    Science.gov (United States)

    As more has been learned about the benefits and harms of prostate-specific antigen (PSA) screening, organizations have begun to recommend against routine screening. Screening is a personal decision that, according to most experts, a man should make in consultation with his doctor, after he has been informed in detail about the potential benefits and harms. |

  12. Qualification of calculation aids for PSA

    International Nuclear Information System (INIS)

    In Germany Probabilistic Safety Analysis (PSA) are part of the evaluation of a nuclear power plants safety. The German PSA guide stipulates that the used software must enable a PSA according to the state of the art. This software must be qualified to assure that its features, mathematic methods and its performance enable a PSA like this. In this research work specifications and requirements are developed, which allow the testing of software. A procedure was developed to qualify PSA software according to the PSA guide and the experiences of users of PSA. Setting up a procedure, a tool for a systematic and uniform examination was crated. Additionally the options, mathematic fundamentals and performance of PSA-programs were analyzed. According to this all programs that were analyzed are capable to sovle their original task, that is the calculation of the safety of high available system based on high available components. Against that the requirements of modern PSA, e.g. to handle less available functions, HRA and fire analyses, based on the use of modern software and the implementation of new developments in the field of PSA are not supported adequately by all programs. (orig.)

  13. Status of the PSA use in the Czech regulatory process

    International Nuclear Information System (INIS)

    A review of previous probabilistic safety assessment (PSA) activities initiated by regulatory body and preparation of the preliminary PSA study and final PSA study (released in January 1994) for the nuclear power plant Dukovany with WWER-440 type 213 reactor is described. A brief information about the NPP Temelin (with WWER-1000) PSA Study, shutdown and PSA risk monitor current activities for the NPP Dukovany, next PSA activities in 1994 and about planned PSA activities in future is attached. (author). 21 refs

  14. Incorporating Level-2 PSA Feature of CONPAS into AIMS-PSA Software

    International Nuclear Information System (INIS)

    CONPAS (CONtainment Performance Analysis System) utilizes a methodology to treat containment phenomena in detail like APET but in simple way. In mid 2000's, KAERI has developed very fast cut set generator FTREX and PC's OS (Operating system) has changed into Windows 95. Thus, KAERI has developed new Level-1 PSA software, called AIMS-PSA (Advanced Information Management System for PSA) to replace KIRAP. Recently, KAERI has been developing an integrated PSA platform, called OCEANS (On-line Consolidator and Evaluator of All mode risk for Nuclear System), for the risk assessment of all power modes and all hazards. CONPAS for Level-2 PSA was developed in 1990's using the Visual Basic 6.0 compiler which is not supported any more. It needs to be updated for the integrated PSA software framework. This paper describes a study to incorporate the features of CONPAS into AIMS-PSA. The basic idea is to follow the approach of CONPAS, but in the integrated way. Various approaches for Level-2 PSA have been used since WASH-1400. APET approach of NUREG-1150 study would be most comprehensive and complex methodology for containment event tree analysis. CONPAS is the Level-2 PSA software to utilize an approach to treat containment phenomena in detail like APET but in simple way. But, new Level-2 PSA software is required to develop more integrated PSA framework. A modified approach of CONPAS is developed and incorporated in AIMS-PSA software that can handle Level-1 and Level-2 PSA in the integrated way (from the viewpoint of event tree and fault tree). AIMS-PSA combines whole Level-2 PSA model to produce a One Top fault tree and to generate cut sets in the same way as Level-1 PSA. Quantification results of Level-2 PSA such as frequency for each STC can be calculated from the minimal cut sets

  15. Factors prompting PSA-testing of asymptomatic men in a country with no guidelines: a national survey of general practitioners.

    LENUS (Irish Health Repository)

    Drummond, Frances J

    2009-01-01

    BACKGROUND: Increased use of prostate specific antigen (PSA) has been associated with increased prostate cancer incidence. Ireland is estimated to have one of the highest prostate cancer incidences in Europe and has no national guidelines for prostate cancer screening. GPs have a pivotal role in influencing PSA testing, therefore, our aim was to describe GP testing practices and to identify factors influencing these. METHODS: A postal survey, including questions on clinical practice and experience, knowledge and demographics was distributed to all GPs (n = 3,683). The main outcomes were (i) PSA testing asymptomatic men and (ii) "inappropriate" PSA testing, defined as testing asymptomatic men aged < 50 or > 75 years. Factors associated with these outcomes were identified using logistic regression. RESULTS: 1,625 GPs responded (response rate corrected for eligibility = 53%). Most respondents (79%) would PSA test asymptomatic men. Of these, 34% and 51% would test asymptomatic men < 50 and > 75 years, respectively. In multivariate analyses, GPs were more likely to test asymptomatic men if they were >or= 50 years, in practice >or= 10 years, female or less knowledgeable about PSA efficacy. Male GPs who would have a PSA test themselves were > 8-times more likely to PSA test asymptomatic men than GPs who would not have a test. GPs who had an asymptomatic patient diagnosed with prostate cancer following PSA testing, were > 3-times more likely to test asymptomatic men. Practice-related factors positively associated with testing included: running \\'well man\\' clinics, performing occupational health checks and performing other tests routinely with PSA. Factors positively associated with \\'inappropriate\\' testing included; being male and willing to have a PSA test, having worked\\/trained in the UK and supporting annual PSA testing. 91% of respondents supported the development of national PSA testing guidelines. CONCLUSION: Our findings suggest that widespread PSA testing

  16. PSA, subjective probability and decision making

    International Nuclear Information System (INIS)

    PSA is the natural way to making decisions in face of uncertainty relative to potentially dangerous plants; subjective probability, subjective utility and Bayes statistics are the ideal tools for carrying out a PSA. This paper reports that in order to support this statement the various stages of the PSA procedure are examined in detail and step by step the superiority of Bayes techniques with respect to sampling theory machinery is proven

  17. Development and perspectives of PSA in Cuba

    International Nuclear Information System (INIS)

    During the last decade the GDA/PSA has carried out the pre-operational PSA task for the Juragua Nuclear Power Plant. Since 1991 the work has been accomplished in the frames of the IAEA Technical Assistance Project CUB/9/008. The paper describes the stages of this study, (concluding with the Final Report of the pre-operational Level 1 PSA Rev. O), its assumptions, limitations and the main results and concluding remarks

  18. Model engineering in a modular PSA

    International Nuclear Information System (INIS)

    For the purpose of PSA (Probabilistic Safety Analysis) for complex industrial systems, often PSA models in the form of fault and event trees are developed to model the risk of unwanted situations (hazards). While the recent decades, PSA models have gained high acceptance and have been developed massively. This lead to an increase in model sizes and complexity. Today, PSA models are often difficult to understand and maintain. This manuscript presents the concept of a modular PSA. A modular PSA tries to cope with the increased complexity by the techniques of modularization and instantiation. Modularization targets to treat a model by smaller pieces (the 'modules') to regain control over models. Instantiation aims to configure a generic model to different contexts. Both try to reduce model complexity. A modular PSA proposes new functionality to manage PSA models. Current model management is rather limited and not efficient. This manuscript shows new methods to manage the evolutions (versions) and deviations (variants) of PSA models in a modular PSA. The concepts of version and variant management are presented in this thesis. In this context, a model comparison and fusion of PSA models is precised. Model comparison provides important feedback to model engineers and model fusion kind of combines the work from different model engineers (concurrent model engineering). Apart from model management, methods to understand the content of PSA models are presented. The methods focus to highlight the dependencies between modules rather than their contents. Dependencies are automatically derived from a model structure. They express relations between model objects (for example a fault tree may have dependencies to basic events). To visualize those dependencies (for example in form of a model cartography) can constitute a crucial aid to model engineers for understanding complex interrelations in PSA models. Within the scope of this thesis, a software named 'Andromeda' has been

  19. Status and use of PSA in Sweden

    International Nuclear Information System (INIS)

    The performance and use of PSA:s in Sweden goes back about two decades. During all of this time, the field of PSA has been developing intensively, both internationally and within Sweden. The latest years have been characterised by an increased use of PSA models and results, and by major extensions of existing PSA models. The aim of this document is to describe PSA in Sweden with respect to development, scope and maturity, as well as to the contents of the analyses and the use of results. PSA activities will be described from the point of view of both the authorities and the utilities. The report gives an overview of the development within the area of PSA in Sweden both its history and current trends. The aim has been to include a reasonable amount of detail, both on the methods and results in PSA:s performed and on the numerous supporting research programs dealing with various aspects of PSA. 39 refs 39 refs

  20. Too Much Sodium PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2012-02-07

    This 60 second PSA is based on the February 2012 CDC Vital Signs report. Ninety percent of Americans age two and older eat too much sodium which can increase your risk for high blood pressure and often leads to heart disease and stroke, two leading causes of death in the US. Learn several small steps you can take to reduce the amount of sodium in your diet.  Created: 2/7/2012 by Centers for Disease Control and Prevention (CDC).   Date Released: 2/7/2012.

  1. Analysis of the Correlationship between Prostate Specific Antigen Related Variables and Risk Factor in Patients with Prostate Carcinoma

    OpenAIRE

    Daoyuan Wang; Tiejun Yang; Yongqiang Zou; Xinqiang Yang

    2015-01-01

    Aim: To investigate the correlation between the related variables of prostate-specific antigen (PSA) and risk factors in patients with prostate carcinoma. Methods: The clinical records of 187 cases with prostate carcinoma, diagnosed by biopsy, were retrospectively analyzed to assess the correlation of PSA density (PSAD), free PSA (FPSA), and FPSA/total PSA (TPSA) with risk factors in prostate carcinoma. Results: The results from "Spearman rank correlation analysis" and "rank sum test"...

  2. Arraying prostate specific antigen PSA and Fab anti-PSA using light assisted molecular immobilization technology

    DEFF Research Database (Denmark)

    Parracino, Antonietta; Neves Petersen, Teresa; Gennaro, Ane Kold Di;

    2010-01-01

    Continuous 295nm excitation of bovine apo-α-lactalbumin (apo-bLA) results in an increase of tryptophan fluorescence quantum yield and in a progressive red-shift in tryptophan fluorescence emission. Furthermore, 295nm excitation in apo-bLA leads to disulphide bridges breakage, leading to free thio...

  3. The PSA testing dilemma: GPs' reports of consultations with asymptomatic men: a qualitative study

    Directory of Open Access Journals (Sweden)

    Shine Brian

    2007-06-01

    Full Text Available Abstract Background The National Health Service Prostate Cancer Risk Management Programme (PCRMP has recommended that screening for prostate cancer is available for asymptomatic men, on the understanding that they have been provided with full and balanced information about the advantages and limitations of the prostate-specific antigen (PSA test. Guidance has been distributed to all GPs in England and Wales to assist in the provision of information to men. This study aimed to elicit GPs' accounts of their discussions with asymptomatic men who consult with concerns about prostate cancer in order to identify the degree to which the PCRMP guidance was reflected in these consultations. Methods Qualitative interview study. Semi-structured telephone interviews with 21 GPs from 18 GP practices in Oxfordshire. Results All GPs reported undertaking some discussion with asymptomatic men about the PSA test. They described focussing most of the discussion on the false-positive and false-negative rates of the test, and the risks associated with a prostate biopsy. They reported less discussion of the potential for diagnosing indolent cancers, the dilemmas regarding treatment options for localised prostate cancer and the potential benefits of testing. Considerable variation existed between GPs in their accounts of the degree of detail given, and GP's presentation of information appeared to be affected by their personal views of the PSA test. Conclusion The GPs in this study appear to recognise the importance of discussions regarding PSA testing; however, a full and balanced picture of the associated advantages and limitations does not seem to be consistently conveyed. Factors specific to PSA testing which appeared to have an impact on the GPs' discussions were the GP's personal opinions of the PSA test, and the need to counter men's primarily positive views of the benefits of PSA testing. Awareness of the impact of their views on the consultations may help GPs

  4. Diagnostic value of [-2]proPSA and PHI index (review of literature

    Directory of Open Access Journals (Sweden)

    A. V. Sidorenkov

    2014-12-01

    Full Text Available Measurement of blood prostate-specific antigen (PSA levels resulted in an increasing number of performed prostate biopsies and the lower age-adjusted PSA threshold led to a larger number of unnecessary prostate biopsies. Today prostate cancer (PC is identified in only 35% of the patients with a total PSA level of 4–10 ng/ml and PSA-negative PC occurs in 20–25%. Obviously, PSA as an independent marker has exhausted its diagnostic potentialities. The new PC markers presented in the literature indubitably deserve close attention and further investigation. The most promising markers also include [-2]proPSA and PHI index. According to the latest evidence available in the literature now, [-2]proPSA and PHI index are the best predictors of PC during both primary and secondary prostate biopsy. Some publications show it possible to use the PHI index in planning both primary and secondary prostate biopsies, by constructing risk normograms, in combination with other individual patient examination parameters, including those with the other latest biomarkers of PC. The use of [-2]proPSA and PHI index in everyday practice can assist in increasing the specificity of PC diagnosis and reducing the number of unnecessary prostate biopsies. The apparent importance of the diagnosis of PC at its early stages (including that using the PHI index made us investigate this topic. Despite a great number of printed papers dealing with this problem, their number continues to increase, but clear guides to make actions in this field are yet to be elaborated and a decision on each specific case is made individually.

  5. Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy.

    Science.gov (United States)

    Rountree, Ryan B; Mandl, Stefanie J; Nachtwey, James M; Dalpozzo, Katie; Do, Lisa; Lombardo, John R; Schoonmaker, Peter L; Brinkmann, Kay; Dirmeier, Ulrike; Laus, Reiner; Delcayre, Alain

    2011-08-01

    MVA-BN-PRO (BN ImmunoTherapeutics) is a candidate immunotherapy product for the treatment of prostate cancer. It encodes 2 tumor-associated antigens, prostate-specific antigen (PSA), and prostatic acid phosphatase (PAP), and is derived from the highly attenuated modified vaccinia Ankara (MVA) virus stock known as MVA-BN. Past work has shown that the immunogenicity of antigens can be improved by targeting their localization to exosomes, which are small, 50- to 100-nm diameter vesicles secreted by most cell types. Exosome targeting is achieved by fusing the antigen to the C1C2 domain of the lactadherin protein. To test whether exosome targeting would improve the immunogenicity of PSA and PAP, 2 additional versions of MVA-BN-PRO were produced, targeting either PSA (MVA-BN-PSA-C1C2) or PAP (MVA-BN-PAP-C1C2) to exosomes, while leaving the second transgene untargeted. Treatment of mice with MVA-BN-PAP-C1C2 led to a striking increase in the immune response against PAP. Anti-PAP antibody titers developed more rapidly and reached levels that were 10- to 100-fold higher than those for mice treated with MVA-BN-PRO. Furthermore, treatment with MVA-BN-PAP-C1C2 increased the frequency of PAP-specific T cells 5-fold compared with mice treated with MVA-BN-PRO. These improvements translated into a greater frequency of tumor rejection in a PAP-expressing solid tumor model. Likewise, treatment with MVA-BN-PSA-C1C2 increased the antigenicity of PSA compared with treatment with MVA-BN-PRO and resulted in a trend of improved antitumor efficacy in a PSA-expressing tumor model. These experiments confirm that targeting antigen localization to exosomes is a viable approach for improving the therapeutic potential of MVA-BN-PRO in humans. PMID:21670078

  6. PSA-based evaluation and rating of operational events

    International Nuclear Information System (INIS)

    The presentation discusses the PSA-based evaluation and rating of operational events, including the following: historical background, procedures for event evaluation using PSA, use of PSA for event rating, current activities

  7. Dosagem e correlação do antígeno prostático específico com as alterações histológicas dos anexos sexuais do hamster sírio Prostate specific antigen-psa dosage and correlation with syrian hamster sexual addiction histologic alterations

    Directory of Open Access Journals (Sweden)

    Dimas José Araújo Vidigal

    2005-06-01

    Full Text Available OBJETIVO: Verificar os níveis de PSA total no Hamster Sírio, Mesocricetus auratus, jovem e adulto e demonstrar possíveis correlações entre esses níveis com as alterações histológicas dos anexos sexuais: próstata, vesículas seminais e testículos. MÉTODO: Foram examinados dez (n=10 Hamsters jovens, com idade inferior a sete semanas de vida e vinte (n=20 Hamsters com idade superior a um ano. Fez-se a dosagem do PSA e estudo histológico dos anexos sexuais em ambos os grupos e procurou-se a correlação entre o PSA encontrado e as alterações histológicas. RESULTADOS: A média de idade para os animais jovens, (grupo controle, foi de 46,7 dias (Desvio-Padrão-DP=1,16. Nos animais adultos, (grupo experimental, a média de idade não foi determinada, embora todos apresentassem idade acima de um ano no momento da morte. A média do peso dos animais jovens quando foram mortos foi de 57kg e dos animais adultos 126,5g. O PSA foi dosado no plasma de todos os animais adultos e em sete dos animais jovens. Em três animais do grupo jovem o PSA não foi detectado. A média do PSA nos animais jovens foi de 0,252ng/mL (nanogramo por mililitro e nos animais adultos de 0,325ng/mL. Os animais jovens não apresentaram alterações histológicas nos anexos sexuais examinados. Entre os Hamsters adultos, quatorze (70% animais apresentaram alguma alteração nos anexos sexuais: dez (50% apresentaram Hiperplasia Benigna da Próstata (HBP; um (5% apresentou HBP, prostatite e inflamação das vesículas seminais; um (5% inflamação supurativa das vesículas seminais; um (5% apresentou infarto testicular e prostatite; um (5% apresentou inflamação das vesículas seminais, sem HBP e prostatite. Não se detectou relação estatística entre os níveis de PSA e a ocorrência de HBP, embora os portadores da hiperplasia prostática exibissem médias de PSA bastante superiores às apresentadas pelos não portadores de hiperplasia. Não foram também determinadas

  8. Decision criteria in PSA applications

    International Nuclear Information System (INIS)

    Along with the adoption of risk informed decision making principles, the need for formal probabilistic decision rule or criteria has been risen. However, there are many practical and theoretical problems in the application of probabilistic criteria. One has to think what is the proper way to apply probabilistic rules together with deterministic ones and how the criteria are weighted with respect to each other. In this report, we approach the above questions from the decision theoretic point of view. We give a short review of the most well known probabilistic criteria, and discuss examples of their use. We present a decision analytic framework for evaluating the criteria, and we analyse how the different criteria behave under incompleteness or uncertainty of the PSA model. As the conclusion of our analysis we give recommendations on the application of the criteria in different decision situations. (au)

  9. Decision criteria in PSA applications

    Energy Technology Data Exchange (ETDEWEB)

    Holmberg, J.E.; Pulkkinen, U.; Rosqvist, T.; Simola, K. [VTT Automation (Finland)

    2001-11-01

    Along with the adoption of risk informed decision making principles, the need for formal probabilistic decision rule or criteria has been risen. However, there are many practical and theoretical problems in the application of probabilistic criteria. One has to think what is the proper way to apply probabilistic rules together with deterministic ones and how the criteria are weighted with respect to each other. In this report, we approach the above questions from the decision theoretic point of view. We give a short review of the most well known probabilistic criteria, and discuss examples of their use. We present a decision analytic framework for evaluating the criteria, and we analyse how the different criteria behave under incompleteness or uncertainty of the PSA model. As the conclusion of our analysis we give recommendations on the application of the criteria in different decision situations. (au)

  10. Correlation Between MRS and Serum PSA in the Diagnosis of Local Recurrence After Radical Prostatectomy

    Directory of Open Access Journals (Sweden)

    M Ghafuri

    2012-08-01

    Full Text Available Background: Multifocality, multicentricity and extension beyond the prostate capsule are all characteristics of prostatic adenocarcinoma that may escape diagnosis by conventional CT scanning or MRI. This study was designed to assess the diagnostic value of magnetic resonance spectroscopy (MRS in prostatic carcinoma and its compatibility with prostatic specific antigen (PSA as the conventional method.Methods: In this cross-sectional study, we recruited 139 patients with previous radical prostatectomy referring to Radiology department of Hazrate-e-Rasul Hospital during the first half of 2011 for the evaluation of local recurrence. Traditionally, local recurrence is defined as serum PSA concentration >0.2 ng/dl. We used 1.5-tesla Siemens Avanto MRI unit with endorectal coil and measured creatine, choline and citrate levels before calculating choline-creatine/citrate ratio. Correlation between MRS findings with PSA concentration was evaluated in regards to the multiple levels of the previously mentioned ratio.Results: Local recurrence was found in 107 (77% patients based on PSA levels. The mean values for serum PSA levels and creatine-choline/citrate ratio were significantly different in patients with and without local recurrence. Creatine-choline/citrate ratios greater than 50, 100 and 150 (as different cut-off points of recurrence were respectively seen in 104, 102 and 97 patients and agreement ratio between MRS and PSA in these levels were 94.1%, 94.4% and 85.1%, respectively. Correlation coefficient between these two methods was 0.481.Conclusion: MRS is a valuable tool for evaluating recurrence inpatients with prostate cancer treated by radical prostatectomy and it is in good agreement with serum PSA levels.

  11. Isotope and Patient Age Predict for PSA Spikes After Permanent Prostate Brachytherapy

    International Nuclear Information System (INIS)

    Purpose: To evaluate prostate-specific antigen (PSA) spikes after permanent prostate brachytherapy in low-risk patients. Methods and Materials: The study population consisted of 164 prostate cancer patients who were part of a prospective randomized trial comparing 103Pd and 125I for low-risk disease. Of the 164 patients, 61 (37.2%) received short-course androgen deprivation therapy. The median follow-up was 5.4 years. On average, 11.1 post-treatment PSA measurements were obtained per patient. Biochemical disease-free survival was defined as a PSA level of ≤0.40 ng/mL after nadir. A PSA spike was defined as an increase of ≥0.2 ng/mL, followed by a durable decline to prespike levels. Multiple parameters were evaluated as predictors for a PSA spike. Results: Of the 164 patients, 44 (26.9%) developed a PSA spike. Of the 46 hormone-naive 125I patients and 57 hormone-naive 103Pd patients, 21 (45.7%) and 8 (14.0%) developed a PSA spike. In the hormone-naive patients, the mean time between implantation and the spike was 22.6 months and 18.7 months for 125I and 103Pd, respectively. In patients receiving neoadjuvant androgen deprivation therapy, the incidence of spikes was comparable between isotopes (125I 28.1% and 103Pd 20.7%). The incidence of spikes was substantially different in patients 125I and/or <65 years of age. Differences in isotope-related spikes are most pronounced in hormone-naive patients

  12. PSA as a tool for decision making

    International Nuclear Information System (INIS)

    The question on ''How safe is safe enough'' is being responded presently by deterministic criteria. Probabilistic criteria in support to more rational and less emotional decisions in regulatory and licensing issues, rationalization of resource allocation and research prioritization, among others, have a potential which is only marginally being explored. This paper discussed PSA limitations and proposes three areas for the use of PSA in decision making, namely: preventing accidents, mitigating accidents, and defining regulatory requirements. Current activities of the International Atomic Energy Agency in these areas are mentioned. PSA studies depict clearly the uncertainties and this is viewed as a positive aspect, which is unique to the use of probabilistic methods. (orig.)

  13. Overview of level 2 PSA and Overview of level 3 PSA

    International Nuclear Information System (INIS)

    The paper presents the PSA framework and an overview of PSA level 2 and 3. The PSA level 2 covers the extension of the PSA level 1, confinement event tree analysis, source term analysis and supporting tasks: structural analysis, equipment and survivability analysis. The Plant Damage States (PDS) are the starting point for the level 2 analysis. Example PDS parameters - containment status; RCS status secondary status; safety injection, containment spray and an example radiological source term table are given. The structural analysis shows that for WWER 440/213 the critical locations appear to be: bubbler tower corners, SG room wall/floor junction, hatches, mechanical and electric penetrations. For WWER 1000 critical locations are similar to PWR - liner tear near airlocks. The PSA level 3 processes are presented and examples for the results (early fatalities, latent cancer fatalities) are shown. The use of PSA in the emergency planning and the effectiveness of the emergency response actions are discussed

  14. Insights from level 1 PSA for Novovoronezh NPP (Unit 5) and PSA-based modifications

    International Nuclear Information System (INIS)

    In the framework of the SWISRUS Project, a level-1 PSA study for Unit 5 of Novovoronezh NPP for internal initiating events has been performed. A number of insights on plant vulnerabilities have been identified. The active participation of plant specialists in the project resulted in a positive plant response, leading to implementation, or planned implementation, of a number of modifications at the plant, based on the PSA results. The effectiveness of the measures taken by the plant, or that are planned to be implemented, are being assessed by the PSA methodology. The plant model is supposed to serve as a basis for a living PSA model for further use by the plant and the regulatory body. The plant senior managers aim to have a living PSA model of the plant as a supporting tool for PSA-based plant safety management and estimation of effectiveness of safety-related improvements to be implemented for Unit 5 of Novovoronezh NPP. (author)

  15. Issues reporting PSA in prostate cancer

    International Nuclear Information System (INIS)

    The National Cancer Institute Prostate; Lung; Colon; Ovarian Cancer Screening (PLCO) project is a multi-center trial developed to investigate the effectiveness of DRE and PSA testing in the early detection and outcome of patients with prostate cancer. Accordingly, the Prostate Cancer Intervention versus Observation Trial (PIVOT) has been launched and is a randomized trial comparing radical prostatectomy versus expectant management for ALCaP. PSA: Initially PSA was thought to be of little value for diagnosis because 20% of men undergoing radical prostatectomy have 'normal' PSA and patients with apparently only symptomatic BPH have 'elevated' levels as follows: 4-10 ng/ml (Tandem-R) - 20%, >10 ng/ml -3%. Yet, PSA has looked attractive as a diagnostic tool in many studies; for example, when PSA was used in a screening approach as the first test which then drove further evaluation (Catalona, Brawer). It was shown that the positive predictive value for PSA's between 4 and 10 is approximately 20% and > 10 approximately 55%. The value of serial PSA's (velocity) is unknown but is under intense study: one major issue is determination of what represents a significant rise (details to be presented). Studies have also revealed that a DRE and PSA are important for optimal results. About 18% of clinically detectable cancers are only DRE positive while about 25 - 30% are only PSA positive. When both a DRE and PSA are used together, very few clinically apparent cancers are missed (3-5%). Recent ROC curves suggest that 4 ng/ml is reasonable. Recently, PSA values for men without apparent cancer were stratified by age, and taking the 2SD, age specific reference values were generated as follows: age 40-49 (0-2.5 ng/ml), 50-59 (0-3.5), 60-69 (0-4.5), 70-70 (0-6.5). Finally, there is the issue about different PSA assays regarding the compatabilities/reliability of the upper limit of normal and serial values. Much of the confusion is because there is no international PSA standard and

  16. Relationship between PSA kinetics and [18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy

    International Nuclear Information System (INIS)

    The aim of the present study was to identify prostate-specific antigen (PSA) threshold levels, as well as PSA velocity, progression rate and doubling time in relation to the detectability and localization of recurrent lesions with [18F]fluorocholine (FC) PET/CT in patients after radical prostatectomy. The study group comprised 82 consecutive patients with biochemical relapse after radical prostatectomy. PSA levels measured at the time of imaging were correlated with the FC PET/CT detection rates in the entire group with PSA velocity (in 48 patients), with PSA doubling time (in 47 patients) and with PSA progression (in 29 patients). FC PET/CT detected recurrent lesions in 51 of the 82 patients (62%). The median PSA value was significantly higher in PET-positive than in PET-negative patients (4.3 ng/ml vs. 1.0 ng/ml; p < 0.01). The optimal PSA threshold from ROC analysis for the detection of recurrent prostate cancer lesions was 1.74 ng/ml (AUC 0.818, 82% sensitivity, 74% specificity). Significant differences between PET-positive and PET-negative patients were found for median PSA velocity (6.4 vs. 1.1 ng/ml per year; p < 0.01) and PSA progression (5.0 vs. 0.3 ng/ml per year, p < 0.01) with corresponding optimal thresholds of 1.27 ng/ml per year and 1.28 ng/ml per year, respectively. The PSA doubling time suggested a threshold of 3.2 months, but this just failed to reach statistical significance (p = 0.071). In a study cohort of patients with biochemical recurrence of prostate cancer after radical prostatectomy there emerged clear PSA thresholds for the presence of FC PET/CT-detectable lesions. (orig.)

  17. Extent of disease in recurrent prostate cancer determined by [{sup 68}Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score

    Energy Technology Data Exchange (ETDEWEB)

    Verburg, Frederik A.; Mottaghy, Felix M. [RWTH University Hospital Aachen, Department of Nuclear Medicine, Aachen (Germany); Maastricht University Medical Center, Department of Nuclear Medicine, Maastricht (Netherlands); Pfister, David; Heidenreich, Axel [RWTH University Hospital Aachen, Department of Urology, Aachen (Germany); Vogg, Andreas; Drude, Natascha I.; Behrendt, Florian F. [RWTH University Hospital Aachen, Department of Nuclear Medicine, Aachen (Germany); Voeoe, Stefan [Maastricht University Medical Center, Department of Nuclear Medicine, Maastricht (Netherlands)

    2016-03-15

    To examine the relationship between the extent of disease determined by [{sup 68}Ga]PSMA-HBED-CC-PET/CT and the important clinical measures prostate-specific antigen (PSA), PSA doubling time (PSAdt) and Gleason score. We retrospectively studied the first 155 patients with recurrent prostate cancer (PCA) referred to our university hospital for [{sup 68}Ga]PSMA-HBED-CC PET/CT. PET/CT was positive in 44 %, 79 % and 89 % of patients with PSA levels of ≤1, 1 - 2 and ≥2 ng/ml, respectively. Patients with high PSA levels showed higher rates of local prostate tumours (p < 0.001), and extrapelvic lymph node (p = 0.037) and bone metastases (p = 0.013). A shorter PSAdt was significantly associated with pelvic lymph node (p = 0.026), extrapelvic lymph node (p = 0.001), bone (p < 0.001) and visceral (p = 0.041) metastases. A high Gleason score was associated with more frequent pelvic lymph node metastases (p = 0.039). In multivariate analysis, both PSA and PSAdt were independent determinants of scan positivity and of extrapelvic lymph node metastases. PSAdt was the only independent marker of bone metastases (p = 0.001). Of 20 patients with a PSAdt <6 months and a PSA ≥2 ng/ml, 19 (95 %) had a positive scan and 12 (60 %) had M1a disease. Of 14 patients with PSA <1 ng/ml and PSAdt >6 months, only 5 (36 %) had a positive scan and 1 (7 %) had M1a disease. [{sup 68}Ga]PSMA-HBED-CC PET/CT will identify PCA lesions even in patients with very low PSA levels. Higher PSA levels and shorter PSAdt are independently associated with scan positivity and extrapelvic metastases, and can be used for patient selection for [{sup 68}Ga]PSMA-HBED-CC PET/CT. (orig.)

  18. Extent of disease in recurrent prostate cancer determined by [68Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score

    International Nuclear Information System (INIS)

    To examine the relationship between the extent of disease determined by [68Ga]PSMA-HBED-CC-PET/CT and the important clinical measures prostate-specific antigen (PSA), PSA doubling time (PSAdt) and Gleason score. We retrospectively studied the first 155 patients with recurrent prostate cancer (PCA) referred to our university hospital for [68Ga]PSMA-HBED-CC PET/CT. PET/CT was positive in 44 %, 79 % and 89 % of patients with PSA levels of ≤1, 1 - 2 and ≥2 ng/ml, respectively. Patients with high PSA levels showed higher rates of local prostate tumours (p < 0.001), and extrapelvic lymph node (p = 0.037) and bone metastases (p = 0.013). A shorter PSAdt was significantly associated with pelvic lymph node (p = 0.026), extrapelvic lymph node (p = 0.001), bone (p < 0.001) and visceral (p = 0.041) metastases. A high Gleason score was associated with more frequent pelvic lymph node metastases (p = 0.039). In multivariate analysis, both PSA and PSAdt were independent determinants of scan positivity and of extrapelvic lymph node metastases. PSAdt was the only independent marker of bone metastases (p = 0.001). Of 20 patients with a PSAdt <6 months and a PSA ≥2 ng/ml, 19 (95 %) had a positive scan and 12 (60 %) had M1a disease. Of 14 patients with PSA <1 ng/ml and PSAdt >6 months, only 5 (36 %) had a positive scan and 1 (7 %) had M1a disease. [68Ga]PSMA-HBED-CC PET/CT will identify PCA lesions even in patients with very low PSA levels. Higher PSA levels and shorter PSAdt are independently associated with scan positivity and extrapelvic metastases, and can be used for patient selection for [68Ga]PSMA-HBED-CC PET/CT. (orig.)

  19. A preliminary investigation of PSA validation methods

    International Nuclear Information System (INIS)

    This document has been prepared to support the initial phase of the Atomic Energy Control Board's program to review and evaluate Probabilistic Safety Assessment (PSA) studies conducted by nuclear generating station designers and licensees. The document provides (1) a review of current and prospective applications of PSA technology in the Canadian nuclear power industry; (2) an assessment of existing practices and techniques for the review or risk and hazard identification studies in the international nuclear power sector and other technological sectors; and (3) proposed analytical framework in which to develop systematic techniques for the scrutiny and evaluation of a PSA model. These frameworks are based on consideration of the mathematical structure of a PSA model and are intended to facilitate the development of methods to evaluate a model relative to intended end-uses. (author). 34 refs., 10 tabs., 3 figs

  20. Proceedings of the 10th Korea-Japan joint workshop on PSA. For Asian PSA network

    International Nuclear Information System (INIS)

    The tenth Korea-Japan Joint Workshop on Probabilistic Safety Assessment (PSA) was held in the Jeju island of Korea, on May 18-20, 2009 organized by Korea Atomic Energy Research Institute (KAERI). The purpose of the workshop was to provide a forum for presentation and discussions on experiences and technical achievements related to PSA, risk-informed and performance-based approach, and other relevant issues in both countries. Since the first Korea-Japan Joint Workshop on PSA started in 1992, the workshops have provided an important and timely opportunity for exchange and discussion of the relevant information to all PSA practitioners and users of risk information in the industry, research, academia and regulatory arena. This was the tenth anniversary of the Joint Workshop with the main theme of 'For Asian PSA Network' and participants included those from China, Taiwan and the United States of America besides Korea and Japan. Two keynote speeches were presented by the former chairmen of this workshop, Prof. Chang-Sun Kang of Seoul National University and Prof. emeritus Shunsuke Kondo of Tokyo University. We had two special lectures, 70 papers presented by experts at 10 technical sessions related PSA, the special session on the status of PSA in Korea, Japan, China and Taiwan and panel discussion on their cooperation in PSA. This report provides the summary of each session, and all the presentation materials presented in the 10th Korea-Japan Joint Workshop on PSA. (author)

  1. IAEA work with guides for PSA quality

    International Nuclear Information System (INIS)

    IAEA has a project on development of a TECDOC 'PSA Quality for Various Applications'. The project develops the guidance document in stages with intermediate meetings with exchange of ideas, thoughts and experience. Draft versions are being produced successively. The objective with the project is to use attributes to describe the quality of different elements of a PSA (Analysis of initiating events, accident progression, system, data, human reliability, etc) making the PSA suitable for application in various risk informed activities. Two of the meetings in this project took place in February 2004 and in July 2004. The February meeting discussed different aspects of PSA quality in relation to applications and a draft of the TECDOC was reviewed. The meeting made recommendations for preparation of a final document and set priorities for further work in the area. The July meeting elaborated the document further in a small working group and a new draft version was prepared. A final version is expected to be published during 2005. The project has come to the conclusion that it is a limited number of PSA element attributes that are specific for a certain application. Most of the attributes concern plant specificity, realism and level of detail in a general manner, how plant specific is the model, how realistic and how detailed? Many attributes have the characteristic that they are good to have, but not necessarily needed to do the job. This last statement is valid both for a baseline PSA and a PSA application. The IAEA project has identified a limited number of attributes that are necessary to describe characteristics needed for specific applications. The PSA scope needed for a specific application is not covered by the project/document, even though it is obvious that different applications will need different scope or approaches to handle scope limitations. The guidance on performing a PSA available today is old. It is a need to review these guides and update with regard

  2. External hazards in PSA program for VVER 440/213

    International Nuclear Information System (INIS)

    The basic PSA study for the Dukovany NPP was completed in 1995. Since then a Living PSA program has come into force. All the PSA related activities are undertaken under the umbrella called Living PSA. They include support of risk management, data collection and information transfer, maintenance and improvement of PSA models. To support regulatory decision making the full scope PSA is under development. External hazards identified are: earthquake initiators, aircraft crushes and extreme rainfalls. Seismic PSA is not scheduled for near future, but team is being build up and a test example of seismic event impact is being modelled for trial evaluation

  3. Fault tree analysis strategy for Living PSA

    International Nuclear Information System (INIS)

    One of the most concerned issues in probabilistic safety assessment (PSA) of nuclear power plants is how to make the procedure be quick and convenient, e.g. with the so-called Living PSA technique. A new programming strategy, i.e., the independent module ordering technique, has been presented to analyzed rapidly fault trees deriving from complicated nuclear power systems, which is also useful for real time analysis of reliability model modification of the fault trees

  4. Development of seismic PSA methodology at JAERI

    International Nuclear Information System (INIS)

    The Japan Atomic Energy Research Institute (JAERI) is developing a methodology for seismic probabilistic safety assessment (PSA) of nuclear power plants, aiming at providing a set of procedures, computer codes and data suitable for performing seismic PSA in Japan. In order to demonstrate the usefulness of JAERI's methodology and to obtain better understanding on the controlling factors of the results of seismic PSAs, a seismic PSA for a BWR is in progress. In the course of this PSA, various improvements were made on the methodology. In the area of the hazard analysis, the application of the current method to the model plant site is being carried out. In the area of response analysis, the response factor method was modified to consider the non-linear response effect of the building. As for the capacity evaluation of components, since capacity data for PSA in Japan are very scarce, capacities of selected components used in Japan were evaluated. In the systems analysis, the improvement of the SECOM2 code was made to perform importance analysis and sensitivity analysis for the effect of correlation of responses and correlation of capacities. This paper summarizes the recent progress of the seismic PSA research at JAERI with emphasis on the evaluation of component capacity and the methodology improvement of systems reliability analysis. (author)

  5. A method for determining a prostate-specific antigen cure after radiation therapy for clinically localized prostate cancer

    International Nuclear Information System (INIS)

    Purpose: A method that allows the determination of a prostate-specific antigen (PSA) cure after definitive management for prostate carcinoma with radiation therapy is presented and tested. Methods and Materials: The method involves a calculation of the patient's theoretical baseline PSA prior to the development of prostate cancer by using three serial rising PSA determinations obtained prior to the institution of therapy. The rate of rise of the PSA prior to therapy and the rate of decline of the PSA posttherapy are calculated, using an exponential model. Two criteria must be satisfied to define a PSA cure. First, the PSA nadir after treatment should be less than the calculated theoretical baseline PSA. Second, the rate of decline of PSA posttreatment should be greater than the rate of rise of the PSA prior to treatment. Results: Applying these two criteria to the patient data base (n 16) at a median follow-up of 19 months enabled the accurate prediction of 6 out of 6 (100%) of patients with documented PSA failure and 7 out of 10 (70%) of patients without PSA failure. Therefore, despite short follow-up, all six patients with PSA failure were predicted. Further follow-up is needed to ascertain if the seven patients predicted to be cured will remain PSA failure free and if the three patients currently without PSA failure in whom the model predicts failure, will subsequently fail. Conclusion: Therefore, using each patient's PSA history as the natural control may eliminate the error that is introduced with defining a PSA cure by using a single value for the PSA nadir at a specified time after radiation therapy

  6. Penile Metastases of Recurrent Prostatic Adenocarcinoma without PSA Level Increase: A Case Report

    OpenAIRE

    Antonio Pierro; Savino Cilla; Cinzia Digesù; Morganti, Alessio G

    2012-01-01

    We report a case of penile metastases from recurrent prostatic adenocarcinoma that was the first sign of a widespread metastatic disease in the absence of any increase in prostate-specific antigen (PSA) level. In April 2011, an 80-year-old man presented to our Radiotherapy Unit with multiple palpable hard nodules in the penis, dysuria, and moderate perineal pain, 7 years after he had received radiotherapy for prostate cancer. Nodules in the penis had appeared in February 2011. The ultrasound ...

  7. Prognostic Significance of PSA, Gleason Score, Bone Metastases in Patients with Metastatic Prostate Cancer Under Palliative Androgen Deprivation Treatment

    International Nuclear Information System (INIS)

    Objective: The aim of this study was to evaluate the prognostic significance of each of the following in the development and progression of hormonal refractory disease in patients with metastatic prostate cancer under hormonal palliative treatment: The initial serum level prostate specific antigen (PSA), the Gleason score (GS), the presence of bone metastases with or without visceral metastases, and the PSA decline. Patients and Methods: During the time period from January 2005 to December 2008, a total of 92 patients with newly diagnosed, histologically confirmed metastatic prostate cancer (MPC) were under palliative androgen deprivation therapy. The age range was 52 to 85 years with a mean age of 66.2±7.9 years. MPC was diagnosed histologically after transrectal ultrasonography guided biopsy. The Gleason score assessment was determined by low power microscopic examination. Metastases were confirmed by positive bone scintigraphy with 925 MBq 99mTc-MDP using a tomographic gamma camera, computerized axial tomography or magnetic resonance imagining. Measurements of PSA levels were conducted by the radioimmunoassay method. The influences of the following prognostic factors were evaluated: The initial serum level of prostate specific antigen (PSA), the Gleason score (GS), the presence of bone metastases with or without visceral metastases, and the PSA decline, on the time to disease progression. Results: The time to progression was significantly delayed in patients with initial PSA level £50 ng/ml (median: 32 months), Gleason Score £7 (median: 33 months), bone metastases only (median: 30 months) and PSA level normalization within 6 months (median: 30 months) compared to that of patients with initial PSA level >50 ng/ml (median: 24 months), Gleason Score >7 (median: 24 months), bone, distant lymph nodes and/or visceral metastases (median: 24 months), PSA level decline (median: 18 months) (p-values were 0.002, 6 sites bone metastases (median: 28 months) (p=0

  8. Danish General Practitioners' Use of Prostate-Specific Antigen in Opportunistic Screening for Prostate Cancer

    DEFF Research Database (Denmark)

    Jessen, Kasper; Søndergaard, Jens; Larsen, Pia Veldt;

    2013-01-01

    Background. The use of prostate-specific antigen test has markedly increased in Danish general practice in the last decade. Despite the national guidelines advice against PSA screening, opportunistic screening is supposed to be the primary reason for this increased number of PSA tests performed...

  9. Variation in general practice prostate-specific antigen testing and prostate cancer outcomes

    DEFF Research Database (Denmark)

    Hjertholm, Peter; Fenger-Grøn, Morten; Vestergaard, Mogens;

    2015-01-01

    Brugen af prostata-specifikt antigen (PSA) er mangedoblet i dansk almen praksis siden introduktionen i 1990’erne. Dansk Urologisk Selskab anbefaler brug af testen ved relevante symptomer og arvelig disposition, men ikke til screening. Alligevel varierer brugen af PSA-tests i almen praksis. Dette ...

  10. Prostataspecifikt antigen, sure fosfataser og rektaleksploration i diagnostik af cancer prostatae

    DEFF Research Database (Denmark)

    Andersen, B R; Knorr, U B; Brasso, K;

    1997-01-01

    Eleven hundred and seven patients referred for urological evaluation including measurement of serumprostate specific antigen (PSA) measurement are reviewed. Prostate cancer was diagnosed in 105 patients. PSA was found to be superior to prostatic acid phosphatase in the discrimination between pros...

  11. Purification of PSA from human semen

    International Nuclear Information System (INIS)

    Full text: 1. Human seminal plasma collected from many volunteers are pooled and passed through a column of phenyl sepharose equilibrated with 1.25 M ammonium sulphate. Elution is carried out with 1.25 M ammonium sulphate initially, to remove the bulk non-adsorbing proteins. Gradient elution of the absorbed proteins with 0.01 M Tris-HCl, 0.25 M NaCl, pH 7.0 buffer gives a sharp peak containing PSA. At each stage, PSA has to be identified by an independent method such as immunodiffusion or an immunoassay. 2. The absorbed protein peak containing PSA is then lyophilised, redissolved in Tris-HCl buffer and chromatographed in a Superdex-75 or Sephadex-75 column. The absorbed proteins elute out as multiple peaks and PSA is eluted as a sharp peak.At each stage, PSA has to be identified by an independent method such as immunodiffusion or an immunoassay. 3. Step 2 is repeated for better purity. 4. The PSA peak is lyophilised, dissolved in Tris-HCl buffer without NaCl and further purified on an ion exchange column (either anion or cation exchange columns such as DEAE Sephadex or CM-Sephadex or Mono Q). Gradient elution using Tris-HCl buffer without NaCl and Tris-HCl buffer with 0.25 M NaCl resulted in a sharp pure PSA peak (homogenous, sharp single band on SDS-PAGE). This procedure is based on that reported by Wang et al., Oncology, 39,1,1982

  12. Development of kits for serum PSA monitoring

    International Nuclear Information System (INIS)

    Solid phase two-site immunoradiometric assays were developed for total PSA and free PSA in human serum using the matched pairs of monoclonal antibodies for PSA, supplied by University of Alberta, Canada. In the case of total PSA, the capture MAb was immobilised on both magnetic particles as well as polypropylene tubes. The IRMAs developed using these were very similar and comparable in their performances. The optimised assays involved two-step incubations (0.5x0.5 h for magnetic particles and 2x2 h for coated tube) at ambient temperature, had the working range of 0 to 200 ng/mL PSA and sensitivity of 0.38 ng/mL (magnetic particles method) and 0.05 ng/mL (coated tubes method). The assay exhibited good inter and intra assay precision, recovery and accuracy. The patient sample values analysed by the in-house kits and CIS bio international kit show good correlation with correlation coefficient of r=0.9693 and CIS kit value = 0.80 x OAEP kit value + 0.8034 (n=83) for magnetic particle based method and r=0.9853, CIS kit value = 1.10 x OAEP kit value - 0.4795 (n=63) for coated tubes method. In the case of free-PSA, the assay was optimised using polypropylene tubes as the solid phase. The assay involved a single step overnight incubation at ambient temperature and exhibited good sensitivity (0.06 ng/mL), and precision (8.24-12.04% for inter assay and 4.41-7.73% for intraassay% C.V.). The developed f-PSA assay shows promising results, but needs further clinical assessment. (author)

  13. Perspectives of Living PSA in NPP Krsko

    International Nuclear Information System (INIS)

    Nuclear power plant Krsko has completed the Level 1/Level 2 Probabilistic Safety Analysis (PSA) for internal initiating events and is in the process of completing the same for the external initiators. The analysis completed up to now has provided a valuable insight into a plant risk profile. In NPP Krsko there is a plan to use the PSA model as a permanent tool for the risk based applications and incorporate it into a decision making process. In order to achieve this there is a need to permanently maintain the PSA model in a manner that it reflects both the plan configuration/design at a time point and the operational experience up to the time point. All the activities aimed toward keeping the PSA model up-to-dated in this sense are usually referred to as a Living PSA (LPSA) program. NPP Krsko is in the process of defining and proceduralizing a LPSA program that would be plant specific and based on known world practices. Further, in order to be suitable for risk based applications the PSA model must be flexible in a sense that modifications to the base case model may be done easily and requantifications performed quickly as to evaluate various conditions imposed by real or hypothetical situations. NPP Krsko PSA model has been based on licensing type software. The requirements specified above dictate the transfer of the overall model to an application oriented software of newer generation with larger capabilities. The transfer becomes a part of a mentioned ongoing effort aimed at establishing LPSA model and concept. The paper present this effort and the perspectives of LPSA concept and risk based applications in NPP Krsko. (author)

  14. DNA signals at isoform promoters.

    Science.gov (United States)

    Dai, Zhiming; Xiong, Yuanyan; Dai, Xianhua

    2016-01-01

    Transcriptional heterogeneity is extensive in the genome, and most genes express variable transcript isoforms. However, whether variable transcript isoforms of one gene are regulated by common promoter elements remain to be elucidated. Here, we investigated whether isoform promoters of one gene have separated DNA signals for transcription and translation initiation. We found that TATA box and nucleosome-disfavored DNA sequences are prevalent in distinct transcript isoform promoters of one gene. These DNA signals are conserved among species. Transcript isoform has a RNA-determined unstructured region around its start site. We found that these DNA/RNA features facilitate isoform transcription and translation. These results suggest a DNA-encoded mechanism by which transcript isoform is generated. PMID:27353836

  15. Evaluation of prostate cancer prevalence in Iranian male population with increased PSA level, a one center experience

    International Nuclear Information System (INIS)

    This study was conducted to evaluate the incidence of prostate cancer (PCa) in Iranian male patients with increased prostate-specific antigen (PSA), and normal or abnormal digital rectal examination (DRE) that underwent prostate biopsy. From March 2006 to April 2009, a total of 346 consecutive males suspected of having PCa due to increased PSA levels underwent transrectal ultrasonography (TRUS)-guided sextant biopsy of the prostate. The total PSA (tPSA), demographic data, incidence of PCa, benign prostate hyperplasia (BPH), and prostatitis were assessed. The patients were divided into two groups according to their PSA values (group A serum tPSA level, 4–10 ng/mL; group B serum tPSA level, 10.1–20.0 ng/mL). Of the 346 biopsied cases, 193 cases (56%) had PCa, 80 cases (23%) had BPH, and 73 cases (21%) had prostatitis. The mean PSA and the age of the carcinoma group were significantly higher than those of the benign group (P < 0.01). The biopsy results were grouped as PCa, BPH, and prostatitis. Incidence of PCa for group A and group B cases were 115 cases (51%), and 78 cases (65%), respectively. In the case of PCa, BPH, and prostatitis, the mean PSAs were 10.02 ng/mL, 8.76 ng/mL, and 8.41 ng/mL, respectively (P < 0.40). TRUS-guided prostate biopsy and interpretation by a skilled team is highly recommended for early detection of PCa or its ruling-out. It seems that a PSA cutoff value of 4 ng/mL may be applied to the Iranian population. Although the chance of PCa is high in the PSA levels of 4–10 ng/mL, the combination of some data, like age and prostate volume, can decrease the rate of unnecessary prostate biopsies. We recommend prostate biopsy when PSA and/or DRE is elevated in symptomatic patients with obstructive and/or irritative lower urinary tract symptoms (LUTS) such as dysuria, frequency, or nocturia. Due to the very high incidence of PCa in the patients with PSA greater than 10 ng/mL, TRUS-guided biopsy is indicated, whatever the findings on DRE and

  16. Imprinted gold 2D nanoarray for highly sensitive and convenient PSA detection via plasmon excited quantum dots.

    Science.gov (United States)

    Song, Hong Yan; Wong, Ten It; Sadovoy, Anton; Wu, Lin; Bai, Ping; Deng, Jie; Guo, Shifeng; Wang, Yi; Knoll, Wolfgang; Zhou, Xiaodong

    2015-01-01

    We designed and fabricated two new nanostructured biosensing chips, with which the sensitive detection of prostate specific antigen (PSA) as low as 100 pg ml(-1) can be achieved, by measuring the plasmon enhanced fluorescence through a conventional dark field microscope. The gold nanostructure arrays, one with gold nanopillars of 140 nm, the other with gold nanoholes of 140 nm, were fabricated via nanoimprinting onto glass substrate, as localized surface plasmon resonance (LSPR) generators to enhance the fluorescent emission of fluorophore, e.g. quantum dot (QD). A sandwich bioassay of capture anti-PSA antibody (cAb)/PSA/detection anti-PSA (dAb) labeled by QD-655 was established on the nanostructures, and the perfect LSPR excitation distance (10-15 nm) between the nanostructure and QD-655 was simulated and controlled by a cleft cAb fragment and streptavidin modified QD. QD was chosen in this study due to its photo stability, broad Stokes shift, and long lifetime. As far as we know, this is the first time that QD is applied for PSA detection on the uniform nanostructured sensing chips based on the LSPR enhanced fluorescence. Due to the miniaturized nanoarray sensing chip (1.8 mm × 1.8 mm), the convenience and specificity for the detection of PSA via the sandwich assay, and the high optical detection sensitivity, the platform has great potential for the development of a portable point-of-care (POC) system for outpatient diagnosis and treatment monitoring. PMID:25360665

  17. Performance of PSA and of PSA density in the diagnosis of prostate carcinoma

    Directory of Open Access Journals (Sweden)

    Antonio Carlos Pereira Martins

    2002-01-01

    Full Text Available OBJECTIVE: The aim of the study was to investigate the influence of the prostate volume and PSA density on the performance of total PSA to diagnosis of prostate carcinoma. METHODS: We analyzed 217 patients (PSA 0-10ng/ml submitted to transrectal sextant prostate biopsy. Criteria for biopsy indication was PSA >2ng/ml and/or digital rectal exam suspicious of prostate cancer. RESULTS: Fifty five patients had prostate neoplasia (25.3% and in 8/55 (25.3% the serum PSA was under 4ng/ml. The sensitivity and specificity of the test were respectively 98.2% / 16.6% at a cut-off point of 2.5ng/ml and 85.4% / 38.8% at cut-off of 4ng/ml. The corresponding values for prostates >40ml or <40ml were: 96.2% / 8.1% and 100% / 27.2% at the cut-off point of 2.5ng/ml, and 92.5% / 20% and 78.5% / 62.3% at a cut-off level of 4ng/ml. For prostates <40ml a PSA cut-off point of 4ng/ml leads to a misdiagnosis in 21.4% of the malignant tumors. The median PSAD of benign prostates are different according to prostate volume (.40ml or <40ml. PSAD at cut-off of 0.08 increases the PSA specificity at both PSA cut-off points. CONCLUSIONS: Prostate volume affects the sensitivity and specificity of PSA and the median values of PSAD. PSAD of 0.08 increases the PSA specificity specially at a cut-off point of 2.5ng/ml in prostates smaller than 40ml.

  18. A methodology for PSA model validation

    International Nuclear Information System (INIS)

    This document reports Phase 2 of work undertaken by Science Applications International Corporation (SAIC) in support of the Atomic Energy Control Board's Probabilistic Safety Assessment (PSA) review. A methodology is presented for the systematic review and evaluation of a PSA model. These methods are intended to support consideration of the following question: To within the scope and depth of modeling resolution of a PSA study, is the resultant model a complete and accurate representation of the subject plant? This question was identified as a key PSA validation issue in SAIC's Phase 1 project. The validation methods are based on a model transformation process devised to enhance the transparency of the modeling assumptions. Through conversion to a 'success-oriented' framework, a closer correspondence to plant design and operational specifications is achieved. This can both enhance the scrutability of the model by plant personnel, and provide an alternative perspective on the model that may assist in the identification of deficiencies. The model transformation process is defined and applied to fault trees documented in the Darlington Probabilistic Safety Evaluation. A tentative real-time process is outlined for implementation and documentation of a PSA review based on the proposed methods. (author). 11 refs., 9 tabs., 30 refs

  19. Dosagem e correlação do antígeno prostático específico com as alterações histológicas dos anexos sexuais do hamster sírio Prostate specific antigen-psa dosage and correlation with syrian hamster sexual addiction histologic alterations

    OpenAIRE

    Dimas José Araújo Vidigal; Alcino Lázaro da Silva; Luiz Mauro Andrade da Fonseca; Dilermando Fazito de Rezende

    2005-01-01

    OBJETIVO: Verificar os níveis de PSA total no Hamster Sírio, Mesocricetus auratus, jovem e adulto e demonstrar possíveis correlações entre esses níveis com as alterações histológicas dos anexos sexuais: próstata, vesículas seminais e testículos. MÉTODO: Foram examinados dez (n=10) Hamsters jovens, com idade inferior a sete semanas de vida e vinte (n=20) Hamsters com idade superior a um ano. Fez-se a dosagem do PSA e estudo histológico dos anexos sexuais em ambos os grupos e procurou-se a corr...

  20. The Serum Level of Prostate Specific Antigen in Polycystic Ovary Syndrome

    International Nuclear Information System (INIS)

    To determine whether serum prostate specific antigen (PSA) level are increased in polycystic ovary syndrome (PCOS), 40 patients with PCOS, and 50 healthy control subjects were enrolled in the study.The subjects were compared by means of serum PSA T SHBG DHEA-S levels. The correlations between PSA and T SHBG DHEA-S were evaluated.Serum PSA levels were found to be significantly higher in PCOS (PSA: 15.64±3.36 pg/mL, in PCOS; PSA: 3.56±0.44pg/mL, in control; P<0.01). Positive correlations between PSA and T (r=0.467, P<0.01) and between PSA and DHEA-S (r=, 0.205 P<0.05) were found. A negative correlation between PSA and SHBG was apparent (r=-0.260, P<0.05). Females with PCOS tended to have higher PSA than females without PCOS (P<0.01). PSA appears to be a promising marker of androgen excess in females suffering from PCOS. (authors)

  1. Analysis of results related to the percent free prostate specific antigen among men without prostate diseases in Xi'an area

    Institute of Scientific and Technical Information of China (English)

    Peng Zhang; Ziming Wang; Tie Chong; Lihua Zhao

    2007-01-01

    Objective: To measure the percent of free prostate specific antigen (fPSA) among men without prostate diseases in Xi'an area, and to study the relationship of percent fPSA with age and pathological grade, clinical stage of prostate cancer (PCa) with percent fPSA, and to analyze the difference between the data in China and theoverseas data to determine appropriate reference range for Chinese male. Methods: A total of 713 participants were enrolled into the study, with PSA, fPSA in serum measured and the percent fPSA calculated. Out of 713 cases, 679 without prostate diseases were divided into 5 groups by age, and then the relationships of PSA, fPSA and percent fPSA with age were studied, respectively. The relationship of pathological grade and clinical stage with percent fPSA of the 34 participants with PCa was also studied. With the help of the related data of men without prostate disease, the appropriate reference range for Chinese male was established. Results: The increases in PSA or fPSA were correlated with age, while there was no significant correlation between age and percent fPSA. The percent fPSA was also correlated with pathological grade and clinical stage of PCa. The percent fPSA of men without prostate disease in Xi'an area was significantly lower than that in the related overseas data. The reference range of percent fPSA for Chinese male was≥15%. Conclusion: Percent fPSA might be more useful than PSA in the detection of prostate cancer. As the percent fPSA is decreased, the pathological grade is decreased, and the clinical stage is increased, the malignant degree is increased. The reference range of≥15% is more appropriate for Chinese male.

  2. A randomised controlled trial of the effects of a web-based PSA decision aid, Prosdex. Protocol

    Directory of Open Access Journals (Sweden)

    Griffiths Jeff

    2007-10-01

    Full Text Available Abstract Background Informed decision making is the theoretical basis in the UK for men's decisions about Prostate Specific Antigen (PSA testing for prostate cancer testing. The aim of this study is to evaluate the effect of a web-based PSA decision-aid, Prosdex, on informed decision making in men. The objective is to assess the effect of Prosdex on six specific outcomes: (i knowledge of PSA and prostate cancer-related issues – the principal outcome of the study; (ii attitudes to testing; (iii decision conflict; (iv anxiety; (v intention to undergo PSA testing; (vi uptake of PSA testing. In addition, a mathematical simulation model of the effects of Prosdex will be developed. Methods A randomised controlled trial with four groups: two intervention groups, one viewing Prosdex and the other receiving a paper version of the site; two control groups, the second controlling for the potential Hawthorn effect of the questionnaire used with the first control group. Men between the ages of 50 and 75, who have not previously had a PSA test, will be recruited from General Practitioners (GPs in Wales, UK. The principal outcome, knowledge, and four other outcome measures – attitudes to testing, decision conflict, anxiety and intention to undergo testing – will be measured with an online questionnaire, used by men in three of the study groups. Six months later, PSA test uptake will be ascertained from GP records; the online questionnaire will then be repeated. These outcomes, and particularly PSA test uptake, will be used to develop a mathematical simulation model, specifically to consider the impact on health service resources. Trial registration Current Controlled Trial: ISRCTN48473735.

  3. Regulatory requirements on PSA level 2: Review, aspects and applications

    International Nuclear Information System (INIS)

    The general requirements concerning utility obligations, probabilistic safety criteria (CDF should not exceed 1.0E-4/reactor year and LERF should not exceed 1.0E-5/reactor year), documentation and results, living PSA requirements and major steps in level 2 PSA are presented. PSA developments in Slovakia, collection and assembly of information, plant damage states, containment performance and failure modes, severe accident progression analyses, containment failure modes and source terms as a part of performed level 2 PSA are discussed. The PSA applications in design and operation evaluation, support to plant upgrade and modifications are also described. At the end, the following conclusion is made: more extensive PSA application needs to foster the exchange of experience and communication between PSA specialists, non-PSA engineers, designers, and the regulatory body staff responsible for safety assessment, inspection and enforcement

  4. Assessment of Atorvastatin Effectiveness on Serum PSA Level in Hypercholesterolemic Males

    Directory of Open Access Journals (Sweden)

    Darya Khosropanah

    2011-12-01

    Full Text Available The previous large retrospective studies demonstrated that treatment with Statins reduces both the incidence of prostate cancer by 50% and serum Prostate Specific Antigen (PSA level up to 40%. However the main problem in those studies was the absence of control groups of men with hypercholesterolemia without Statin treatment. We performed a small prospective controlled clinical trial to assess the influence of the treatment with Atorvastatin on serum PSA in men with hypercholesterolemia referred to our educational and treatment center from October 2007 to March 2008. In this study, among the newly diagnosed males with hypercholesterolemia (LDL > 130 mg/dl, 40 patients with LDL more than 190 mg/dl were selected as a case group and were treated with Atorvastatin (20 mg/day. Among the same population and in the same period, another 40 patients with LDL between 130 and 190 mg/dl were selected as first control group and were treated only with low fat diet. Another 40 patients with normal serum cholesterol and without any treatment were selected as second control group. The lipid profile and serum PSA level of patients of all groups were tested at the first and third months after the therapy. After completion of data, the mean serum lipids and PSA level were measured in both visits and compared with each other by paired t-test. Also the mean PSA change in two visits between three groups was compared by ANOVA and Tukey HSD test. There was not any significant difference in mean baseline PSA between hypercholesterolemic and normocholesterolemic patients (P=0.547. In case group, mean PSA and LDL was reduced by 14.1% (P=0.0001 and 30% (P=0.0001 respectively by second visit. In first control group, mean PSA was not changed significantly (P=0.337, whereas mean LDL in this group was reduced by 9.6% (P= 0.0001. Similarly in the second control group mean PSA was not changed significantly (P=0.309 by second visit. In addition, mean change of PSA in case group

  5. Summary review of PSA topics in connection with Romanian regulatory body activities

    International Nuclear Information System (INIS)

    This presentation includes the Romanian regulatory body guide; PSA level 1 requirements; PSA level 1 project status; PSA level 2 support activities; Scenario for PSA activities; external and internal cooperation

  6. Power Plant with CO2 Capture based on PSA Cycle

    OpenAIRE

    Stene, Henrik Sørskår; Moen, Ole Marius

    2014-01-01

    Two coal-fired power plants with CO2 capture by Pressure Swing Adsorption (PSA) havebeen modeled and simulated. The two power plants considered were IntegratedGasification Combined Cycle (IGCC) and conventional Pulverized Coal Combustion (PCC). Amathematical model of the PSA process for each of the power plants was developed and thegoal was to evaluate the feasibility of PSA as a technology for decarbonisation. Theperformance with CO2 capture by PSA was compared to a reference plant without C...

  7. Screen for Life: Meryl Streep PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2013-05-16

    In this 30 second PSA, Academy Award®-winning actress Meryl Streep urges viewers to get screened for colorectal cancer.  Created: 5/16/2013 by Centers for Disease Control and Prevention (CDC).   Date Released: 5/16/2013.

  8. Screen for Life: Meryl Streep PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2013-05-16

    In this 60 second PSA, Academy Award®-winning actress Meryl Streep urges viewers to get screened for colorectal cancer.  Created: 5/16/2013 by Centers for Disease Control and Prevention (CDC).   Date Released: 5/16/2013.

  9. STD Awareness PSA - College 2 (:30)

    Centers for Disease Control (CDC) Podcasts

    2010-04-22

    This PSA, targeted to college-aged youth and young adults, encourages listeners to get tested for STDs.  Created: 4/22/2010 by Centers for Disease Control and Prevention (CDC).   Date Released: 4/22/2010.

  10. STD Awareness PSA - College 1 (:30)

    Centers for Disease Control (CDC) Podcasts

    2010-04-22

    This PSA, targeted to college-aged youth and young adults, encourages listeners to get tested for STDs.  Created: 4/22/2010 by Centers for Disease Control and Prevention (CDC).   Date Released: 4/22/2010.

  11. STD Awareness PSA - Male Announcer 2 (:30)

    Centers for Disease Control (CDC) Podcasts

    2010-04-22

    This PSA encourages listeners to get tested for STDs. Target - Men who have sex with other men.  Created: 4/22/2010 by Centers for Disease Control and Prevention (CDC).   Date Released: 4/22/2010.

  12. PSA procedure guide for MOX fuel fabrication facilities

    International Nuclear Information System (INIS)

    This document is a procedure guide developed by Japan Atomic Energy Agency for PSA (Probabilistic Safety Assessment) of MOX fuel Fabrication Facilities. The procedure guide consists of two parts. The first part describes the procedure of PSA. The second part shows the practical examples of PSA of a typical facility with information applicable to the practical assessment. (author)

  13. False positives observed on the Seratec® PSA SemiQuant Cassette Test with condom lubricants.

    Science.gov (United States)

    Bitner, Sara E

    2012-11-01

    In the course of the validation of a new component of the prostate-specific antigen (PSA) SemiQuant Cassette Test marketed by Seratec(®) , a false-positive reaction was observed when testing samples collected from the surface of unused, lubricated condoms. A variety of personal lubricants and condoms were tested to determine the frequency of the false positive, as well as its potential source. Samples were extracted in both water and the manufacturer-provided buffer, and the test was performed according to the manufacturer's suggested protocol. The false positive was observed intermittently, but occurred consistently with samples containing nonoxynol-9, a strong detergent utilized as a spermicide. The reaction may be attributable to the combination of latex and nonoxynol-9. Because of the unreliability of the test to confirm the presence of PSA in samples collected from condoms, the PSA cassette is an unsuitable method for confirming the presence of seminal fluid in condoms. PMID:22494324

  14. Performance indicators at Embalse NPP: PSA and safety system indicators based on PSA models

    International Nuclear Information System (INIS)

    Several indicators have been implemented at Embalse NPP. The objective was selecting some representative parameters to evaluate the performance of both the plant and the personnel activities, important for safety. A first set of indicators was defined in accordance with plant technical staff criteria. A complementary set of them was addressed later based on WANO guidance. This report presents the set of indicators used at Embalse NPP, centering the description to related to safety systems performance indicators (SSPI). Some considerations are done about the calculation methods, the need for aligning and updating their values following Embalse Probabilistic Safety Assessment (PSA) development, and some pros and cons of using the PSA model for getting systems indicators. Owing to the fact that PSA ownership by utilities is also a subject of the meeting, some characteristics of the organization of the PSA Project are described at the beginning of the report. At Embalse NPP a Level 1 PSA has been developed under the responsibility of its own plant and with an important contribution from the IAEA. PSA was developed at the site, conducting this to a study strongly interactive with the station staff. (author)

  15. Quantitative mathematical modeling of PSA dynamics of prostate cancer patients treated with intermittent androgen suppression

    Institute of Scientific and Technical Information of China (English)

    Yoshito Hirata; Koichiro Akakura; Celestia S.Higano; Nicholas Bruchovsky; Kazuyuki Aihara

    2012-01-01

    If a mathematical model is to be used in the diagnosis,treatment,or prognosis of a disease,it must describe the inherent quantitative dynamics of the state.An ideal candidate disease is prostate cancer owing to the fact that it is characterized by an excellent biomarker,prostate-specific antigen (PSA),and also by a predictable response to treatment in the form of androgen suppression therapy.Despite a high initial response rate,the cancer will often relapse to a state of androgen independence which no longer responds to manipulations of the hormonal environment.In this paper,we present relevant background information and a quantitative mathematical model that potentially can be used in the optimal management of patients to cope with biochemical relapse as indicated by a rising PSA.

  16. Predictive simulations and optimization of nanowire field-effect PSA sensors including screening

    KAUST Repository

    Baumgartner, Stefan

    2013-05-03

    We apply our self-consistent PDE model for the electrical response of field-effect sensors to the 3D simulation of nanowire PSA (prostate-specific antigen) sensors. The charge concentration in the biofunctionalized boundary layer at the semiconductor-electrolyte interface is calculated using the propka algorithm, and the screening of the biomolecules by the free ions in the liquid is modeled by a sensitivity factor. This comprehensive approach yields excellent agreement with experimental current-voltage characteristics without any fitting parameters. Having verified the numerical model in this manner, we study the sensitivity of nanowire PSA sensors by changing device parameters, making it possible to optimize the devices and revealing the attributes of the optimal field-effect sensor. © 2013 IOP Publishing Ltd.

  17. Prostate specific antigen testing policy worldwide varies greatly and seems not to be in accordance with guidelines : A systematic review

    NARCIS (Netherlands)

    Van der Meer, Saskia; Löwik, Sabine; Hirdes, Willem H.; Nijman, Rien M.; Van der Meer, Klaas; Hoekstra-Weebers, Josette E. H. M.; Blanker, Marco H.

    2012-01-01

    Background: Prostate specific antigen (PSA) testing is widely used, but guidelines on follow-up are unclear. Methods: We performed a systematic review of the literature to determine follow-up policy after PSA testing by general practitioners (GPs) and non-urologic hospitalists, the use of a cut-off

  18. Expression System Based on an MTIIa Promoter to Produce hPSA in Mammalian Cell Cultures.

    Science.gov (United States)

    Santos, Anderson K; Parreira, Ricardo C; Resende, Rodrigo R

    2016-01-01

    Because of the limitations of standard culture techniques, the development of new recombinant protein expression systems with biotechnological potential is a key challenge. Ideally, such systems should be able to effectively and accurately synthesize a protein of interest with intrinsic metabolic capacity. Here, we describe such a system that was designed based on a plasmid vector containing promoter elements derived from the metallothionein MTIIa promoter, as well as processing and purification elements. This promoter can be induced by heavy metals in a culture medium to induce the synthesis of human prostate-specific antigen (hPSA), which has been modified to insert elements for purification, proteolysis, and secretion. We optimized hPSA production in this system by comparing the effects and contributions of ZnCl2, CdCl2, and CuSO4 in HEK293FT, HeLa, BHK-21, and CHO-K1 cells. We also compared the effectiveness of three different transfection agents: multi-walled carbon nanotubes, Lipofectamine 2000, and X-tremeGENE HP Reagent. hPSA production was confirmed via the detection of enhanced green fluorescent protein fluorescence, and cell viability was determined. The expression of hPSA was compared with that of the native protein produced by LNCaP cells, using enzyme-linked immunosorbent assay and sodium dodecyl sulfate polyacrylamide gel electrophoresis. X-tremeGENE reagent, the BHK-21 cell line, and CuSO4 showed the highest hPSA production rates. Furthermore, BHK-21 cells were more resistant to the oxidative stress caused by 100 μM CuSO4. These results suggest that the proposed optimized inducible expression system can effectively produce recombinant proteins with desired characteristics for a wide range of applications in molecular biology. PMID:27582737

  19. Is extended biopsy protocol justified in all patients with PSA ≥ 20 ng/mL?

    Institute of Scientific and Technical Information of China (English)

    Xiaojun Deng; Jian Chu; Bo Yang; Feng Liu; Weifeng Wang; Jidong Hao; Jiansheng Wan; Hui Liu

    2014-01-01

    Objective: The aim of this study was to investigate whether it was necessary to increase the number of cores at initial prostate biopsy with patients of prostate-specific antigen (PSA) ≥ 20 ng/mL and to explore an appropriate individual-ized transrectal ultrasonograhpy (TRUS)-guided prostate biopsy for the detection of prostate cancer in men suspicious of prostate cancer.Methods:A total of 115 patients with PSA ≥ 20 ng/mL and suspicious of prostate cancer were prospectively randomized to perform TRUS-guided biopsy. Patients were randomized to a “6 + X” cores or a “10 + X” cores protocol. The primary end point was cancer detection rate. Secondary end points were cancer characteristics, rate of complications and the level of pain experienced by patients during TRUS-guided prostate biopsy.Results:Preoperative variables were similar in both groups. The overal prostate cancer detection rate was 73.9%. The “10 + X” cores strategy increased cancer detection rate only 9.7% in patients with PSA ≥ 20 ng/mL but < 50 ng/mL, while there was no diference between the two strategies for cancer detection in patients with PSA ≥ 50.1 ng/mL. The number of extended biopsy cores and pain score of extended biopsy in prostate cancer patients increased significantly (P < 0.001).Conclusion:Our findings suggest that there is no significant advantage in using extended biopsy protocol in al patients with PSA ≥ 20 ng/mL.

  20. PSA as a tool of RBMK upgrading efficiency analysis

    International Nuclear Information System (INIS)

    RBMK reactors being channel-type graphite moderated reactors required updating of ''PSA standard methodology''. RBMK PSA concept was developed when performing Ignalina NPP study which resulted in a full scope level 1 PSA. Findings of the study on the plant weaknesses allowed to compose a list of proposals which lead to core damage risk reduction from 2E-4 to 6E-5 1/year. For the Leningrad NPP a simplified method of PSA was used in order to evaluate existing safety improvement measures. Each measure was weighted in terms of risk to rank them according to their importance. However, the results should be specified by the full scope PSA

  1. Analysis of Serum Total and Free PSA Using Immunoaffinity Depletion Coupled to SRM: Correlation with Clinical Immunoassay Tests

    Energy Technology Data Exchange (ETDEWEB)

    Liu, Tao; Hossain, Mahmud; Schepmoes, Athena A.; Fillmore, Thomas L.; Sokoll, Lori J.; Kronewitter, Scott R.; Izmirlian, Grant; Shi, Tujin; Qian, Weijun; Leach, Robin; Thompson, Ian M.; Chan, Daniel W.; Smith, Richard D.; Kagan, Jacob; Srinivastava, Sudhir; Rodland, Karin D.; Camp, David G.

    2012-08-03

    Sandwich immunoassay is the standard technique used in clinical labs for quantifying protein biomarkers for disease detection, monitoring and therapeutic intervention. Albeit highly sensitive, the development of a specific immunoassay is rather time-consuming and associated with extremely high cost due to the requirement for paired immunoaffinity reagents of high specificity. Recently, mass spectrometry-based methods, specifically selected reaction monitoring mass spectrometry (SRM-MS), have been increasingly applied to measure low abundance biomarker candidates in tissue and biofluids, owing to high sensitivity and specificity, simplicity of assay configuration, and great multiplexing capability. In this study, we report for the first time the development of immunoaffinity depletion-based workflows and SRM-MS assays that enable sensitive and accurate quantification of total and free prostate-specific antigen (PSA) in serum without the requirement for specific PSA antibodies. With stable isotope dilution and external calibration, low ng/mL level detection of both total and free PSA was consistently achieved in both PSA-spiked female serum samples and actual patient serum samples. Moreover, comparison of the results obtained when SRM PSA assays and conventional immunoassays were applied to the same samples showed very good correlation (R2 values ranging from 0.90 to 0.99) in several independent clinical serum sample sets, including a set of 33 samples assayed in a blinded test. These results demonstrate that the workflows and SRM assays developed here provide an attractive alternative for reliably measuring total and free PSA in human blood. Furthermore, simultaneous measurement of free and total PSA and many other biomarkers can be performed in a single analysis using high-resolution liquid chromatographic separation coupled with SRM-MS.

  2. Development of Integrated PSA Database and Application Technology

    International Nuclear Information System (INIS)

    The high quality of PSA is essential for the risk informed regulation and applications. The main elements of PSA are the model, methodology, reliability data, and tools. The purpose of the project is to develop the reliability database for the Korean nuclear power plants and PSA analysis and management system. The reliability database system has been developed and the reliability data has been collected for 4 types of reliability data such as the reactor trip, the piping, the component and the common cause failure. The database provides the reliability data for PSAs and risk informed applications. The FTREX software is the fastest PSA quantification engine in the world. The license agreement between KAERI and EPRI is made to sell FTREX to the members of EPRI. The advanced PSA management system AIMS- PSA has been developed. The PSA model is stored in the database and solved by clicking one button. All the information necessary for the KSNP Level-1 and 2 PSA is stored in the PSA information database. It provides the PSA users a useful mean to review and analyze the PSA

  3. A Joint Report on PSA for New and Advanced Reactors

    International Nuclear Information System (INIS)

    This report addresses the application of Probabilistic Safety Assessment (PSA) to new and advanced nuclear reactors. As far as advanced reactors are concerned, the objectives were to characterize the ability of current PSA technology to address key questions regarding the development, acceptance and licensing of advanced reactor designs, to characterize the potential value of advanced PSA methods and tools for application to advanced reactors, and to develop recommendations for any needed developments regarding PSA for these reactors. As far as the design and commissioning of new nuclear power plants is concerned, the objectives were to identify and characterize current practices regarding the role of PSA, to identify key technical issues regarding PSA, lessons learned and issues requiring further work; to develop recommendations regarding the use of PSA, and to identify future international cooperative work on the identified issues. In order to reach these objectives, questionnaires had been sent to participating countries and organisations

  4. Development of PSA projects for Mochovce NPP Unit 1

    International Nuclear Information System (INIS)

    For the Mochovce NPP safety measurements project realisation, a list of totally 87 safety measures grouped according their purposes to reach recent international requirements on nuclear safety and reliability was elaborated. In this paper an overview of the Mochovce NPP safety measures is given and it is stressed on the measures related to the PSA (AA-08 - Shutdown and Low Power PSA (SPSA) and AA-10 - Full Power PSA Level 1). The scope of PSA level 1 and SPSA projects developed for Unit 1 are described and the main results are discussed. The Core Damage Frequency (CDF) calculation, contribution of the IEs to the shutdown CDF (total CDF=3.83E-06/year) and to the full power CDF (total CDF=1.66E-04/year) are shown. The developed PSA models can be adopted in the future for the following purposes: living PSA; real time risk monitoring; technical specifications and STIs optimization; level 2 PSA

  5. Luminescence energy transfer detection of PSA in red region based on Mn2+-enhanced NaYF4:Yb, Er upconversion nanorods.

    Science.gov (United States)

    Zhang, Jianguo; Wang, Shaozhen; Gao, Ni; Feng, Dexiang; Wang, Lun; Chen, Hongqi

    2015-10-15

    A new turn-on luminescence energy transfer (LET) system has been designed for the detection of prostate specific antigen (PSA, a cancer marker) that utilizes Mn(2+)-enhanced long wavelength luminescence NaYF4:Yb, Er upconversion nanorods as the donor and gold nanorods as the acceptor. The Mn(2+)-doped NaYF4:Yb,Er upconversion luminescence nanorods with an emission peak located in the red region were synthesized. The presence of Mn(2+) markedly increased the luminescence intensity over that of the NaYF4:Yb, Er upconversion nanomaterials (excited by a 980 nm continuous wavelength laser). The surfaces of Mn(2+)-doped NaYF4:Yb, Er upconversion nanorods were modified with poly(acrylic acid). Antibodies against prostate specific antigen were bound to the surface of the carboxyl-functionalized upconversion nanorods, which acted as the energy donor in this LET system. Gold nanorods with an absorption band at ~666 nm were synthesized by the seed growth method, acted as the energy acceptor. The emission band of the upconversion nanorods overlapped well with the absorption band of the gold nanorods. The luminescence was quenched because of the electrostatic interactions that shortened the distance between the donor (negatively charged) and the accepter (positively charged).When the PSA antigen was added into the system, the energy acceptor and the energy donors were separated because the binding affinity between PSA and anti-PSA was greater than the electrostatic interactions, and thereby the luminescence was recovered. The linear range of detecting PSA was from 0.1172 to 18.75 ng/mL (R=0.995), with a limit of detection for PSA as low as 0.1129 ng/mL. The method was successfully applied to the sensing of PSA in human serum samples. PMID:25996781

  6. Early detection of prostate cancer in Syria using T.PSA and F.PSA

    International Nuclear Information System (INIS)

    The aim of the current study is performing an initial prostate cancer screening test using PSA and F PSA tumour markers. A total of 3000 men in 40-75 years of age were participated in this study. Demographic and clinical data for subjects were collected by the programme staff. Total PSA and free PSA assays were determined using the ImunoTech total and free PSA assay kits, based on IRMA technique (kindly provided by the International Atomic Energy Agency). Criteria for participating in this study included : 1) men of age 50-75 (men of age as low as 40 were included in case of positive family history). 2) No previous history of prostate cancer. The following parameters were followed to refer the suspicious cases to a specialized hospital specific tests: 1)PSA>3 ng/ml . 2)High PSA value according to the participant age group. 3) Low F/TPSA ratio. In the hospital the following tests were performed:1) Complete clinical exam including DRE.2)TRUS in some cases.3) Biopsy for highly suspicious cases. 4)The low suspicious cases were retested in six months. Out of 338 cases referred to a specialized hospital, 264 cases were shown prostatic benign prostatic hyperplasia (BPH),while 36 cases proved to be prostatic cancer. However, the contact was lost in 36 cases because of changing the phone number or travelling outside the country . The detection rate of prostate cancer among all participating cases in this study was 1.2%, while this ratio was 10.7% among the referred cases. F/TPSA ratio has shown a good ability to discriminate between prostate cancer and benign prostatic hyperplasia. (author)

  7. Changes in antigenicity of porcine serum albumin in gamma-irradiated sausage extract by treatment with pepsin and trypsin

    Energy Technology Data Exchange (ETDEWEB)

    Kim, Koth-Bong-Woo-Ri; Song, Eu-Jin [Department of Food Science and Technology/Institute of Food Science, Pukyong National University, Busan 608-737 (Korea, Republic of); Lee, So-Young [Traditional Food Research Group, Korea Food Research Institute, Seongnam 463-746 (Korea, Republic of); Park, Jin-Gyu [Radiation Food Science and Biotechnology, Advanced Radiation Technology Institute, Korea Atomic Energy Research Institute, Jeongup 580-185 (Korea, Republic of); Lee, Ju-Woon [National Federation of Fisheries Cooperatives, Fisheries Economic Institute, Seoul 138-827 (Korea, Republic of); Byun, Myung-Woo [Department of Culinary Nutrition, Woosong University, Daejon 300-718 (Korea, Republic of); Ahn, Dong-Hyun, E-mail: dhahn@pknu.ac.kr [Department of Food Science and Technology/Institute of Food Science, Pukyong National University, Busan 608-737 (Korea, Republic of)

    2011-11-15

    Pork is known as an allergenic food with porcine serum albumin (PSA, 66 kDa) representing the major allergen. This study was conducted to investigate the change in antigenicity of PSA in gamma-irradiated sausage extract treated with pepsin and trypsin. Sausage products (A and B) were irradiated at 1, 3, 10, and 20 kGy. After irradiation, sausage proteins were extracted and digested with pepsin (1:200, 30 min) and trypsin (1:300, 5, 30, 60, 90, and 120 min). The binding ability of PSA in extracts of the irradiated sausages (A and B) decreased by over 3 kGy relative to the binding ability of PSA in extracts of intact sausages and showed no notable differences when the dose of radiation ranged from 3 to 20 kGy. After treatment with pepsin and trypsin, the binding ability of PSA in extracts of the irradiated sausages was decreased more relative to that of intact sausages and showed no significant differences when the period of trypsin treatment is increased or when the dose of irradiation is increased. The sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) results indicated that there was no visible change in the intensity of the PSA band in extracts of the irradiated sausages. After pepsin and trypsin treatment, the intensity of PSA band faded with increasing doses of irradiation. In conclusion, antigenicity of PSA in pork sausages could be reduced by gamma irradiation. - Highlights: > Change in antigenicity of PSA in irradiated sausage extract (ISE) was examined. > Binding ability of PSA in ISE was decreased compared to intact extract. > Binding ability of PSA in ISE after enzyme treatments was also further decreased. > Intensity of PSA band in ISE after enzyme treatments became weak.

  8. Changes in antigenicity of porcine serum albumin in gamma-irradiated sausage extract by treatment with pepsin and trypsin

    International Nuclear Information System (INIS)

    Pork is known as an allergenic food with porcine serum albumin (PSA, 66 kDa) representing the major allergen. This study was conducted to investigate the change in antigenicity of PSA in gamma-irradiated sausage extract treated with pepsin and trypsin. Sausage products (A and B) were irradiated at 1, 3, 10, and 20 kGy. After irradiation, sausage proteins were extracted and digested with pepsin (1:200, 30 min) and trypsin (1:300, 5, 30, 60, 90, and 120 min). The binding ability of PSA in extracts of the irradiated sausages (A and B) decreased by over 3 kGy relative to the binding ability of PSA in extracts of intact sausages and showed no notable differences when the dose of radiation ranged from 3 to 20 kGy. After treatment with pepsin and trypsin, the binding ability of PSA in extracts of the irradiated sausages was decreased more relative to that of intact sausages and showed no significant differences when the period of trypsin treatment is increased or when the dose of irradiation is increased. The sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) results indicated that there was no visible change in the intensity of the PSA band in extracts of the irradiated sausages. After pepsin and trypsin treatment, the intensity of PSA band faded with increasing doses of irradiation. In conclusion, antigenicity of PSA in pork sausages could be reduced by gamma irradiation. - Highlights: → Change in antigenicity of PSA in irradiated sausage extract (ISE) was examined. → Binding ability of PSA in ISE was decreased compared to intact extract. → Binding ability of PSA in ISE after enzyme treatments was also further decreased. → Intensity of PSA band in ISE after enzyme treatments became weak.

  9. Experience from the comparison of two PSA-studies

    International Nuclear Information System (INIS)

    Two probabilistic safety assessments (PSA) made for nearly identical reactors units (Forsmark 3 and Oskarshamn 3) have been compared. Two different analysis teams made the PSAs, and the analyses became quite different. The goal of the study is to identify, clarify and explain differences between PSA-studies. The purpose is to understand limitations and uncertainties in PSA, to explain reasons for differences between PSA-studies, and to give recommendations for comparison of PSA-studies and for improving the PSA-methodology. The reviews have been made by reading PSA-documentation, using the computer model and interviewing persons involved in the projects. The method and findings have been discussed within the project group. Both the PSA-project and various parts in the PSA-model have been reviewed. A major finding was that the two projects had different purpose and thus had different resources, scope and even methods in their study. The study shows that comparison of PSA results from different plants is normally not meaningful. It takes a very deep knowledge of the PSA studies to make a comparison of the results and usually one has to ensure that the compared studies have the same scope and are based on the same analysis methods. Harmonisation of the PSA-methodology is recommended in the presentation of results, presentation of methods, scope main limitation and assumption, and definitions for end states, initiating events and common cause failures. This would facilitate the comparison of the studies. Methods for validation of PSA for different application areas should be developed. The developed PSA review standards can be applied for a general validation of a study. The most important way to evaluate the real feasibility of PSA can take place only with practical applications. The PSA-documentation and models can be developed to facilitate the communication between PSA-experts and users. In any application consultation with the PSA-expert is however needed. Many

  10. Prostate-specific antigen bounce following stereotactic body radiation therapy for prostate cancer

    Directory of Open Access Journals (Sweden)

    Charles C. Vu

    2014-01-01

    Full Text Available Introduction: Prostate-specific antigen (PSA bounce after brachytherapy has been well-documented. This phenomenon has also been identified in patients undergoing stereotactic body radiation therapy (SBRT. While the parameters that predict PSA bounce have been extensively studied in prostate brachytherapy patients, this study is the first to analyze the clinical and pathologic predictors of PSA bounce in prostate SBRT patients. Materials and Methods: Our institution has maintained a prospective database of patients undergoing SBRT for prostate cancer since 2006. Our study population includes patients between May 2006 and November 2011 who have at least 18 months of follow-up. All patients were treated using the CyberKnife treatment system. The prescription dose was 3500-3625cGy in 5 fractions.Results: 120 patients were included in our study. Median PSA follow-up was 24 months (range 18-78 months. 34 (28% patients had a PSA bounce. The median time to PSA bounce was 9 months, and the median bounce size was 0.50ng/mL. On univariate analysis, only younger age (p = .011 was shown to be associated with an increased incidence of PSA bounce. Other patient factors, including race, prostate size, prior treatment by hormones, and family history of prostate cancer, did not predict PSA bounces. None of the tumor characteristics studied, including Gleason score, pre-treatment PSA, T-stage, or risk classification by NCCN guidelines, was associated with increased incidence of PSA bounces. Younger age was the only statistically significant predictor of PSA bounce on multivariate analysis (OR = 0.937, p = 0.009.Conclusion: PSA bounce, which has been reported after prostate brachytherapy, is also seen in a significant percentage of patients after CyberKnife SBRT. Close observation rather than biopsy can be considered for these patients. Younger age was the only factor that predicted PSA bounce.

  11. PSA Bounce and Biochemical Failure After Brachytherapy for Prostate Cancer: A Study of 820 Patients With a Minimum of 3 Years of Follow-Up

    International Nuclear Information System (INIS)

    Purpose: To determine clinical or dosimetric factors associated with a prostate-specific antigen (PSA) bounce, as well as an association between a PSA bounce and biochemical relapse-free survival (bRFS), in patients treated with iodine-125 brachytherapy. Methods and Materials: A variety of clinical and treatment factors were examined in 820 patients who had a minimum of 3 years of PSA follow-up with T1-T2cN0M0 prostate cancer. Four different PSA threshold values were used for defining a PSA bounce: a PSA rise of ≥0.2, ≥0.4, ≥0.6, and ≥0.8 ng/mL. Results: A PSA bounce of ≥0.2, ≥0.4, ≥0.6, and ≥0.8 ng/mL was noted in 247 patients (30.1%), 161 (19.6%), 105 (12.8%), and 78 (9.5%), respectively. The median time to the first PSA rise was 17.4, 16.25, 16.23, and 15.71 months, respectively, vs. 34.35 months for a biochemical failure (p < 0.0001). A PSA rise of ≥0.2 ng/mL was the only definition for which there was a significant difference in bRFS between bounce and non-bounce patients. The 5-year bRFS rate of patients having a PSA bounce of ≥0.2 was 97.7% vs. 91% for those who did not have a PSA bounce (p = 0.0011). On univariate analysis for biochemical failure, age, risk group, and PSAs per year had a statistically significant correlation with PSA bounce of ≥0.2 ng/mL. On multivariate analysis, age and PSAs per year remained statistically significant (p < 0.0001 and p = 0.0456, respectively). Conclusions: A bounce definition of a rise ≥0.2 ng/mL is a reliable definition among several other definitions. The time to first PSA rise is the most valuable factor for distinguishing between a bounce and biochemical failure.

  12. Diagnostische Wertigkeit von PSA und DVT

    OpenAIRE

    Wolff, Carolina Johanna

    2014-01-01

    Die radiologische Diagnostik, die auf einem abgestuftem Untersuchungsschema beruht, ist heute fester Bestandteil in der Zahnärztlichen Chirurgie. Die zur Basisuntersuchung gehörende Panorama-Schichtaufnahme liefert grundlegende Informationen durch Darstellung der Organ- und Funktionseinheit und stellt somit die radiologische Grundlage für viele diagnostische Fragen dar. Durch gewissenhafte Beurteilung stellt die PSA somit ein im Hinblick auf die Therapieentscheidung wichtiges, sondern auch in...

  13. Take Charge. Take the Test. PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2012-03-07

    As part of the Take Charge. Take the Test. campaign, this 30 second PSA encourages African American women to get tested for HIV. Locations for a free HIV test can be found by visiting hivtest.org/takecharge or calling 1-800-CDC-INFO (1-800-232-4636).  Created: 3/7/2012 by National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP).   Date Released: 3/7/2012.

  14. Definition of initiating events for PSA uses

    International Nuclear Information System (INIS)

    Initiating events (IEs) have been shown to be of great importance in the evaluation of core damage frequency (CDF) in PSAs. Inclusion of additional IEs for obtaining completeness or the updating of the frequency of IEs when new data become available have been found to greatly influence PSA CDF results. In spite of their importance, many different approaches are commonly used in the treatment of IEs in PSA. Therefore, some guidance on increasing uniformity and standardization is appropriate. Furthermore, the wide variety of IE data and the approaches used in published PSAs can be compared and presented for the benefit of PSA specialists. The IAEA, within the framework of its programme to develop guidelines for conducting PSAs, is producing a number of reports that provide such guidance. One of the important tasks that the reports encourage, as part of the PSA Level 1 study, is the selection, grouping and frequency evaluation of IEs. (The IAEA report on IEs will be published in 1992). The paper summarizes the results of a review of the definition of IEs in PSAs in the USA and Europe for LWRs. It provides a short historical background by considering various approaches that have been used in previous PSAs. It follows the IE data development over the last 15 years. It then provides a review of selection approaches in some recent PSAs. A discussion of completeness of the IE list is given and a table exemplifying several lists of IE groupings is included. The relative importance of some of the IE groups used in two PSAs is shown for BWRs and PWRs. The review also covers the treatment of IE frequencies. Various methodologies are listed and examples are given. Sources of data for the evaluation of IE frequencies are outlined. The paper emphasizes approaches that allow for the use of actual operating experience accumulated during plant specific studies and from LERs. It suggests that these approaches be used whenever sufficient plant specific data exist. (author). 24 refs, 4

  15. Communication Can Save Lives PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2015-08-04

    This 60 second public service announcement (PSA) is based on the August 2015 CDC Vital Signs report. Antibiotic-resistant germs cause at least 23,000 deaths each year. Learn how public health authorities and health care facilities can work together to save lives.  Created: 8/4/2015 by National Center for Emerging and Zoonotic Infectious Diseases (NCEZID).   Date Released: 8/4/2015.

  16. More Adults Are Walking PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2012-07-31

    This 60 second PSA is based on the August 2012 CDC Vital Signs report. While more adults are walking, only half get the recommended amount of physical activity. Listen to learn how communities, employers, and individuals may help increase walking.  Created: 7/31/2012 by Centers for Disease Control and Prevention (CDC).   Date Released: 8/7/2012.

  17. Stop C. difficile Infections PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2012-03-06

    This 60 second PSA is based on the March 2012 CDC Vital Signs report. C. difficile is a germ that causes diarrhea linked to 14,000 deaths in the US each year. This podcast helps health care professionals learn how to prevent C. difficile infections.  Created: 3/6/2012 by Centers for Disease Control and Prevention (CDC).   Date Released: 3/6/2012.

  18. Safer Food Saves Lives PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2015-11-03

    This 60 second PSA is based on the November 2015 CDC Vital Signs report. Contaminated food sent to several states can cause multistate outbreaks of foodborne illness and make a lot of people seriously ill. Learn what can be done to prevent and stop outbreaks.  Created: 11/3/2015 by National Center for Emerging and Zoonotic Infectious Diseases (NCEZID).   Date Released: 11/3/2015.

  19. Prioritization of design changes based on PSA

    International Nuclear Information System (INIS)

    Effective use of Probabilistic Safety Analyses (PSA) in the day to day plant operation is subject of intensive discussions among plant operators and regulators. There are several possible applications in which the PSA can be used, among those also to use the PSA approach for the quantification of influence of different proposed design changes to nuclear safety - influence on public safety - health. NPP Krsko is one of those plants that successfully completed its PSA project, with Level 1 and Level 2 analyses and effective know-how transfer. It also faces a number of regulatory and internally generated requirements for different design changes, mainly due to the fact that the plant is committed to continuous augmentation of nuclear safety. It is considered that the available tools and knowledge should be used and therefore applicable methodology should be developed for effective prioritization of proposed design changes by performing cost-benefit analyses for all major modifications - focusing on their influence on nuclear safety. Based on the above a new method for prioritization of design changes is proposed. The method uses Level 1 results (in the sense of plant damage states and their frequencies) directly as an input for further processing - first decision step to decide whether the proposed modification has or has no influence on nuclear safety. In Level 2 analyses the combination of probabilistic and deterministic approach was adopted. In fact the results of the deterministic analyses of severe accidents are treated in probabilistic manner due to large uncertainty of results. Finally to be able to perform plant specific cost benefit analyses so called partial Level 3 was defined. The proposed methods was preliminary tested and it gave favorable results. (author)

  20. Neoadjuvant hormone therapy and external-beam radiation for localized high-risk prostate cancer: The importance of PSA nadir before radiation

    International Nuclear Information System (INIS)

    Purpose To examine the impact of various patient, disease, and treatment characteristics on outcome in patients treated with neoadjuvant hormone therapy (NAHT) and external-beam radiation therapy (EBRT) for clinically localized, high-risk prostate adenocarcinoma (initial prostate-specific antigen [PSA] level >20, Gleason score 8-10 or Stage ≥ T3). Methods and Materials A retrospective chart review was conducted on 407 patients treated between 1991 and 2001 with NAHT and EBRT for high-risk prostate cancer. The effect of tumor (PSA level, Gleason score, and T stage) and treatment (NAHT duration, total-hormone duration, preradiation PSA) characteristics on rates of biochemical disease-free survival (bDFS), prostate cancer-specific survival, and overall survival were examined. Results Median follow-up time was 78 months (range: 5-140 months). Actuarial bDFS at 5 years was 52% (95% confidence interval [CI], 46% to 57%) for the entire group. On multivariate analysis, initial PSA level (p = 0.004), Gleason score (p = 0.005), and preradiation PSA level (p < 0.001) were predictive of bDFS, whereas age, T stage, duration of NAHT, and duration of total hormone therapy were not predictive of outcomes. Gleason score and preradiation PSA level were also predictive of prostate cancer-specific survival rates. Conclusion Improved bDFS in patients with high-risk prostate cancer was associated with lower initial PSA level, lower Gleason score, and lower preradiation PSA level. The duration of NAHT did not have an impact on outcomes, but the preradiation PSA was an important predictor of bDFS in high-risk patients

  1. Level 2 PSA applications. Focus on advanced containment systems

    International Nuclear Information System (INIS)

    Use of PSA Level 1 results for PSA application on system design, operation testing and maintenance is common practice, e.g. by living PSA and risk-informed decision making. New or modernized NPP include both core melt prevention and mitigating features which improve the performance of the plant to cope with severe accidents. PSA Level 1 is not well suited for PSA application on systems, structures and components designed to mitigate severe accident scenarios, as the impact on the core damage frequency (CDF) is usually negligible. Instead, the PSA applications on such systems need to be based on the impact on Level 2 PSA results. Most commonly the large early release frequency (LERF) is calculated as PSA Level 2 result. If PSA application on severe accident mitigation systems are based on LERF later and smaller releases might not be addressed correctly. In this presentation, the source term risk, which is calculated by multiplying the frequency of the release with the size of the release, is used as additional risk measure. Both the LERF and the source term risk are important measures and provide rationale for different types of systems. However, these measures can only be evaluated correctly if a best-estimate approach is used for Level 2 PSA. If possible conservatisms from Level 1 PSA are transferred to the Level 2 PSA, this may skew the result and misrepresent the impact of mitigating systems. This paper illustrates the possible uses of a Level 2 PSA results for PSA application and provides examples of systems in existing NPP for which the risk impact can only be evaluated based on Level 2 PSA results. Examples of such systems are: Passive hydrogen recombiners (PARs), Filtered containment venting, Containment isolation. Review of periodic testing strategy by risk informed periodic testing is an essential PSA application. The most important parameter is the test interval of components modeled in the Fault Tree modeling of the PSA. To be able to evaluate the

  2. Empiric antibiotics therapy for mildly elevated prostate specific antigen: Helpful to avoid unnecessary biopsies?

    Directory of Open Access Journals (Sweden)

    Andrea Fandella

    2014-09-01

    Full Text Available Purpose: The management of mildly elevated (4.0-10.0 ng/ml prostate specific antigen (PSA is uncertain. Immediate prostate biopsy, antibiotic treatment, or monitoring PSA level for 1-3 months is still in controversy. Materials and Methods: We retrospectively analysed the effect of empiric antibiotics on an increased PSA in a mono-institutional study. We analysed the data of 100 patients with a PSA of 4-10 ng/ml and normal digital rectal examination undergoing their first prostate biopsy. Patients were divided in two different cohorts. One cohort was submitted to antibiotic therapy (Levoxacin 500 mg daily for 20 days and both cohort had a re-dosing of PSA before the prostate biopsy. Results: Average age of the whole group of patients was 66.48 ± 8.32 years and their average initial PSA level was 6.67 ± 1.57 ng/mL. In the treated group (N = 49 29 patients had a decreasing PSA value from mean baseline PSA value of 6.6 ± 1.54 ng/ml to the re-dosed mean PSA level of 5.4 ± 1,61 ng/ml (p = 0.7; 20 patients didn’t experience a decrease PSA value, with a mean PSA level of 6.9 ± 1.68 ng/ml. In the control group (N = 51, 30 patients had a decrease of PSA level from mean baseline PSA level of 6.5 ± 1,59 ng/ml to a re-dosed PSA level of 5.5 ± 1.57 ng/ml; 21 patients didn’t experience a decrease of PSA value, with a mean PSA level of 6.7 ± 1.71 ng/ml. Multivariate analysis of age, PSA changes, antibiotics therapy and biopsy results (presence or absence of cancer revealed no significant difference between the two cohorts. Sepsis after biopsy occurred in 3 patient in the antibiotics group (6% and in one of the control group (2%. Conclusions: The study, even with some limitations, does not seem to show an advantage due to the administration of antibacterial therapy to reduce PSA values before prostate biopsy and subsequently to reduce unnecessary prostate biopsies.

  3. Enhanced immunogenicity of pneumococcal surface adhesin A (PsaA in mice via fusion to recombinant human B lymphocyte stimulator (BLyS

    Directory of Open Access Journals (Sweden)

    Mambula Salamatu S

    2011-02-01

    Full Text Available Abstract Background B lymphocyte stimulator (BLyS is a member of the tumor necrosis factor superfamily of ligands that mediates its action through three known receptors. BLyS has been shown to enhance the production of antibodies against heterologous antigens when present at elevated concentrations, supporting an immunostimulatory role for BLyS in vivo. Methods We constructed a fusion protein consisting of human BLyS and Pneumococcal Surface Adhesin A (PsaA and used this molecule to immunize mice. The immunostimulatory attributes mediated by BLyS in vivo were evaluated by characterizing immune responses directed against PsaA. Results The PsaA-BLyS fusion protein was able to act as a co-stimulant for murine spleen cell proliferation induced with F(ab'2 fragments of anti-IgM in vitro in a fashion similar to recombinant BLyS, and immunization of mice with the PsaA-BLyS fusion protein resulted in dramatically elevated serum antibodies specific for PsaA. Mice immunized with PsaA admixed with recombinant BLyS exhibited only modest elevations in PsaA-specific responses following two immunizations, while mice immunized twice with PsaA alone exhibited undetectable PsaA-specific serum antibody responses. Sera obtained from PsaA-BLyS immunized mice exhibited high titers of IgG1, IgG2a, IgG2b, and IgG3, but no IgA, while mice immunized with PsaA admixed with BLyS exhibited only elevated titers of IgG1 following two immunizations. Splenocytes from PsaA-BLyS immunized mice exhibited elevated levels of secretion of IL-2, IL-4 and IL-5, and a very modest but consistent elevation of IFN-γ following in vitro stimulation with PsaA. In contrast, mice immunized with either PsaA admixed with BLyS or PsaA alone exhibited modestly elevated to absent PsaA-specific recall responses for the same cytokines. Mice deficient for one of the three receptors for BLyS designated Transmembrane activator, calcium modulator, and cyclophilin ligand [CAML] interactor (TACI exhibited

  4. Identification of a Novel Proteoform of Prostate Specific Antigen (SNP-L132I) in Clinical Samples by Multiple Reaction Monitoring.

    OpenAIRE

    Végvári, Ákos; Sjödin, Karin; Rezeli, Melinda; Malm, Johan; Lilja, Hans; Laurell, Thomas; Marko-Varga, György

    2013-01-01

    Prostate specific antigen (PSA) is a well-established tumor marker that is frequently employed as model biomarker in the development and evaluation of emerging quantitative proteomics techniques, partially as a result of wide access to commercialized immunoassays serving as “gold standards.” We designed a multiple reaction monitoring (MRM) assay to detect PSA proteoforms in clinical samples (n = 72), utilizing the specificity and sensitivity of the method. We report, for the first time, a PSA...

  5. PSA-operations synergism for the advanced test reactor shutdown operations PSA

    International Nuclear Information System (INIS)

    The Advanced Test Reactor (ATR) Probabilistic Safety Assessment (PSA) for shutdown operations, cask handling, and canal draining is a successful example of the importance of good PSA-operations synergism for achieving a realistic and accepted assessment of the risks and for achieving desired risk reduction and safety improvement in a best and cost-effective manner. The implementation of the agreed-upon upgrades and improvements resulted in the reductions of the estimated mean frequency for core or canal irradiated fuel uncovery events, a total reduction in risk by a factor of nearly 1000 to a very low and acceptable risk level for potentially severe events

  6. Medications and surgical interventions for benign prostatic hyperplasia are potential confounders of prostate-specific antigen.

    Science.gov (United States)

    Modi, Parth; Helfand, Brian T; McVary, Kevin T

    2010-07-01

    Prostate-specific antigen (PSA) is the most widely used marker for prostate cancer (CaP) screening and monitoring benign prostatic hyperplasia (BPH) progression. However, lack of an established abnormal threshold and the presence of other benign processes confound the interpretation of PSA levels. Many factors besides inflammation, trauma, and instrumentation can influence PSA levels; specifically, BPH and its associated medical and surgical therapies frequently complicate the interpretation of this serum blood test. For example, the commonly used 5 alpha reductase inhibitor (5ARI) medications directly affect PSA levels by decreasing prostate volume. The amount of time and potentially even the 5ARI formulary a patient is administered has been implicated to directly impact the degree of reduction in PSA (a proxy for prostate volume). In addition, each of the currently available surgical procedures for BPH appears to remove varying amounts of prostatic adenoma. This directly confounds CaP screening because each procedure is associated with a relatively specific postoperative nadir PSA level, and PSA kinetics are not well described in the literature. Taken together, it is important for clinicians to comprehend that BPH and its associated medical and surgical interventions should directly influence their interpretation of PSA and PSA velocity when screening for CaP or following BPH progression. PMID:20467844

  7. 10-year biochemical (prostate-specific antigen) control of prostate cancer with 125I brachytherapy

    International Nuclear Information System (INIS)

    Purpose: To report 10-year biochemical (prostate-specific antigen [PSA]) outcomes for patients treated with 125I brachytherapy as monotherapy for early-stage prostate cancer. Methods and Materials: One hundred and twenty-five consecutively treated patients, with clinical Stage T1-T2b prostate cancer were treated with 125I brachytherapy as monotherapy, and followed with PSA determinations. Kaplan-Meier estimates of PSA progression-free survival (PFS), on the basis of a two consecutive elevations of PSA, were calculated. Aggregate PSA response by time interval was assessed. Comparisons were made to an earlier-treated cohort. Results: The overall PSA PFS rate achieved at 10 years was 87% for low-risk patients (PSA125I achieves a high rate (87%) of biochemical and clinical control in patients with low-risk disease at 10 years. The decline of PSA following brachytherapy with low-dose-rate isotopes can be protracted. Absolute PSA and PFS curves merge, and are comparable at 10 years

  8. PSA bounces after neoadjuvant androgen deprivation and external beam radiation: Impact on definitions of failure

    International Nuclear Information System (INIS)

    Purpose: To determine the characteristics of prostate specific antigen (PSA) bounces after external beam radiation therapy (EBRT) with neoadjuvant androgen deprivation and their impact on definitions of biochemical failure. Methods and Materials: Characteristics of bounce were calculated for all patients treated by EBRT with neoadjuvant androgen deprivation at our institution between 1992 and 1998 (preexclusion analysis). Calculations were repeated for the subgroup that satisfied additional inclusion/exclusion criteria (postexclusion analysis). The percentage of bounces scoring as false positives according to the ASTRO definition of biochemical failure was compared with those for three alternative definitions (Vancouver, Nadir-plus-two, and Nadir-plus-three) using McNemar's tests. Results: Thirty-nine percent (preexclusion cohort) and 56% (postexclusion cohort) of patients demonstrated a PSA bounce. Twenty percent (preexclusion analysis) and 25% (postexclusion analysis) of these bounces scored as biochemical failure according to the ASTRO definition. The Nadir-plus-three definition scored the smallest percentage of bounces as failure, but the difference between this definition and the ASTRO definition reached statistical significance in neither preexclusion nor postexclusion analyses (p ≥ 0.070). Conclusions: A substantial proportion of patients treated by EBRT with neoadjuvant deprivation experienced a PSA bounce. A large percentage of these bounces scored as biochemical failure according to the ASTRO definition. The Nadir-plus-three definition is less vulnerable to this bias

  9. Penile Metastases of Recurrent Prostatic Adenocarcinoma without PSA Level Increase: A Case Report

    Directory of Open Access Journals (Sweden)

    Antonio Pierro

    2012-01-01

    Full Text Available We report a case of penile metastases from recurrent prostatic adenocarcinoma that was the first sign of a widespread metastatic disease in the absence of any increase in prostate-specific antigen (PSA level. In April 2011, an 80-year-old man presented to our Radiotherapy Unit with multiple palpable hard nodules in the penis, dysuria, and moderate perineal pain, 7 years after he had received radiotherapy for prostate cancer. Nodules in the penis had appeared in February 2011. The ultrasound and magnetic resonance (MR imaging suggested the diagnosis of multiple penile metastases. A total body computed tomography scan revealed a systemic spread of the disease, with multiple metastases in the liver, bones, and lungs. PSA level was 0.126 ng/ml. A fine needle aspiration biopsy of the liver lesion was undertaken, and the histopathologic examination revealed the prostatic origin of the metastases, so androgen deprivation therapy was started. The diagnosis of metastases should be considered in a patient with prior history of prostate malignancies presenting with solid nodules in the penis, even if the PSA level is low.

  10. Evaluation of prostate cancer prevalence in Iranian male population with increased PSA level, a one center experience

    Directory of Open Access Journals (Sweden)

    Moslemi MK

    2011-06-01

    Full Text Available Mohammad Kazem Moslemi1, Fariborz Lotfi2, Seyed Ali Tahvildar31Department of Urology, Kamkar Hospital, School of Medicine, Qom University of Medical Sciences, Qom, Iran; 2School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran; 3Department of Urology, School of Medicine, Islamic Azad University, Qom Branch, Qom, IranPurpose: This study was conducted to evaluate the incidence of prostate cancer (PCa in Iranian male patients with increased prostate-specific antigen (PSA, and normal or abnormal digital rectal examination (DRE that underwent prostate biopsy.Materials and methods: From March 2006 to April 2009, a total of 346 consecutive males suspected of having PCa due to increased PSA levels underwent transrectal ultrasonography (TRUS-guided sextant biopsy of the prostate. The total PSA (tPSA, demographic data, incidence of PCa, benign prostate hyperplasia (BPH, and prostatitis were assessed.Results: The patients were divided into two groups according to their PSA values (group A serum tPSA level, 4–10 ng/mL; group B serum tPSA level, 10.1–20.0 ng/mL. Of the 346 biopsied cases, 193 cases (56% had PCa, 80 cases (23% had BPH, and 73 cases (21% had prostatitis. The mean PSA and the age of the carcinoma group were significantly higher than those of the benign group (P < 0.01. The biopsy results were grouped as PCa, BPH, and prostatitis. Incidence of PCa for group A and group B cases were 115 cases (51%, and 78 cases (65%, respectively. In the case of PCa, BPH, and prostatitis, the mean PSAs were 10.02 ng/mL, 8.76 ng/mL, and 8.41 ng/mL, respectively (P < 0.40.Conclusion: TRUS-guided prostate biopsy and interpretation by a skilled team is highly recommended for early detection of PCa or its ruling-out. It seems that a PSA cutoff value of 4 ng/mL may be applied to the Iranian population. Although the chance of PCa is high in the PSA levels of 4–10 ng/mL, the combination of some data, like age and prostate volume, can

  11. Predictive value of prostate-specific antigen for prostate cancer

    DEFF Research Database (Denmark)

    Shepherd, Leah; Borges, Alvaro Humberto; Ravn, Lene;

    2014-01-01

    INTRODUCTION: Although prostate cancer (PCa) incidence is lower in HIV+ men than in HIV- men, the usefulness of prostate-specific antigen (PSA) screening in this population is not well defined and may have higher false negative rates than in HIV- men. We aimed to describe the kinetics and...

  12. Brug af undersøgelse for prostataspecifikt antigen

    DEFF Research Database (Denmark)

    Mukai, Thomas; Bro, Flemming; Pedersen, Knud Venborg;

    2010-01-01

    Introduktion: Cancer prostatae (CP) er den hyppigste kræftform blandt danske mænd, og incidensen er stigende. CP er ofte asymptomatisk, hvilket vanskeliggør klinisk diagnosticering. I udredningen for CP kan man benytte en prøve for prostataspecifikt antigen (PSA)-niveau. Dansk Urologisk Selskab har...

  13. The open PSA initiative for next generation probabilistic safety assessment

    International Nuclear Information System (INIS)

    The open PSA initiative round table discussion session is to bring the PSA community up-to-date on our meetings, workshops, and working groups during the last year. We will have members of the initiative speak on their point of view of the initiative, what they have gained, and where we as a group want to go during the next year. The main idea is to use appropriate modules of different computer codes for a specific purpose which requires a common platform and a common PSA format. In this short paper we introduce our main project for this year: the open PSA model exchange format. (orig.)

  14. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer

    International Nuclear Information System (INIS)

    Background and purpose: To determine the kinetics of serum prostate-specific antigen (PSA) after radiation therapy of localized prostate cancer and to evaluate whether such kinetics provide prognostic information. Materials and methods: Eight hundred forty-one men with serial PSA determinations who underwent external beam radiation without androgen ablation were analyzed to determine postradiation PSA kinetic parameters (half-life and doubling time) and to correlate these parameters with disease outcome. Non-linear regression techniques were used to determine half-lives and doubling times. Results: The postradiation serum PSA data fitted well to first order kinetic models. The median PSA half-life was 1.6 months (range 0.5-9.2 months). There was no correlation between half-life and T-stage or Gleason grade. A significant but quantitatively weak correlation was present between the pretreatment PSA level and half-life; lower pretreatment levels were associated with longer half-lives. Half-life did not correlate with disease outcome whether the endpoint was local recurrence, distant metastasis or rising PSA. In 263 men with a rising postradiation PSA profile the median PSA doubling time was 12.2 months (range 0.8-80.2 months). Faster doubling times were significantly associated with higher T-stage, higher Gleason grade and higher pretreatment PSA levels. Thus, patients with initially adverse disease developed faster rising PSA values after treatment than patients with less adverse disease. The most striking correlation was between rapid doubling time and the likelihood of metastatic relapse. Patients who developed metastases had a median PSA doubling time of 4.2 months compared to a median doubling time of 11.7 months in patients who developed local recurrence. Overall, patients with a PSA doubling time of less than 8 months had a 7-year actuarial metastatic rate of 54%, while patients with a PSA doubling time exceeding 8 months had only a 7% metastatic rate

  15. Differential roles of PML isoforms

    Directory of Open Access Journals (Sweden)

    MouniraKChelbi-Alix

    2013-05-01

    Full Text Available The tumor suppressor promyelocytic leukemia protein (PML is fused to the retinoic acid receptor alpha in patients suffering from acute promyelocytic leukemia (APL. Treatment of APL patients with arsenic trioxide (As2O3 reverses the disease phenotype by a process involving the degradation of the fusion protein via its PML moiety. Several PML isoforms are generated from a single PML gene by alternative splicing. They share the same N-terminal region containing the RBCC/TRIM motif but differ in their C-terminal sequences. Recent studies of all the PML isoforms reveal the specific functions of each. Here, we review the nomenclature and structural organization of the PML isoforms in order to clarify the various designations and classifications found in different databases. The functions of the PML isoforms and their differential roles in antiviral defense also are reviewed. Finally, the key players involved in the degradation of the PML isoforms in response to As2O3 or other inducers are discussed.

  16. Impedance-Based Miniaturized Biosensor for Ultrasensitive and Fast Prostate-Specific Antigen Detection

    Directory of Open Access Journals (Sweden)

    Ganna Chornokur

    2011-01-01

    Full Text Available This paper reports the successful fabrication of an impedance-based miniaturized biosensor and its application for ultrasensitive Prostate-Specific Antigen (PSA detection in standard and real human plasma solution, spiked with different PSA concentrations. The sensor was fabricated using photolithographic techniques, while monoclonal antibodies specific to human PSA were used as primary capture antibodies. Electrochemical impedance spectroscopy (EIS was employed as a detection technique. The sensor exhibited a detection limit of 1 pg/ml for PSA with minimal nonspecific binding (NSB. This detection limit is an order of magnitude lower than commercial PSA ELISA assays available on the market. The sensor can be easily modified into an array for the detection of other biomolecules of interest, enabling accurate, ultrasensitive, and inexpensive point-of-care sensing technologies.

  17. Role of digital rectal examination and prostate specific antigen in detecting carcinoma prostate

    International Nuclear Information System (INIS)

    Objective: To investigate the ability of digital rectal examination (DRE) and prostrate specific antigen (PSA) in detecting carcinoma prostrate. Results: Digital rectal examination has shown sensitivity of 63% and specificity of 73.22%. The sensitivity of PSA was 87% and specificity was 70.8%. The positive predictive value for DRE and PSA was 57.5% and 78.04% respectively. Negative predictive value was 73.22% and 85.22% respectively. P value was statistically significant <0.037. In the second part of study a baseline serum PSA level in age-matched 200 patients without history of prostatism was estimated. Conclusion: It was concluded that PSA represent an important adjunct to DRE for detection of prostate carcinoma. (author)

  18. PSA Response to Neoadjuvant Androgen Deprivation Therapy Is a Strong Independent Predictor of Survival in High-Risk Prostate Cancer in the Dose-Escalated Radiation Therapy Era

    Energy Technology Data Exchange (ETDEWEB)

    McGuire, Sean E., E-mail: semcguir@mdanderson.org [Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas (United States); Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas (United States); Lee, Andrew K. [Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas (United States); Cerne, Jasmina Z. [Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas (United States); Munsell, Mark F. [Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas (United States); Levy, Lawrence B. [Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas (United States); Kudchadker, Rajat J. [Department of Radiation Physics, University of Texas MD Anderson Cancer Center, Houston, Texas (United States); Choi, Seungtaek L.; Nguyen, Quynh N.; Hoffman, Karen E.; Pugh, Thomas J.; Frank, Steven J. [Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas (United States); Corn, Paul G.; Logothetis, Christopher J. [Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas (United States); Kuban, Deborah A. [Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas (United States)

    2013-01-01

    Purpose: The aim of the study was to evaluate the prognostic value of prostate-specific antigen (PSA) response to neoadjuvant androgen deprivation therapy (ADT) prior to dose-escalated radiation therapy (RT) and long-term ADT in high-risk prostate cancer. Methods and Materials: We reviewed the charts of all patients diagnosed with high-risk prostate cancer and treated with a combination of long-term ADT (median, 24 months) and dose-escalated (median, 75.6 Gy) RT between 1990 and 2007. The associations among patient, tumor, and treatment characteristics with biochemical response to neoadjuvant ADT and their effects on failure-free survival (FFS), time to distant metastasis (TDM), prostate cancer-specific mortality (PCSM) and overall survival (OS) were examined. Results: A total of 196 patients met criteria for inclusion. Median follow-up time for patients alive at last contact was 7.0 years (range, 0.5-18.1 years). Multivariate analysis identified the pre-RT PSA concentration (<0.5 vs {>=}0.5 ng/mL) as a significant independent predictor of FFS (P=.021), TDM (P=.009), PCSM (P=.039), and OS (P=.037). On multivariate analysis, pretreatment PSA (iPSA) and African-American race were significantly associated with failure to achieve a pre-RT PSA of <0.5 ng/mL. Conclusions: For high-risk prostate cancer patients treated with long-term ADT and dose-escalated RT, a pre-RT PSA level {>=}0.5 ng/mL after neoadjuvant ADT predicts for worse survival measures. Both elevated iPSA and African-American race are associated with increased risk of having a pre-RT PSA level {>=}0.5 ng/mL. These patients should be considered for clinical trials that test newer, more potent androgen-depleting therapies such as abiraterone and MDV3100 in combination with radiation.

  19. PSA Response to Neoadjuvant Androgen Deprivation Therapy Is a Strong Independent Predictor of Survival in High-Risk Prostate Cancer in the Dose-Escalated Radiation Therapy Era

    International Nuclear Information System (INIS)

    Purpose: The aim of the study was to evaluate the prognostic value of prostate-specific antigen (PSA) response to neoadjuvant androgen deprivation therapy (ADT) prior to dose-escalated radiation therapy (RT) and long-term ADT in high-risk prostate cancer. Methods and Materials: We reviewed the charts of all patients diagnosed with high-risk prostate cancer and treated with a combination of long-term ADT (median, 24 months) and dose-escalated (median, 75.6 Gy) RT between 1990 and 2007. The associations among patient, tumor, and treatment characteristics with biochemical response to neoadjuvant ADT and their effects on failure-free survival (FFS), time to distant metastasis (TDM), prostate cancer-specific mortality (PCSM) and overall survival (OS) were examined. Results: A total of 196 patients met criteria for inclusion. Median follow-up time for patients alive at last contact was 7.0 years (range, 0.5-18.1 years). Multivariate analysis identified the pre-RT PSA concentration (<0.5 vs ≥0.5 ng/mL) as a significant independent predictor of FFS (P=.021), TDM (P=.009), PCSM (P=.039), and OS (P=.037). On multivariate analysis, pretreatment PSA (iPSA) and African-American race were significantly associated with failure to achieve a pre-RT PSA of <0.5 ng/mL. Conclusions: For high-risk prostate cancer patients treated with long-term ADT and dose-escalated RT, a pre-RT PSA level ≥0.5 ng/mL after neoadjuvant ADT predicts for worse survival measures. Both elevated iPSA and African-American race are associated with increased risk of having a pre-RT PSA level ≥0.5 ng/mL. These patients should be considered for clinical trials that test newer, more potent androgen-depleting therapies such as abiraterone and MDV3100 in combination with radiation.

  20. Prostate cancer in patients from rural and suburban areas – PSA value, Gleason score and presence of metastases in bone scan

    Directory of Open Access Journals (Sweden)

    Wojciech Szot

    2014-11-01

    Full Text Available [b]Introduction[/b]. Prostate cancer is the second most common neoplasm among men both worldwide and in Poland. In prostate cancer, bone metastasis is related to a poorer prognosis. A diagnosis of metastatic bone disease is important in prostate cancer patients prior to therapy. Prostate specific antigen (PSA serum value is used both as a screening tool and for staging of prostate cancer. aim. To evaluate whether there is a link between symptoms presented by patients, pain in particular, and the presence, number and location of bone metastases as assessed by bone scan scintigraphy in concordance with PSA values and Gleason scores. [b]material[/b]. A group of 186 patients (aged: 68.38±6.16 diagnosed with prostate cancer, from rural and suburban areas of Małopolska province, that was directed for bone scan scintigraphy to the Nuclear Medicine Dept, John Paul II Hospital in Kraków. [b]methods[/b]. Analysis of all laboratory findings (including PSA value and a biopsy were performed. Then, bone scan scintigraphy was done with the use of methylene disphosphonate (MDP labeled with Tc-99m. [b]results[/b]. In patients with a Gleason value ≤7 and a PSA value ≤20 ng/ml, the cutoff value for a negative bone scan with a confidence interval of 0.95 was established at a PSA value below 10 ng/ml (p<0.01. Correlations were established between PSA value and presence of metastases in bone scan (r=0.45, p=0.05, the number of metastases (r=0.66, p<0.01, and their presence in particular body regions. [b]conclusions[/b]. The correlation between PSA value and both presence and number of metastases confirms the usefulness of bone scan scintigraphy in prostate cancer staging. The cutoff value for negative bone scan with a 95% confidence interval was established at PSA = 10 ng/ml.

  1. The source of pretreatment serum prostate-specific antigen in clinically localized prostate cancer--T, N, or M?

    International Nuclear Information System (INIS)

    Purpose: Prostate-specific antigen (PSA) is an important marker for prostate cancer and has been shown to be secreted from the primary tumor and from metastases. However, the relative contribution of the primary and micrometastatic disease to the serum level of PSA in patients with clinically localized disease has not been delineated. This study addresses the source of pretreatment serum PSA in patients with clinically localized disease. Methods and Materials: The fall in serum PSA level following radical prostatectomy (280 patients; 105 T1, 165 T2, 10 T3) or definitive radiotherapy (427 patients; 122 T1, 147 T2, 158 T3/T4) was analyzed with the assumption that any fall in PSA following local treatment reflects the fraction of PSA produced in the prostate and its primary tumor. Results: Serum PSA level became undetectable in 277 of the 280 (99%) patients within 6 months of radical prostatectomy. The three patients who did not achieve undetectable levels had postsurgical values ≤ 0.9 ng/ml. Following definitive radiotherapy, nadir serum PSA values were between ≤ 0.3 and 20.3 ng/ml, with mean and median values of 1.9 and 1.2 ng/ml, respectively. Nadir PSA was undetectable in 52 patients (12%). Four patients' PSA did not fall, but rose from the start, and each developed metastatic disease within 9 months, and in each metastases appeared to contribute to pretreatment serum PSA. In the remaining patients, the maximal factor by which PSA fell to its nadir was higher the higher the pretreatment PSA level. We present arguments that this is most consistent with the hypothesis that virtually all detectable pretreatment serum PSA derives from the primary tumor. Confirmatory evidence that little of the pretreatment serum PSA came from metastases was obtained by extrapolating the rising PSA profile in 97 patients back to pretreatment time. Back-extrapolated PSA contributed a mean of 7% and a median of 5% to the pretreatment serum value. Because such back-extrapolated values

  2. Prostate-Specific Antigen Bounce After High-Dose-Rate Monotherapy for Prostate Cancer

    International Nuclear Information System (INIS)

    Purpose: To characterize the magnitude and kinetics of prostate-specific antigen (PSA) bounces after high-dose-rate (HDR) monotherapy and determine relationships between certain clinical factors and PSA bounce. Methods and Materials: Longitudinal PSA data and various clinical parameters were examined in 157 consecutive patients treated with HDR monotherapy between 1996 and 2005. We used the following definition for PSA bounce: rise in PSA ≥threshold, after which it returns to the prior level or lower. Prostate-specific antigen failure was defined per the Phoenix definition (nadir +2 ng/mL). Results: A PSA bounce was noted in 67 patients (43%). The number of bounces per patient was 1 in 45 cases (67%), 2 in 19 (28%), 3 in 2 (3%), 4 in 0, and 5 in 1 (1%). The median time to maximum PSA bounce was 1.3 years, its median magnitude was 0.7, and its median duration was 0.75 years. Three patients (2%) were noted to have PSA failure. None of the 3 patients who experienced biochemical failure exhibited PSA bounce. In the fully adjusted model for predicting each bounce, patients aged <55 years had a statistically significant higher likelihood of experiencing a bounce (odds ratio 2.22, 95% confidence interval 1.38-3.57, P=.001). There was also a statistically significant higher probability of experiencing a bounce for every unit decrease in Gleason score (odds ratio 1.52, 95% confidence interval 1.01-2.04, P=.045). Conclusions: A PSA bounce occurs in a significant percentage of patients treated with HDR monotherapy, with magnitudes varying from <1 in 28% of cases to ≥1 in 15%. The median duration of bounce is <1 year. More bounces were identified in patients with lower Gleason score and age <55 years. Further investigation using a model to correlate magnitude and frequency of bounces with clinical variables are under way

  3. Joint enhancement strategy applied in ECL biosensor based on closed bipolar electrodes for the detection of PSA.

    Science.gov (United States)

    Shi, Hai-Wei; Zhao, Wei; Liu, Zhen; Liu, Xi-Cheng; Wu, Mei-Sheng; Xu, Jing-Juan; Chen, Hong-Yuan

    2016-07-01

    A highly sensitive electrogenerated chemiluminescence (ECL) biosensor was developed on the basis of a closed bipolar electrode (BPE) apparatus for the analysis of prostate specific antigen (PSA). Bipolar modifications bring up two different stages of enhancement on the same electrode. Anodic enhancement was conducted by modifying gold nanoparticles (Au NPs) to catalyze the anodic ECL reaction between luminol and hydrogen peroxide. Cathodic introduction of thionine tagged PSA antibody led to a further pertinently enhancement synchronized with the PSA amount variation, because the existence of thionine greatly increased the rate of electron gains on cathode, leading to the corresponding acceleration of anodic ECL reaction. The more thionine modified target molecules were introduced, the faster luminol was oxidized, the higher faraday current approached, and sensitive quantification was realized in correlation with the responsive ECL intensity differences. The quantification resulted in a good determination range between 0.1pg/mL and 0.1µg/mL. This strategy mainly took advantage of the special structure of closed BPE to realize a simultaneous amplification on both ends of BPE. Moreover, the platform had a potential of providing a multi-functional strategy for the realization of other bio-detections by simply substituting the PSA sandwich structure with other bio-structures. PMID:27154662

  4. Prostate-specific antigen in the early detection of prostate cancer

    OpenAIRE

    Thompson, Ian M; Ankerst, Donna P.

    2007-01-01

    Throughout Canada, the United States and much of Europe, prostate-specific antigen (PSA) screening for prostate cancer has proliferated over the past 2 decades, leading to dramatic increases in detection rates of prostate cancer. Although it has unquestionably led to increased detection of cancer and a migration to lower-stage and -volume tumours, it is still unknown whether PSA screening significantly reduces mortality from prostate cancer. Often thought to be dichotomous (i.e., either norma...

  5. PSA - A utility perspective from the United Kingdom

    International Nuclear Information System (INIS)

    This paper provides an outline of the three stages of PSA used for the Sizewell B PWR. These stages cover the use of PSA during design, licensing and (in future) operation of Sizewell B. The paper discusses each of these stages in some detail, highlighting the differences in approach and lessons learnt at each stage. (author)

  6. Level 2 PSA methodology and severe accident management

    International Nuclear Information System (INIS)

    The objective of the work was to review current Level 2-PSA (Probabilistic Safety Assessment) methodologies and practices and to investigate how Level 2-PSA can support severe accident management programmes, i.e. the development, implementation, training and optimisation of accident management strategies and measures. For the most part, the presented material reflects the state in 1996. Current Level 2 PSA results and methodologies are reviewed and evaluated with respect to plant type specific and generic insights. Approaches and practices for using PSA results in the regulatory context and for supporting severe accident management programmes by input from level 2 PSAs are examined. The work is based on information contained in: PSA procedure guides, PSA review guides and regulatory guides for the use of PSA results in risk informed decision making; plant specific PSAs and PSA related literature exemplifying specific procedures, methods, analytical models, relevant input data and important results, use of computer codes and results of code calculations. The PSAs are evaluated with respect to results and insights. In the conclusion section, the present state of risk informed decision making, in particular in the level 2 domain, is described and substantiated by relevant examples

  7. Electrochemical immunosensor for prostate-specific antigen using self-assembled oligophenylethynylenethiol monolayer containing dendrimer

    International Nuclear Information System (INIS)

    Electrochemical immunosensor for prostate-specific antigen (PSA) was fabricated with a self-assembled 4-(2-(4-(acetylthio)phenyl)ethynyl)benzoic acid (APBA) as a bioreceptor. In order to enhance the electrochemical activity of PSA detection, poly(amidoamine) dendrimer was linked on the APBA self-assembled monolayer (SAM). The formation and electrical properties of the SAMs were investigated by surface plasmon resonance and cyclic voltammetry, respectively. The surface morphology of PSA sandwich complex onto the APBA SAM was studied by atomic force microscopy.

  8. Label-free electrochemical aptasensing of the human prostate-specific antigen using gold nanospears.

    Science.gov (United States)

    Rahi, A; Sattarahmady, N; Heli, H

    2016-08-15

    Gold nanospears were electrodeposited with the assistance of arginine as a soft template and precise selection of experimental parameters. The nanospears were then employed as a transducer to immobilize an aptamer of prostate-specific antigen (PSA) and fabrication of a label-free electrochemical aptasensor. The aptasensor was employed for the detection of PSA with a linear concentration range of 0.125-200ngmL(-1) and a limit of detection of 50pgmL(-1). The aptasensor was successfully applied to detect PSA in blood serum samples of healthy and patient persons. PMID:27260456

  9. Study on nuclear power plant aircraft accidents impacts PSA method

    International Nuclear Information System (INIS)

    Nuclear power plant (NPP) Probabilistic Safety Assessment (PSA) can be divided to internal events PSA and external events PSA. Because of the nature of aircraft accidents impacts, extreme in destroy degree and low frequency, analysts usually treat aircraft impacts as a special external event. There is not any mature method for NPP aircraft impacts PSA. The paper titled Accident For Aircraft Crash Into Analysis Hazardous Facilities is published by U.S. Department of Energy (DOE). The DOE guide could be the main base for this paper, referring to the demand for aircraft impact in NUREG-0800, seeking to develop a particular method for NPP aircraft impacts PSA in China. The method and content in this paper can be applied in similar work and may provide some advices for the future work. (authors)

  10. Daily Pill Can Prevent HIV PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2015-11-24

    This 60 second public service announcement (PSA) is based on the November 24, 2015 CDC Vital Signs report. Preexposure prophylaxis, or PrEP, is a daily medicine that can be used to prevent getting HIV. PrEP is for people who don’t have HIV but who are at very high risk for getting it from sex or injection drug use. Unfortunately, many people who can benefit from PrEP aren’t taking it.  Created: 11/24/2015 by National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP).   Date Released: 11/24/2015.

  11. PSA based vital area identification for NPPs

    International Nuclear Information System (INIS)

    Identification of vital areas in a facility involves assessing the facility and the locations, whose sabotage can result in undesirable (radiological) consequences. Probabilistic Safety Assessment (PSA) technique can find the component failures leading to core damage (a surrogate for radiological consequence) in a systematic manner, which can be extended to identification of vital areas. This paper describes the procedure for the generation of location sets (set of locations whose sabotage can lead to possible core damage) and protection sets (set of locations that must be protected to prevent possible core damage). In addition, measures such as vulnerability and protectability have been introduced, which can be used to rank location sets and protection sets. (author)

  12. Advanced prostatic carcinomas with low serum levels of prostate-specific antigen

    Directory of Open Access Journals (Sweden)

    Cerović Snežana J.

    2002-01-01

    Full Text Available The serum levels of prostate-specific antigen (PSA represent a significant diagnostic and monitoring parameter of prostatic carcinoma (PC. The aim of the study was to establish correlation of serum PSA level in addition to grade, histological type, and clinical stage of PC in patients with normal or intermediary PSA serum level. In 37 untreated PC patients with preoperative serum PSA levels ranging between 0.1 and 9.6 ng/ml, paraffin-embedded tissue and serum samples were immunohistological studied and immunoassay for PSA was done. The most representative was poorly differentiated PC with D stage In serum samples from PC patients 27 (73.7% normal (≤ 4.0 ng/ml, and 10 (27.3% intermediate (4.1-10 ng/ml PSA levels were found Immunohistochemistry, in 36 PC (97.3% had demonstrated the expression of PSA. Our study results had shown low serum PSA levels in some patients with advanced poorly differentiated PC.

  13. Analysis of prostate-specific antigen transcripts in chimpanzees, cynomolgus monkeys, baboons, and African green monkeys.

    Directory of Open Access Journals (Sweden)

    James N Mubiru

    Full Text Available The function of prostate-specific antigen (PSA is to liquefy the semen coagulum so that the released sperm can fuse with the ovum. Fifteen spliced variants of the PSA gene have been reported in humans, but little is known about alternative splicing in nonhuman primates. Positive selection has been reported in sex- and reproductive-related genes from sea urchins to Drosophila to humans; however, there are few studies of adaptive evolution of the PSA gene. Here, using polymerase chain reaction (PCR product cloning and sequencing, we study PSA transcript variant heterogeneity in the prostates of chimpanzees (Pan troglodytes, cynomolgus monkeys (Macaca fascicularis, baboons (Papio hamadryas anubis, and African green monkeys (Chlorocebus aethiops. Six PSA variants were identified in the chimpanzee prostate, but only two variants were found in cynomolgus monkeys, baboons, and African green monkeys. In the chimpanzee the full-length transcript is expressed at the same magnitude as the transcripts that retain intron 3. We have found previously unidentified splice variants of the PSA gene, some of which might be linked to disease conditions. Selection on the PSA gene was studied in 11 primate species by computational methods using the sequences reported here for African green monkey, cynomolgus monkey, baboon, and chimpanzee and other sequences available in public databases. A codon-based analysis (dN/dS of the PSA gene identified potential adaptive evolution at five residue sites (Arg45, Lys70, Gln144, Pro189, and Thr203.

  14. Applications of probabilistic safety assessment (PSA) for nuclear power plants

    International Nuclear Information System (INIS)

    This report, which compiles information on a comprehensive set of PSA applications in the areas of NPP design, operation, and accident mitigation and management, is the culmination of an IAEA project on PSA Applications and Tools to Improve NPP Safety. In this regard, the Technical Committee Meeting (TCM) held in Madrid in February 1998 allowed participants to review and provide very valuable comments for this report. Several important facts related to PSA and its applications were highlighted during this TCM: living PSAs are the basis for the risk informed approach to decision making; development and use of safety/risk monitors as tools for configuration management is spreading fast; the different uses of PSA to support NPP testing and maintenance planning and optimization are amongst the most widespread PSA applications; plant specific PSAs are being used to support the safety upgrading programmes of plants built to earlier standards; not all countries have a regulatory framework for the use of the probabilistic approach in decision making. Some countries are still far from 'risk-informed' regulation, and this means that there is still considerable work ahead, both for regulators and utilities, to clarify approaches, to establish a framework and to reach a common understanding in relation to the use of PSA in decision making. This report is based on the premise that the use of PSA can provide useful information for the decision maker. This report is intended to provide an overview of current PSA applications. Section 2 addresses the PSA application process, outlines the general requirements for PSA tools and provides a discussion on PSA aspects such as PSA level, scope and level of detail, which have to be considered when planning/performing PSA applications. Section 3 discusses the technical aspects of individual applications and is divided into three parts. Section 3.1 is dedicated to the design related PSA applications. The second part of Section 3 considers

  15. Effect of a 2-year home-based endurance training intervention on physiological function and PSA doubling time in prostate cancer patients

    DEFF Research Database (Denmark)

    Hvid, Thine; Lindegaard, Birgitte; Winding, Kamilla; Iversen, Peter; Brasso, Klaus; Solomon, Thomas P J; Pedersen, Bente K; Hojman, Pernille

    2016-01-01

    AIM: Physical activity after prostate cancer diagnosis has been shown to reduce the risk of disease progression. Here, we aimed to evaluate the effect of a 2-year home-based endurance training intervention on body composition, biomarkers levels, and prostate-specific antigen (PSA) doubling time as...... a surrogate end-point for progressing disease. METHODS: Out-clinic patients with either biochemical recurrence following radical prostatectomy or patients managed on active surveillance were randomized to either 24 months (3 times/week) of home-based endurance training or usual care. Aerobic fitness......, body composition, insulin sensitivity, and biomarkers were measured at 0, 6, and 24 months of intervention. PSA doubling time (PSADT) was calculated based on monthly PSA measurements. RESULTS: Twenty-five patients were enrolled, and 19 patients completed the study. PSADT increased in the training group...

  16. A case report of monitoring PSA level changes in two prostate cancer patients treated with Mountain Ginseng Pharmacopuncture and Sweet Bee Venom along with western anticancer therapy

    Directory of Open Access Journals (Sweden)

    Yeonhee Lee

    2011-12-01

    Full Text Available Objectives: The purpose of this report is to find out how Mountain Ginseng Pharmacopuncture(MGP and Sweet Bee Venom(SBV treatments are effective on prostate cancer patients by monitoring Prostate specific antigen(PSA values. Methods: We treated two prostate cancer patients with MGP and SBV from October 2008 to April 2011. One patient had localized prostate cancer, the other was in the terminal stage of prostate cancer with lung and bone metastasis and both had been receiving western anticancer therapy. We had monitored the changes of PSA value. Results: In case 1, MGP and SBV treatments seemed to be helpful in preventing the recurrence of localized prostate cancer. In case 2, PSA value was decreased by MGP treatment. Conclusions: It is conceivable that MGP and SBV are effective treatments for patients with prostate cancer.

  17. A framework for a quality assurance programme for PSA

    International Nuclear Information System (INIS)

    Reviews organized by the IAEA of probabilistic safety assessments (PSAs) of nuclear facilities have, in the past years, shown significant progress in the technical methods and data used for these studies. The IAEA has made a considerable effort to support the development of technical capabilities for PSA in Member States and in writing technical procedures for carrying out PSAs. However, the reviews have also shown significant deficiencies in quality assurance (QA) for PSAs, ranging from no QA at all to inappropriate, inefficient or unbalanced QA. As a PSA represents a very complex model which describes the risk associated with a nuclear facility, an appropriate and efficient QA programme is crucial to obtain a quality PSA. Historically, in the first integral PSAs, many of the PSA elements were handled by independent groups. These elements were finally integrated and put together in the overall model. Many of the interfaces between the elements or tasks were handled as appropriate by exchanging information in oral or written form. Since WASH-1400, the first integral PSA, the process of constructing the PSA model has been further developed. PSA elements previously considered separately can now be handled together with the capable software developed in recent years. Software has made interface control and data transfer easier to perform, but also permits the development of more detailed and complex models. Previously, QA for PSA projects was organized in an ad hoc manner and was sometimes very limited. In recent years, increasingly comprehensive QA programmes have been developed and implemented for PSA projects. Today, a comprehensive, effective and performance-oriented QA is considered to be essential for a reliable and credible PSA. This report describes the framework for developing an adequate QA programme for PSA studies. The framework is based on and is in accordance with the related QA guidelines of the IAEA for safety in nuclear power plants and other nuclear

  18. Regulatory review of probabilistic safety assessment (PSA) Level 2

    International Nuclear Information System (INIS)

    Probabilistic safety assessment (PSA) is increasingly being used as part of the decision making process to assess the level of safety of nuclear power plants. The methodologies in use are maturing and the insights gained from the PSAs are being used along with those from deterministic analysis. Many regulatory authorities consider the current state of the art in PSA to be sufficiently well developed for results to be used centrally in the regulatory decision making process-referred to as risk informed regulation. For these applications to be successful, it will be necessary for the regulatory authority to have a high degree of confidence in the PSA. However, at the 1994 IAEA Technical Committee Meeting on Use of PSA in the Regulatory Process and at the OECD Nuclear Energy Agency Committee for Nuclear Regulatory Activities (CNRA) 'Special Issues' meeting in 1997 on Review Procedures and Criteria for Different Regulatory Applications of PSA, it was recognized that formal regulatory review guidance for PSA did not exist. The senior regulators noted that there was a need to produce some international guidance for reviewing PSAs to establish an agreed basis for assessing whether important technological and methodological issues in PSAs are treated adequately and to verify that conclusions reached are appropriate. In 1997, the IAEA and OECD Nuclear Energy Agency agreed to produce, in cooperation, guidance on Regulatory Review of PSA. This led to the publication of IAEA-TECDOC-1135 on the Regulatory Review of Probabilistic Safety Assessment (PSA) Level 1, which gives advice for the review of Level 1 PSA for initiating events occurring at power plants. This TECDOC extends the coverage to address the regulatory review of Level 2 PSA.These publications are intended to provide guidance to regulatory authorities on how to review the PSA for a nuclear power plant to gain confidence that it has been carried out to an acceptable level of quality so that it can be used as the

  19. Time-resolved fluorescence imaging (TRFI) for direct immunofluorescence of PSA and alpha-1-antichymotrypsin in prostatic tissue sections.

    Science.gov (United States)

    Bjartell, A; Siivola, P; Hulkko, S; Pettersson, K; Rundt, K; Lilja, H; Lövgren, T

    1999-05-01

    We have developed a direct immunofluorescence technique utilising chelates of the lanthanide ions europium and terbium conjugated to monoclonal IgGs (Mabs) against prostate-specific antigen (PSA) and alpha-1-antichymotrypsin (ACT) for the detection and quantification on the same tissue section. Strong signals without disturbance from tissue autofluorescence were demonstrated in paraffin sections of ten benign and six malignant prostate tissue specimens. The signal intensity increased linearly with the amount of labelled Mab until epitope saturation began. The highest concentrations of bound IgG in tissue sections were 27.3 fmol/pixel for ACT and 7.2 for PSA. Time-resolved fluorescence imaging (TRFI) offers an attractive method for histochemical studies based on specific and quantitative detection of fluorescent lanthanide chelates. PMID:12496823

  20. Development of radioimmunometric assay for the determination of free and total prostate-specific antigen in human serum

    International Nuclear Information System (INIS)

    In the present study, we describe sensitive and reliable immunoradiometric assays (IRMA) for the determination of free (f-PSA) and total (complexed as well as free, t-PSA) prostate-specific antigen in human serum. The assays employ matched pairs of anti-PSA monoclonal antibodies (MAb66 and MAb30 or MAb10). The polystyrene tubes are coated with MAb66 (capture antibody) and the detection antibody MAb30 or MAb10 was labeled with 125I. The minimum detectable dose of f-PSA was less than 0.03 ng/mL, and the assay could determine free PSA concentrations of up to 26 ng/mL; in the case of t-PSA, the minimum detectable dose was less than 0.04 ng/mL while the assay could determine total PSA concentrations of up to 112 ng/mL without dilution of the sample. The intra- and inter-assay variations (%CV) for f-PSA were less than 3% and 15% respectively and for t-PSA less than 2% and 9%, respectively. The results obtained using 44 serum samples correlated well with those obtained by commercially available IRMA kits. (author)

  1. PSA modeling of long-term accident sequences

    International Nuclear Information System (INIS)

    In the traditional Level 1 PSA, the long term of the accident sequences is usually taken into account in a simplified manner. For example, some of the mitigations which are needed at long term are taken into account in the PSA, but the analysis and the associated failures probabilities quantification are estimated based on generic assessments. In the context of the extension of PSA scope to include the external hazards, in France, both operator (EDF) and IRSN work for the improvement of methods to better take into account in the PSA the long term of accident sequences induced by initiators which affect the whole site containing several nuclear installations (reactors, fuel pools, ...). This is an essential prerequisite for the development of external hazards PSA. It has to be noted that in the French PSA, even before Fukushima, this type of accident sequences was already taken into account, many insight being used, as complementary information, to enhance the safety level of the plants. The recent French and international operating experience is an opportunity for tuning the actual PSA methods for long term accident sequences modeling. The paper presents the main results of the ongoing efforts in this area. (author)

  2. An Eight-Year Experience of HDR Brachytherapy Boost for Localized Prostate Cancer: Biopsy and PSA Outcome

    International Nuclear Information System (INIS)

    Purpose: To evaluate the biochemical recurrence-free survival (bRFS), the 2-year biopsy outcome and the prostate-specific antigen (PSA) bounce in patients with localized prostate cancer treated with an inversely planned high-dose-rate (HDR) brachytherapy boost. Materials and methods: Data were collected from 153 patients treated between 1999 and 2006 with external beam pelvic radiation followed by an HDR Ir-192 prostate boost. These patients were given a boost of 18 to 20 Gy using inverse-planning with simulated annealing (IPSA).We reviewed and analyzed all prostate-specific antigen levels and control biopsies. Results: The median follow-up was 44 months (18-95 months). When categorized by risk of progression, 74.5% of patients presented an intermediate risk and 14.4% a high one. Prostate biopsies at 2 years posttreatment were negative in 86 of 94 patients (91.5%), whereas two biopsies were inconclusive. Biochemical control at 60 months was at 96% according to the American Society for Therapeutic Radiology and Oncology and the Phoenix consensus definitions. A PSA bounce (PSA values of 2 ng/mL or more above nadir) was observed in 15 patients of 123 (9.8%). The median time to bounce was 15.2 months (interquartile range, 11.0-17.7) and the median bounce duration 18.7 months (interquartile range, 12.1-29). The estimate of overall survival at 60 months was 97.1% (95% CI, 91.6-103%). Conclusions: Considering that inverse planned HDR brachytherapy prostate boosts led to an excellent biochemical response, with a 2-year negative biopsy rate, we recommend a conservative approach in face of a PSA bounce even though it was observed in 10% of patients

  3. Discoveries and application of prostate-specific antigen, and some proposals to optimize prostate cancer screening

    Directory of Open Access Journals (Sweden)

    Tokudome S

    2016-05-01

    Full Text Available Shinkan Tokudome,1 Ryosuke Ando,2 Yoshiro Koda,3 1Department of Nutritional Epidemiology, National Institute of Health and Nutrition, Shinjuku-ku, Tokyo, 2Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Mizuho-ku, Nagoya, 3Department of Forensic Medicine and Human Genetics, Kurume University School of Medicine, Kurume, Japan Abstract: The discoveries and application of prostate-specific antigen (PSA have been much appreciated because PSA-based screening has saved millions of lives of prostate cancer (PCa patients. Historically speaking, Flocks et al first identified antigenic properties in prostate tissue in 1960. Then, Barnes et al detected immunologic characteristics in prostatic fluid in 1963. Hara et al characterized γ-semino-protein in semen in 1966, and it has been proven to be identical to PSA. Subsequently, Ablin et al independently reported the presence of precipitation antigens in the prostate in 1970. Wang et al purified the PSA in 1979, and Kuriyama et al first applied an enzyme-linked immunosorbent assay for PSA in 1980. However, the positive predictive value with a cutoff figure of 4.0 ng/mL appeared substantially low (~30%. There are overdiagnoses and overtreatments for latent/low-risk PCa. Controversies exist in the PCa mortality-reducing effects of PSA screening between the European Randomized Study of Screening for Prostate Cancer (ERSPC and the US Prostate, Lung, Colorectal, and Ovarian (PLCO Cancer Screening Trial. For optimizing PCa screening, PSA-related items may require the following: 1 adjustment of the cutoff values according to age, as well as setting limits to age and screening intervals; 2 improving test performance using doubling time, density, and ratio of free: total PSA; and 3 fostering active surveillance for low-risk PCa with monitoring by PSA value. Other items needing consideration may include the following: 1 examinations of cell proliferation and cell cycle markers

  4. Combination of signal intensity measurements of lesions in the peripheral zone of prostate with MRI and serum PSA level for differentiating benign disease from prostate cancer

    International Nuclear Information System (INIS)

    The aim of this study was to predict the benign or malignant nature of a prostatic lesion by defining a threshold value of signal intensity ratio and a limiting value of serum prostate-specific antigen (PSA) in patients with elevated PSA level. Twenty-six patients with elevated PSA level and no hypoechogenic lesions at endosonography underwent MR imaging using an endorectal body phased-array coil at 1.5 T (Siemens Magnetom Symphony). A T2-weighted turbo-spin-echo (TSE) pulse sequence was applied in a transverse orientation. Two radiologists evaluated the images. In the presence of a pathological finding they defined regions of interest (ROI) in the suspicious pathological area of the peripheral zone and in muscle for reference. The quotient of the two ROIs was calculated and then correlated with the actual PSA level. Diagnosis was confirmed by prostate biopsy. Ten of 12 patients with quotients smaller than 4 showed cancer at histology. Nine of 12 men with cancer proven by biopsy had PSA levels higher than 10 ng/ml. A significant difference (p < 0.001) was found between the quotients of cancer and quotients of chronic prostatitis, fibrosis, or glandular atrophy. The accuracy of tumor differentiation of the method was 77 %. Measurement of signal intensity quotients in the peripheral zone of the prostate in combination with knowledge of defined limits of PSA levels the technique could be helpful in detecting additional cancer areas for prostate biopsy. False-negative tumor results of standard sextant biopsy can be reduced. In men with high PSA values the method has a role in differentiating between patients who require prostate biopsy and those of clinical observation. (orig.)

  5. Detection of Local, Regional, and Distant Recurrence in Patients With PSA Relapse After External-Beam Radiotherapy Using 11C-Choline Positron Emission Tomography

    International Nuclear Information System (INIS)

    Purpose: An elevated serum prostate-specific antigen (PSA) level cannot distinguish between local-regional recurrences and the presence of distant metastases after treatment with curative intent for prostate cancer. With the advent of salvage treatment such as cryotherapy, it has become important to localize the site of recurrence (local or distant). In this study, the potential of 11C-choline positron emission tomography (PET) to identify site of recurrence was investigated in patients with rising PSA after external-beam radiotherapy (EBRT). Methods and Materials: Seventy patients with histologically proven prostate cancer treated with EBRT and showing biochemical recurrence as defined by American Society for Therapeutic Radiology and Oncology consensus statement and 10 patients without recurrence underwent a PET scan using 400 MBq 11C-choline intravenously. Biopsy-proven histology from the site of suspicion, findings with other imaging modalities, clinical follow-up and/or response to adjuvant therapy were used as comparative references. Results: None of the 10 patients without biochemical recurrence had a positive PET scan. Fifty-seven of 70 patients with biochemical recurrence (median PSA 9.1 ng/mL; mean PSA 12.3 ng/mL) showed an abnormal uptake pattern (sensitivity 81%). The site of recurrence was only local in 41 of 57 patients (mean PSA 11.1 ng/mL at scan), locoregionally and/or distant in 16 of 57 patients (mean PSA 17.7 ng/mL). Overall the positive predictive value and negative predictive value for 11C-choline PET scan were 1.0 and 0.44 respectively. Accuracy was 84%. Conclusions: 11C-choline PET scan is a sensitive technique to identify the site of recurrence in patients with PSA relapse after EBRT for prostate cancer.

  6. Detection of recurrent prostate cancer with 18F-fluorocholine PET/CT in relation to PSA level at the time of imaging

    International Nuclear Information System (INIS)

    The purpose of this study was to evaluate fluorine-18 fluorocholine (FCH) positron emission tomography (PET)/CT for the detection of recurrent prostate cancer in relation to prostate-specific antigen (PSA) level. FCH PET/CT was performed in 50 patients with rising PSA levels at follow-up of primary treatment of prostate cancer (radical prostatectomy in 28, radiation therapy in 13, and brachytherapy in 9). PET detection rates were determined at various PSA thresholds and examined by receiver operating characteristic analysis. Findings consistent with recurrent prostate cancer were noted on FCH PET/CT in 31/50 (62%) patients, with positive findings in 17/18 (94%), and 11/13 (85%), 2/7 (29%), and 1/12 (8%) patients with PSA >4, >2-4, >0.5-2, and ≤0.5 ng/mL, respectively. These findings were indicative of local/regional recurrence in 23 cases and systemic recurrence in 8 cases, with only a single route of recurrence (id est (i.e.), either hematogenous, lymphatic, or intraprostatic) in 84% of PET scans with positive findings. Abnormal tumor activity was detected in 88% of patients with a PSA level of 1.1 ng/mL or higher, and in only 6% of patients with a PSA level below this threshold value. FCH PET/CT may serve to identify the route of tumor progression in patients with recurrent prostate cancer; however, the likelihood of tumor detection may be related to the PSA level at the time of imaging. (author)

  7. Regulatory review of probabilistic safety assessment (PSA) level 1

    International Nuclear Information System (INIS)

    Probabilistic safety assessment (PSA) is increasingly being used as part of the decision making process to assess the level of safety of nuclear power plants. The methodologies in use are maturing and the insights gained from the PSAs are being used along with those from the deterministic analysis. Many regulatory authorities consider that the current state of the art in PSA (especially Level 1 PSA) is sufficiently well developed that it can be used centrally in the regulatory decision making process - referred to as 'risk informed regulation'. For these applications to be successful, it will be necessary for regulatory authorities to have a high degree of confidence in PSA. However, at the IAEA Technical Committee Meeting on Use of PSA in the Regulatory Process in 1994 and at the OECD Nuclear Energy Agency Committee for Nuclear Regulatory Activities (CNRA) 'Special Issues' Meeting in 1997 on Review Procedures and Criteria for Different Regulatory Applications of PSA, it was recognized that formal regulatory review guidance for PSA did not exist. The senior regulators noted that there was a need to produce some international guidance for reviewing PSAs to establish an agreed basis for assessing whether important technological and methodological issues in PSAs are treated adequately and to verify that conclusions reached are appropriate. In 1997 the IAEA and OECD Nuclear Energy Agency agreed to produce in co-operation a technical document on the regulatory review of PSA. This publication is intended to provide guidance to regulatory authorities on how to review the PSA for a nuclear power plant to gain confidence that it has been carried out to an acceptable standard so that it can be used as the basis for taking risk informed decisions within a regulatory decision making process. The document gives guidance on how to set about reviewing a PSA and on the technical issues that need to be addressed. This publication gives guidance for the review of Level 1 PSA for

  8. Quality assurance in the Juragua Nuclear Power Plant preoperational PSA

    International Nuclear Information System (INIS)

    Quality Assurance (QA) is nowadays an important requirement for the competence of any production or service, making possible to get the desired quality at the lowest cost In the case of PSA, which are multidisciplinary, very detailed and complex analysis, with many interfaces between analyst tasks, QA plays an important role as a tool for the analytical process management, and it is recognized as one of the PSA issues which require additional development In this paper the QA system developed for the Juragua NPP preoperational PSA, its antecedents and the experiences of its application are described

  9. Level-1, -2 and -3 PSA for AHWR

    International Nuclear Information System (INIS)

    In the first phase Level-1 PSA has been carried out to identifying Postulated Initiating Events (PIEs) which may lead to Severe Core Damage (SCD) of the AHWR. In the second phase, a Level-2 PSA examines two enveloping severe reactor accidents through a combination of probabilistic and deterministic approaches, in order to determine the release of radio nuclides from containment, including the physical processes that are involved in the loss of structural integrity of the reactor core. In the third phase, a Level-3 PSA analyses the transport of radio nuclides through the environment and assesses the public health risk for the two scenarios considered. (author)

  10. Development of Tsunami PSA method for Korean NPP site

    International Nuclear Information System (INIS)

    A methodology of tsunami PSA was developed in this study. A tsunami PSA consists of tsunami hazard analysis, tsunami fragility analysis and system analysis. In the case of tsunami hazard analysis, evaluation of tsunami return period is major task. For the evaluation of tsunami return period, numerical analysis and empirical method can be applied. The application of this method was applied to a nuclear power plant, Ulchin 56 NPP, which is located in the east coast of Korean peninsula. Through this study, whole tsunami PSA working procedure was established and example calculation was performed for one of real nuclear power plant in Korea

  11. Use of probabilistic safety assessment for operational safety. PSA '91

    International Nuclear Information System (INIS)

    Around 250 participants, representing 32 IAEA Member States and 4 international organizations, reviewed recent developments and discussed directions for future efforts in the area of probabilistic safety assessment (PSA) and particularly on its use for operational safety. During the symposium 61 papers and 27 posters were presented covering a wide spectrum of activities in areas such as: experience with ''living'' PSAs, PSA applications in decision making, the use of PSA for evaluating operating experience for operator training and for accident management, and probabilistic safety criteria. A separate abstract was prepared for each of these presentations. Refs, figs and tabs

  12. AP1000 PSA model and its model format conversion

    International Nuclear Information System (INIS)

    The probabilistic safety assessment (PSA) model of the third generation nuclear power technology (AP1000) is built with CAFTA code, while the RiskSpectrum code is used in our institute. Based on the analysis of the data files of the two codes, the conversion code CAFTA2RS is developed to extract information from the PSA model built with CAFTA, modify the data format that incompatible with RiskSpectrum, convert the gate type, such as AANB, EQU and so on, to the gate type acceptable with RS, and finally convert the PSA model from the format of CAFTA code to the format of RiskSpectrum code automatically. (authors)

  13. Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients

    Energy Technology Data Exchange (ETDEWEB)

    Caster, Joseph M.; Falchook, Aaron D. [Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (United States); Hendrix, Laura H. [Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (United States); Chen, Ronald C., E-mail: Ronald_chen@med.unc.edu [Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (United States); Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (United States); Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (United States)

    2015-06-01

    Purpose: Radiation oncologists rely on available clinical information (biopsy Gleason score and prostate-specific antigen [PSA]) to determine the optimal treatment regimen for each prostate cancer patient. Existing published nomograms correlating clinical to pathologic extent of disease were based on patients treated in the 1980s and 1990s at select academic institutions. We used the Surveillance, Epidemiology, and End Results (SEER) database to examine pathologic outcomes (Gleason score and cancer stage) in early prostate cancer patients based on biopsy Gleason score and PSA concentration. Methods and Materials: This analysis included 25,858 patients whose cancer was diagnosed between 2010 and 2011, with biopsy Gleason scores of 6 to 7 and clinical stage T1 to T2 disease, who underwent radical prostatectomy. In subgroups based on biopsy Gleason score and PSA level, we report the proportion of patients with pathologically advanced disease (positive surgical margin or pT3-T4 disease) or whose Gleason score was upgraded. Logistic regression was used to examine factors associated with pathologic outcomes. Results: For patients with biopsy Gleason score 6 cancers, 84% of those with PSA <10 ng/mL had surgical T2 disease with negative margins; this decreased to 61% in patients with PSA of 20 to 29.9 ng/mL. Gleason score upgrading was seen in 43% (PSA: <10 ng/mL) to 61% (PSA: 20-29.9 ng/mL) of biopsy Gleason 6 patients. Patients with biopsy Gleason 7 cancers had a one-third (Gleason 3 + 4; PSA: <10 ng/mL) to two-thirds (Gleason 4 + 3; PSA: 20-29.9 ng/mL) probability of having pathologically advanced disease. Gleason score upgrading was seen in 11% to 19% of patients with biopsy Gleason 4 + 3 cancers. Multivariable analysis showed that higher PSA and older age were associated with Gleason score upgrading and pathologically advanced disease. Conclusions: This is the first population-based study to examine pathologic extent of disease and pathologic Gleason score

  14. Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients

    International Nuclear Information System (INIS)

    Purpose: Radiation oncologists rely on available clinical information (biopsy Gleason score and prostate-specific antigen [PSA]) to determine the optimal treatment regimen for each prostate cancer patient. Existing published nomograms correlating clinical to pathologic extent of disease were based on patients treated in the 1980s and 1990s at select academic institutions. We used the Surveillance, Epidemiology, and End Results (SEER) database to examine pathologic outcomes (Gleason score and cancer stage) in early prostate cancer patients based on biopsy Gleason score and PSA concentration. Methods and Materials: This analysis included 25,858 patients whose cancer was diagnosed between 2010 and 2011, with biopsy Gleason scores of 6 to 7 and clinical stage T1 to T2 disease, who underwent radical prostatectomy. In subgroups based on biopsy Gleason score and PSA level, we report the proportion of patients with pathologically advanced disease (positive surgical margin or pT3-T4 disease) or whose Gleason score was upgraded. Logistic regression was used to examine factors associated with pathologic outcomes. Results: For patients with biopsy Gleason score 6 cancers, 84% of those with PSA <10 ng/mL had surgical T2 disease with negative margins; this decreased to 61% in patients with PSA of 20 to 29.9 ng/mL. Gleason score upgrading was seen in 43% (PSA: <10 ng/mL) to 61% (PSA: 20-29.9 ng/mL) of biopsy Gleason 6 patients. Patients with biopsy Gleason 7 cancers had a one-third (Gleason 3 + 4; PSA: <10 ng/mL) to two-thirds (Gleason 4 + 3; PSA: 20-29.9 ng/mL) probability of having pathologically advanced disease. Gleason score upgrading was seen in 11% to 19% of patients with biopsy Gleason 4 + 3 cancers. Multivariable analysis showed that higher PSA and older age were associated with Gleason score upgrading and pathologically advanced disease. Conclusions: This is the first population-based study to examine pathologic extent of disease and pathologic Gleason score

  15. Minimally Informative Prior Distributions for PSA

    Energy Technology Data Exchange (ETDEWEB)

    Dana L. Kelly; Robert W. Youngblood; Kurt G. Vedros

    2010-06-01

    A salient feature of Bayesian inference is its ability to incorporate information from a variety of sources into the inference model, via the prior distribution (hereafter simply “the prior”). However, over-reliance on old information can lead to priors that dominate new data. Some analysts seek to avoid this by trying to work with a minimally informative prior distribution. Another reason for choosing a minimally informative prior is to avoid the often-voiced criticism of subjectivity in the choice of prior. Minimally informative priors fall into two broad classes: 1) so-called noninformative priors, which attempt to be completely objective, in that the posterior distribution is determined as completely as possible by the observed data, the most well known example in this class being the Jeffreys prior, and 2) priors that are diffuse over the region where the likelihood function is nonnegligible, but that incorporate some information about the parameters being estimated, such as a mean value. In this paper, we compare four approaches in the second class, with respect to their practical implications for Bayesian inference in Probabilistic Safety Assessment (PSA). The most commonly used such prior, the so-called constrained noninformative prior, is a special case of the maximum entropy prior. This is formulated as a conjugate distribution for the most commonly encountered aleatory models in PSA, and is correspondingly mathematically convenient; however, it has a relatively light tail and this can cause the posterior mean to be overly influenced by the prior in updates with sparse data. A more informative prior that is capable, in principle, of dealing more effectively with sparse data is a mixture of conjugate priors. A particular diffuse nonconjugate prior, the logistic-normal, is shown to behave similarly for some purposes. Finally, we review the so-called robust prior. Rather than relying on the mathematical abstraction of entropy, as does the constrained

  16. Hiperplasia Prostática Benigna e PSA: o efeito dominó Benign prostatic hyperplasia and PSA: the domino effect Hiperplasia benigna de prostata y PSA: el efecto dominó

    Directory of Open Access Journals (Sweden)

    José Agostinho Santos

    2012-12-01

    Full Text Available

    Após a publicação de uma recomendação contra o rastreio câncer prostático pela U.S. Preventive Services Task Force, a comunidade médica não poderá desvincular-se das particularidades relacionadas com o antígeno prostático específico (PSA. O enfoque dado às guidelines da Hiperplasia Prostática surge pela possível partilha, a determinado ponto da sua abordagem, de um trilho que cursa também com a solicitação do PSA. Os resultados de dois grandes ensaios clínicos constituem o maior corpo da evidência actual e deles sobressai que o número de homens que evitaram a morte por câncer prostático após submetidos ao rastreio foi reduzido. Há evidência de que 100-200 em 1000 homens rastreados terão um falso-positivo, a maioria dos quais será biopsada, com possíveis danos psicológicos e orgânicos. O Médico de Família deverá relembrar que não é recomendado que se ofereça esta análise, sem que primeiro discuta, juntamente com o paciente, as questões inerentes ao PSA.

    After U.S. Preventive Services Task Force published a recommendation against prostate cancer screening, the medical community cannot extricate itself from all specific features associated with the prostate-specific antigen (PSA. The focus given to the guidelines of the Prostatic Hyperplasia happens for the possible sharing of a certain point of its approach with the prostatic cancer case-finding, that is the PSA test. The results of two large clinical trials represent the largest body of evidence and they say the number of men who avoided prostate cancer death after subjected to screening was reduced. There is evidence that 100-200 in 1000 screened men will have a false-positive, most of which will have a biopsy with possible psychological damage and organic. The GP should remember that it is not recommended to provide this test, without first discussing together with

  17. Evaluation of Serum Testosterone and Prostate Specific Antigen Levels in Sprague-Dawley Female Rats Bearing Mammary Tumours Induced by Dimethylbenz (A) Anthracene

    International Nuclear Information System (INIS)

    Breast Cancer is one of the most common malignancies among women in the world and is a leading cause of morbidity and mortality in females of both developed and developing countries. The present work aimed to study the diagnostic value of prostate specific antigen (PSA) for breast cancer and the importance of treatment by blue green algae Spirulina platensis supplementation on PSA and testosterone levels. Two different analytical techniques based on micro particle enzyme immunoassay (MPIA) and enzyme linked fluorescent assay (ILFA) for quantitative determination of total PSA (free PSA and PSA complexed to alpha-1-antichymptrypsin) were studied in the diagnosis of breast cancer before and after Spirulina platensis supplementation. Female rats secret PSA from female prostate gland, serum testosterone and PSA concentrations were not detected in control and rats supplemented by Spirulina platensis groups. Serum testosterone and PSA concentration were significantly higher (P< 0.05) in rats bearing mammary tumours than rats bearing mammary tumours supplemented with Spirulina platensis. These results suggest that the clinical applicability of total PSA for breast cancer diagnosis and the biological mechanism behind its increase should be further investigated. Finally, the physiological mechanism behind the total PSA increase in breast cancer and its ramifications with respect to tumour progression should be further investigated.

  18. An introductory course of the probabilistic safety assessment (PSA) for LWR. (2) Application of PSA technology to plant management

    International Nuclear Information System (INIS)

    The probabilistic safety assessment (PSA) technology has been well developed and in several countries risk information derived by the probabilistic assessment has been used for making nuclear safety assurance activities reasonable and efficient. In Japan risk informed approach has been positively studied and then an introductory course of the PSA technology as its basis was prepared in serial form. This is the second issue shown application examples of the PSA technology in Japan and USA. Application examples of risk informed approach in order industries are also reviewed. (T. Tanaka)

  19. PSA Level 2 activities for RBMK reactors

    International Nuclear Information System (INIS)

    Probabilistic safety analyses (PSAs) of the boiling water graphite moderated pressure tube reactors (RBMKs) have been developed only recently and they are limited to Level 1. Activities at the IAEA were first motivated because of the difficulties to characterize core damage for RBMK reactors. Core damage probability is used in documents of the IAEA as a convenient single valued measure, for example for probabilistic safety criteria. The limited number of PSAs that have been completed for the RBMK reactors have shown that several special features of these channel type reactors necessitate revisiting of the characterization of core damage for these reactors. Furthermore, it has become increasingly evident that detailed deterministic analysis of DBAs and beyond design basis accidents reveal considerable insights into RBMK response to various accident conditions. These analyses can also help in better characterizing the outstanding phenomenological uncertainties, improved EOPs and AM strategies, including potential risk-beneficial accident negative backfits. The deterministic efforts should be focused first on elucidating accident progression processes and phenomena, and second on finding, qualifying and implementing procedures to minimize the risk of severe accident states The IAEA PSA procedures were mainly developed in New of vessel type LWRs, and would therefore require extensions to make them directly applicable. to channel type reactors. (author) (author)

  20. Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced 18F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy

    International Nuclear Information System (INIS)

    To evaluate the accuracy of contrast-enhanced 18F-choline PET/CT in restaging patients with prostate cancer after radical prostatectomy in relation to PSA, PSA velocity (PSAve) and PSA doubling time (PSAdt). PET/CT was performed in 49 patients (age range 58-87 years) with rising PSA (mean 4.13 ng/ml) who were divided in four groups according to PSA level: ≤1 ng/ml, 1 to ≤2 ng/ml, 2 to ≤4 ng/ml, and >4 ng/ml. PSAve and PSAdt were measured. PET and CT scans were interpreted separately and then together. PET/CT diagnosed relapse in 33 of the 49 patients (67%). The detection rates were 20%, 55%, 80% and 87% in the PSA groups ≤1, 1 to ≤2, 2 to ≤4 and >4 ng/ml, respectively. PET/CT was positive in 7 of 18 patients (38.9%) with a PSA ≤2 ng/ml, and in 26 of 31 (83.9%) with a PSA >2 ng/ml. PET/CT was positive in 7 of 25 patients (84%) with PSAdt ≤6 months, and in 12 of 24 patients (50%) with PSAdt >6 months, and was positive in 26 of 30 patients (86%) with a PSAve >2 ng/ml per year, and in 7 of 19 patients (36.8%) with PSAve ≤2 ng/ml per year. PET alone was positive in 31 of 49 patients (63.3%), and of these 31 patients, CT was negative in 14 but diagnosed bone lesions in 2 patients in whom PET alone was negative. CT with the administration of intravenous contrast medium did not provide any further information. Detection rate of 18F-choline imaging is closely related to PSA and PSA kinetics. In particular, 18F-choline PET/CT is recommended in patients with PSA >2 ng/ml, PSAdt ≤6 months and PSAve >2 ng/ml per year. CT is useful for detecting bone metastases that are not 18F-choline-avid. The use of intravenous contrast agent seems unnecessary. (orig.)

  1. Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced {sup 18}F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy

    Energy Technology Data Exchange (ETDEWEB)

    Schillaci, Orazio [University ' ' Tor Vergata' ' , Department of Biopathology and Diagnostic Imaging, Interventional, Rome (Italy); IRCCS Neuromed, Department of Nuclear Medicine and Molecular Imaging, Pozzilli (Italy); Calabria, Ferdinando [IRCCS Neuromed, Department of Nuclear Medicine and Molecular Imaging, Pozzilli (Italy); Tavolozza, Mario; Caracciolo, Cristiana Ragano; Orlacchio, Antonio; Danieli, Roberta; Simonetti, Giovanni [University ' ' Tor Vergata' ' , Department of Biopathology and Diagnostic Imaging, Interventional, Rome (Italy); Agro, Enrico Finazzi; Miano, Roberto [University Hospital ' ' Tor Vergata' ' , Department of Urology, Rome (Italy)

    2012-04-15

    To evaluate the accuracy of contrast-enhanced {sup 18}F-choline PET/CT in restaging patients with prostate cancer after radical prostatectomy in relation to PSA, PSA velocity (PSAve) and PSA doubling time (PSAdt). PET/CT was performed in 49 patients (age range 58-87 years) with rising PSA (mean 4.13 ng/ml) who were divided in four groups according to PSA level: {<=}1 ng/ml, 1 to {<=}2 ng/ml, 2 to {<=}4 ng/ml, and >4 ng/ml. PSAve and PSAdt were measured. PET and CT scans were interpreted separately and then together. PET/CT diagnosed relapse in 33 of the 49 patients (67%). The detection rates were 20%, 55%, 80% and 87% in the PSA groups {<=}1, 1 to {<=}2, 2 to {<=}4 and >4 ng/ml, respectively. PET/CT was positive in 7 of 18 patients (38.9%) with a PSA {<=}2 ng/ml, and in 26 of 31 (83.9%) with a PSA >2 ng/ml. PET/CT was positive in 7 of 25 patients (84%) with PSAdt {<=}6 months, and in 12 of 24 patients (50%) with PSAdt >6 months, and was positive in 26 of 30 patients (86%) with a PSAve >2 ng/ml per year, and in 7 of 19 patients (36.8%) with PSAve {<=}2 ng/ml per year. PET alone was positive in 31 of 49 patients (63.3%), and of these 31 patients, CT was negative in 14 but diagnosed bone lesions in 2 patients in whom PET alone was negative. CT with the administration of intravenous contrast medium did not provide any further information. Detection rate of {sup 18}F-choline imaging is closely related to PSA and PSA kinetics. In particular, {sup 18}F-choline PET/CT is recommended in patients with PSA >2 ng/ml, PSAdt {<=}6 months and PSAve >2 ng/ml per year. CT is useful for detecting bone metastases that are not {sup 18}F-choline-avid. The use of intravenous contrast agent seems unnecessary. (orig.)

  2. The trends in prostate specific antigen usage amongst United Kingdom urologists – a questionnaire based study

    Directory of Open Access Journals (Sweden)

    Holmes Chris H

    2008-11-01

    Full Text Available Abstract Background Worldwide, the use of prostate specific antigen (PSA testing as a screen for prostate cancer is contentious. Whilst there is no National UK Screening programme, many men undergo opportunistic screening. This study investigates UK urologist's usage of PSA and the awareness surrounding the Department of Health (DoH PSA guidelines. Methods Urologists were sent a questionnaire regarding PSA cut-off values. Results Of the 733 urologists eligible to participate in this study 346 returned completed questionnaires giving a response rate of 47%. The most commonly generally used age-related PSA cut-off values (36% of respondents are – 3.5 ng/ml for 50 – 59 year olds, 4.5 ng/ml for 60 – 69 year olds and 6.5 ng/ml for over 70 year olds. Two-thirds (58%, 200/346 of respondents were aware of the DoH PSA guidelines but only 20% (n = 69/346 follow these guidelines. The majority of respondents (68%, n = 234/346 used higher PSA cut-offs than recommended by the DoH. The level of compliance showed marked regional variation with a range from 7% to 44% (median 19%. In addition, it was apparent that lower PSA cut-off values were used in private practice as opposed to the National Health Service. Conclusion A nationwide lack of agreement on PSA cut-off values may generate a variable standard of care both regionally and in NHS versus private practice. Generally, higher PSA cut-off values are being used than recommended by the DoH guidance.

  3. Prostate-specific antigen and hormone receptor expression in male and female breast carcinoma

    Directory of Open Access Journals (Sweden)

    Cohen Cynthia

    2010-09-01

    Full Text Available Abstract Background Prostate carcinoma is among the most common solid tumors to secondarily involve the male breast. Prostate specific antigen (PSA and prostate-specific acid phosphatase (PSAP are expressed in benign and malignant prostatic tissue, and immunohistochemical staining for these markers is often used to confirm the prostatic origin of metastatic carcinoma. PSA expression has been reported in male and female breast carcinoma and in gynecomastia, raising concerns about the utility of PSA for differentiating prostate carcinoma metastasis to the male breast from primary breast carcinoma. This study examined the frequency of PSA, PSAP, and hormone receptor expression in male breast carcinoma (MBC, female breast carcinoma (FBC, and gynecomastia. Methods Immunohistochemical staining for PSA, PSAP, AR, ER, and PR was performed on tissue microarrays representing six cases of gynecomastia, thirty MBC, and fifty-six FBC. Results PSA was positive in two of fifty-six FBC (3.7%, focally positive in one of thirty MBC (3.3%, and negative in the five examined cases of gynecomastia. PSAP expression was absent in MBC, FBC, and gynecomastia. Hormone receptor expression was similar in males and females (AR 74.1% in MBC vs. 67.9% in FBC, p = 0.62; ER 85.2% vs. 68.5%, p = 0.18; and PR 51.9% vs. 48.2%, p = 0.82. Conclusions PSA and PSAP are useful markers to distinguish primary breast carcinoma from prostate carcinoma metastatic to the male breast. Although PSA expression appeared to correlate with hormone receptor expression, the incidence of PSA expression in our population was too low to draw significant conclusions about an association between PSA expression and hormone receptor status in breast lesions.

  4. Review of APR+ Level 2 PSA. Revision 2

    Energy Technology Data Exchange (ETDEWEB)

    Lehner, John R. [Brookhaven National Lab. (BNL), Upton, NY (United States); Mubayi, Vinod [Brookhaven National Lab. (BNL), Upton, NY (United States); Pratt, W. Trevor [Brookhaven National Lab. (BNL), Upton, NY (United States); Kim, Do Sam [Korea Institute of Nuclear Safety (KINS), Daejeon (Korea, Republic of); Cho, Yong Jin [Korea Institute of Nuclear Safety (KINS), Daejeon (Korea, Republic of); Cho, Sang Jin [Korea Institute of Nuclear Safety (KINS), Daejeon (Korea, Republic of); Kim, In Goo [Korea Institute of Nuclear Safety (KINS), Daejeon (Korea, Republic of)

    2012-02-17

    Brookhaven National Laboratory (BNL) assisted the Korea Institute of Nuclear Safety (KINS) in reviewing the Level 2 Probabilistic Safety Assessment (PSA) of the APR+ Advanced Pressurized Water Reactor (PWR) prepared by the Korea Hydro & Nuclear Power Co., Ltd (KHNP) and KEPCO Engineering & Construction Co., Inc. (KEPCO-E&C). The work described in this report involves a review of the APR+ Level 2 PSA submittal [Ref. 1]. The PSA and, therefore, the review is limited to consideration of accidents initiated by internal events. As part of the review process, the review team also developed three sets of Requests for Additional Information (RAIs). These RAIs were provided to KHNP and KEPCO-E&C for their evaluation and response. This final detailed report documents the review findings for each technical element of the PSA and includes consideration of all of the RAIs made by the reviewers as well as the associated responses. This final report was preceded by an interim report [Ref. 2] that focused on identifying important issues regarding the PSA. In addition, a final meeting on the project was held at BNL on November 21-22, 2011, where BNL and KINS reviewers discussed their preliminary review findings with KHNP and KEPCO-E&C staffs. Additional information obtained during this final meeting was also used to inform the review findings of this final report. The review focused not only on the robustness of the APR+ design to withstand severe accidents, but also on the capability and acceptability of the Level 2 PSA in terms of level of detail and completeness. The Korean nuclear regulatory authorities will decide whether the PSA is acceptable and the BNL review team is providing its comments for KINS consideration. Section 2.0 provides the basis for the BNL review. Section 3.0 presents the review of each technical element of the PSA. Conclusions and a summary are presented in Section 4.0. Section 5.0 contains the references.

  5. Point Lepreau Generating Station (PLGS) Level 2 PSA

    International Nuclear Information System (INIS)

    NB Power Nuclear has developed a PSA that incorporates a high degree of operational information and site-specific data to evaluate risk metrics based on the way the plant is actually operated and maintained. Unique characteristics of the PSA prepared for Point Lepreau Generating Station was presented. The high degree of model depth or resolution has enabled quick turn-around time in response to operational queries and the ability to quickly evaluate the impact of any system design modification. (author)

  6. Application of PSA in modifying plant technical specifications

    International Nuclear Information System (INIS)

    The Combustion Engineering Owners Group (CEOG) has undertaken an initiative to use Probabilistic Safety Analysis (PSA), in conjunction with other considerations, to obtain relief from unnecessarily restrictive aspects of plant technical specifications. This paper provides a summary of the integrated use of PSA along with deterministic and practical operational considerations in justifying AOT extensions for inoperability of one Safety Injection Tank (SIT), a single Low Pressure Safety Injection (LPSI) subtrain and one Emergency Diesel Generator (EDG)

  7. Child Injury: What You Need to Know PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2012-04-16

    This 60 second PSA is based on the April 2012 CDC Vital Signs report. Many childhood deaths and injuries are preventable, including those caused by crashes, suffocation, poisoning, drowning, fires, and falls. The PSA discusses ways to help prevent these deaths and injuries.  Created: 4/16/2012 by Centers for Disease Control and Prevention (CDC).   Date Released: 4/16/2012.

  8. Inference of Isoforms from Short Sequence Reads

    Science.gov (United States)

    Feng, Jianxing; Li, Wei; Jiang, Tao

    Due to alternative splicing events in eukaryotic species, the identification of mRNA isoforms (or splicing variants) is a difficult problem. Traditional experimental methods for this purpose are time consuming and cost ineffective. The emerging RNA-Seq technology provides a possible effective method to address this problem. Although the advantages of RNA-Seq over traditional methods in transcriptome analysis have been confirmed by many studies, the inference of isoforms from millions of short sequence reads (e.g., Illumina/Solexa reads) has remained computationally challenging. In this work, we propose a method to calculate the expression levels of isoforms and infer isoforms from short RNA-Seq reads using exon-intron boundary, transcription start site (TSS) and poly-A site (PAS) information. We first formulate the relationship among exons, isoforms, and single-end reads as a convex quadratic program, and then use an efficient algorithm (called IsoInfer) to search for isoforms. IsoInfer can calculate the expression levels of isoforms accurately if all the isoforms are known and infer novel isoforms from scratch. Our experimental tests on known mouse isoforms with both simulated expression levels and reads demonstrate that IsoInfer is able to calculate the expression levels of isoforms with an accuracy comparable to the state-of-the-art statistical method and a 60 times faster speed. Moreover, our tests on both simulated and real reads show that it achieves a good precision and sensitivity in inferring isoforms when given accurate exon-intron boundary, TSS and PAS information, especially for isoforms whose expression levels are significantly high.

  9. Perioperative prostate specific antigen levels among coronary artery bypass grafting patients: Does extracorporeal circulation and body temperature induce prostate specific antigen levels alterations?

    Science.gov (United States)

    Patris, Emmanuel; Giakoumidakis, Konstantinos; Patris, Vasileios; Kuduvalli, Manoj; Argiriou, Mihalis; Charitos, Christos; Kalaitzis, Christos; Touloupidis, Stavros

    2015-01-01

    Purpose: The purpose of this study is to compare the perioperative total prostate specific antigen (tPSA) levels among coronary artery bypass grafting (CABG) patients with and without extracorporeal circulation (ECC), to investigate the changes overtime of tPSA in each group separately and to determine the effect of body core temperature on tPSA levels. Materials and Methods: A prospective study was conducted. Our sample was allocated to: (a) Seven patients who underwent off pump CABG (Group I) and (b) 16 CABG patients with ECC (Group II). The levels of tPSA were measured preoperatively (baseline), intra-operatively and at the 4th postoperative day. We compared the two groups on their tPSA levels and we investigated the changes of tPSA overtime in each group separately. Results: Intra-operative serum samples were obtained in significantly lower body temperature in patients of Group II than in those of Group I (31°C vs. 36.9°C, P < 0.001). In each group separately, postoperative tPSA levels were increased significantly compared to the baseline values (2.55 ng/ml vs. 0.39 ng/ml for Group I, P = 0.005 and 4.36 ng/ml vs. 0.77 for Group II, P < 0.001). CABG patients with ECC had significantly lower intra-operative tPSA levels than the baseline values (0.67 ng/ml vs. 0.77 ng/ml, P = 0.008). We did not observe significant differences of tPSA levels between the two groups. Conclusions: CABG surgery affects similarly the perioperative tPSA independently the involvement of ECC. Although all patients had significantly higher early postoperative tPSA levels, only those who underwent CABG with ECC had exceeded normal values and significantly decreased intra-operative tPSA. Hypothermia seems to be the causal factor of tPSA reduction. PMID:25657546

  10. Magnetic-particle-based, ultrasensitive chemiluminescence enzyme immunoassay for free prostate-specific antigen

    International Nuclear Information System (INIS)

    Graphical abstract: -- Highlights: •A low-cost and rapid assay for f-PSA in serum was developed using MMP-based CLEIA. •f-PSA detection: 0.1–30 ng mL−1 concentration range; 0.1 ng mL−1 detection limit. •The proposed method showed high sensitivity, good reproducibility and stability. •The strategy showed great potential in the fabrication of MMP-based f-PSA test kits. -- Abstract: We report a magnetic-particle (MMP)-based chemiluminescence enzyme immunoassay (CLEIA) for free prostate-specific antigen (f-PSA) in human serum. In this method, the f-PSA is sandwiched between the anti-PSA antibody coated MMPs and alkaline phosphatase (ALP)-labeled anti-f-PSA antibody. The signal produced by the emitted photons from the chemiluminescent substrate (4-methoxy-4-(3-phosphatephenyl)-spiro-(1,2-dioxetane-3,2′-adamantane)) is directly proportional to the amount of f-PSA in a sample. The present MMP-based assay can detect f-PSA in the range of 0.1–30 ng mL−1 with the detection limit of 0.1 ng mL−1. The linear detection range could match the concentration range within the “diagnostic gray zone” of serum f-PSA levels (4–10 ng mL−1). The detection limit was sufficient for measuring clinically relevant f-PSA levels (>4 ng mL−1). Furthermore, the method was highly selective; it was unaffected by cross-reaction with human glandular kallikrein-2, a kallikrein-like serine protease that is 80% similar to f-PSA. The proposed method was finally applied to determine f-PSA in 40 samples of human sera. Results obtained using the method showed high correlation with those obtained using a commercially available microplate CLEIA kit (correlation coefficient, 0.9821). This strategy shows great potential application in the fabrication of diagnostic kits for determining f-PSA in serum

  11. Magnetic-particle-based, ultrasensitive chemiluminescence enzyme immunoassay for free prostate-specific antigen

    Energy Technology Data Exchange (ETDEWEB)

    Liu, Ruping [College of Electronic Information and Optical Engineering, Nankai University, Tianjin 300071 (China); Wang, Cheng [College of Electronic Information and Optical Engineering, Nankai University, Tianjin 300071 (China); Department of Mechanical Engineering, Columbia University, New York 10027 (United States); Jiang, Quan [Institute of Material Science and Engineering, Wuhan University of Technology, Wuhan 430070 (China); Zhang, Wei; Yue, Zhao [College of Electronic Information and Optical Engineering, Nankai University, Tianjin 300071 (China); Liu, Guohua, E-mail: liugh@nankai.edu.cn [College of Electronic Information and Optical Engineering, Nankai University, Tianjin 300071 (China)

    2013-11-01

    Graphical abstract: -- Highlights: •A low-cost and rapid assay for f-PSA in serum was developed using MMP-based CLEIA. •f-PSA detection: 0.1–30 ng mL{sup −1} concentration range; 0.1 ng mL{sup −1} detection limit. •The proposed method showed high sensitivity, good reproducibility and stability. •The strategy showed great potential in the fabrication of MMP-based f-PSA test kits. -- Abstract: We report a magnetic-particle (MMP)-based chemiluminescence enzyme immunoassay (CLEIA) for free prostate-specific antigen (f-PSA) in human serum. In this method, the f-PSA is sandwiched between the anti-PSA antibody coated MMPs and alkaline phosphatase (ALP)-labeled anti-f-PSA antibody. The signal produced by the emitted photons from the chemiluminescent substrate (4-methoxy-4-(3-phosphatephenyl)-spiro-(1,2-dioxetane-3,2′-adamantane)) is directly proportional to the amount of f-PSA in a sample. The present MMP-based assay can detect f-PSA in the range of 0.1–30 ng mL{sup −1} with the detection limit of 0.1 ng mL{sup −1}. The linear detection range could match the concentration range within the “diagnostic gray zone” of serum f-PSA levels (4–10 ng mL{sup −1}). The detection limit was sufficient for measuring clinically relevant f-PSA levels (>4 ng mL{sup −1}). Furthermore, the method was highly selective; it was unaffected by cross-reaction with human glandular kallikrein-2, a kallikrein-like serine protease that is 80% similar to f-PSA. The proposed method was finally applied to determine f-PSA in 40 samples of human sera. Results obtained using the method showed high correlation with those obtained using a commercially available microplate CLEIA kit (correlation coefficient, 0.9821). This strategy shows great potential application in the fabrication of diagnostic kits for determining f-PSA in serum.

  12. Mass-sensing BioCD Protein Array towards Clinical Application: Prostate Specific Antigen Detection in Patient Sera

    CERN Document Server

    Wang, Xuefeng; Nolte, David D; Ratliff, Timothy L

    2009-01-01

    Mass-sensing biosensor arrays for protein detection require no fluorophores or enzyme labels. However, few mass biosensor protein arrays have demonstrated successful application in high background samples, such as serum. In this paper, we test the BioCD as a mass biosensor based on optical interferometry of antibodies covalently attached through Schiff-base reduction. We use the BioCD to detect prostate specific antigen (PSA, a biomarker of prostate cancer) in patient sera in a 96-well anti-PSA microarray. We have attained a 4 ng/ml detection limit in full serum and have measured PSA concentrations in three patient sera.

  13. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer.

    Science.gov (United States)

    Pavlenko, M; Roos, A-K; Lundqvist, A; Palmborg, A; Miller, A M; Ozenci, V; Bergman, B; Egevad, L; Hellström, M; Kiessling, R; Masucci, G; Wersäll, P; Nilsson, S; Pisa, P

    2004-08-16

    Prostate-specific antigen (PSA) is a serine protease secreted at low levels by normal luminal epithelial cells of the prostate and in significantly higher levels by prostate cancer cells. Therefore, PSA is a potential target for various immunotherapeutical approaches against prostate cancer. DNA vaccination has been investigated as immunotherapy for infectious diseases in patients and for specific treatment of cancer in certain animal models. In animal studies, we have demonstrated that vaccination with plasmid vector pVAX/PSA results in PSA-specific cellular response and protection against tumour challenge. The purpose of the trial was to evaluate the safety, feasibility and biological efficacy of pVAX/PSA vaccine in the clinic. A phase I trial of pVAX/PSA, together with cytokine granulocyte/macrophage-colony stimulating factor (GM-CSF) (Molgramostim) and IL-2 (Aldesleukin) as vaccine adjuvants, was carried out in patients with hormone-refractory prostate cancer. To evaluate the biologically active dose, the vaccine was administered during five cycles in doses of 100, 300 and 900 microg, with three patients in each cohort. Eight patients were evaluable. A PSA-specific cellular immune response, measured by IFN-gamma production against recombinant PSA protein, and a rise in anti-PSA IgG were detected in two of three patients after vaccination in the highest dose cohort. A decrease in the slope of PSA was observed in the two patients exhibiting IFN-gamma production to PSA. No adverse effects (WHO grade >2) were observed in any dose cohort. We demonstrate that DNA vaccination with a PSA-coding plasmid vector, given with GM-CSF and IL-2 to patients with prostate cancer, is safe and in doses of 900 microg the vaccine can induce cellular and humoral immune responses against PSA protein. PMID:15280930

  14. Discoveries and application of prostate-specific antigen, and some proposals to optimize prostate cancer screening

    Science.gov (United States)

    Tokudome, Shinkan; Ando, Ryosuke; Koda, Yoshiro

    2016-01-01

    The discoveries and application of prostate-specific antigen (PSA) have been much appreciated because PSA-based screening has saved millions of lives of prostate cancer (PCa) patients. Historically speaking, Flocks et al first identified antigenic properties in prostate tissue in 1960. Then, Barnes et al detected immunologic characteristics in prostatic fluid in 1963. Hara et al characterized γ-semino-protein in semen in 1966, and it has been proven to be identical to PSA. Subsequently, Ablin et al independently reported the presence of precipitation antigens in the prostate in 1970. Wang et al purified the PSA in 1979, and Kuriyama et al first applied an enzyme-linked immunosorbent assay for PSA in 1980. However, the positive predictive value with a cutoff figure of 4.0 ng/mL appeared substantially low (∼30%). There are overdiagnoses and overtreatments for latent/low-risk PCa. Controversies exist in the PCa mortality-reducing effects of PSA screening between the European Randomized Study of Screening for Prostate Cancer (ERSPC) and the US Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. For optimizing PCa screening, PSA-related items may require the following: 1) adjustment of the cutoff values according to age, as well as setting limits to age and screening intervals; 2) improving test performance using doubling time, density, and ratio of free: total PSA; and 3) fostering active surveillance for low-risk PCa with monitoring by PSA value. Other items needing consideration may include the following: 1) examinations of cell proliferation and cell cycle markers in biopsy specimens; 2) independent quantification of Gleason grading; 3) developing ethnicity-specific staging nomograms based on tumor stage, PSA value, and Gleason score; 4) delineation of the natural history; 5) revisiting the significance of the androgen/testosterone hypothesis; and 6) devoting special attention to individuals with a certain genetic predisposition. Finally

  15. Discoveries and application of prostate-specific antigen, and some proposals to optimize prostate cancer screening.

    Science.gov (United States)

    Tokudome, Shinkan; Ando, Ryosuke; Koda, Yoshiro

    2016-01-01

    The discoveries and application of prostate-specific antigen (PSA) have been much appreciated because PSA-based screening has saved millions of lives of prostate cancer (PCa) patients. Historically speaking, Flocks et al first identified antigenic properties in prostate tissue in 1960. Then, Barnes et al detected immunologic characteristics in prostatic fluid in 1963. Hara et al characterized γ-semino-protein in semen in 1966, and it has been proven to be identical to PSA. Subsequently, Ablin et al independently reported the presence of precipitation antigens in the prostate in 1970. Wang et al purified the PSA in 1979, and Kuriyama et al first applied an enzyme-linked immunosorbent assay for PSA in 1980. However, the positive predictive value with a cutoff figure of 4.0 ng/mL appeared substantially low (∼30%). There are overdiagnoses and overtreatments for latent/low-risk PCa. Controversies exist in the PCa mortality-reducing effects of PSA screening between the European Randomized Study of Screening for Prostate Cancer (ERSPC) and the US Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. For optimizing PCa screening, PSA-related items may require the following: 1) adjustment of the cutoff values according to age, as well as setting limits to age and screening intervals; 2) improving test performance using doubling time, density, and ratio of free: total PSA; and 3) fostering active surveillance for low-risk PCa with monitoring by PSA value. Other items needing consideration may include the following: 1) examinations of cell proliferation and cell cycle markers in biopsy specimens; 2) independent quantification of Gleason grading; 3) developing ethnicity-specific staging nomograms based on tumor stage, PSA value, and Gleason score; 4) delineation of the natural history; 5) revisiting the significance of the androgen/testosterone hypothesis; and 6) devoting special attention to individuals with a certain genetic predisposition. Finally

  16. Natural History of Untreated Prostate Specific Antigen Radiorecurrent Prostate Cancer in Men with Favorable Prognostic Indicators

    Directory of Open Access Journals (Sweden)

    Neil E. Martin

    2014-01-01

    Full Text Available Background and Purpose. Life expectancy data could identify men with favorable post-radiation prostate-specific antigen (PSA failure kinetics unlikely to require androgen deprivation therapy (ADT. Materials and Methods. Of 206 men with unfavorable-risk prostate cancer in a randomized trial of radiation versus radiation and ADT, 53 experienced a PSA failure and were followed without salvage ADT. Comorbidity, age and established prognostic factors were assessed for relationship to death using Cox regression analyses. Results. The median age at failure, interval to PSA failure, and PSA doubling time were 76.6 years (interquartile range [IQR]: 71.8–79.3, 49.1 months (IQR: 37.7–87.4, and 25 months (IQR: 13.1–42.8, respectively. After a median follow up of 4.0 years following PSA failure, 45% of men had died, none from prostate cancer and no one had developed metastases. Both increasing age at PSA failure (HR: 1.14; 95% CI: 1.03–1.25; P=0.008 and the presence of moderate to severe comorbidity (HR: 12.5; 95% CI: 3.81–41.0; P2 years following post-radiation PSA failure appear to be good candidates for observation without ADT intervention.

  17. Electrochemical immunoassay for the prostate specific antigen using ceria mesoporous nanospheres

    International Nuclear Information System (INIS)

    We report on a sensitive electrochemical immunoassay for the prostate specific antigen (PSA). An immunoelectrode was fabricated by coating a glassy carbon electrode with multiwalled carbon nanotubes, poly(dimethyldiallylammonium chloride), CeO2 and PSA antibody (in this order) using the layer-by-layer method. The immunosensor is then placed in a sample solution containing PSA and o-phenylenediamine (OPD). It is found that the CeO2 nanoparticles facilitate the electrochemical oxidation of OPD, and this produces a signal for electrochemical detection of PSA that depends on the concentration of PSA. There is a linear relationship between the decrease in current and the concentration of PSA in the 0.01 to 1,000 pg mL−1 concentration range, and the detection limit is 4 fg mL−1. The assay was successfully applied to the detection of PSA in serum samples. This new differential pulse voltammetric immunoassay is sensitive and acceptably precise, and the fabrication of the electrode is well reproducible. (author)

  18. Highlights of the PSA analyses performed for the RRR

    International Nuclear Information System (INIS)

    In July 2000, ANSTO signed a contract with the Argentinian company INVAP S.E. for the design, construction and commissioning of a replacement research reactor (RRR). INVAP contracted CEDIAC to prepare the Probabilistic Safety Assessment (PSA) for the RRR in support of the ANSTO application for the construction licence. The PSA is complementary to the Safety Analysis, in the sense that it asks questions such as 'What if the Postulated Initiating Events were to occur and more than one piece of equipment were to fail? What if several things were to go wrong?' The PSA attempts to determine all the possible combinations of how the plant could respond to an initiating event, group all the possible outcomes, obtain conservative estimates of the frequency, and bounding estimates of the consequences (i.e., doses to the worst exposed individual of the public). The frequency and consequence constitute the risk, and when evaluated for all possible events can be compared against the safety objectives set out in the regulatory principles. Besides the basic objective of the PSA, which is the quantitative evaluation of the risks associated with the RRR, and its comparison to the regulatory objectives, the PSA studies have been performed in parallel with the basic engineering phase of the project. Therefore, preliminary results from 'the risk point of view' were used as input to the design process, thus permitting improvements to be made to the design, and resulting in an effective reduction of the residual risk. To perform the PSA studies several methodological developments were made, in order to obtain a representative list of internal and external initiating events, to treat component and human-related failures, to consider common-cause failures, and to consider some specific aspects of the design (i.e., fail-safe components, passive systems, and lack of need for support systems). The PSA studies were performed to obtain not only quantitative estimations of the risk, but also

  19. Seismic probabilistic safety assessment (PSA): an update

    International Nuclear Information System (INIS)

    the NEA Committee on the Safety of Nuclear Installations (CSNI) organised a Specialists' Meeting on Seismic Probabilistic Safety Assessment (SPSA) of Nuclear Facilities which took place on Jeju Island, Republic of Korea on 6-8 November 2006. The main objectives of the meeting were to review recent advances in SPSA methodology, to discuss practical applications, to review the current state of the art, and to identify methodology issues on which further research would be beneficial. One specific objective was to compare the situation today with the situation in 1999, date of the previous SPSA workshop, and to develop a set of findings and recommendations that would update the previous ones. Ample time was allotted to discussing the current situation and developments in SPSA, probabilistic seismic hazard analysis (PSHA) and seismic margin assessment (SMA). About 75 specialists from 15 countries participated, providing a large amount of technical material and information that form the basis for this article. Participants concluded that there are some areas in which follow-up work would be highly desirable on an international level. One of them would be a comparison of seismic hazard studies from countries with high, medium and low seismicity. The PSHA results should be compared to all available observations, especially for return periods where records are available, in order to improve the confidence in the results. Any PSHA activity would benefit from review by all stakeholders: plant owners, regulators, PSA managers, systems analysts and fragility analysts, since bias in the seismic hazard values may have significant effect on cost, risk and licensing effort. Moreover, because of the rapid progress in using SPSA, it may be necessary to revisit the ten-years old NEA/CSNI state-of-the-art report on SPSA. Collecting information from conventional industrial sites after large earthquakes may be a good way to increase current knowledge about operator and emergency

  20. Development of level 2 PSA technology

    Energy Technology Data Exchange (ETDEWEB)

    Kim, Dong Ha; Park, Soo Yong; Kim, See Darl; Song, Yong Mann; Ahn, Kwang Il; Park, Jae Wu; Jin, Young Ho

    1997-07-01

    The objective of this project is the development of the computer code system for level 2 probabilistic safety assessment (PSA) of nuclear power plants. The scope of the project can be divided into three areas. The first area is to develop the computer code (CONPAS) which can quantify the accident progression event trees. CONPAS beta version has been developed this year and it is comprised of four modules : (1) EDITOR for generating the event tree logic diagrams and (2) COMPUTER for event tree quantification and for additional use of the calculated results. (3) TEXT EDITOR and (4) CODE PLOTTER. Comparing with the existing computer code, the present code provides a flexible code reusability and user interface, convenient edition of logic diagram, data operation, and systematic quantification of the results. The methodology development of containment structural analysis is the second area. The specific tasks included the collection and analysis of the containment failure modes for the various containment types, and the methodology establishment for the containment structure analysis. Over twenty large dry PWR containments, the database for containment failure mode and pressure has been constructed and the simplified fragility model has been proposed to calculate the containment failure probability. They will be used as an important input not only in the containment analysis but also in the source term analysis. For the last, source term analyzing methodology and its applied computer code that is named as `KORSOR` are developed. KORSOR which used parametric model approach combined modules which consist of accident sequence input module via user`s logic rule, random sample generating module, parametric database module, and source term uncertainty quantification module. The characteristics of parametric data which use din the source term analyzing model is analyzed and the constructing idea and example for the parametric database is suggested. (author). 67 refs., 66 tabs

  1. Prostate-specific antigen-positive extramammary Paget's disease--association with prostate cancer

    DEFF Research Database (Denmark)

    Hammer, Anne; Hager, Henrik; Steiniche, Torben

    2008-01-01

    Extramammary Paget's disease (EMPD) is a rare intraepidermal adenocarcinoma that primarily affects the anogenital region. Cases of EMPD reacting with PSA (prostate-specific antigen) have previously been associated with underlying prostate cancer. However, a recent case of EMPD in our department has...... led us to question the value of PSA as an indicator of underlying prostate cancer. Clinical and pathological data were obtained for 16 cases of EMPD. Formalin-fixed, paraffin-embedded tissue blocks from the primary skin lesions were investigated using PSA and other immunohistochemical markers. 5 of...... the 16 cases of EMPD stained positive for PSA (2 women and 3 men). However, no reactivity was seen for the prostatic marker P501S. Three of the five patients had been diagnosed with internal malignant disease-two with prostate cancer, stage 1. Immunohistochemical investigations of the tumour specimens...

  2. PSA doubling time for prediction of [11C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy

    International Nuclear Information System (INIS)

    Previous studies have shown that the positive detection rate of [11C]choline positron emission tomography/computed tomography (PET/CT) depends on prostate-specific antigen (PSA) plasma levels. This study compared PSA levels and PSA doubling time (PSADT) to predict [11C]choline PET/CT findings. PSADT was retrospectively calculated in 170 prostate cancer (PCa) patients with biochemical failure after radical prostatectomy who underwent [11C]choline PET/CT. PSADT was calculated as PSADT = ln2/m, where m is the slope of the linear regression line of the natural log of PSA values. At least three PSA measurements were used (median: 4; range: 3-16), separated by at least 3 months, each with a minimum increase of 0.20 ng/ml. PET/CT findings were validated using criteria based on histological analysis and clinical and imaging data. Statistical analysis was performed using the t test, chi-square test, analysis of variance and binary logistic regression. Regression-based coefficients were used to develop a nomogram predicting the probability of positive [11C]choline PET/CT and 200 bootstrap resamples were used for internal validation. The median PSA was 1.25 ng/ml (range: 0.23-48.6 ng/ml), and the median PSADT was 7.0 months (range: 0.97-45.3 months). [11C]choline PET/CT was positive in 75 of 170 patients (44%). PET/CT findings were validated using histological criteria (11%) and clinical and imaging criteria (89%). The overall accuracy of [11C]choline PET/CT was 88%. Multivariate logistic regression showed that high PSA and short PSADT were significant (p 11C]choline PET/CT [PSA: odds ratio (OR) = 1.43; 95% confidence interval (CI): 1.15-1.78; PSADT: OR = 1.12; 95% CI: 1.04-1.21]. The percentage of patients with positive [11C]choline PET/CT was 27% for PSADT >6 months, 61% for PSADT between 3 and 6 months and 81% for PSADT 11C]choline uptake in the skeleton significantly increased (p 6 months to 52% for PSADT 11C]choline uptake in the prostatectomy bed were 0% for PSADT 6

  3. Assay-specific artificial neural networks for five different PSA assays and populations with PSA 2-10 ng/ml in 4,480 men.

    Science.gov (United States)

    Stephan, Carsten; Xu, Chuanliang; Cammann, Henning; Graefen, Markus; Haese, Alexander; Huland, Hartwig; Semjonow, Axel; Diamandis, Eleftherios P; Remzi, Mesut; Djavan, Bob; Wildhagen, Mark F; Blijenberg, Bert G; Finne, Patrik; Stenman, Ulf-Hakan; Jung, Klaus; Meyer, Hellmuth-Alexander

    2007-03-01

    Use of percent free PSA (%fPSA) and artificial neural networks (ANNs) can eliminate unnecessary prostate biopsies. In a total of 4,480 patients from five centers with PSA concentrations in the range of 2-10 ng/ml an IMMULITE PSA-based ANN (iANN) was compared with other PSA assay-adapted ANNs (nANNs) to investigate the impact of different PSA assays. ANN data were generated with PSA, fPSA (assays from Abbott, Beckman, DPC, Roche or Wallac), age, prostate volume, and DRE status. In 15 different ROC analyses, the area under the curve (AUC) in the PSA ranges 2-4, 2-10, and 4-10 ng/ml for the nANN was always significantly larger than the AUC for %fPSA or PSA. The nANN and logistic regression models mostly also performed better than the iANN. Therefore, for each patient population, PSA assay-specific ANNs should be used to optimize the ANN outcome in order to reduce the number of unnecessary biopsies. PMID:17333205

  4. Long distance bicycle riding causes prostate-specific antigen to increase in men aged 50 years and over.

    Directory of Open Access Journals (Sweden)

    Sandra L Mejak

    Full Text Available OBJECTIVES: To investigate whether bicycle riding alters total prostate-specific antigen (tPSA serum concentrations in healthy older men. METHODS: 129 male participants, ranging in age from 50 to 71 years (mean 55 years, rode in a recreational group bicycle ride of between 55 and 160 kilometers. Blood samples for tPSA analysis were drawn within 60 minutes before starting, and within 5 minutes after completing the ride. The pre-cycling and post-cycling tPSA values were log transformed for normality and compared using paired t-tests. Linear regression was used to assess the relationship between changes in tPSA with age and distance cycled. RESULTS: Bicycle riding caused tPSA to increase by an average of 9.5% (95% CI = 6.1-12.9; p<0.001 or 0.23 ng/ml. The number of participants with an elevated tPSA (using the standard PSA normal range cut-off of 4.0 ng/ml increased from two pre-cycle to six post-cycle (or from five to eight when using age-based normal ranges. Univariate linear regression analysis revealed that the change in tPSA was positively correlated with age and the distance cycled. CONCLUSIONS: Cycling causes an average 9.5% increase in tPSA, in healthy male cyclists ≥50 years old, when measured within 5 minutes post cycling. We considered the increase clinically significant as the number of participants with an elevated PSA, according to established cut-offs, increased post-ride. Based on the research published to date, the authors suggest a 24-48 hour period of abstinence from cycling and ejaculation before a PSA test, to avoid spurious results.

  5. Long Distance Bicycle Riding Causes Prostate-Specific Antigen to Increase in Men Aged 50 Years and Over

    Science.gov (United States)

    Mejak, Sandra L.; Bayliss, Julianne; Hanks, Shayne D.

    2013-01-01

    Objectives To investigate whether bicycle riding alters total prostate-specific antigen (tPSA) serum concentrations in healthy older men. Methods 129 male participants, ranging in age from 50 to 71 years (mean 55 years), rode in a recreational group bicycle ride of between 55 and 160 kilometers. Blood samples for tPSA analysis were drawn within 60 minutes before starting, and within 5 minutes after completing the ride. The pre-cycling and post-cycling tPSA values were log transformed for normality and compared using paired t-tests. Linear regression was used to assess the relationship between changes in tPSA with age and distance cycled. Results Bicycle riding caused tPSA to increase by an average of 9.5% (95% CI = 6.1–12.9; p<0.001) or 0.23 ng/ml. The number of participants with an elevated tPSA (using the standard PSA normal range cut-off of 4.0 ng/ml) increased from two pre-cycle to six post-cycle (or from five to eight when using age-based normal ranges). Univariate linear regression analysis revealed that the change in tPSA was positively correlated with age and the distance cycled. Conclusions Cycling causes an average 9.5% increase in tPSA, in healthy male cyclists ≥50 years old, when measured within 5 minutes post cycling. We considered the increase clinically significant as the number of participants with an elevated PSA, according to established cut-offs, increased post-ride. Based on the research published to date, the authors suggest a 24–48 hour period of abstinence from cycling and ejaculation before a PSA test, to avoid spurious results. PMID:23418500

  6. Seismic PSA of nuclear power plants a case study

    International Nuclear Information System (INIS)

    Seismic Probabilistic Safety Assessment (Seismic PSA) analysis is an external event PSA analysis. The objective of seismic PSA for the plants is to examine the existence of plant vulnerabilities against postulated earthquakes by numerically assessing the plant safety and to take appropriate measures to enhance the plant safety. Seismic PSA analysis integrates the seismic hazard analysis, seismic response analysis, seismic fragility analysis and system reliability/ accident sequence analysis. In general, the plant consists of normally operating and emergency standby systems and components. The failure during an earthquake (induced directly by excessive inertial stresses or indirectly following the failure of some other item) of an operating component will lead to a change in the state of the plant. In that case, various scenarios can follow depending on the initiating event and the status of other sub-systems. The analysis represents these possible chronological sequences by an event tree. The event trees and the associated fault trees model the sub-systems down to the level of individual components. The procedure has been applied for a typical Indian nuclear power plant. From the internal event PSA level I analysis significant contribution to the Core Damage Frequency (CDF) was found due to the Fire Water System. Hence, this system was selected to establish the procedure of seismic PSA. In this report the different elements that go into seismic PSA analysis have been discussed. Hazard curves have been developed for the site. Fragility curve for the seismically induced failure of Class IV power has been developed. The fragility curve for fire-water piping system has been generated. Event tree for Class IV power supply has been developed and the dominating accident sequences were identified. CDF has been estimated from these dominating accident sequences by convoluting hazard curves of initiating event and fragility curves of the safety systems. (author)

  7. Use of PSA to prioritize NPP walk down activities

    International Nuclear Information System (INIS)

    Full text of publication follows: an international team of experts, organized by the Institute of Risk Research of the Academic Senate of the University of Vienna, conducted a walk down assessment of the Mochovce Nuclear Power Plant (NPP) in May 1998. The Mochovce NPP is a VVER-440/213 station which has been in final construction and implementation of a safety improvement program since 1996. In preparation for the walk down, available plant design information was organized into a probabilistic safety assessment (PSA) format in order to assist in prioritizing walk down activities. The PSA was also used to understand the likely impact on core damage frequency (CDF) resulting from implementation of the safety improvement program. The PSA employed event trees from the Dukovany PSA, modified to represent the system designs at Mochovce, to assess internal hazards. External hazards were assessed based on an evaluation performed in 1995, with consideration given to upgrades planned to be implemented up to 1998. Failure events were identified directly based on the Dukovany PSA and other sources, and quantified using data from the Dukovany PSA, other non-Mochovce PSAs, and generic data. The PSA was used to identify a suite of dominant accident sequences from internal and external causes. The impact of safety improvements on these sequences was then assessed. The 'pre-fix' and 'post-fix' cases were compared to identify the change in risk due to implementation of the safety improvement program. Following the walk down, the 'post-fix' case was updated based on insights gained from the walk down. This revised case was used to aid in understanding the risk significance of issues identified during the walk down. (author)

  8. Quantitative Time-Resolved Fluorescence Imaging of Androgen Receptor and Prostate-Specific Antigen in Prostate Tissue Sections.

    Science.gov (United States)

    Krzyzanowska, Agnieszka; Lippolis, Giuseppe; Helczynski, Leszek; Anand, Aseem; Peltola, Mari; Pettersson, Kim; Lilja, Hans; Bjartell, Anders

    2016-05-01

    Androgen receptor (AR) and prostate-specific antigen (PSA) are expressed in the prostate and are involved in prostate cancer (PCa). The aim of this study was to develop reliable protocols for reproducible quantification of AR and PSA in benign and malignant prostate tissue using time-resolved fluorescence (TRF) imaging techniques. AR and PSA were detected with TRF in tissue microarrays from 91 PCa patients. p63/ alpha-methylacyl-CoA racemase (AMACR) staining on consecutive sections was used to categorize tissue areas as benign or cancerous. Automated image analysis was used to quantify staining intensity. AR intensity was significantly higher in AMACR+ and lower in AMACR- cancer areas as compared with benign epithelium. The PSA intensity was significantly lower in cancer areas, particularly in AMACR- glands. The AR/PSA ratio varied significantly in the AMACR+ tumor cells as compared with benign glands. There was a trend of more rapid disease progression in patients with higher AR/PSA ratios in the AMACR- areas. This study demonstrates the feasibility of developing reproducible protocols for TRF imaging and automated image analysis to study the expression of AR and PSA in benign and malignant prostate. It also highlighted the differences in AR and PSA protein expression within AMACR- and AMACR+ cancer regions. PMID:27026295

  9. Conformational difference in human IgG2 disulfide isoforms revealed by hydrogen/deuterium exchange mass spectrometry.

    Science.gov (United States)

    Zhang, Aming; Fang, Jing; Chou, Robert Y-T; Bondarenko, Pavel V; Zhang, Zhongqi

    2015-03-17

    Both recombinant and natural human IgG2 antibodies have several different disulfide bond isoforms, which possess different global structures, thermal stabilities, and biological activities. A detailed mapping of the structural difference among IgG2 disulfide isoforms, however, has not been established. In this work, we employed hydrogen/deuterium exchange mass spectrometry to study the conformation of three major IgG2 disulfide isoforms known as IgG2-B, IgG2-A1, and IgG2-A2 in two recombinant human IgG2 monoclonal antibodies. By comparing the protection factors between amino acid residues in isoforms B and A1 (the classical form), we successfully identified several local regions in which the IgG2-B isoform showed more solvent protection than the IgG2-A1 isoform. On the basis of three-dimensional structural models of IgG2, these identified regions were located on the Fab domains, close to the hinge, centered on the side where the two Fab arms faced each other in spatial proximity. We speculated that in the more solvent-protected B isoform, the two Fab arms were brought into contact by the nonclassical disulfide bonds, resulting in a more compact global structure. Loss of Fab domain flexibility in IgG2-B could limit its ability to access cell-surface epitopes, leading to reduced antigen binding potency. The A2 isoform was previously found to have disulfide linkages similar to those of the classical A1 isoform, but with different biophysical behaviors. Our data indicated that, compared to IgG2-A1, IgG2-A2 had less solvent protection in some heavy-chain Fab regions close the hinge, suggesting that the A2 isoform had more flexible Fab domains. PMID:25730439

  10. Aberrant sialylation of a prostate-specific antigen: Electrochemical label-free glycoprofiling in prostate cancer serum samples.

    Science.gov (United States)

    Pihikova, Dominika; Kasak, Peter; Kubanikova, Petra; Sokol, Roman; Tkac, Jan

    2016-08-31

    Electrochemical detection method allowing to detect prostate-specific antigen (PSA), a biomarker of prostate cancer (PCa), with PSA glycoprofiling was applied in an analysis of PCa serum samples for the first time. Electrochemical impedance spectroscopy (EIS) as a label-free method with immobilized anti-PSA was applied for PSA detection and lectins to glycoprofile captured PSA on the same surface. A proper choice of blocking agent providing high selectivity of biosensor detection with the immobilized anti-PSA antibody was done. The biosensor could detect PSA down to 100 ag/mL with a linear concentration working range from 100 ag/mL up to 1 μg/mL, i.e. 10 orders of concentration magnitude and the sensitivity of (5.5 ± 0.2)%/decade. The results showed that a commercial carbo-free blocking solution was the best one, reducing non-specific binding 55-fold when compared to the immunosensor surface without any blocking agent applied, while allowing to detect PSA. The biosensor response obtained after addition of lectin (i.e. proportional to the amount of a particular glycan on PSA) divided by the biosensor response obtained after incubation with a sample (i.e. proportional to the PSA level in the sample) was applied to distinguish serum samples of PCa patients from those of healthy individuals. The results showed that Maackia amurensis agglutinin (MAA) recognizing α-2,3-terminal sialic acid can be applied to distinguish between these two sets of samples since the MAA/PSA response obtained from the analysis of the PCa samples was significantly higher (5.3-fold) compared to the MAA/PSA response obtained by the analysis of samples from healthy individuals. Thus, combined analysis of serological PSA levels together with PSA glycoprofiling of aberrant glycosylation of PSA (i.e. increase in the level of α-2,3-terminal sialic acid) has a potential to improve detection of PCa. PMID:27506346

  11. Predictive value of serum prostate specific antigen in detecting bone metastasis in prostate cancer patients using bone scintigraphy

    International Nuclear Information System (INIS)

    Radionuclide bone scan (BS) used to be the investigation of choice for detecting osseous metastases in prostate cancer. Now, with the availability serum prostate specific antigen (PSA) testing, clinicians do have a timely, cost-effective method to determine those patients who are highly unlikely to have osseous metastases. We determine the utility of PSA for predicting the presence of skeletal metastasis on BSs in prostate cancer patients. Retrospective analysis of medical records of 322 consecutive prostate cancers patients subjected to BS during the last 3 years was done. 52 cases were excluded due to following reasons: Serum PSA not available, hormonal or other therapy given prior to serum PSA measurement, and/or BS, and symptomatic for bone metastasis. In remaining 270 cases, PSA value and BS were evaluated. BS was performed with Tc99m methylene diphosphonate (MDP) as per the standard protocol. BS was found to be positive in 153/270 (56%) and negative in 117 (46%) patients. Of the 153 positive cases, 108 (70%) had serum PSA > 100 ng/ml, 42 (28%) had PSA of 20-100 ng/ml and only 3 (2%) had PSA < 20 ng/ml. All the patients with PSA > 100 ng/ml had multiple skeletal metastasis. Of the 117 negative cases, 110 (94%) had a PSA < 20 ng/ml, 5 had between 20 and 100 ng/ml and only 2 (1.8%) had PSA > 100 ng/ml. Of the 113 patients with serum PSA < 20 ng/ml, 110 (97.4%) did not show any bony metastasis. 150/157 (95.5%) patients with PSA > 20 ng/ml had bone metastasis. Using this criterion, 110 (40.7%) scans would have been omitted. Serum PSA < 20 ng/ml have high predictive value in ruling out skeletal metastasis. Our data are in corroboration with results from previous studies that BS should be performed only if PSA > 20 ng/ml. Using this cut-off, unnecessary investigation can be avoided. Avoiding BS in this group of patients would translate into a significant cost-saving and reduction in their psychological and physical burden

  12. Ni2+-Dependent and PsaR-Mediated Regulation of the Virulence Genes pcpA, psaBCA, and prtA in Streptococcus pneumoniae.

    Directory of Open Access Journals (Sweden)

    Irfan Manzoor

    Full Text Available Previous studies have shown that the transcriptional regulator PsaR regulates the expression of the PsaR regulon consisting of genes encoding choline binding protein (PcpA, the extracellular serine protease (PrtA, and the Mn2+-uptake system (PsaBCA, in the presence of manganese (Mn2+, zinc (Zn2+, and cobalt (Co2+. In this study, we explore the Ni2+-dependent regulation of the PsaR regulon. We have demonstrated by qRT-PCR analysis, metal accumulation assays, β-galactosidase assays, and electrophoretic mobility shift assays that an elevated concentration of Ni2+ leads to strong induction of the PsaR regulon. Our ICP-MS data show that the Ni2+-dependent expression of the PsaR regulon is directly linked to high, cell-associated, concentration of Ni2+, which reduces the cell-associated concentration of Mn2+. In vitro studies with the purified PsaR protein showed that Ni2+ diminishes the Mn2+-dependent interaction of PsaR to the promoter regions of its target genes, confirming an opposite effect of Mn2+ and Ni2+ in the regulation of the PsaR regulon. Additionally, the Ni2+-dependent role of PsaR in the regulation of the PsaR regulon was studied by transcriptome analysis.

  13. Detection of prostate specific antigen in serum at the femto-gram per milliliter level using the intrinsic amplification of a field-effect enzymatic immuno-sensing system

    International Nuclear Information System (INIS)

    Ultrasensitive detection of prostate specific antigen (PSA) has been achieved by applying the field-effect enzymatic detection (FEED) technique to the sandwich immuno-sensing technique. The voltage-controlled intrinsic amplification provided by FEED enabled the detection of PSA contained in serum on the femto-gram/mL level. Two electrochemical approaches used to obtain the amperometric detection signal resulted in similar detection limits and sensitivities. The lowest PSA detection limit achieved was 27 fg mL−1. The high selectivity of the detection system was reflected in the fact that PSA detection was successful on the fg mL−1 level, where biological substances other than PSA had a 1-million-fold higher concentration. Electron transfer through the immunological sandwich nanostructure has been observed in the detection of biomarkers. However, our results showed that electron transfer through the nanostructure could be controlled using an external voltage, leading to an ultralow detection limit for PSA

  14. Experience in PSA fault tree modularization at the ASCO NPP

    International Nuclear Information System (INIS)

    Probabilistic Safety Analysis (PSA) is a basic tool in decision-making for the optimization of back fittings, procedures and maintenance practices. ASCO NPP PSA was developed with a high level of detail in the models. This required considerable computer resources (long running time) to carry out the quantification. The quantification time had therefore to be flexible to allow continuous evaluation of the impact on the estimation and reduction of risk in the plant, and also to facilitate post-PSA applications. The most suitable way of achieving this flexibility was by compacting and reducing the detailed fault trees of the project by means of a modularization process. The purpose of the paper is to present the practical experience acquired with modularization carried out in the UTE UNITEC-INYPSA-EMPRESARIOS AGRUPADOS framework and the method applied, the support computer programs devised and their degree of effectiveness. (Author)

  15. Simulation and optimization of an industrial PSA unit

    Directory of Open Access Journals (Sweden)

    Barg C.

    2000-01-01

    Full Text Available The Pressure Swing Adsorption (PSA units have been used as a low cost alternative to the usual gas separation processes. Its largest commercial application is for hydrogen purification systems. Several studies have been made about the simulation of pressure swing adsorption units, but there are only few reports on the optimization of such processes. The objective of this study is to simulate and optimize an industrial PSA unit for hydrogen purification. This unit consists of six beds, each of them have three layers of different kinds of adsorbents. The main impurities are methane, carbon monoxide and sulfidric gas. The product stream has 99.99% purity in hydrogen, and the recovery is around 90%. A mathematical model for a commercial PSA unit is developed. The cycle time and the pressure swing steps are optimized. All the features concerning with complex commercial processes are considered.

  16. Prostate-Specific Antigen at 4 to 5 Years After Low-Dose-Rate Prostate Brachytherapy Is a Strong Predictor of Disease-Free Survival

    Energy Technology Data Exchange (ETDEWEB)

    Lo, Andrea C. [Department of Radiation Oncology, British Columbia Cancer Agency Vancouver Centre, Vancouver, British Columbia (Canada); Department of Surgery, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia (Canada); Morris, W. James, E-mail: JMorris@bccancer.bc.ca [Department of Radiation Oncology, British Columbia Cancer Agency Vancouver Centre, Vancouver, British Columbia (Canada); Department of Surgery, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia (Canada); Lapointe, Vincent [Department of Medical Physics, British Columbia Cancer Agency Vancouver Centre, Vancouver, British Columbia (Canada); Hamm, Jeremy [Department of Population Oncology, British Columbia Cancer Agency Vancouver Centre, Vancouver, British Columbia (Canada); Keyes, Mira; Pickles, Tom; McKenzie, Michael [Department of Radiation Oncology, British Columbia Cancer Agency Vancouver Centre, Vancouver, British Columbia (Canada); Department of Surgery, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia (Canada); Spadinger, Ingrid [Department of Surgery, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia (Canada); Department of Medical Physics, British Columbia Cancer Agency Vancouver Centre, Vancouver, British Columbia (Canada)

    2014-01-01

    Purpose: To determine (1) the prognostic utility of prostate-specific antigen (PSA) concentration at 45 to 60 months (48mPSA) after low-dose-rate prostate brachytherapy (LDR-PB); (2) the predictors of 48mPSA; and (3) the prognostic utility of directional trends between PSA levels at 24, 36, and 48 months after LDR-PB. Methods and Materials: Between 1998 and 2008, 2223 patients with low- and intermediate-risk prostate cancer received LDR-PB monotherapy. A cohort of 1434 of these patients was identified with a documented 48mPSA and no evidence of disease relapse prior to the 48mPSA. In addition, a subset of this cohort (n=585) was identified with ≥72 months of follow-up and documented PSA values at both 24 and 36 months after implantation. Results: Median follow-up time was 76 months. Eight-year Kaplan-Meier disease-free survival (DFS) rates were 100% vs 73.4% for patients with 48mPSA ≤0.2 vs those with >0.2 ng/mL; 99.1% versus 53.8% for a 48mPSA threshold of ≤0.4 versus >0.4 ng/mL, respectively; and 97.3% versus 0% for a threshold of ≤1.0 versus >1.0 ng/mL, respectively. On multivariate analysis, the only factor predictive of DFS was 48mPSA (P<.0001). On subset analysis (n=585), 29 patients had a PSA rise (defined as >0.2 ng/mL) between 24 and 36 months, 24 patients had a rise between 36 and 48 months, and 11 patients had rises over both intervals. Failure rates in these patients were 52%, 79%, and 100%, respectively. On multivariate analysis, initial PSA, androgen deprivation therapy, and dose to 90% of the prostate significantly correlated with 48mPSA but together accounted for only ∼5% of its total variance. Conclusions: The 48mPSA after LDR-PB is highly predictive of long-term DFS. Patients with 48mPSA ≤0.4 ng/mL had a <1% risk of disease relapse at 8 years, whereas all patients with 48mPSA >1.0 ng/mL relapsed. Consecutive PSA rises of >0.2 ng/mL from 24 to 36 months and from 36 to 48 months were also highly predictive of subsequent failure.

  17. Requirements and capabilities of PSA for safety management applications

    International Nuclear Information System (INIS)

    The International Atomic Energy Agency (IAEA) has prepared a draft document providing guidance to the Member States on the various application areas for PSAs for the intended applications. Requirements for applying a PSA in each of the specific application areas have been defined. This includes definition of the objectives of the application, PSA modeling and data requirements, calculational capabilities, and the requirements for presentation of results. This document provides an example for one of the 17 areas, namely ''Evaluation of Surveillance and Maintenance Activities.''

  18. Determining the quality of probabilistic safety assessment (PSA) for applications in nuclear power plants

    International Nuclear Information System (INIS)

    Probabilistic safety assessment (PSA) of nuclear power plants (NPPs) complements the traditional deterministic analysis and is widely recognized as a comprehensive, structured approach to identifying accident scenarios and deriving numerical estimates of risks dealing with NPP operation and associated plant vulnerabilities. Increasingly, during the last years, PSA has been broadly applied to support numerous applications and risk-informed decisions on various operational and regulatory matters. The expanded use of PSA in the risk-informed decision making process requires that PSA possess certain features to ensure its technical consistency and quality. This publication is aimed to further promote the use and application of PSA techniques in Member States. The publication provides a comprehensive list of PSA applications and describes what technical features (termed 'attributes') of a PSA should be satisfied to reliably support the PSA applications of interest. A consideration has been also given to the basic set of attributes characterizing a 'base case PSA' that is performed with the purpose of assessing the overall plant safety. This publication can support PSA practitioners in appropriate planning of a PSA project taking into account possible uses of the PSA in the future. The publication can be also used by reviewers as an aid in assessing the quality of PSAs and judging the adequacy of a PSA for particular applications. In addition, it is also foreseen to use the publication to support the independent peer reviews conducted by the IAEA in the framework of the International Probabilistic Safety Assessment Review Team (IPSART) safety service

  19. The Short isoform of the CEACAM1 receptor in intestinal T cells regulates mucosal immunity and homeostasis via Tfh cell induction

    OpenAIRE

    Chen, Lanfen; Chen, Zhangguo; Baker, Kristi; Halvorsen, E lizabeth M.; da Cunha, Andre Pires; Flak, Magdalena B.; Gerber, Georg; Huang, Yu-Hwa; Hosomi, Shuhei; Arthur, J anelle C.; Dery, Ken J.; Nagaishi, Takashi; Beauchemin, Nicole; Kathryn V Holmes; Joshua W K Ho

    2012-01-01

    Carcinoembryonic antigen cell adhesion molecule like I (CEACAM1) is expressed on activated T cells and signals through either a long (L) cytoplasmic tail containing immune receptor tyrosine based inhibitory motifs, which provide inhibitory function, or a short (S) cytoplasmic tail with an unknown role. Previous studies on peripheral T cells show that CEACAM1-L isoforms predominate with little to no detectable CEACAM1-S isoforms in mouse and human. We show here that this was not the case in ti...

  20. Level 2 PSA for the WWER 440/213 Dukovany NPP

    International Nuclear Information System (INIS)

    A brief review of PSA for the Dukovany NPP unit 1 is given. Main characteristics of the used methodology for PSA level 2, containment failure modes, PSA 1 and PSA 2 interface are discussed. Large event tree (APET) method, Hydrogen model, results for release classes and containment failure (case with PTS and without PTS) and these for plant damage state vectors are presented. Based on the obtained from PSA level 2 results the following conclusions have been made: 1) The limited scope PSA 2 proved to be a very good tool especially when comparing risk importance of individual phenomena, presently critical; 2) Before the next revision of limited scope PSA 2 for power states, some problems have to be solved, for example: better containment strength curve; better scenarios - MELCOR 1.8.5 analyses including SAMG; decreasing conservatism of natural leak from the intact containment; improved knowledge of steam explosions including cavity strength; 3) Next PSA 2 revision can not before 2005

  1. PSA doubling time for prediction of [{sup 11}C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy

    Energy Technology Data Exchange (ETDEWEB)

    Giovacchini, Giampiero; Garcia Parra, Rita [University of Milano-Bicocca, Center for Molecular Bioimaging, Milan (Italy); Picchio, Maria; Gianolli, Luigi [San Raffaele Scientific Institute, Department of Nuclear Medicine, Milan (Italy); Scattoni, Vincenzo; Briganti, Alberto; Montorsi, Francesco [San Raffaele Scientific Institute, Department of Urology, Milan (Italy); Messa, Cristina [University of Milano-Bicocca, Center for Molecular Bioimaging, Milan (Italy); National Research Council, Institute for Bioimaging and Molecular Physiology, Milan (Italy); San Gerardo Hospital, Department of Nuclear Medicine, Monza (Italy)

    2010-06-15

    Previous studies have shown that the positive detection rate of [{sup 11}C]choline positron emission tomography/computed tomography (PET/CT) depends on prostate-specific antigen (PSA) plasma levels. This study compared PSA levels and PSA doubling time (PSADT) to predict [{sup 11}C]choline PET/CT findings. PSADT was retrospectively calculated in 170 prostate cancer (PCa) patients with biochemical failure after radical prostatectomy who underwent [{sup 11}C]choline PET/CT. PSADT was calculated as PSADT = ln2/m, where m is the slope of the linear regression line of the natural log of PSA values. At least three PSA measurements were used (median: 4; range: 3-16), separated by at least 3 months, each with a minimum increase of 0.20 ng/ml. PET/CT findings were validated using criteria based on histological analysis and clinical and imaging data. Statistical analysis was performed using the t test, chi-square test, analysis of variance and binary logistic regression. Regression-based coefficients were used to develop a nomogram predicting the probability of positive [{sup 11}C]choline PET/CT and 200 bootstrap resamples were used for internal validation. The median PSA was 1.25 ng/ml (range: 0.23-48.6 ng/ml), and the median PSADT was 7.0 months (range: 0.97-45.3 months). [{sup 11}C]choline PET/CT was positive in 75 of 170 patients (44%). PET/CT findings were validated using histological criteria (11%) and clinical and imaging criteria (89%). The overall accuracy of [{sup 11}C]choline PET/CT was 88%. Multivariate logistic regression showed that high PSA and short PSADT were significant (p < 0.05) predictors of positive [{sup 11}C]choline PET/CT [PSA: odds ratio (OR) = 1.43; 95% confidence interval (CI): 1.15-1.78; PSADT: OR = 1.12; 95% CI: 1.04-1.21]. The percentage of patients with positive [{sup 11}C]choline PET/CT was 27% for PSADT >6 months, 61% for PSADT between 3 and 6 months and 81% for PSADT <3 months. The percentage of patients who displayed pathological [{sup 11}C

  2. Investigation of contactless detection using a giant magnetoresistance sensor for detecting prostate specific antigen.

    Science.gov (United States)

    Sun, Xuecheng; Zhi, Shaotao; Lei, Chong; Zhou, Yong

    2016-08-01

    This paper presents a contactless detection method for detecting prostate specific antigen with a giant magnetoresistance sensor. In contactless detection case, the prostate specific antigen sample preparation was separated from the sensor that prevented the sensor from being immersed in chemical solvents, and made the sensor implementing in immediately reuse without wash. Experimental results showed that applied an external magnetic field in a range of 50 Oe to 90 Oe, Dynabeads with a concentration as low as 0.1 μg/mL can be detected by this system and could give an approximate quantitation to the logarithmic of Dynabeads concentration. Sandwich immunoassay was employed for preparing PSA samples. The PSA capture was implemented on a gold film modified with a self-assembled monolayer and using biotinylated secondary antibody against PSA and streptavidinylated Dynabeads. With DC magnetic field in the range of 50 to 90 Oe, PSA can be detected with a detection limit as low as 0.1 ng/mL. Samples spiked with different concentrations of PSA can be distinguished clearly. Due to the contactless detection method, the detection system exhibited advantages such as convenient manipulation, reusable, inexpensive, small weight. So, this detection method was a promising candidate in biomarker detection, especially in point of care detection. PMID:27379844

  3. Study on the status of breast and prostate cancers in Gazira State using (CA-15-3 and PSA) technology

    International Nuclear Information System (INIS)

    This study was conducted in Algezira State in two environmentally and economically different areas. The people in these areas were divided into two groups in the study: group (A) people who live alongside the Blue Nile bank. Group people who live away how the Blue Nile, I e in midland between the Blue Nile and White Nile which is called (AI-Bajour). The aim of the study was to recognize the normal rate of breast cancer markers(Carbohydrate Antigen 15-3), which is one of the most common cancers, and the prostate cancer (Prostate Cancer Markers), as compared with the global normal rate, in order to early detect and treat these types of cancers. The study was conducted on 336 men and 304 women, who are different in ages, work and social status. The researcher used an experimental, descriptive and analytical method, and the SPSS program for analysis. The study showed that the results of normal rate as compared with previous studies are typical to the breast cancer markers (carbohydrate antigen 15-3, ranging between (0-40) ngm/ml, where as the normal rate of the prostate cancer markers (PSA) ranges between (0-4) ngm/ml, and according to the previous African and American studies. The studies also showed that the results are different according to the group are different according to the group involved. There is an increase in normal rates of group (A) in the PSA markers. From 177 men, 49 had rated of (4-10) ng/ml, 6 had very high rates (10-20)ng/ml and extremely high rates of 2 samples (>20)ng/ml. It was noticed that the abnormal increase rate is directly proportional to the age development. The study showed high results of breast cancer markers (Carbohydrate antigen 15-3), as compared with the global normal rate (0-40)ng/ml, 6 had very high rates (60-100)ng/ml and extremely high rates (>100)ng/ml. Two women of uterus cancer died. Again the abnormal increase in the rates is directly proportional to age development. The study showed that the results of group (B) is

  4. Hand Hygiene in Healthcare Settings 2 PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2010-08-19

    This 30 second PSA encourages people to wash their hands often while in the hospital or visiting someone in the hospital. It also encourages them to remind their healthcare providers to wash their hands, too.  Created: 8/19/2010 by Centers for Disease Control and Prevention (CDC).   Date Released: 8/19/2010.

  5. Hand Hygiene in Healthcare Settings 1 PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2010-08-19

    This 30 second PSA encourages people to wash their hands often while in the hospital or visiting someone in the hospital. It also encourages them to remind their healthcare providers to wash their hands, too.  Created: 8/19/2010 by Centers for Disease Control and Prevention (CDC).   Date Released: 8/19/2010.

  6. On-line maintenance PSA support at NPP Krsko

    International Nuclear Information System (INIS)

    In 1997 Krsko NPP initiated the on-line maintenance (OLM) practice. On-line maintenance constitutes of corrective activities, preventive activities, surveillance activities, tests and inspections, as well as calibrations and modifications, taking place during the normal power operations. The on-line maintenance is a multidisciplinary process consisting of activity specification, planning, and preparation and performing of the OLM activity of interest. The primary role of the PSA group is to assess from the risk perspective, using the plant-specific NEK PSA model, system unavailability and the impact to the plant operational risk. The intent is to support planning of the on-line maintenance activities from the risk perspective. The risk evaluation of the OLM activities is based on the probability of core damage evaluation for the defined discrete plant configuration states, determined by the OLM activities. Within this application, the optimized, plant-specific PSA model is used on Risk Spectrum platform. To perform the risk assessment of the on-line maintenance activities, first the systems to be affected are defined based on the planned OLM activities. The next important step is the assessment of the planned work schedule. To define the final schedule, the co-ordination and optimizing the planned OLM activities needs activation of all participating departments, supported also from PSA group. The P3 (i.e. Primavera) planning tool system windows are defined for different systems and groups of systems, and the activities are sorted in particular weeks according to these windows. (author)

  7. Asian and Pacific Islander HIV/AIDS Awareness PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2010-05-12

    In this PSA, Asians and Pacific Islanders are encouraged to talk about HIV and get tested for HIV.  Created: 5/12/2010 by Centers for Disease Control and Prevention (CDC).   Date Released: 5/12/2010.

  8. EVA: An integrated information system for living PSA management

    International Nuclear Information System (INIS)

    During the operating life of a nuclear power plant, many changes occur in components, systems, and operating procedures which continuously modify the configuration of the power plant. Performance of a PSA requires an updated model of plant configuration at a given time, and due to the dynamic nature of plant operation this model becomes quickly obsolete. This issue, together with the big amount of information involved, make of capital importance the use of a computer software tool in order to obtain an immediate revision of a PSA. In this context, UITESA has developed a PC software tool to be used on living PSA projects (EVA), which allows an easy query and update of PSA evaluation. EVA has been built as a relational data base core and several independent modules sharing this data base information. Main characteristics and functionality of this tool are discussed on this paper: Relational data base core, which includes information about systems, components, allocations, segments, basic events, fault trees, initiating events, sequences, tests and maintenance procedures on components, etc.; menu based interface to data base updating and queries; automatic quantification procedure; automatic data based updating as result of modifications on components test and maintenance procedures, failure rates, etc.; sensibility, importance and uncertainty analysis of quantified models; automatic document edition tool; automatic modular fault tree generation in basis of simplified system diagrams. (author)

  9. Lessons learned in applying PSA methods to technical specification optimization

    International Nuclear Information System (INIS)

    The paper presents some results of PSA application in the evaluation of Technical Specification. Two plant-specific studies are addressed in relation to Seabrook NPP and South Texas Project plants. Technical approach to TS evaluation is highlighted. Some insights and lessons learned are presented. (author). 9 refs, 4 figs, 1 tab

  10. Reducing the Risk of Methadone Overdose PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2012-07-03

    This 60 second PSA is based on the July 2012 CDC Vital Signs report. Approximately 14 people die every day of overdoses related to methadone. Listen to learn how to reduce your risk of an overdose.  Created: 7/3/2012 by Centers for Disease Control and Prevention (CDC).   Date Released: 7/3/2012.

  11. Use of living PSA in regulatory decision making in Finland

    Energy Technology Data Exchange (ETDEWEB)

    Virolainen, R. [STUK - Radiation and Nuclear Safety Authority. Nuclear Reactor Regulation, Helsinki (Finland)

    1999-09-01

    Consideration of severe accidents beyond the traditional design basis, including full core melt accidents, has become an important ingredient of regulatory process in Finland. Increasingly, decisions are being based, at least in part, on results of plant-specific Probabilistic Safety Assessments (PSA) studies. Plant-specific level-1 and level 2 PSA studies, including internal initiators, fires, flooding and harsh weather conditions are required by STUK. These studies are used in a living fashion both at the utilities and a STUK. PSA has got an important role in the safety management at Loviisa and Olkiluoto (OL) plants and in the regulatory process of STUK. While PSA is recognised as an effective tool and review method for many different regulatory and safety management purposes, we have to acknowledge its limitations, which are often related to the level of modelling or methods, not yet mature enough for some specific applications. Hence, in context of the aforementioned activities, STUK has to use both deterministic and probabilistic reviews in parallel while controlling and regulating the issues. (au)

  12. A COMPARATIVE STUDY OF PROSTATIC SPECIFIC ANTIGEN DENSITY AND ITS CORRELATED HISTOPATHOLOGY IN THE DIAGNOSIS OF BENIGN AND MALIGNANT PROSTATIC DISEASES

    Directory of Open Access Journals (Sweden)

    Shravan R

    2015-07-01

    Full Text Available BACKGROUND : Carcinoma of prostate gland is the most common malignancy above 65 yrs of age in men. Most patients with early - stage Ca prostate are asymptomatic. The presence of symptoms often suggests locally advanced or metastatic disease. It is important to detect Ca prostate at an early stage so that mortality due to this malignancy can be minimized. The specific threshold for prostate - specific antigen (PSA to delineate patients who are at the highest risk has been controversial. It is wiser to refine PSA by its derivative parameter like PSAD (PSA/Vol . which can be used as a better diagnostic tool in early detection of Ca Prostate.

  13. GIS Technologies For The New Planetary Science Archive (PSA)

    Science.gov (United States)

    Docasal, R.; Barbarisi, I.; Rios, C.; Macfarlane, A. J.; Gonzalez, J.; Arviset, C.; De Marchi, G.; Martinez, S.; Grotheer, E.; Lim, T.; Besse, S.; Heather, D.; Fraga, D.; Barthelemy, M.

    2015-12-01

    Geographical information system (GIS) is becoming increasingly used for planetary science. GIS are computerised systems for the storage, retrieval, manipulation, analysis, and display of geographically referenced data. Some data stored in the Planetary Science Archive (PSA), for instance, a set of Mars Express/Venus Express data, have spatial metadata associated to them. To facilitate users in handling and visualising spatial data in GIS applications, the new PSA should support interoperability with interfaces implementing the standards approved by the Open Geospatial Consortium (OGC). These standards are followed in order to develop open interfaces and encodings that allow data to be exchanged with GIS Client Applications, well-known examples of which are Google Earth and NASA World Wind as well as open source tools such as Openlayers. The technology already exists within PostgreSQL databases to store searchable geometrical data in the form of the PostGIS extension. An existing open source maps server is GeoServer, an instance of which has been deployed for the new PSA, uses the OGC standards to allow, among others, the sharing, processing and editing of data and spatial data through the Web Feature Service (WFS) standard as well as serving georeferenced map images through the Web Map Service (WMS). The final goal of the new PSA, being developed by the European Space Astronomy Centre (ESAC) Science Data Centre (ESDC), is to create an archive which enables science exploitation of ESA's planetary missions datasets. This can be facilitated through the GIS framework, offering interfaces (both web GUI and scriptable APIs) that can be used more easily and scientifically by the community, and that will also enable the community to build added value services on top of the PSA.

  14. Correlation between Tc-99m HMDP bone scintigrams and prostate-specific antigen in prostatic cancer patients

    International Nuclear Information System (INIS)

    To evaluate the clinical utility of prostate-specific antigen (PSA), 32 patients with prostatic carcinoma (PCA) and 13 patients without PCA underwent PSA measurement (normal, 0-4 ng/mL) at the time of bone scintigraphy. All patients without PCA had normal PSA values. The results in the 32 patients with PCA were divided into two groups of 16 each: (1) abnormal PSA levels and (2) normal PSA levels. Twelve patients in group 2 had no skeletal metastasis, one had regression of skeletal metastases, and three had unchanged bone lesions in a 6-12-month period. In group 1, 14 patients' bone images showed positive metastases; two patients with negative bone scans had had recent digital rectal or TUR. The authors conclude that PSA measurement may enhance bone imaging interpretation and provide valuable clinical monitoring of PCA. In a patient with a positive bone scan and an unknown primary, PSA measurement may determine definitely whether the metastasis originated from PCA

  15. Prostate specific antigen in boys with precocious puberty before and during gonadal suppression by GnRH agonist treatment

    DEFF Research Database (Denmark)

    Juul, A; Müller, J; Skakkebaek, N E

    1997-01-01

    In healthy boys, the pituitary-gonadal axis exhibits diurnal variation in early puberty. Serum testosterone levels are higher during the night and low or immeasurable during the day. These fluctuating levels of circulating androgens in early pubertal boys are difficult to monitor. Prostate specific...... antigen (PSA) is a marker of the androgen-dependent prostatic epithelial cell activity and it is used in the diagnosis and surveillance of adult patients with prostatic cancer. We have measured PSA concentrations in serum from boys with precocious puberty before and during gonadal suppression with Gn......RH agonists to evaluate the effect of normal and precocious puberty on PSA levels and to study the correlation between testosterone and PSA in boys....

  16. Lycopene can reduce prostate-specific antigen velocity in a phase Ⅱ clinical study in Chinese population

    Institute of Scientific and Technical Information of China (English)

    Zhang Xin; Yang Yong; Wang Qi

    2014-01-01

    Background Epidemiological studies have shown that lycopene has anti-prostate cancer effect.In vitro tests also confirmed that it can promote apoptosis of prostate cancer cells.We investigated the effect of whole-tomato supplement lycopene on the prostate-specific antigen velocity in selected prostate cancer patients.Methods Twenty selected prostate cancer patients were given whole-tomato supplement lycopene 10 mg per day for about 6 months.Blood samples of patients were collected weekly to measure serum prostate-specific antigen (PSA) values.PSA velocity slope,which reflects the change of PSA,and the degree of change were also calculated.By comparing the values of average PSA velocity slope (rise or fall of PSA) before and after the administration of lycopene,the effect of lycopene can be evaluated.Blood chemistry analysis was regular followed as safety control.Results Three patients in the research group withdrew within 3 weeks because of inability to conform.The rest 17 patients continued for an average period of 6 months.Two patients withdrew because of cancer progression (PSA rise) who later received active treatment.The average fall in PSA was equivalent to 2.56% over (i.e.an average slope/d of -0.000 28) the first 3 months.In the last 3 months,average fall in PSA was equivalent to 31.58% (i.e.an average slope/d of-0.003 51).The Wilcoxon rank-sum test showed a statistically significant decrease of PSA velocity slope overall (P=0.000 9).Analysis of the PSA doubling time (pre-vs.post-treatment) showed a median increase over 3 months but this was not statistically significant (P=0.21).No toxic side effect was observed during the whole process.The results indicate that the average PSA change is "decline" in patients,and the degree of the decline is accelerated.Conclusion Administration of lycopene was able to reduce PSA velocity in this study group.

  17. FSH isoform pattern in classic galactosemia

    OpenAIRE

    Gubbels, Cynthia S.; Thomas, Chris M.G.; Wodzig, Will K. W. H.; Olthaar, André J.; Jaeken, Jaak; Sweep, Fred C. G. J.; Rubio-Gozalbo, M. Estela

    2010-01-01

    Female classic galactosemia patients suffer from primary ovarian insufficiency (POI). The cause for this long-term complication is not fully understood. One of the proposed mechanisms is that hypoglycosylation of complex molecules, a known secondary phenomenon of galactosemia, leads to FSH dysfunction. An earlier study showed less acidic isoforms of FSH in serum samples of two classic galactosemia patients compared to controls, indicating hypoglycosylation. In this study, FSH isoform patterns...

  18. Development of IPRO-ZONE to Construct One Top Fire Event PSA Model

    International Nuclear Information System (INIS)

    An internal fire event probabilistic safety assessment (PSA) model has been generally quantified by modifications of a pre-developed internal events PSA model. New accident sequence logics not covered in the internal events PSA model are separately developed to incorporate them into the fire PSA model. Kang et al. proposed modification rules to construct the one top fire events PSA model by using the pre-developed one top internal events PSA model. A one top fault tree is a one fault tree representing the PSA logics including all the event trees and fault trees for the core damage frequency (CDF) and large early release frequency (LERF) quantifications. Constructions of one top fire events PSA model are needed for risk management due to fire in risk-informed decision-makings such as risk informed technical specification changes, fire significant determination process, on-line maintenance, etc. To manually construct one top fire events PSA model, a PSA analyst should determine components failure modes relating to the equipment or cables located in each fire compartment or scenario, estimate their failure probabilities, and modeled them into PSA logics. KAERI has been developing the IPRO-ZONE (interface program for constructing zone effect table) to construct one top fire events PSA model. With the output of the IPRO-ZONE, the AIMS, and internal event one top PSA model, one top fire events PSA model is automatically constructed. The output of the IPRO-ZONE include information on fire zones/fire scenarios, fire propagation areas, equipment failure modes affected by a fire, internal PSA basic events corresponding to fire-induced equipment failure modes, and fire events to be modeled. In this paper, we introduce the overview of the IPRO-ZONE, and the approaches for determining component failure modes and modeling of fire induced equipment failure events

  19. Isoform Specificity of Protein Kinase Cs in Synaptic Plasticity

    Science.gov (United States)

    Sossin, Wayne S.

    2007-01-01

    Protein kinase Cs (PKCs) are implicated in many forms of synaptic plasticity. However, the specific isoform(s) of PKC that underlie(s) these events are often not known. We have used "Aplysia" as a model system in order to investigate the isoform specificity of PKC actions due to the presence of fewer isoforms and a large number of documented…

  20. Local prostate cancer radiotherapy after prostate-specific antigen progression during primary hormonal therapy

    International Nuclear Information System (INIS)

    The outcome of patients after radiotherapy (RT) for localized prostate cancer in case of prostate-specific antigen (PSA) progression during primary hormonal therapy (HT) is not well known. A group of 27 patients presenting with PSA progression during primary HT for local prostate cancer RT was identified among patients who were treated in the years 2000–2004 either using external-beam RT (EBRT; 70.2Gy; n=261) or Ir-192 brachytherapy as a boost to EBRT (HDR-BT; 18Gy + 50.4Gy; n=71). The median follow-up period after RT was 68 months. Median biochemical recurrence free (BRFS), disease specific (DSS) and overall survival (OS) for patients with PSA progression during primary HT was found to be only 21, 54 and 53 months, respectively, with a 6-year BRFS, DSS and OS of 19%, 41% and 26%. There were no significant differences between different RT concepts (6-year OS of 27% after EBRT and 20% after EBRT with HDR-BT). Considering all 332 patients in multivariate Cox regression analysis, PSA progression during initial HT, Gleason score>6 and patient age were found to be predictive for lower OS (p<0.001). The highest hazard ratio resulted for PSA progression during initial HT (7.2 in comparison to patients without PSA progression during primary HT). PSA progression and a nadir >0.5 ng/ml during initial HT were both significant risk factors for biochemical recurrence. An unfavourable prognosis after PSA progression during initial HT needs to be considered in the decision process before local prostate radiotherapy. Results from other centres are needed to validate our findings

  1. Using PSA, biopsy Gleason score, clinical stage, and the percentage of positive biopsies to identify optimal candidates for prostate-only radiation therapy

    International Nuclear Information System (INIS)

    Purpose: An identification of prostate cancer patients most likely to benefit from prostate-only radiation was made based upon the pretreatment prostate-specific antigen (PSA), biopsy Gleason score, clinical stage, percentage of positive biopsies, and the 5-year postoperative PSA outcome. Methods: Between 1989 and 2000, 2099 patients underwent radical prostatectomy for clinically localized prostate cancer. The primary end points were pathologic evidence of seminal vesicle invasion 2(SVI), extracapsular extension (ECE) with or without positive surgical margins, and the 5-year postoperative PSA outcome. Results: Pretreatment PSA, biopsy Gleason score, and clinical stage were used to assign patients to low-, intermediate-, and high-risk groups. These risk groups were stratified by the percentage of positive biopsies and the primary pathologic and biochemical outcomes examined. The rates of SVI, ECE with positive margin, and no biochemical evidence of disease (bNED) for low-risk patients with ≤50% positive biopsies were 2%, 7%, and 93%, respectively. Patients with >50% positive biopsies had higher rates of SVI and ECE (5% and 11%, respectively) and 52% bNED (p<0.0001). For intermediate-risk patients with ≤17% positive biopsies, the rates of SVI, ECE with positive margin, and bNED were 3%, 9%, and 90%, respectively. As the percentage of positive biopsies increased above 17% in intermediate-risk patients, there was a statistically significant increase in SVI and ECE and a significant decrease in bNED. Conclusions: Low-risk patients with ≤50% positive biopsies and intermediate-risk patients with ≤17% positive biopsies had a very low risk of SVI and ECE with positive surgical margins. Given that the presence of SVI and ECE with positive surgical margins was uncommon (<10%) with a ≥90% PSA failure-free survival after radical prostatectomy, these patients may be optimal candidates for radiation therapy directed at the prostate only (prostate gland + 1.5-cm margin)

  2. Use of level 2 and level 3 PSA for regulatory decision making in South Africa

    International Nuclear Information System (INIS)

    PSA has been used in South Africa for regulatory decision making for over a decade. Recent changes in the methodology of source term analysis and off-site consequence analysis following worldwide trends are discussed in relation to an earlier PSA model. Nuclear safety criteria to be applied to the results of the PSA are presented. The use of Level 3 PSA for regulatory purposes is discussed with reference to actual situations in which various PSA models have been used to identify potential safety problems and to provide a basis for deciding on corrective actions. (author). 3 refs, 7 figs, 4 tabs

  3. Multiple antigen peptide dendrimer elicits antibodies for detecting rat and mouse growth hormone binding proteins

    OpenAIRE

    Aguilar, Roberto M.; Talamantes, Frank J.; Bustamante, Juan J.; Muñoz, Jesus; Treviño, Lisa R.; Martinez, Andrew O.; Haro, Luis S.

    2009-01-01

    The membrane-bound rat growth hormone receptor (GH-R) and an alternatively spliced isoform, the soluble rat GH binding protein (GH-BP), are comprised of identical N-terminal GH binding domains, however, their C-terminal sequences differ. Immunological reagents are needed to distinguish between the two isoforms in order to understand their respective roles in mediating the actions of GH. Accordingly, a tetravalent multiple antigen peptide (MAP) dendrimer with four identical branches of a C-ter...

  4. Confirmation of a Low α/β Ratio for Prostate Cancer Treated by External Beam Radiation Therapy Alone Using a Post-Treatment Repeated-Measures Model for PSA Dynamics

    International Nuclear Information System (INIS)

    Purpose: To estimate the α/β ratio of prostate cancer treated with external beam radiation only by use of a model of long-term prostate-specific antigen (PSA) dynamics. Methods and Materials: Repeated measures of PSA from 5,093 patients from 6 institutions treated for localized prostate cancer by external beam radiation therapy (EBRT) without planned androgen deprivation were analyzed. A biphasic linear mixed model described the post-treatment evolution of PSA, rather than a conventional model of time to biochemical recurrence. The model was adjusted for standard prognostic factors (T stage, initial PSA level, and Gleason score) and cohort-specific effects. The radiation dose fractionation effect was estimated from the long-term rate of rise of PSA level. Results: Adjusted for other factors, total dose of EBRT and sum of squared doses per fraction were associated with long-term rate of change of PSA level (p = 0.0017 and p = 0.0003, respectively), an increase of each being associated with a lower rate of rise. The α/β ratio was estimated at 1.55 Gy (95% confidence band, 0.46-4.52 Gy). This estimate was robust to adjustment of the linear mixed model. Conclusions: By analysis of a large EBRT-only cohort along with a method that uses all the repeated measures of PSA after the end of treatment, a low and precise α/β was estimated. These data support the use of hypofractionation at fractional doses up to 2.8 Gy but cannot presently be assumed to accurately represent higher doses per fraction.

  5. Value of Prostate-Specific Antigen and Prostate-Specific Antigen Density in Detection of Prostate Cancer in an Iranian Population of Men

    Directory of Open Access Journals (Sweden)

    Mahyar Ghafoori

    2009-08-01

    Full Text Available

    Introduction: The objective of this study was to evaluate the value of serum prostate-specific antigen (PSA and prostate-specific antigen density (PSAD in the diagnosis of prostate cancer.

    Materials and Methods: A total of 330 consecutive patients suspected of having prostate cancer due to either abnormal digital rectal examination or elevated serum PSA levels underwent transrectal ultrasonography-guided sextant biopsy of the prostate. The PSA and PSAD values were assessed based on the biopsy results.

    Results: One hundred and twenty-one patients (36.7% had prostate cancer. In this group, the mean PSA was 31.60 ± 30.85 ng/mL (range, 1.9 ng/mL to 166.0 ng/mL and the mean PSAD was 0.83 ± 1.01 (range, 0.04 ng/mL/cm3 to 6.38 ng/mL/cm3. In those without prostate cancer the mean PSA and PSAD levels were 13.80 ± 18.72 ng/mL (range, 0.4 ng/mL to 130.0 ng/mL; P < .001 and 0.24 ± 0.32 (range of 0.01 ng/mL/cm3 to 2.29 ng/mL/cm3; P < .001. The receiver operating characteristic curve analysis revealed that the discriminating power of serum PSA for detecting prostate cancer, as estimated by the area under the curve, was 0.74 while that for PSAD was 0.81 (P < .001. For the PSA range of 3.5 ng/mL to 41 ng/mL (gray zone the areas under the curve was 0.68 for PSA, while it was 0.78 for PSAD (P < .001.

    Conclusion: The use of PSAD instead of PSA in the diagnosis of prostatic cancer improves the diagnostic accuracy.

  6. Upgrade of Common Cause Failure Modelling of NPP Krsko PSA

    International Nuclear Information System (INIS)

    Over the last thirty years the probabilistic safety assessments (PSA) have been increasingly applied in technical engineering practice. Various failure modes of system of concern are mathematically and explicitly modelled by means of fault tree structure. Statistical independence of basic events from which the fault tree is built is not acceptable for an event category referred to as common cause failures (CCF). Based on overview of current international status of modelling of common cause failures in PSA several steps were made related to primary technical basis for methodology and data used for CCF model upgrade project in NPP Krsko (NEK) PSA. As a primary technical basis for methodological aspects of CCF modelling in Krsko PSA the following documents were considered: NUREG/CR-5485, NUREG/CR-4780, and Westinghouse Owners Group documents (WOG) WCAP-15674 and WCAP-15167. Use of these documents is supported by the most relevant guidelines and standards in the field, such as ASME PRA Standard and NRC Regulatory Guide 1.200. WCAP documents are in compliance with NUREG/CR-5485 and NUREG/CR-4780. Additionally, they provide WOG perspective on CCF modelling, which is important to consider since NEK follows WOG practice in resolving many generic and regulatory issues. It is, therefore, desirable that NEK CCF methodology and modelling is in general accordance with recommended WOG approaches. As a primary basis for CCF data needed to estimate CCF model parameters and their uncertainty, the main used documents were: NUREG/CR-5497, NUREG/CR-6268, WCAP-15167, and WCAP-16187. Use of NUREG/CR-5497 and NUREG/CR-6268 as a source of data for CCF parameter estimating is supported by the most relevant industry and regulatory PSA guides and standards currently existing in the field, including WOG. However, the WCAP document WCAP-16187 has provided a basis for CCF parameter values specific to Westinghouse PWR plants. Many of events from NRC / INEEL database were re-classified in WCAP

  7. Summary report for the second TUV-workshop proceedings on living PSA application

    International Nuclear Information System (INIS)

    This workshop on living PSA Application was organized to support the OECD/NEA CSNI-Principal Working Group No.5 on Risk Assessment for an international exchange of experience on living PSA application. The first session was devoted to Living PSA Applications and the second session to Tools for Living PSA. Living PSA Applications: Reasons for performing PSA (regulatory requirement, targets; corporate requirement, targets; safety related activity prioritization; other); Logistic of Living PSA Management (Corporate management involvement, Decision making levels and guidance, Plant level involvement, Required personnel commitment, Frequency and extent of re-quantification of PSA, Types of safety/risk parameters to be monitored, Quality assurance on maintaining Living PSA); Examples of Application (Experiences of application, State of Living PSA/e.g. all accident sequences involved, Details of component level involvement). Tools for Living PSA: Data Collection Systems and Codes (Source and type of data collected, Probabilistic parameter quantification, Interface to basic event data, Data code systems). An executive summary of the workshop is given

  8. Comparing case studies results and capabilities of Psaman Package versus Riskspectrum PSA professional code

    Energy Technology Data Exchange (ETDEWEB)

    Mladin, Daniela; Radu, Gabriela; Mladin, Mirea [Institute for Nuclear Research, Campului 1, 115400 Mioveni, Arges (Romania); Prisecaru, Ilie [Power Engineering Department, University ' Politehnica' of Bucharest, 313 Splaiul Independentei, Bucharest (Romania)

    2010-07-01

    International practice emphasized the use of suitable tools for development of Probabilistic Safety Assessment (PSA) for nuclear installations. The PSA analyses developed for the Cernavoda Nuclear Power Plant and TRIGA SSR 14 MW Research Reactor were performed using the PSA computer code package PSAMAN developed in the Institute for Nuclear Research Pitesti. Later on, RiskSpectrum PSA Professional code PSA for Romanian TRIGA SSR research reactor was used standalone and in comparison with Romanian PSAMAN package aiming at further developing and validating of the later code. The paper presents case study results and capabilities of Romanian PSAMAN package versus those of RiskSpectrum PSA Professional code, version 2.10.04, in the frame of the PSA project for Romanian TRIGA Steady State Reactor (SSR) 14 MW. (authors)

  9. Carcinoma-associated antigens

    International Nuclear Information System (INIS)

    This invention relates to novel antigens associated with breast carcinoma, anti-sera specific to said antigens, 125I-labeled forms of said antigens and methods of detecting said antigens in serum or plasma. The invention also relates to a diagnostic kit containing standardised antigens or antisera or marked forms thereof for the detection of said antigens in human blood, serum or plasma. (author)

  10. PSA for the shutdown mode for nuclear power plants

    International Nuclear Information System (INIS)

    The meeting, which was attended by more than 75 participants from 20 countries, provided a broad discussion forum where all the currently active major shutdown PSA programmes were reviewed. The meeting also addressed the issues related to actual performance of shutdown PSA studies as well as insight gained from the studies. This document, which was prepared during the TCM, contains the results of extensive discussions which were held in specific working groups. The papers presented at the meeting provide a comprehensive overview of the state of the art of shutdown risk assessment and remedial measures taken to reduce the risk in outages. It is hoped that this document will be very useful to all individuals with interest in increasing safety during outages at NPPs. Refs, figs and tabs

  11. PSA use in accident management studies in Japan

    International Nuclear Information System (INIS)

    The safety of NPPs in Japan is secured by stringent safety regulations based on the deterministic method, minimizing the possibility a severe accident to a technologically negligible level. PSA is not required in the current regulatory procedures. Accident management based on PSA is a 'knowledge-based' action dependent on utilities' technical knowledge aimed at further reduction of the risk which is kept small enough by existing measures. The paper discusses the following three kinds of PSAs that have been conducted practically and efficiently on NPPs to provide supplemental information about their safety characteristics in addition to the deterministic evaluation used in the regulatory safety review: PSAs on typical NPPs, PSAs on all NPPs to examine candidates for accident management, and PSAs as part of periodic safety review (PSR). 1 fig., 5 tabs

  12. International survey of living PSA and safety indicators

    International Nuclear Information System (INIS)

    The report contains an international overview of applications of living probabilistic assessment and development of operational safety indicators. Features of an ideal living PSA tool are summarized as well as a limited survey of code systems for managing a living probabilistic safety assessment (living PSA) is included. The international survey is used as an input for planning and performance of related tasks within the nordic NKS/SIK-1 project conducted in 1990-93. The research notes are distributed to the Nordic organizations involved or interested in the subject. The report includes an overview and conclusions from technical reports and articles available and presentations and discussions related to development and use of above methods for the evaluation and management of the operational safety of nuclear power plants. A large part of this material is based on material collected and discussed in connection to international specialist meetings relating to the subject

  13. Prostate specific antigen testing policy worldwide varies greatly and seems not to be in accordance with guidelines: a systematic review

    Directory of Open Access Journals (Sweden)

    Van der Meer Saskia

    2012-10-01

    Full Text Available Abstract Background Prostate specific antigen (PSA testing is widely used, but guidelines on follow-up are unclear. Methods We performed a systematic review of the literature to determine follow-up policy after PSA testing by general practitioners (GPs and non-urologic hospitalists, the use of a cut-off value for this policy, the reasons for repeating a PSA test after an initial normal result, the existence of a general cut-off value below which a PSA result is considered normal, and the time frame for repeating a test. Data sources. MEDLINE, Embase, PsychInfo and the Cochrane library from January 1950 until May 2011. Study eligibility criteria. Studies describing follow-up policy by GPs or non-urologic hospitalists after a primary PSA test, excluding urologists and patients with prostate cancer. Studies written in Dutch, English, French, German, Italian or Spanish were included. Excluded were studies describing follow-up policy by urologists and follow-up of patients with prostate cancer. The quality of each study was structurally assessed. Results Fifteen articles met the inclusion criteria. Three studies were of high quality. Follow-up differed greatly both after a normal and an abnormal PSA test result. Only one study described the reasons for not performing follow-up after an abnormal PSA result. Conclusions Based on the available literature, we cannot adequately assess physicians’ follow-up policy after a primary PSA test. Follow-up after a normal or raised PSA test by GPs and non-urologic hospitalists seems to a large extent not in accordance with the guidelines.

  14. Changing prostate-specific antigen outcome after surgery or radiotherapy for localized prostate cancer during the prostate-specific antigen era

    International Nuclear Information System (INIS)

    Purpose: To evaluate the change in prostate-specific antigen (PSA) outcome after radical prostatectomy (RP) or external beam radiotherapy (EBRT), controlling for follow-up during the PSA era. Methods and Materials: The study cohort consisted of 1440 patients with clinically localized prostate cancer managed with RP (n=1059) or EBRT (n=381) between 1989 and 2000. A single genitourinary pathologist reviewed all pathology specimens. For patients with a 2-year minimal follow-up, the 2-year actual PSA outcome stratified by risk group (low vs. high) was calculated for three periods (January 1, 1989 to December 31, 1992; January 1, 1993 to December 31, 1996; and January 1, 1997 to December 31, 2000) and compared for each treatment modality. PSA failure was defined using the American Society for Therapeutic Radiology and Oncology consensus definition for all patients, and comparisons were made using a chi-square metric. Results: During the study period, the proportion of patients treated with RP and EBRT with low-risk disease increased significantly (p <0.0001) from 60% to 89% and from 26% to 76%, respectively. In addition, the 2-year actual PSA outcome also improved from 60% to 82% (RP: p<0.0001) and from 67% to 91% (RT: p=0.0008). The 2-year actual PSA outcome was not significantly different in the low-risk patients but improved during the three periods in the high-risk patients treated with RP (from 20% to 39% to 75%, p=0.0004) or EBRT (from 50% to 59% to 83%, p=0.01). This improvement in PSA outcome could be explained by a shift toward a more favorable PSA level (RP: p=0.0002; RT: p=0.006) and clinical T stage (RP: p=0.0008, RT: p<0.0001) distribution for patients with biopsy Gleason score ≥7 disease. Conclusion: Improved PSA outcome during the PSA era after RP or EBRT has resulted from a shift in presentation toward low-risk disease and earlier detection of high-grade disease

  15. Recent Developments in Level 2 PSA and Severe Accident Management

    International Nuclear Information System (INIS)

    In 1997, CSNI WGRISK produced a report on the state of the art in Level 2 PSA and severe accident management - NEA/CSNI/R(1997)11. Since then, there have been significant developments in that more Level 2 PSAs have been carried out worldwide for a variety of nuclear power plant designs including some that were not addressed in the original report. In addition, there is now a better understanding of the severe accident phenomena that can occur following core damage and the way that they should be modelled in the PSA. As requested by CSNI in December 2005, the objective of this study was to produce a report that updates the original report and gives an account of the developments that have taken place since 1997. The aim has been to capture the most significant new developments that have occurred rather than to provide a full update of the original report, most of which is still valid. This report is organised using the same structure as the original report as follows: Chapter 2: Summary on state of application, results and insights from recent Level 2 PSAs. Chapter 3: Discussion on key severe accident phenomena and modelling issues, identification of severe accident issues that should be treated in Level 2 PSAs for accident management applications, review of severe accident computer codes and the use of these codes in Level 2 PSAs. Chapter 4: Review of approaches and practices for accident management and SAM, evaluation of actions in Level 2 PSAs. Chapter 5: Review of available Level 2 PSA methodologies, including accident progression event tree / containment event tree development. Chapter 6: Aspects important to quantification, including the use of expert judgement and treatment of uncertainties. Chapter 7: Examples of the use of the results and insights from the Level 2 PSA in the context of an integrated (risk informed) decision making process

  16. Regulatory requirement of the Juragua nuclear Power Plant PSA

    International Nuclear Information System (INIS)

    Probabilistic Safety Assessment has proved to be a powerful tool for improving the knowledge of the safety insides of Nuclear Power Plants and increasing the efficiency of the safety measures adopted by both operators and regulators. In this paper the regulatory approach adopted in Cuba with regard to the PSA , the scope of the requirement and the basis and proposal of this decision are presented

  17. Teen Pregnancy - What You Need to Know PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2011-04-05

    This 60 second PSA is based on the April, 2011 CDC Vital Signs report. Having a child during the teen years comes at a high cost to the young mother, her child, and the community. Get tips to help break the cycle of teen pregnancy.  Created: 4/5/2011 by Centers for Disease Control and Prevention (CDC).   Date Released: 4/5/2011.

  18. Take Charge. Take the Test. "You Know" PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2012-03-07

    As part of the Take Charge. Take the Test. campaign, this 60 second PSA encourages African American women to get tested for HIV. Locations for a free HIV test can be found by visiting hivtest.org/takecharge or calling 1-800-CDC-INFO (1-800-232-4636).  Created: 3/7/2012 by National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP).   Date Released: 3/7/2012.

  19. Summary report of seismic PSA of BWR model plant

    International Nuclear Information System (INIS)

    This report presents a seismic PSA (Probabilistic Safety Assessment) methodology developed at the Japan Atomic Energy Research Institute (JAERI) for evaluating risks of nuclear power plants (NPPs) and the results from an application of the methodology to a BWR plant in Japan, which is termed Model Plant'. The seismic PSA procedures developed at JAERI are to evaluate core damage frequency (CDF) and have the following four steps: (1) evaluation of seismic hazard, (2) evaluation of realistic response, (3) evaluation of component capacities and failure probabilities, and (4) evaluation of conditional probability of system failure and CDF. Although these procedures are based on the methodologies established and used in the United States, they include several unique features: (1) seismic hazard analysis is performed with use of available knowledge and database on seismological conditions in Japan; (2) response evaluation is performed with a response factor method which is cost effective and associated uncertainties can be reduced with use of modern methods of design calculations; (3) capacity evaluation is performed with use of test results available in Japan in combination with design information and generic capacity data in the U.S.A.; (4) systems reliability analysis, performed with use of the computer code SECOM-2 developed at JAERI, includes identification of dominant accident sequences, importance analysis of components and systems as well as the CDF evaluation with consideration of the effect of correlation of failures by a newly developed method based on the Monte Carlo method. The effect of correlation has been recognized as an important issue in seismic PSAs. The procedures was used to perform a seismic PSA of a 1100 MWe BWR plant. Results are shown as well as the insights derived and future research needs identified in this seismic PSA. (J.P.N.)

  20. Asthma - What You Need to Know PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2011-05-03

    This 60 second Public Service Announcement (PSA) is based on the May, 2011 CDC Vital Signs report. Children and adults can have asthma and attacks can be frightening. To help control asthma, know the warning signs of an attack, stay away from asthma triggers, and follow your health care provider's advice.  Created: 5/3/2011 by Centers for Disease Control and Prevention (CDC).   Date Released: 5/3/2011.

  1. Long-term Prostate-specific Antigen Velocity in Improved Classification of Prostate Cancer Risk and Mortality

    DEFF Research Database (Denmark)

    Ørsted, David Dynnes; Bojesen, Stig E; Kamstrup, Pia R;

    2013-01-01

    BACKGROUND: It remains unclear whether adding long-term prostate-specific antigen velocity (PSAV) to baseline PSA values improves classification of prostate cancer (PCa) risk and mortality in the general population. OBJECTIVE: To determine whether long-term PSAV improves classification of PCa risk...

  2. The Use and Results of Prostate-Specific Antigen Testing in General Practice in the Former Aarhus County

    DEFF Research Database (Denmark)

    Mukai, Thomas; Bro, Flemming; Pedersen, Knud Venborg;

    Background: Prostate Cancer (PC) is the most common type of cancer among Danish men, and the incidence is increasing. PC is often asymptomatic, making it difficult to establish a clinical diagnosis. The general practitioner can use prostate-specific antigen (PSA) testing as a tool for diagnosing ...

  3. Prostate Cancer Detection and Dutasteride : Utility and Limitations of Prostate-Specific Antigen in Men with Previous Negative Biopsies

    NARCIS (Netherlands)

    van Leeuwen, Pim J.; Koelble, Konrad; Huland, Hartwig; Hambrock, Thomas; Barentsz, Jelle; Schroder, Fritz H.

    2011-01-01

    Context: We addressed the question whether the change of serum prostate-specific antigen (PSA) in men who use 5 alpha-reductase inhibitor (5-ARI) dutasteride is sensitive for the detection of aggressive prostate cancer (PCa). Objective: The case of a man using dutasteride diagnosed with Gleason 7 tr

  4. Basic concept of new screening method for external event PSA

    International Nuclear Information System (INIS)

    After the TEPCO's Fukushima Daiichi nuclear power station accident, the importance of developing Probabilistic Safety Assessment (PSA) method is recognized not only for earthquakes in external events but also for broader external events. According to the external events assessment conducted by the U.S. Nuclear Regulatory Commission (NRC) in the 1980s, various external events were used to be selected by two screening methods first, and then estimated Core Damage Frequency (CDF) by the PSA method for the selected external events. However, at several nuclear power plant sites, there is a possibility to remain the too many external events that are not screened out by the above conventional screening methods because these depend on site and the feature of hazard. The purpose of this study is to propose a new screening method in addition to the conventional ones for external event PSA by focusing on failures of components for the fulfillment of CDF target value. In this paper, the proposed method was specifically applied to strong wind (i.e. typhoon), which has the highest frequency and the strongest wind velocity in Japan. As a result, we recognized the possibility of screening out typhoons from the view point of wind-resistant load although further investigation is necessary in terms of the safety functional failures of components. (author)

  5. Development of the Level 1 PSA Model for PGSFR Regulatory

    International Nuclear Information System (INIS)

    SFR (sodium-cooled fast reactor) is Gen-IV nuclear energy system, which is designed for stability, sustainability and proliferation resistance. KALIMER-600 and PGSFR (Prototype Gen-IV SFR) are under development in Korea with enhanced passive safety concepts, e.g. passive reactor shutdown, passive residual heat removal, and etc. Risk analysis from a regulatory perspective is necessary for regulatory body to support the safety and licensing review of SFR. Safety issues should be identified in the early design phase in order to prevent the unexpected cost increase and the delay of PGSFR licensing schedule. In this respect, the preliminary PSA Model of KALIMER-600 had been developed for regulatory. In this study, the development of PSA Level 1 Model is presented. The important impact factors in the risk analysis for the PGSFR, such as Core Damage Frequency (CDF), have been identified and the related safety insights have been derived. The PSA level 1 model for PGSFR regulatory is developed and the risk analysis is conducted. Regarding CDF, LOISF frequency, uncertainty parameter for passive system CCF, loss of 125V DC control center bus and damper CCF are identified as the important factors. Sensitivity analyses show that the CDF would be differentiated (lowered) according to their values

  6. A method for using expert judgement in PSA

    International Nuclear Information System (INIS)

    The report discusses an expert judgement methodology development for applications at all levels of probabilistic safety assessment (PSA). The main applications are expected to be at PSA-levels 1 and 2. The method consists of several phases, including the selection and training of the experts, elicitation of experts' judgements, probabilistic modeling and combination of experts' judgements and documentation of the judgement process. The expert training and elicitation process is rather similar to that applied in the NUREG-1150 study. The combination of experts judgements is based on a Bayesian framework utilizing hierarchic models. The posterior distributions of the variables under analysis can be interpreted as a Bayesian counterpart of the combined or aggregated (consensus) distributions, and they are determined by applying Markov chain Monte-Carlo methods. The properties of the method are illustrated by some simple examples. The method is tested in a case study belonging to the benchmark exercise on the use of expert judgement in level 2 PSA, organized as a concerted action of European Commission Fourth Framework Programme on Nuclear Fission Safety. (14 refs.)

  7. Overview of Digital I and C PSA Research in KAERI

    International Nuclear Information System (INIS)

    This paper provides an overview of the ongoing research activities on probabilistic safety assessment (PSA) of digital instrumentation and control (I and C) systems in nuclear power plants (NPPs) performed by Korea Atomic Energy Research Institute (KAERI). The research activities are performed mainly on the methodology aspect and the model aspect of the digital I and C PSA. The methodology aspect includes the development of a new safety-critical software reliability analysis method by integrating the advantages of existing software reliability analysis methods, the fault coverage estimation method based on the fault injection experiments, and a new human reliability analysis method for computer-based main control rooms (MCRs) based on human performance data from the APR-1400 simulator. The model aspect includes the development of the digital-based safety-critical I and C systems such as digitalized reactor protection system (RPS) and engineered safety features component control system (ESF-CCS). The research results are expected to be used to address various issues such as the licensing issues related to digital I and C PSA for advanced digital-based NPPs

  8. Absolute Quantification of Endogenous Ras Isoform Abundance.

    Directory of Open Access Journals (Sweden)

    Craig J Mageean

    Full Text Available Ras proteins are important signalling hubs situated near the top of networks controlling cell proliferation, differentiation and survival. Three almost identical isoforms, HRAS, KRAS and NRAS, are ubiquitously expressed yet have differing biological and oncogenic properties. In order to help understand the relative biological contributions of each isoform we have optimised a quantitative proteomics method for accurately measuring Ras isoform protein copy number per cell. The use of isotopic protein standards together with selected reaction monitoring for diagnostic peptides is sensitive, robust and suitable for application to sub-milligram quantities of lysates. We find that in a panel of isogenic SW48 colorectal cancer cells, endogenous Ras proteins are highly abundant with ≥260,000 total Ras protein copies per cell and the rank order of isoform abundance is KRAS>NRAS≥HRAS. A subset of oncogenic KRAS mutants exhibit increased total cellular Ras abundance and altered the ratio of mutant versus wild type KRAS protein. These data and methodology are significant because Ras protein copy number is required to parameterise models of signalling networks and informs interpretation of isoform-specific Ras functional data.

  9. The effect of high level natural ionizing radiation on expression of PSA, CA19-9 and CEA tumor markers in blood serum of inhabitants of Ramsar, Iran

    International Nuclear Information System (INIS)

    Since several high level natural radiation areas (HLNRAs) exist on our planet, considerable attention has been drawn to health issues that may develop as the result of visiting or living in such places. City of Ramsar in Iran is an HNLRA, and is a tourist attraction mainly due to its hot spas. However, the growing awareness over its natural radiation sources has prompted widespread scientific investigation at national level. In this study, using an ELISA method, the level of expression of three tumor markers known as carcinoembryonic antigen (CEA), prostate-specific antigen (PSA) and carcino antigen 19-9 (CA19-9) in blood serum of 40 local men of Ramsar (subject group) was investigated and compared to 40 men from the city of Noshahr (control group). Noshahr was previously identified as a normal level natural radiation area (NLNRA) that is some 85 km far from Ramsar. According to statistical analysis, there was a significant difference in the levels of PSA and CA19-9 markers between the two groups (p < 0.001) with those of Ramsar being considerably higher. CEA level did not show any difference. Although some of the volunteers tested positive to the markers, they were in good health as confirmed by the physician. Moreover, the high number of positive markers in Noshahr was considerable. Therefore, future study is needed to further validate this result and to determine the level of positivity to tumor markers in both cities. -- Highlights: • Expression of three tumor markers was examined in 80 volunteers from Ramsar. • There was a significant difference in the levels of PSA and CA19-9 markers. • Some of the volunteers from the control city of Noshahr also tested positive. • Radiation might have caused an adaptive response in people of Ramsar. • Further study is necessary to re-confirm the positivity to tumor marker

  10. A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy

    International Nuclear Information System (INIS)

    Prostate cancer (PCa) is the second leading cause of cancer deaths in men in the United States. The prostate-specific antigen (PSA), often found at high levels in the serum of PCa patients, has been used as a marker for PCa detection and as a target of immunotherapy. The murine IgG1 monoclonal antibody AR47.47, specific for human PSA, has been shown to enhance antigen presentation by human dendritic cells and induce both CD4 and CD8 T-cell activation when complexed with PSA. In this study, we explored the properties of a novel mouse/human chimeric anti-PSA IgE containing the variable regions of AR47.47 as a potential therapy for PCa. Our goal was to take advantage of the unique properties of IgE in order to trigger immune activation against PCa. Binding characteristics of the antibody were determined by ELISA and flow cytometry. In vitro degranulation was determined by the release of β-hexosaminidase from effector cells. In vivo degranulation was monitored in human FcεRIα transgenic mice using the passive cutaneous anaphylaxis assay. These mice were also used for a vaccination study to determine the in vivo anti-cancer effects of this antibody. Significant differences in survival were determined using the Log Rank test. In vitro T-cell activation was studied using human dendritic cells and autologous T cells. The anti-PSA IgE, expressed in murine myeloma cells, is properly assembled and secreted, and binds the antigen and FcεRI. In addition, this antibody is capable of triggering effector cell degranulation in vitro and in vivo when artificially cross-linked, but not in the presence of the natural soluble antigen, suggesting that such an interaction will not trigger systemic anaphylaxis. Importantly, the anti-PSA IgE combined with PSA also triggers immune activation in vitro and in vivo and significantly prolongs the survival of human FcεRIα transgenic mice challenged with PSA-expressing tumors in a prophylactic vaccination setting. The anti-PSA IgE exhibits

  11. Analysis of common cause failure in Wolsong 2/3/4 NPPs PSA

    International Nuclear Information System (INIS)

    Wolsong 2/3/4 Nuclear Power Plants (WS 2/3/4 NPPs) are CANDU 6 type Pressurized Heavy Water Reactors (PHWRs) being built in Wolsong site of Korea by Korea Power Electric Corporation (KEPCO). WS 2/3/4 NPPs are designed by Atomic Energy of Canada Ltd. (AECL). AECL performs Probabilistic Safety Assessment (PSA) for these NPPs. In this PSA, however, the effect of Common Cause Failure (CCF) is not analyzed due to the limitation of CANDU reliability data. Since the CCF is regarded as one of the most dominant contributors to the total core damage frequency (CDF) in Pressurized Water Reactor (PWR) PSA. KEPCO and Korea Atomic Energy Research Institute (KAERI) initiated WS 2/3/4 NPPs Level 2 PSA which includes the CCF analysis and detailed HRA. In WS 2/3/4 NPPs Level 2 PSA, the authors reviewed the CCF data used in PWR PSA, and applied these data for WS 2/3/4 NPPs Level 2 PSA. The MGL method is implemented for the CCF analysis of WS 2/3/4 NPPs. The analyzed results show that the effect of CCF is not negligible in CANDU PSA as well as in PWR PSA. So the CCF data of CANDU plants should be collected and incorporated into CANDU PSA

  12. Image Guided Hypofractionated Radiotherapy by Helical Tomotherapy for Prostate Carcinoma: Toxicity and Impact on Nadir PSA

    Directory of Open Access Journals (Sweden)

    Salvina Barra

    2014-01-01

    Full Text Available Aim. To evaluate the toxicity of a hypofractionated schedule for primary radiotherapy (RT of prostate cancer as well as the value of the nadir PSA (nPSA and time to nadir PSA (tnPSA as surrogate efficacy of treatment. Material and Methods. Eighty patients underwent hypofractionated schedule by Helical Tomotherapy (HT. A dose of 70.2 Gy was administered in 27 daily fractions of 2.6 Gy. Acute and late toxicities were graded on the RTOG/EORTC scales. The nPSA and the tnPSA for patients treated with exclusive RT were compared to an equal cohort of 20 patients treated with conventional fractionation and standard conformal radiotherapy. Results. Most of patients (83% did not develop acute gastrointestinal (GI toxicity and 50% did not present genitourinary (GU toxicity. After a median follow-up of 36 months only grade 1 of GU and GI was reported in 6 and 3 patients as late toxicity. Average tnPSA was 30 months. The median value of nPSA after exclusive RT with HT was 0.28 ng/mL and was significantly lower than the median nPSA (0.67 ng/mL of the conventionally treated cohort (P=0.02. Conclusions. Hypofractionated RT schedule with HT for prostate cancer treatment reports very low toxicity and reaches a low level of nPSA that might correlate with good outcomes.

  13. Prospective investigation of change in the prostate-specific antigens after various urologic procedures

    Directory of Open Access Journals (Sweden)

    Park SC

    2015-07-01

    Full Text Available Seung Chol Park,1 Yu Seob Shin,2 Li Tao Zhang,2 Dal Sik Kim,3 Sung Zoo Kim,4 Nam Cheol Park,5 Tai Young Ahn,6 Je Jong Kim,7 Sung Won Lee,8 Insuk So,9 Jong Kwan Park2,10,11 1Department of Urology, Wonkwang University School of Medicine and Hospital, Iksan, South Korea; 2Department of Urology, 3Department of Laboratory Medicine, 4Department of Physiology, Medical School, Institute for Medical Sciences, Chonbuk National University, Jeonju, 5Department of Urology, College of Medicine, Pusan National University Hospital, Busan, 6Department of Urology, College of Medicine, Ulsan University, Seoul, 7Department of Urology, College of Medicine, Korea University, Seoul, 8Department of Urology, Samsung Medical Center, College of Medicine, SungKyunkwan University, Seoul, 9Department of Physiology, College of Medicine, Seoul National University, Seoul, 10Research Institute of Clinical Medicine, Chonbuk National University, 11Biomedical Research Institute and Clinical Trial Center, Chonbuk National University Hospital, Jeonju, South KoreaPurpose: Prostate-specific antigen (PSA is the most important marker in the diagnosis and follow-up of patients with prostate cancer. The primary objective of this study was to evaluate the effect of various urologic procedures in prostatic area on serum free and total PSA levels.Subjects and methods: A series of 62 patients (8 after digital rectal examination [DRE], 12 after transrectal ultrasonography [TRUS], 11 after rigid cystoscopy, 13 after prostatic massage, 8 after TRUS-guided prostate biopsy, and 10 after transurethral resection of prostate [TURP] were enrolled in the study. Blood samples were taken from each patient before procedure and at 10, 30, 60, and 120 minutes after procedures.Results: Prostate massage, rigid cystoscopy, TURP, and TRUS-guided prostate biopsy caused statistically significant rise in total and free PSA levels in the serum. There was no significant increase in total and free PSA levels in the

  14. Ikaros isoforms:The saga continues

    Institute of Scientific and Technical Information of China (English)

    Laura; A; Perez-Casellas; Aleksandar; Savic; Sinisa; Dovat

    2011-01-01

    Through alternate splicing,the Ikaros gene produces multiple proteins.Ikaros is essential for normal hematopoiesis and possesses tumor suppressor activity.Ikaros isoforms interact to form dimers and potentially multimeric complexes.Diverse Ikaros complexes produced by the presence of different Ikaros isoforms are hypothesized to confer distinct functions.Small dominantnegative Ikaros isoforms have been shown to inhibit the tumor suppressor activity of full-length Ikaros.Here,we describe how Ikaros activity is regulated by the coordinated expression of the largest Ikaros isoforms IK-1 and IK-H.Although IK-1 is described as full-length Ikaros,IK-H is the longest Ikaros isoform.IK-H,which includes residues coded by exon 3B (60 bp that lie between exons 3 and 4),is abundant in human but not murine hematopoietic cells.Specific residues that lie within the 20 amino acids encoded by exon 3B give IK-H DNA-binding characteristics that are distinct from those of IK-1.Moreover,IK-H can potentiate or inhibit the ability of IK-1 to bind DNA.IK-H binds to the regulatory regions of genes that are upregulated by Ikaros,but not genes that are repressed by Ikaros.Although IK-1 localizes to pericentromeric heterochromatin,IK-H can be found in both pericentromeric and non-pericentromeric locations.Anti-silencing activity of gamma satellite DNA has been shown to depend on the binding of IK-H,but not other Ikaros isoforms.The unique features of IK-H,its influence on Ikaros activity,and the lack of IK-H expression in mice suggest that Ikaros function in humans may be more complex and possibly distinct from that in mice.

  15. Predicting Gleason score using the initial serum total prostate-specific antigen in Black men with symptomatic prostate adenocarcinoma in Nigeria

    Directory of Open Access Journals (Sweden)

    Nnabugwu II

    2016-07-01

    Full Text Available Ikenna I Nnabugwu, Emeka I Udeh, Fredrick O Ugwumba, Francis O Ozoemena Urology Unit, Department of Surgery, College of Medicine, Enugu Campus, University of Nigeria, Enugu, Nigeria Background: Men of Black African descent are known to have the highest incidence of prostate cancer. The disease is also more aggressive in this group possibly due to biologically more aggressive tumor or late presentation. Currently, serum prostate-specific antigen (PSA assay plays a significant role in making the diagnosis of prostate cancer. However, the obtained value of serum PSA may not directly relate with the Gleason score (GS, a measure of tumor aggression in prostate cancer. This study explores the relationship between serum total PSA at presentation (iPSA and GS.Patients and methods: The iPSA of patients with histologically confirmed prostate cancer was compared with the obtained GS of the prostate biopsy specimens. The age of the patients at presentation and the prostate volumes were also analyzed with respect to the iPSA and GS. The data were analyzed retrospectively using IBM SPSS Version 20. Pearson correlation was used for numeric variables, whereas Fisher’s exact test was used for categorical variables. Significance was set at P≤0.05.Results: There were 205 patients from January 2010 to November 2013 who satisfied the inclusion criteria. iPSA as well as age at presentation and prostate volume were not found to significantly correlate with the primary Gleason grade, the secondary Gleason grade, or the GS. However, the presence of distant metastasis was identified to significantly correlate positively with GS.Conclusion: GS may not be confidently predicted by the iPSA. Higher iPSA does not correlate with higher GS and vice versa. Keywords: PSA, patient age, prostate volume, prostate adenocarcinoma, Gleason score

  16. Defining the appropriate radiation dose for pretreatment PSA no. <=no. 10 ng/mL prostate cancer

    International Nuclear Information System (INIS)

    Purpose: To investigate whether a dose response exists for biochemical no evidence of disease (bNED) control in prostate cancer patients with pretreatment prostate-specific antigen (PSA) no. =no. 7600 cGy. Median dose in these three groups was 7067 cGy, 7278 cGy, and 7734 cGy, respectively. Univariate analysis was performed to determine differences in bNED control (American Society for Therapeutic Radiology and Oncology [ASTRO] Consensus Guidelines definition of failure) by dose group for the entire cohort, for 310 good prognosis patients (T1-T2A, Gleason score 2-6, absence of PNI), and for 178 poor prognosis patients (T2B-T3 or Gleason score 7-10 or presence of PNI) . Multivariate analysis (MVA) was performed to determine if dose was an independent predictor of bNED control. Median follow-up was 36 months. Results: A dose response was not demonstrated for the entire group of patients with pretreatment PSA no. =no. 7600 cGy were associated with 5-year bNED control rates of 73%, 86%, and 89%, respectively (p = 0.12). MVA demonstrated prognosis group (p = 0.038) to be the only independent predictor of bNED control. Good prognosis patients had a 5-year bNED of 85% and no dose response was seen. The subgroup of poor prognosis patients demonstrated a 5-year bNED control rate of 81% and a dose response was seen for those receiving no. >=no. 7600 cGy, compared to the two lower dose groups (94% vs. 75% vs. 70%; p = 0.0062). MVA for the poor prognosis subset demonstrated dose (p = 0.01) to be the only independent predictor for improved bNED control. Conclusions: The poor prognosis subset of PSA no. <=no. 10 ng/mL prostate cancer patients benefit from dose escalation. A dose response is not demonstrated for prostate cancer patients with pretreatment PSA no. <=no. 10 ng/mL and other favorable features

  17. Ultrasensitive immunoassay for free prostate-specific antigen based on ferrocene carboxylate enhanced cathodic electrochemiluminescence of peroxydisulfate

    International Nuclear Information System (INIS)

    The catalytic effect of ferrocene carboxylate (FCC; in the form of nanocrystals) on the cathodic electrochemiluminescence (ECL) of peroxodisulfate was studied and applied to an ECL immunoassay to quantify free prostate-specific antigen (fPSA). The nanocrystals were entrapped in graphene previously functionalized with poly(dimethyldiallylammonium chloride) to give a solid-state nanohybrid referred to as FCC-Gr-PDDA. When cast onto a glassy carbon electrode (GCE), the ECL of peroxodisulfate is strongly enhanced. An immunoelectrode was then constructed by coating the positively charged nanohybrids matrix of FCC-Gr-PDDA with negatively charged gold nanoparticles and then immobilizing antibody against fPSA on the Au-NPs. The resulting electrode is then incubated with samples containing fPSA. An immunocomplex is formed in the presence of fPSA, and this prevents the solid-state nanohybrid film to enhance the ECL of the peroxodisulfate luminophor. The observed decrease in ECL intensity is directly related to the concentration of fPSA antigen in the range from 0.005 to 5 ng mL−1, and the detection limit is as low as 1.7 pg mL−1. The method is deemed to provide a widely applicable and general platform for ECL-based immunoassays. (author)

  18. Body mass index in relation to serum prostate-specific antigen levels and prostate cancer risk.

    Science.gov (United States)

    Bonn, Stephanie E; Sjölander, Arvid; Tillander, Annika; Wiklund, Fredrik; Grönberg, Henrik; Bälter, Katarina

    2016-07-01

    High Body mass index (BMI) has been directly associated with risk of aggressive or fatal prostate cancer. One possible explanation may be an effect of BMI on serum levels of prostate-specific antigen (PSA). To study the association between BMI and serum PSA as well as prostate cancer risk, a large cohort of men without prostate cancer at baseline was followed prospectively for prostate cancer diagnoses until 2015. Serum PSA and BMI were assessed among 15,827 men at baseline in 2010-2012. During follow-up, 735 men were diagnosed with prostate cancer with 282 (38.4%) classified as high-grade cancers. Multivariable linear regression models and natural cubic linear regression splines were fitted for analyses of BMI and log-PSA. For risk analysis, Cox proportional hazards regression models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) and natural cubic Cox regression splines producing standardized cancer-free probabilities were fitted. Results showed that baseline Serum PSA decreased by 1.6% (95% CI: -2.1 to -1.1) with every one unit increase in BMI. Statistically significant decreases of 3.7, 11.7 and 32.3% were seen for increasing BMI-categories of 25 prostate cancer risk although results were indicative of a positive association to incidence rates of high-grade disease and an inverse association to incidence of low-grade disease. However, findings regarding risk are limited by the short follow-up time. In conclusion, BMI was inversely associated to PSA-levels. BMI should be taken into consideration when referring men to a prostate biopsy based on serum PSA-levels. PMID:26914149

  19. Simple and robust antibody microarray-based immunoassay platform for sensitive and selective detection of PSA and hK2 toward accurate diagnosis of prostate cancer

    Directory of Open Access Journals (Sweden)

    S.W. Lee

    2015-03-01

    Full Text Available This paper reports the development of an easy to use antibody microarray-based immunoassay platform for sensitive and selective duplex detection of PSA (prostate specific antigen and hK2 (human kallikrein 2. Using PDMS wells in a 3 × 9 array on epoxy-coated glass slides 27 duplex immunoassays can be performed in parallel. Automated microarraying provided fast and reproducible antibody arraying in each assay well. To achieve highly sensitive and selective detection of each biomarker, we evaluated and optimized the density of each of the immobilized capture antibodies. The assay platform showed a limit of detection (LOD of each biomarker (PSA and hK2 of less than 10 pg/mL and a dynamic range of 104–105 orders of magnitude. Neither the PSA nor the hK2 antibody array showed any cross-reaction against each others target proteins or other plasma proteins. These results emphasize the importance of density optimization of capture antibody on the surface in order to achieve a sensitive and selective multiplex immunoassay.

  20. Predictive value of PSA velocity over early clinical and pathological parameters in patients with localized prostate cancer who undergo radical retropubic prostatectomy

    Directory of Open Access Journals (Sweden)

    Martinez Carlos A.L.

    2004-01-01

    Full Text Available OBJECTIVES: To analyze the behavior of the prostate specific antigen velocity (PSAV in localized prostate adenocarcinoma. MATERIALS AND METHODS: We conducted a retrospective study of 500 men who had localized prostate adenocarcinoma, who underwent radical retropubic prostatectomy between January 1986 and December 1999. The PSAV was calculated for each patient and subsequently, the values were correlated with 5 groups: age, initial PSA value, clinical stage, tumor volume and Gleason score. RESULTS: The behavior of PSAV presented statistic significance with an increment between 1.3 ng/mL and 9.6 ng/mL, ranging from 38.6% and 59.8% when compared with the initial PSA value (p < 0.0001, clinical stage (p = 0.0002, tumor volume (p < 0.0001 and Gleason score (p = 0.0009. CONCLUSION: PSAV up to 2.5 ng/mL/year is associated with factors of good prognosis, such as initial PSA below 10 mg/mL, clinical stage T1, tumor volume below 20% and Gleason score lower than 7.

  1. Electrochemiluminescence PSA assay using an ITO electrode modified with gold and palladium, and flower-like titanium dioxide microparticles as ECL labels

    International Nuclear Information System (INIS)

    We report on the synthesis of flower-like 3D titanium dioxide (fl-TiO2) using a hydrothermal method. This material possesses a large specific surface and displays an electrochemiluminescence (ECL) intensity that is much stronger than the one of TiO2 nanoparticles having smooth surfaces. It was used to label the secondary antibody in a sandwich immunoassay. A thin layer of metallic gold (Au) and palladium (Pd) was deposited on an indium tin oxide (ITO) electrode by code-position at a potential of 0.2 V in the respective chloride solutions. The Au/Pd-modified ITO electrode showed good conductivity. An ECL based immunoassay for the prostate specific antigen (PSA) was then worked out by immobilizing the first antibody on the Au/Pd layer on the ITO electrode, then exposing the electrode to a sample containing PSA, then forming the sandwich with the fl-TiO2 labeled secondary antibody, and finally measuring the intensity of ECL at a potential of −1.5 V. This ECL sensor has a response range that extends from 0.001 to 600 ng∙mL−1, a lower detection limit of 0.32 pg∙mL−1, good specificity, acceptable stability and good reproducibility. It gave satisfactory results when used for the determination of PSA in (spiked) diluted solutions of human serum. (author)

  2. Treatment Outcomes in Non-Metastatic Prostate Cancer Patients With Ultra-High Prostate-Specific Antigen

    International Nuclear Information System (INIS)

    Purpose: It is commonly believed that prostate cancer patients with very high prostate-specific antigen (PSA) levels are unlikely to benefit from definitive local treatment, and patients with very high PSA are often underrepresented in, or excluded from, randomized clinical trials. Consequently, little is known about their optimal treatment or prognosis. We performed a registry-based analysis of management and outcome in this population of patients. Methods and Materials: Our provincial Cancer Registry was used to identify all men who were diagnosed with prostate cancer from 1990 to 2001. A retrospective chart review provided information on stage, Gleason score, PSA at diagnosis, and treatment. In this study, ultra-high PSA was defined as PSA of ≥50 ng/ml. For a more complete perspective, treatment outcomes of patients with PSA of 20 to 49.9 ng/ml were also studied. Results: Of the 8378 men diagnosed with prostate cancer during this period, 6,449 had no known nodal or distant metastatic disease. The median follow-up of this group was 67.2 months (range, 0–192 months). A total of 1534 patients had PSA of ≥20 ng/ml. Among the 995 patients with PSA 20 to 49.9 ng/ml, 85 had radical prostatectomy (RP), and their 5- and 10-year cause-specific survivals (CSS) were 95% and 84%, respectively. The 497 patients treated with radiotherapy (RT) had 5- and 10-year CSS of 92% and 71%. For the 332 patients with PSA 50–99.9 ng/ml, RT was associated with 5- and 10-year CSS of 81% and 55%. For the 207 patients with PSA of ≥100 ng/ml, RT was associated with 5- and 10-year CSS of 80% and 54%. Conclusions: This is the largest series in the world on non metastatic cancer patients with ultra-high PSA at diagnosis. Even in the setting of a very high presenting PSA level, prostatectomy and radiotherapy are often associated with prolonged survival.

  3. The Practicality of Targeted Prostate Biopsy Procedures on the Dominant Side of the Tumor Determined by Magnetic Resonance Imaging in Elderly Patients with High Serum Levels of Prostate-Specific Antigen

    OpenAIRE

    Huh, Jung Sik; Kim, Bong Soo; Kim, Young Joo; Kim, Sung Dae; Park, Kyung Kgi

    2015-01-01

    Purpose To examine the possibility of reducing the number of cores per prostate biopsy in elderly patients with high levels of prostate-specific antigen (PSA) without significantly lowering the detection rate of prostate cancer. Materials and Methods Two hundreds sixteen men with PSA levels >20 ng/mL who underwent prostate biopsies from May 2009 to April 2013 were retrospectively reviewed. With the help of magnetic resonance imaging (MRI), the laterality of the dominant tumor burden in patien...

  4. Expression of androgen receptor and prostate-specific antigen in male breast carcinoma

    International Nuclear Information System (INIS)

    The androgen-regulated proteins prostate-specific antigen (PSA) and prostate-specific acid phosphatase (PSAP) are present in high concentrations in normal prostate and prostatic cancer and are considered to be tissue-specific to prostate. These markers are commonly used to diagnose metastatic prostate carcinoma at various sites including the male breast. However, expression of these two proteins in tumors arising in tissues regulated by androgens such as male breast carcinoma has not been thoroughly evaluated. In this study we analyzed the expression of PSA, PSAP and androgen receptor (AR) by immunohistochemistry in 26 cases of male breast carcinomas and correlated these with the expression of other prognostic markers. AR, PSA and PSAP expression was observed in 81%, 23% and 0% of carcinomas, respectively. Combined expression of AR and PSA was observed in only four tumors. Although the biological significance of PSA expression in male breast carcinomas is not clear, caution should be exercised when it is used as a diagnostic marker of metastatic prostate carcinoma

  5. The RFA regulatory sequence-binding protein in the promoter of prostate-specific antigen gene

    Institute of Scientific and Technical Information of China (English)

    CHEN; Weiwen; (陈蔚文); ZHANG; Jianye; (张建业); Charles; Y; F; Young; ZHANG; Lianying; (张莲英); CHEN; Liucun; (陈留存); ZHAO; Jian; (赵健)

    2003-01-01

    To assure what sequence associated with the androgen regulation, a 15 bp region at the upstream of the ARE of prostate-specific antigen (PSA) promoter, termed RFA, was found indispensable for androgen receptor (AR)-mediated transactivation of PSA promoter. In transfection and CAT assays, some nucleotides substitution in RFA could significantly decrease the androgen inducibility for PSA promoter. The in vitro DNA binding assay demonstrated that RFA bound specifically with some non-receptor protein factors in prostate cell nucleus, but the mutant type of RFA lost this ability, so RFA might be a novel accessory cis-element. The RFA-binding proteins were isolated and purified by affinity chromatography using RFA probes. SDS-PAGE and preliminary protein identification showed these proteins possessed sequence high homology with multifunctional protein heterogeneous nuclear ribonucleoprotein A1, A2 (hnRNP A1, A2). RFA-binding proteins possibly cooperate with AR-mediated transactivation for PSA promoter as coactivator. The study results will facilitate further understanding the mechanism and tissue specificity of PSA promoter.

  6. Survivin isoforms and clinicopathological characteristics in colorectal adenocarcinomas using real-time qPCR

    Science.gov (United States)

    Pavlidou, Anastasia; Dalamaga, Maria; Kroupis, Christos; Konstantoudakis, George; Belimezi, Maria; Athanasas, George; Dimas, Kleanthi

    2011-01-01

    AIM: To investigate three isoforms of survivin in colorectal adenocarcinomas. METHODS: We used the LightCycler Technology (Roche), along with a common forward primer and reverse primers specific for the splice variants and two common hybridization probes labeled with fluorescein and LightCycler-Red fluorophore (LC-Red 640). Real time quantitative polymerase chain reaction (PCR) was performed on cDNAs from 52 tumor specimens from colorectal cancer patients and 10 unrelated normal colorectal tissues. In the patients group, carcinoembryonic antigen (CEA) and CA19-9 tumor markers were also measured immunochemically. RESULTS: Wild type survivin mRNA isoform was expressed in 48% of the 52 tumor samples, survivin-2b in 38% and survivin-ΔΕx3 in 29%, while no expression was found in normal tissues. The mRNA expression of wild type survivin presented a significant correlation with the expression of the ratio of survivin-2b, survivin-ΔΕx3, survivin-2b/wild type survivin and survivin-ΔΕx3/wild type survivin (P < 0.001). The mRNA expression of wild-survivin and survivin-ΔΕx3 was related with tumor size and invasion (P = 0.006 and P < 0.005, respectively). A significant difference was found between survivin-2b and morphologic cancer type. Also, the ratio of survivin-ΔEx3/wild-survivin was significantly associated with prognosis. No association was observed between the three isoforms and grade, metastasis, Dukes stage and gender. The three isoforms were not correlated with CEA and CA19-9. CONCLUSION: Survivin isoforms may play a role in cell apoptosis and their quantification could provide information about clinical management of patients suffering from colorectal cancer. PMID:21472129

  7. Survivin isoforms and clinicopathological characteristics in colorectal adenocarcinomas using real-time qPCR

    Institute of Scientific and Technical Information of China (English)

    Anastasia Pavlidou; Maria Dalamaga; Christos Kroupis; George Konstantoudakis; Maria Belimezi; George Athanasas; Kleanthi Dimas

    2011-01-01

    AIM: To investigate three isoforms of survivin in colorectal adenocarcinomas. METHODS: We used the LightCycler Technology (Roche), along with a common forward primer and reverse primers specific for the splice variants and two common hybridization probes labeled with fluorescein and LightCycler- Red fluorophore (LC-Red 640). Real time quantitative polymerase chain reaction (PCR) was performed on cDNAs from 52 tumor specimens from colorectal cancer patients and 10 unrelated normal colorectal tissues. In the patients group, carcinoembryonic antigen (CEA) and CA19-9 tumor markers were also measured immunochemically. RESULTS: Wild type survivin mRNA isoform was expressed in 48% of the 52 tumor samples, survivin-2b in 38% and survivin-ΔΕx3 in 29%, while no expression was found in normal tissues. The mRNA expression of wild type survivin presented a significant correlation with the expression of the ratio of survivin-2b, survivin-ΔΕx3, survivin-2b/wild type survivin and survivin-ΔΕx3/wild type survivin (P < 0.001). The mRNA expression of wildsurvivin and survivin-ΔΕx3 was related with tumor size and invasion (P = 0.006 and P < 0.005, respectively). A significant difference was found between survivin-2b and morphologic cancer type. Also, the ratio of survivin-ΔEx3/ wild-survivin was significantly associated with prognosis. No association was observed between the three isoforms and grade, metastasis, Dukes stage and gender. The three isoforms were not correlated with CEA and CA19-9. CONCLUSION: Survivin isoforms may play a role in cell apoptosis and their quantification could provide information about clinical management of patients suffering from colorectal cancer.

  8. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer

    International Nuclear Information System (INIS)

    Purpose: This study was undertaken to: (a) define the prognostic significance of pretreatment serum prostate-specific antigen (PSA) levels in localized prostate cancer treated with radiation; (b) define the prognostic usefulness of postradiation PSA levels; (c) evaluate the outcome of radiation using PSA as an endpoint. Methods and Materials: Disease outcome in 707 patients with Stages T1 (205 men), T2 (256 men), T3 (239 men), and T4 (7 men), receiving definitive external radiation as sole therapy, was evaluated using univariate and multivariate techniques. Results: At a mean follow-up of 31 months, 157 patients (22%) developed relapse or a rising PSA. Multivariate analysis revealed pretreatment PSA level to be the most significant prognostic factor, with lesser though significant contributions due to Gleason grade (2-6 vs. 7-10) and transurethral resection in (T3(T4)) disease. The following four prognostic groupings were defined: group I, PSA ≤ 4 ng/ml, any grade; group II, 4 20, any grade. Five-year actuarial relapse rates in these groups were: I, 12%; II, 34%; III, 40%; and IV, 81%. Posttreatment nadir PSA was an independent determinant of outcome and only patients with nadir values < 1 ng/ml fared well (5-year relapse rate 20%). Using rising PSA as an endpoint the 461 patients with (T1(T2)) disease had an actuarial freedom from disease rate of 70% at 5 years, which appeared to plateau, suggesting that many were cured. No plateau was evident for (T3(T4)) disease. Conclusion: Pretreatment serum PSA is the single most important predictor of disease outcome after radiation for local prostate cancer. Tumor grade has a lesser though significant prognostic role. Postirradiation nadir PSA value during the first year is a sensitive indicator of response to treatment. Only nadir values < 1 ng/ml are associated with a favorable outlook. A significant fraction of men with (T1(T2)) disease may be cured with radiation. There was no evidence for a cured fraction among

  9. p53 isoforms change p53 paradigm

    OpenAIRE

    Bourdon, JC

    2014-01-01

    Although p53 defines cellular responses to cancer treatment it is not clear how p53 can be used to control cell fate outcome. Data demonstrate that so-called p53 does not exist as a single protein, but is in fact a group of p53 protein isoforms whose expression can be manipulated to control the cellular response to treatment.

  10. New isoforms of rat Aquaporin-4

    DEFF Research Database (Denmark)

    Moe, Svein Erik; Sorbo, Jan Gunnar; Søgaard, Rikke;

    2008-01-01

    Aquaporin-4 (AQP4) is a brain aquaporin implicated in the pathophysiology of numerous clinical conditions including brain edema. Here we show that rat AQP4 has six cDNA isoforms, formed by alternative splicing. These are named AQP4a-f, where AQP4a and AQP4c correspond to the two classical M1 and M...

  11. Nano-iniferter based imprinted sensor for ultra trace level detection of prostate-specific antigen in both men and women.

    Science.gov (United States)

    Patra, Santanu; Roy, Ekta; Madhuri, Rashmi; Sharma, Prashant K

    2015-04-15

    In this work, a sensitive and selective electrochemical sensor for detection of prostate specific antigen (PSA) was developed using surface imprinting and nanotechnology. The multiwalled carbon nanotubes (MWCNTs) decorated with manganese nanoparticles was functionalized with thio-group to make a nano-iniferter. This nano-iniferter was used as a platform to synthesize a three-dimensional molecularly imprinted polymer matrix for PSA by controlled radical polymerization technique. The PSA-sensor displayed good analytical performance for the detection of PSA by square wave and differential pulse stripping voltammetric techniques. The limit of detection was calculated as low as 0.25pgL(-1) (from SWSV) and 3.04pgL(-1) (from DPSV) at signal to noise ratio of 3. The proposed sensor was successfully applied for the determination of PSA in human blood serum, urine, and forensic samples without any cross-reactivity. Thus this sensor offers high selectivity, sensitivity, simplicity and clinical applicability for PSA determination in sera of both the men and women, which have not been reported together in the previously reported systems. The sensor may be used as a better alternative for the commercially available ELISA kits for PSA determination. PMID:25460874

  12. Workshop on PSA applications, Sofia, Bulgaria, 7-11 October 1996. Lecturing materials

    International Nuclear Information System (INIS)

    The objective of this workshop was to present detailed, systematic and useful information about PSA-based tools and PSA applications. The first presentation of the workshop was titled ''The role of PSA in safety management''. This topic served to introduce the workshop and to highlight several concepts that were afterwards stressed during the week, i.e. the defence in depth principle and the use of deterministic and probabilistic approaches in a complementary way. This presentation provided a basis for the discussion of ''PSA applications''. As a complement to the theoretical lectures, there was a workshop during which three different exercises were run in parallel. For two of these, computer-based PSA tools were used. One of them was focused towards the analysis of design modifications and the other one towards demonstrating configuration control strategies. The objective of the third practice was to obtain Allowed Outage Times using different PSA-based approaches and to discuss the differences observed and the insights obtained. To conclude the workshop, stress was put on the importance of the quality of the PSA (the development of a high quality Living PSA should be the first step), the necessity to be cautious (before taking decisions both the qualitative and numerical results should be carefully analyzed), and the logical order for the implementation of PSA applications. Refs, figs, tabs

  13. Comparison of various methods to quantify a fault tree for Seismic PSA

    Energy Technology Data Exchange (ETDEWEB)

    Han, Sang Hoon; Park, Jin Hee; Kim, Dong San; Lim, Ho-Gon; Jang, Seung Cheol [KAERI, Daejeon (Korea, Republic of)

    2015-05-15

    Typically, quantification (evaluation of frequency) of a sequence in a PSA is performed by generating minimal cut sets and quantifying it using REA (Rare event approximation) or MCUB (Minimal cut upper bound) method. MCUB gives more exact value than REA. But, it is known that REA and MCUB method may produce very conservative value when a probability of each event is larger than 0.1 such as in seismic PSA. The PSA software AIMS-PSA and FTREX developed in KAERI use REA and MCUB method to quantify a PSA model. Thus, it is necessary to verify the quantification result for seismic PSA. There are several method/software available for the verification. ACUBE developed by EPRI quantifies the pre-generated minimal cut sets using BDD (binary decision diagram) method. FTeMC developed by KAERI is based on Monte Carlo method. FtBdd developed by KAERI is based on BDD, but it can be applied for small fault trees. In section 2, a simple example is provided to characterize various methods. The results of those methods are compared for a seismic PSA model. REA and MCUB may produce very conservative value for a seismic PSA model which includes events whose probabilities are large. It is not easy to get the exact value for every case. We should recognize the limitation of each method/software when analyzing the quantification results for PSA. To verify the results, a supporting analysis can be used using other software such as Monte Carlo method.

  14. Development of a Base Model for the New Fire PSA Training

    International Nuclear Information System (INIS)

    US NRC/EPRI issued a new fire PSA method represented by NUREG/CR 6850, and have been training many operators and inspectors to widely spread the new method. However, there is a limitation in time and efficiency for many foreigners, who generally have communication problem, to participate in the EPRI/NRC training to learn the new method. Since it is about time to introduce the new fire PSA method as a regulatory requirement for the fire protection in Korea, a simple and easy-understandable base model for the fire PSA training is required, and KAERI-KINS is jointly preparing the base model for the new fire PSA training. This paper describes how the base model is developed. Using an imaginary simple NPP, a base model of fire PSA following the new fire PSA method was developed in two ways from the internal PSA model. Since we have the base model and know the process of making the fire PSA model, the training for the new fire PSA method can be in detail performed in Korea

  15. Les discriminations syndicales saisies par le droit à PSA

    OpenAIRE

    Chappe, Vincent-Arnaud

    2015-01-01

    Cet article porte sur le processus d’appropriation du droit de la non-discrimination syndicale à PSA. Il analyse la façon dont, dans le sillage d’une mobilisation judiciaire dans la deuxième moitié des années 1990, des accords de droit syndical ont été signés permettant une reconfiguration en profondeur des relations sociales et l’élimination des formes les plus criantes de discrimination. Ce processus s’est néanmoins accompagné d’une forme de professionnalisation ambigüe de l’activité syndic...

  16. Application of the uncertainty analysis in the PSA

    International Nuclear Information System (INIS)

    The uncertainty of integrality and hypothesis condition while modeling, data input uncertainty is analyzed in Probability Safety Assessment, as well as the causes of said factors. Aiming at the uncertainty of the parameter input in PSA has specified the theory and method for the uncertainty analysis of Risk Spectrum Software. 13 initial events and average of core damage frequency have achieved after ration calculation to the uncertainty of input data. To token both curve of uncertainty is recommend which Probability Density Function and Cumulative Density Function

  17. Maintenance optimization by using PSA results in the RCM context

    International Nuclear Information System (INIS)

    Reliability Centered Maintenance (RCM) is a systematic methodology to identify efficient activities to prevent potential component failures. Several RCM pilot studies have been successfully performed but it is generally recognized that further improvements are needed. Last year the Polytechnic University of Valencia, together with Cofrentes Nuclear Power Plant started a pilot project whose objective was to develop an integrated RCM tool. This tool should be able to use PSA results in the first stages of the process. This paper presents the state of this work and outlines further developments. (author). 1 ref., 5 figs, 2 tabs

  18. A survey on the quantitative incorporation organizational factors into PSA

    International Nuclear Information System (INIS)

    The effects of organizational factors on the human performance and safety in nuclear power plants have been known through the results of research for several years. The organizational factor, which belongs to 11 elements of PSR (Periodic Safety Review), has been an important research area. In this study the state-of-the-art of qualitative and quantitative evaluation methodologies on organizational factors has been surveyed. The results of this study may contribute to developing a quantitative evaluation methodology on organizational factors as well as the basic research for conducting the PSR research, and for incorporating the quality of organization factors into PSA

  19. Colorectal Cancer - What You Need to Know PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2011-07-05

    This 60 second Public Service Announcement (PSA) is based on the July, 2011 CDC Vital Signs report. Colorectal cancer kills about 50,000 men and women every year. Screening can save lives! Screening can find abnormal growths so they can be removed before turning into cancer, and can find the cancer early, when it's easiest to treat. If you're over 50, talk to your doctor about getting screened for colorectal cancer.  Created: 7/5/2011 by Centers for Disease Control and Prevention (CDC).   Date Released: 7/5/2011.

  20. A multi-institutional analysis comparing adjuvant and salvage radiation therapy for high-risk prostate cancer patients with undetectable PSA after prostatectomy

    International Nuclear Information System (INIS)

    Background and purpose: In men with adverse pathology at the time of radical prostatectomy (RP), the most appropriate timing to administer radiotherapy (RT) remains a subject for debate. To determine whether salvage radiotherapy (SRT) upon early prostate-specific antigen (PSA) relapse is equivalent to immediate adjuvant radiotherapy (ART) post RP. Material and methods: 130 patients receiving ART and 89 receiving SRT were identified. All had an undetectable PSA after RP. Homogeneous subgroups were built based on the status (±) of lymphatic invasion (LVI) and surgical margins (SM), to allow a comparison of ART and SRT. Biochemical disease-free survival (bDFS) was calculated from the date of surgery and from the end of RT. The multivariate analysis was performed using the Cox Proportional hazard model. Results: In the SM-/LVI- and SM+/LVI- groups, SRT was a significant predictor of a decreased bDFS from the date of surgery, while in the SM+/LVI+ group, there was a trend towards significance. From the end of RT, SRT was also a significant predictor of a decreased bDFS in three patient groups: SM-/LVI-, SM+/LVI- and SM+/LVI+. Gleason score >7 showed to be another factor on multivariate analysis associated with decreased bDFS in the SM-/LVI- group, from the date of surgery and end of RT. Preoperative PSA was a significant predictor in the SM-/LVI- group from the date of RP only. Conclusions: Immediate ART post RP for patients with high risk features in the prostatectomy specimen significantly reduces bDFS after RP compared with early SRT upon PSA relapse.

  1. Computer software for PSA level 1 analysis used and developed within the framework of the IAEA's inter-regional PSA programme

    International Nuclear Information System (INIS)

    An inter-regional technical cooperation programme on Probabilistic Safety Assessment (PSA) was initiated 1985 by the IAEA. An important element of this programme is the assistance in the selection and application of appropriate computer software. Because Personal Computers (PCs) are increasingly utilized as convenient workstations for PSA analysis and considering the needs of Member States, the IAEA has initiated a project to develop a PC software package for fault tree and event tree analysis. The features of this software package are outlined. A description of the PSA related software library at the IAEA is also presented. (orig.)

  2. Normalization of prostate specific antigen in patients treated with intensity modulated radiotherapy for clinically localized prostate cancer

    International Nuclear Information System (INIS)

    The purpose of this study was to determine the expected time to prostate specific antigen (PSA) normalization with or without neoadjuvant androgen deprivation (NAAD) therapy after treatment with intensity modulated radiotherapy (IMRT) for patients with clinically localized prostate cancer. A retrospective cohort research design was used. A total of 133 patients with clinical stage T1c to T3b prostate cancer (2002 AJCC staging) treated in a community setting between January 2002 and July 2005 were reviewed for time to PSA normalization using 1 ng/mL and 2 ng/mL as criteria. All patients received IMRT as part of their management. Times to PSA normalization were calculated using the Kaplan-Meier method. Significance was assessed at p < 0.05. Fifty-six of the 133 patients received NAAD (42.1%). Thirty-one patients (23.8%) received radiation to a limited pelvic field followed by an IMRT boost, while 99 patients received IMRT alone (76.2%). The times to serum PSA normalization < 2 ng/mL when treated with or without NAAD were 298 ± 24 and 302 ± 33 days (mean ± SEM), respectively (p > 0.05), and 303 ± 24 and 405 ± 46 days, respectively, for PSA < 1 ng/mL (p < 0.05). Stage T1 and T2 tumors had significantly increased time to PSA normalization < 1 ng/mL in comparison to Stage T3 tumors. Also, higher Gleason scores were significantly correlated with a faster time to PSA normalization < 1 ng/mL. Use of NAAD in conjunction with IMRT leads to a significantly shortened time to normalization of serum PSA < 1 ng/mL in patients with clinically localized prostate cancer

  3. An analysis of pretreatment characteristics and the risk of PSA failure by race and ethnicity in prostate cancer patients treated with definitive radiotherapy

    International Nuclear Information System (INIS)

    Purpose/Objective: This study was performed to: (1) determine the pretreatment characteristics of racially and ethnically diverse men who were treated with definitive radiotherapy for prostate cancer and; (2) to assess whether race or ethnicity is an independent prognostic factor for biochemical failure using the serum PSA (prostate specific antigen) as a marker of disease free status. Materials and Methods: Between 1987 and 1995, 505 men, (including 487 with pretreatment PSA determined), were treated with radiotherapy for adenocarcinoma of the prostate in the Department of Radiation Oncology at the UCSF or its affiliated hospitals and form the basis of this analysis. These patients were referred from local VA, County, HMO and private facilities in the Northern California Bay Area and represent a diverse group by race, ethnicity and social economic status. PSA failure was defined as a PSA >1.0 ng/ml or rises of ≥ 0.5 ng/ml in 1 year. Results: The median PSA for all patients was 11.5 ng/ml and the mean was 20.8 ng/ml. The mean Gleason score was 5.95, and was similar among treatment groups. Twenty percent of the patients were T1, 56% were T2 and 24% were T3/4. The maximum dose at depth (Dmax) was 71.5 in 42% of the patients. Seventy two men (14%) received neoadjuvant +/- adjuvant hormonal therapy combined with radiotherapy. With a median follow-up exceeding 2 years, 47% of the patients are disease free at 4 years. Major pretreatment characteristics by race or ethnicity are summarized below: On univariate analysis, the relative risk of PSA failure in Blacks compared to Whites was 1.04 (95% confidence interval, 0.72- 1.52, p = 0.82) and in others compared to Whites was 1.12 (95% confidence interval, 0.55 - 2.28, p = 0.77). On multivariate analysis, neither race nor ethnicity were independently significant predictors of outcome. For example, the relative risk of PSA failure in Blacks was 0.88 (95% confidence interval, 0.59 - 1.32, p = 0.53). Factors that influenced

  4. Improvements in progress for Russia's new PSA law

    International Nuclear Information System (INIS)

    Russian legislation making production sharing agreements (PSAs) fully legal under Russian law passed the upper house of the Russian Parliament (Federal Council) on December 19, 1995, was signed into law by President Boris Yeltsin on December 31, 1995, and took effect on January 11, 1996. While PSA legislation remains the central legal basis for large scale investment in the Russian petroleum sector, company views towards investment in this sector are tied to much more than the extent of legal guarantees. Investor attitudes are also shaped by expectations regarding political stability, behavior of Russian regulatory authorities, and prospects for the Russian economy. Furthermore, Western investors in the petroleum sector have some experience in dealing with the Russian government and existing frameworks for investment, particularly the joint venture (JV) deals with Russian entities and the often changing regulatory and tax treatment of these ventures. It is the view of the authors that attitudes among some Western companies in Russia on the political and economic environment may be too pessimistic and shaped more by press reports than actual conditions. News reports on violence, political instability, and a disastrous economy are not entirely borne out by the facts. Russian, of course, faces serious political and economic problems which must be carefully evaluated, but the overall outlook is much more complex, and some positive developments are underway. This paper reviews the economic, oil production and industry outlook as a result of the PSA law

  5. Importance of the multi-modules study in PSA

    International Nuclear Information System (INIS)

    The current approach that has taken the Probabilistic Safety Analysis (PSA) consists of doing all the APS analysis including the existence of multi-units in the nuclear power plants (NPP), this new approach seeks to analyze the risk of site, evaluating all reactors together. The main reasons for this trend are: the accident occurred on March 2011 in Fukushima Daiichi in Japan, with serious consequences in more than one reactor of the NPP and the current planning and construction of new Small Modular Reactors, which host more than one module on the same NPP and are connected to a single control room. This study analyzes how to model the risk of a multi-module NPP. In 2013, the ASME/ANS standard for advanced reactors that are not light-water reactors was published, in which the requirements to realize a PSA including multi-units or modules are shown; however, does not describe the methodology to do that. This article presents a methodology to calculate the risk of the site in a PBMR plant with two modules. This methodology consists of two models of trees of different events, one that evaluates to a single PBMR module and another that evaluates the two modules together. Both models are responsible to show their differences and compare results to finally demonstrate the need for new methodologies for risk analysis site in multi-modules and units. (Author)

  6. External events analysis in PSA studies for Czech NPPs

    International Nuclear Information System (INIS)

    The purpose of the paper is to summarize current status of natural external hazards analysis in the PSA projects maintained in Czech Republic for both Czech NPPs - Dukovany and Temelin. The focus of the presentation is put upon the basic milestones in external event analysis effort - identification of external hazards important for Czech NPPs sites, screening out of the irrelevant hazards, modeling of plant response to the initiating events, including the basic activities regarding vulnerability and fragility analysis (supported with on-site analysis), quantification of accident sequences, interpretation of results and development of measures decreasing external events risk. The following external hazards are discussed in the paper, which have been addressed during several last years in PSA projects for Czech NPPs: 1)seismicity, 2)extremely low temperature 3)extremely high temperature 4)extreme wind 5)extreme precipitation (water, snow) 6)transport of dangerous substances (as an example of man-made hazard with some differences identified in comparison with natural hazards) 7)other hazards, which are not considered as very important for Czech NPPs, were screened out in the initial phase of the analysis, but are known as potential problem areas abroad. The paper is a result of coordinated effort with participation of experts and staff from engineering support organization UJV Rez, a.s. and NPPs located in Czech Republic - Dukovany and Temelin. (authors)

  7. Development of a PSA workstation for operational safety management

    International Nuclear Information System (INIS)

    This paper describes several efforts for the development of PSA(Probabilistic Safety Assessment) Workstation in KAERI (Korea Atomic Energy Research Institute) to manage operational safety of Nuclear Power Plants (NPPs); (1) development of PSA modeling tool, KIRAP, (2) development of a risk monitor, Risk Monster, (3) development of plant information system, EPIS, (4) development of reliability centered maintenance(RCM) tool, RAM-Pro. KIRAP supplies fault tree(FT) editor, quantification engine (Kcut), event tree(ET) editor, and database management tool(KwDBMan) in Window environment. Risk Monster supports for plant operators and maintenance schedulers to monitor plant risk and to avoid high peak risk by rearranging maintenance work schedule. EPIS (Electro Plant Information System) supplies plant information related to components such as equipment list and specification, maintenance work history data, preventive maintenance (PM) items list, spare parts information, technical specification information, design change information, and P and ID, etc. RAM-Pro help RCM by providing maintenance history data management (RAM-Hist), reliability analyzer (RAM-Rel), and RAM-RCM which are used for FFA(Functional Failure Analysis), FMEA(Failure Mode Effect Analysis) and LTA(Logical Tree Analysis) in RCM. (author)

  8. PSA based vulnerability and protectability analysis for NPPs

    International Nuclear Information System (INIS)

    Highlights: ► The paper describes the generation of location sets and protection sets. ► Vulnerability and protectability used to rank location sets and protection sets. ► Ranking helps in adequacy of protection measures employed in various locations. ► The procedure for PSA based vital area identification is demonstrated. ► This method has found practical applicability for Indian NPP. -- Abstract: Identification of vital areas in a facility involves assessing the facility and the locations, whose sabotage can result in undesirable (radiological) consequences. Probabilistic Safety Assessment (PSA) technique can find the component failures leading to core damage (a surrogate for radiological consequence) in a systematic manner, which can be extended to identification of vital areas. This paper describes the procedure for the generation of location sets (set of locations whose sabotage can lead to possible core damage) and protection sets (set of locations that must be protected to prevent possible core damage). In addition, measures such as vulnerability and protectability have been introduced, which can be used to rank location sets and protection sets.

  9. Psa study of ETRR-2 Gadolinium injection system

    International Nuclear Information System (INIS)

    one of the main safety feature of ETRR-2, egypt test and reactor 3 2 (new reactor), is the use of a redundant and diverse shutdown systems, called second shutdown system SSS. This system operates through injection of a high absorbing material, gadolinium Gd solution, into four rectangular chambers surrounding the reactor core. In view of the fact that the core is super-moderated, the injected neutron poison between the core and the reflector will cause an immediate reactor shutdown. The SSS triggers due to: manual, seismic, fails of actuation of the first shutdown system FSS, or high power neutron flux signal. Because of safety importance of this new system design, the present probabilistic safety assessment PDA study is initiated. The study carried ou in view of the system acceptable unavailability together with the effects of failure probabilities of relevant parameters and basic events. The effect of system design modifications (remove of high power signal and addition of nitrogen filtering line) on reactor safety and system unavailability is analyzed. A new proposed PSA model which take into consideration all possible failure modes of the system components is developed. The results show that the modification done on the system improves its unavailability while increases the minimal cut sets. The proposed model unavailability is greater (bad) than the designer model (That contains many hypothesis). human error contribution on system unavailability is reflected on failure type of gadolinium concentration. The IAEA psa pack IV code is utilized for calculation purposes

  10. PSA results for Hanford high level waste Tank 101-SY

    International Nuclear Information System (INIS)

    Los Alamos National Laboratory has performed a comprehensive probabilistic safety assessment (PSA) that includes consideration of external events for the weapons-production wastes stored in tank number 241-SY-101, commonly known as Tank 101-SY, as configured in December 1992. This tank, which periodically releases (''burps'') a gaseous mixture of hydrogen, nitrous oxide, ammonia, and nitrogen, was analyzed because of public safety concerns associated with the potential for release of radioactive tank contents should this gas mixture be ignited during one of the burps. In an effort to mitigate the burping phenomenon, an experiment is underway in which a large pump has been inserted into the tank to determine if pump-induced circulation of the tank contents will promote a slow, controlled release of the gases. This PSA for Tank 101-SY, which did not consider the pump experiment or future tank-remediation activities, involved three distinct tasks. First, the accident sequence analysis identified and quantified those potential accidents whose consequences result in tank material release. Second, characteristics and release paths for the airborne and liquid radioactive source terms were determined. Finally, the consequences, primarily onsite and offsite potential health effects resulting from radionuclide release, were estimated, and overall risk curves were constructed. An overview of each of these tasks and a summary of the overall results of the analysis are presented in the following sections

  11. PSA based plant modifications and back-fits

    International Nuclear Information System (INIS)

    The mandate of Principal Working Group No. 5 - Risk Assessment states that 'The group should deal with the technology and methods for identifying contributors to risk and assessing their importance, and appropriate exchanges of information on current research'. Since being formulated in 1982, along with this mandate, the group has also endeavored to develop a common understanding of the different approaches taken in risk assessment. The focus of this report is to provide knowledge to experts on the role Probabilistic Safety Assessment (PSA) has had in safety decision making. PSA is a powerful tool for improving Nuclear Power Plant safety by identifying weaknesses in design or operation and setting priorities for plant modifications and back-fits. While the use is well recognised, it is also true that any safety decision is generally based on several elements, both probabilistic and deterministic. This document provides a general overview of insights gained from the representative set of examples collected from Member countries (Finland, France, Germany, Japan, Korea, Netherlands, Spain, Sweden, Switzerland, United Kingdom, United States). The report starts with basic types of plant modifications which were carried out (e.g. hardware or software, important or minor, etc.) and the characteristics of the PSAs used in the examples (e.g. level and scope, specific or generic, on-going or terminated, etc.). The insights gained from this small collection are then reviewed. The appendix gives a full text version of the Member country contributions

  12. A Tsunami PSA for Nuclear Power Plants in Korea

    International Nuclear Information System (INIS)

    For the evaluation of safety of NPP caused by Tsunami event, probabilistic safety assessment (PSA) method was applied in this study. At first, an empirical tsunami hazard analysis performed for an evaluation of tsunami return period. A procedure for tsunami fragility methodology was established, and target equipment and structures for investigation of Tsunami Hazard assessment were selected. A several fragility calculations were performed for equipment in Nuclear Power Plant and finally accident scenario of tsunami event in NPP was presented. Finally, a system analysis performed in the case of tsunami event for an evaluation of a CDF of Ulchin 56 NPP site. For the evaluation of safety of NPP caused by Tsunami event, probabilistic safety assessment (PSA) method was applied. A procedure for tsunami fragility methodology was established, and target equipment and structures for investigation of Tsunami Hazard assessment were selected. A several fragility calculations were performed for equipment in Nuclear Power Plant and finally accident scenario of tsunami event in NPP was presented. As a result, in the case of tsunami event, functional failure is mostly governed total failure probability of facilities in NPP site

  13. Development of a Review Guide for a Level-3 PSA of Nuclear Power Plants

    International Nuclear Information System (INIS)

    A probabilistic safety assessment (PSA) provides a systematic analysis to identify and quantify all the risks that a plant imposes to the operators, general public and the environment. The main benefits of a PSA is to provide insights into the safety aspects of a plant design, performance, and the potential environmental impacts of postulated accidents, including the identification of dominant risk contributors, and a comparison of the options for reducing a risk. Among the three levels of a PSA, a Level-3 PSA provides insights into the relative importance of a accident prevention and mitigative measures expressed in terms of the adverse consequences for the health of the public, and the contamination of land, air, water, and foodstuffs. Finally, a Level-3 PSA provides insights into the relative effectiveness of emergency response planning aspects of an off-site accident management, and into the economic impacts. Regulatory bodies are generally responsible for the specification of safety criteria which can be related to PSAs at Level-1, -2, and -3. Examples of these criteria are the frequency of a severe core damage for a Level-1, and the frequency of large releases of radionuclides for a Level-2 PSA. The most commonly used Level-3 related safety criteria are early and cancer fatality risks. The regulatory body in Korea has developed the review guides for the Level-1 and -2 PSA. And the current regulatory structure for the licensing of nuclear power plants is established for an LWR-oriented structure. However, the accomplishment of a Level-3 PSA as well as Level-1 and -2 PSA is necessary in order to establish the risk-informed and performance-based regulatory structure for the licensing of future nuclear power plants. In such a situation, the need for the accomplishment of a Level-3 PSA is increasing. Therefore, the main goal of this study is to develop a review guide for the Level-3 PSA

  14. Histopathological findings in extended prostate biopsy with PSA ≤ 4 ng/mL

    Directory of Open Access Journals (Sweden)

    Katia R. Leite

    2008-06-01

    Full Text Available OBJECTIVE: Cancer detection has been reported in up to 27% of patients when lowering the PSA cutoff to 2.5 ng/mL. Although this practice could increase the number of biopsies performed, it also could lead to more frequent detection of significant prostate cancers at an organ-confined stage and/or a less aggressive state. This study describes the incidence of malignancy and tumor characteristics in extended prostate biopsies with PSA ≤ 4 ng/mL. MATERIALS AND METHODS: Prostate biopsies from 1081 patients where examined, 275 (25.4% patients had PSA level ≤ 4 ng/mL. RESULTS: Cancer was diagnosed in 32.0% and 35.7% of patients with PSA ≤ 4 ng/mL and > 4 ng/mL, respectively (p = 0.906. The median Gleason score was 7 independent of PSA > or ≤ 4 ng/mL (p = 0.078. The median number of cores positive for tumor was 4 and 3, respectively, for PSA > 4 ng/mL and PSA ≤ 4 ng/mL (p = 0.627. There was a difference in the total percent of tumors involving all cores, 11% and 7% for PSA > or ≤ 4 ng/mL (p = 0.042. Fifty-six patients underwent radical prostatectomy, 12 had PSA ≤ 4 ng/mL. In both groups, a diagnosis of cancer was accurate with no differences in Gleason score, tumor volume or staging for both groups. CONCLUSION: When PSA is below 4 ng/mL, cancer is detected in a proportion equal to the proportion diagnosed with a PSA > 4 ng/mL, and tumor characteristics are similar between the two groups. Only clinically significant tumors were diagnosed following radical prostatectomy.

  15. The Different Reduction Rate of Prostate-Specific Antigen in Dutasteride and Finasteride

    OpenAIRE

    Choi, Yong Hyeuk; Cho, Sung Yong; Cho, In Rae

    2010-01-01

    Purpose To compare and analyze the therapeutic effects and changes in the prostate-specific antigen (PSA) level with treatment with finasteride or dutasteride for benign prostatic hyperplasia (BPH) for 1 year. Materials and Methods We retrospectively investigated patients who suffered from BPH for 1 year between January 2005 and December 2008. For treatment groups, we divided the patients into two groups: one was treated with alfuzosin and finasteride and the other was treated with alfuzosin ...

  16. Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: An analysis of Radiation Therapy Oncology Group Protocol 92-02

    International Nuclear Information System (INIS)

    Purpose: We evaluated whether posttreatment prostatic-specific antigen doubling time (PSADT) was predictive of prostate cancer mortality by testing the Prentice requirements for a surrogate endpoint. Methods and Materials: We analyzed posttreatment PSA measurements in a cohort of 1,514 men with localized prostate cancer (T2c-4 and PSA level Cox = 0.002), PSADT Cox Cox Cox Cox = 0.4). The significant posttreatment PSADTs were also significant predictors of CSS (pCox< 0.001). After adjusting for T stage, Gleason score and PSA, all of Prentice's requirements were not met, indicating that the effect of PSADT on CSS was not independent of the randomized treatment. Conclusions: Prostatic specific antigen doubling time is significantly associated with CSS, but did not meet all of Prentice's requirements for a surrogate endpoint of CSS. Thus, the risk of dying of prostate cancer is not fully explained by PSADT

  17. Histocompatibility antigen test

    Science.gov (United States)

    ... more common in certain autoimmune diseases . For example, HLA-B27 antigen is found in many people (but not ... More Ankylosing spondylitis Autoimmune disorders Bone marrow transplant HLA-B27 antigen Kidney transplant Reactive arthritis Update Date 2/ ...

  18. Impact of Neoadjuvant Prostate-Specific Antigen Kinetics on Biochemical Failure and Prostate Cancer Mortality: Results From a Prospective Patient Database

    Energy Technology Data Exchange (ETDEWEB)

    Foo, Marcus, E-mail: Marcus.Foo@petermac.org [Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne (Australia); Lavieri, Mariel [Department of Industrial and Operations Engineering, University of Michigan, Ann Arbor, Michigan (United States); Pickles, Tom [Department of Radiation Oncology, British Columbia Cancer Agency, Vancouver, BC (Canada)

    2013-02-01

    Purpose: To confirm findings from an earlier report showing that neoadjuvant (NA) prostate-specific antigen (PSA) halving time (PSAHT) impacts biochemical failure (BF) rates, and to examine its association with prostate cancer-specific survival (PCSS), in a large prospective cohort of patients. Methods and Materials: A total of 502 patients were selected from a prospective database, who had localized prostate adenocarcinoma treated with 2-12 months of neoadjuvant androgen deprivation therapy (N-ADT) followed by external beam radiation therapy (EBRT) between 1994 and 2000, and had at least 2 NA PSA values. Seventy-four percent of patients had high-risk prostate cancer. Median initial PSA value, N-ADT duration, total ADT duration, and radiation therapy dose were 14 ng/mL, 6.9 months, 10.8 months, and 68 Gy, respectively. Results: At a median follow-up of 9.9 years, 210 patients have had a BF. Median PSAHT was 18 days. On univariate analysis, PSAHT was not shown to predict for BF (P=.69) or PCSS (P=.28). However, NA nadir PSA (nanPSA) and post-therapy nadir PSA (ptnPSA), when analyzed as continuous or categoric variables, predicted for BF (P<.001) and PCSS (P<.001). On multivariate analysis, nanPSA (P=.037) and ptnPSA (P<.001) continued to be significantly associated with BF. However, N-ADT duration lost significance (P=.67), and PSAHT remained a nonsignificant predictor (P=.97). For PCSS, multivariate analysis showed nanPSA (P=.049) and ptnPSA (P<.001) to be significant. Again PSAHT (P=.49) remained nonsignificant. Conclusions: In this large, prospective cohort of patients, NA PSA kinetics, expressed as PSAHT, did not predict BF or PCSS. However, nadir PSAs, in both the NA and post-therapy settings, were significant predictors of BF and PCSS. Optimization of therapy could potentially be based on early PSA response, with shorter durations of ADT for those predicted to do favorably, and intensification of therapy for those likely to have poorer outcomes.

  19. Pretreatment prostate-specific antigen values in patients with prostate cancer: 1989 patterns of care study process survey

    International Nuclear Information System (INIS)

    Purpose: A Patterns of Care Study (PCS) national survey was conducted to show the national averages for processes of radiation therapy care for prostate cancer patients in 1989. In the current study we report an analysis of pretreatment prostate-specific antigen (PSA) by stage, grade, and ethnic origin. Methods and Materials: Process data were collected from 672 patients treated in 1989 at 71 separate institutions. Four hundred and twenty-seven (64%) of these patients had a pretreatment PSA value recorded. Three hundred and forty-three of the 427 patients were treated with external beam irradiation alone and were selected for the current analysis. The 1992 AJCC staging system was used. Results: There was a significant increase in pretreatment PSA with increasing stage. The median values of PSA were 8.3 ngm/ml in the T1 group (n = 65), 11.2 ngm/ml in the T2 group (n = 178), and 20.9 ngm/ml in the T3 group (n = 90) (p < 0.001). Ten patients were not staged. There was a significant increase in pretreatment PSA with decreasing differentiation. The median pretreatment PSA was 9.7 ngm/ml in well-differentiated tumors (n = 109), 13.0 ngm/ml in moderately differentiated tumors (n = 163), and 22.0 ngm/ml in poorly differentiated tumors. (n = 61) (p < 0.001). Ten patients had no differentiation recorded. African Americans (24) showed a significant increase in pretreatment PSA compared to Caucasians (304). The respective medians were 23.2 ng/ml and 11.9 ng/ml (p = 0.04). They also show more poorly differentiated tumors (33% vs. 17%) and more T3 tumors (46% vs. 25%). Other minorities, although small in number (n = 9) were similar to African Americans. Conclusion: Pretreatment PSA levels were established for patients treated with external beam irradiation in 1989 in the United States. They increase with stage and decreasing differentiation. African Americans and other minorities show a doubling of median values compared to Caucasians' pretreatment PSA with an increase in stage

  20. Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior

    International Nuclear Information System (INIS)

    Purpose: The distribution of pretreatment and posttreatment prostate specific antigen (PSA) doubling times (PSADT) varies widely. This report examines the pretreatment PSADT as an independent predictor of biochemical freedom from disease (bNED) and describes the clinical utility of PSADT. Methods and Materials: Ninety-nine patients with T1-3 NX, M-0 prostate cancer treated between February 1989 and November 1993 have pretreatment PSADTs calculated from three or more PSA levels. Biochemical disease-free (bNED) survival (failure is PSA ≥ 1.5 ngm/ml and rising) is evaluated by multivariate analysis of common prognostic indicators and PSADT. Results: Prostate-specific antigen doubling time (PSADT) is a significant predictor of survival along with radiation dose. Patients with a pretreatment PSADT of < 12 months show 50% failure by 18 months, while those with a PSADT that is not increasing show only 3% failure at 3 years. Conclusions: Prostate-specific antigen doubling time (PSADT) is a predictor of bNED outcome in prostate cancer. Patients with PSADT < 12 months have aggressive disease and should be considered for multimodal therapy. Slow PSADT (≥ 5 years) is observed in 57% of patients, and this end point may be considered in the decision to observe rather than to treat. After treatment failure, the PSADT may be used to determine which patients do not need immediate androgen deprivation

  1. Differential water permeability and regulation of three aquaporin 4 isoforms

    DEFF Research Database (Denmark)

    Fenton, Robert A.; Moeller, Hanne B; Zelenina, Marina;

    2010-01-01

    Aquaporin 4 (AQP4) is expressed in the perivascular glial endfeet and is an important pathway for water during formation and resolution of brain edema. In this study, we examined the functional properties and relative unit water permeability of three functional isoforms of AQP4 expressed...... in the brain (M1, M23, Mz). The M23 isoform gave rise to square arrays when expressed in Xenopus laevis oocytes. The relative unit water permeability differed significantly between the isoforms in the order of M1 > Mz > M23. None of the three isoforms were permeable to small osmolytes nor were they affected...... by changes in external K(+) concentration. Upon protein kinase C (PKC) activation, oocytes expressing the three isoforms demonstrated rapid reduction of water permeability, which correlated with AQP4 internalization. The M23 isoform was more sensitive to PKC regulation than the longer isoforms...

  2. Lipoprotein lipase isoelectric point isoforms in humans

    DEFF Research Database (Denmark)

    Badia-Villanueva, M.; Carulla, P.; Carrascal, M.;

    2014-01-01

    characterization of these forms was carried out by 2DE combined with Western blotting and mass spectrometry (MALDI-TOF/MS and LC-MS/MS). Further studies are needed to discover their molecular origin, the pattern of pI isoforms in human tissues, their possible physiological functions and possible modifications of......-heparin plasma (PHP), LPL consists of a pattern of more than 8 forms of the same apparent molecular weight, but different isoelectric point (pI). In the present study we describe, for the first time, the existence of at least nine LPL pI isoforms in human PHP, with apparent pI between 6.8 and 8.6. Separation and...

  3. Review of UCN 5,6 Fire PSA Model based on ANS Fire PRA Standard

    Energy Technology Data Exchange (ETDEWEB)

    Yang, Joon Eon; Lee, Yoon Hwan

    2006-12-15

    Recently, under the de-regulation environment, nuclear industry has attempted various approaches to improve the economics of Nuclear Power Plants (NPP). This approach uses the fire risk and performance information to manage the resources effectively and efficiently that are used in the operation of NPP. In fire risk informed/performance-based decision/operation, fire PSA quality is one of the most important things. The nuclear industry and regulatory body of U.S.A have developed a measure to evaluate the quality of fire PSA. ANS (American Nuclear Society) has developed a guidance called 'ANS Fire PRA Methodology Standard'. However, in Korea, there have been no attempts to evaluate the quality of fire PSA model itself. Therefore, we cannot be sure about the quality of fire PSA whether or not the present fire PSA model can be used for the risk-informed applications such as mentioned above. We can say that the evaluation of fire PSA model quality is the basis for the fire risk informed/performance-based decision/operation. In this report, we have evaluated the quality of fire PSA model for Ulchin 5 and 6 units based on the ANS Fire PRA Standard. We, also, have derived what items are to be improved to upgrade the quality of fire PSA model and how it can be improved. This report can be used as the base of the fire risk informed/performance-based decision/operation work in Korea.

  4. Distribution of PSA-NCAM in normal, Alzheimer's and Parkinson's disease human brain.

    Science.gov (United States)

    Murray, Helen C; Low, Victoria F; Swanson, Molly E V; Dieriks, Birger V; Turner, Clinton; Faull, Richard L M; Curtis, Maurice A

    2016-08-25

    Polysialated neural cell adhesion molecule (PSA-NCAM) is a membrane bound glycoprotein widely expressed during nervous system development. While commonly described in the neurogenic niches of the adult human brain, there is limited evidence of its distribution in other brain regions. PSA-NCAM is an important regulator of cell-cell interactions and facilitates cell migration and plasticity. Recent evidence suggests these functions may be altered in neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD). This study provides a detailed description of the PSA-NCAM distribution throughout the human brain and quantitatively compares the staining load in cortical regions and sub-cortical structures between the control, AD and PD brain. Our results provide evidence of widespread, yet specific, PSA-NCAM expression throughout the human brain including regions devoid of PSA-NCAM in the rodent brain such as the caudate nucleus (CN) and cerebellum (CB). We also detected a significant reduction in PSA-NCAM load in the entorhinal cortex (EC) of cases that was inversely correlated with hyperphosphorylated tau load. These results demonstrate that PSA-NCAM-mediated structural plasticity may not be limited to neurogenic niches and is conserved in the aged brain. We also provide evidence that PSA-NCAM is reduced in the EC, a region severely affected by AD pathology. PMID:27282086

  5. Human actions treatment in the Juragua NPP pre-operational PSA

    International Nuclear Information System (INIS)

    The human reliability analysis is an important part of the Probabilistic Safety Analysis (PSA). Because Juragua NPP PSA has been accomplished during construction stage of the plant, no specific operational procedures nor experience for human reliability analysis task taking into account the worlds current methodologies in this field and the actual situation of the plant. This papers describes the approach we followed

  6. Routine PSA Testing: An Analysis of the Controversy Concerning Its Use

    Directory of Open Access Journals (Sweden)

    Namath S. Hussain

    2005-01-01

    Full Text Available Prostate cancer is the leading cause of cancer in American males today. PSA screening has been used for over 10 years as an important diagnostic tool for the disease. Because of its lack of sensitivity and specificity, however, PSA testing should be used with caution.

  7. Review of UCN 5,6 Fire PSA Model based on ANS Fire PRA Standard

    International Nuclear Information System (INIS)

    Recently, under the de-regulation environment, nuclear industry has attempted various approaches to improve the economics of Nuclear Power Plants (NPP). This approach uses the fire risk and performance information to manage the resources effectively and efficiently that are used in the operation of NPP. In fire risk informed/performance-based decision/operation, fire PSA quality is one of the most important things. The nuclear industry and regulatory body of U.S.A have developed a measure to evaluate the quality of fire PSA. ANS (American Nuclear Society) has developed a guidance called 'ANS Fire PRA Methodology Standard'. However, in Korea, there have been no attempts to evaluate the quality of fire PSA model itself. Therefore, we cannot be sure about the quality of fire PSA whether or not the present fire PSA model can be used for the risk-informed applications such as mentioned above. We can say that the evaluation of fire PSA model quality is the basis for the fire risk informed/performance-based decision/operation. In this report, we have evaluated the quality of fire PSA model for Ulchin 5 and 6 units based on the ANS Fire PRA Standard. We, also, have derived what items are to be improved to upgrade the quality of fire PSA model and how it can be improved. This report can be used as the base of the fire risk informed/performance-based decision/operation work in Korea

  8. EASI—enrichment of alternatively spliced isoforms

    OpenAIRE

    Julian P Venables; Burn, John

    2006-01-01

    Alternative splicing produces more than one protein from the majority of genes and the rarer forms can have dominant functions. Instability of alternative transcripts can also hinder the study of regulation of gene expression by alternative splicing. To investigate the true extent of alternative splicing we have developed a simple method of enriching alternatively spliced isoforms (EASI) from PCRs using beads charged with Thermus aquaticus single-stranded DNA-binding protein (T.Aq ssb). This ...

  9. Functional studies of sodium pump isoforms

    DEFF Research Database (Denmark)

    Clausen, Michael Jakob

    The Na+,K+-ATPase is an essential ion pump found in all animal cells. It uses the energy from ATP hydrolysis to export three Na+ and import two K+, both against their chemical gradients and for Na+ also against the electrical potential. Mammals require four Na+,K+-ATPase isoforms that each have...... synthesized cohorts of pumps from the Golgi apparatus to the plasma membrane....

  10. Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir

    International Nuclear Information System (INIS)

    Patients with early stage prostate cancer have a variety of curative radiotherapy options, including conventionally-fractionated external beam radiotherapy (CF-EBRT) and hypofractionated stereotactic body radiotherapy (SBRT). Although results of CF-EBRT are well known, the use of SBRT for prostate cancer is a more recent development, and long-term follow-up is not yet available. However, rapid post-treatment PSA decline and low PSA nadir have been linked to improved clinical outcomes. The purpose of this study was to compare the PSA kinetics between CF-EBRT and SBRT in newly diagnosed localized prostate cancer. 75 patients with low to low-intermediate risk prostate cancer (T1-T2; GS 3 + 3, PSA < 20 or 3 + 4, PSA < 15) treated without hormones with CF-EBRT (>70.2 Gy, <76 Gy) to the prostate only, were identified from a prospectively collected cohort of patients treated at the University of California, San Francisco (1997–2012). Patients were excluded if they failed therapy by the Phoenix definition or had less than 1 year of follow-up or <3 PSAs. 43 patients who were treated with SBRT to the prostate to 38 Gy in 4 daily fractions also met the same criteria. PSA nadir and rate of change in PSA over time (slope) were calculated from the completion of RT to 1, 2 and 3 years post-RT. The median PSA nadir and slope for CF-EBRT was 1.00, 0.72 and 0.60 ng/ml and -0.09, -0.04, -0.02 ng/ml/month, respectively, for durations of 1, 2 and 3 years post RT. Similarly, for SBRT, the median PSA nadirs and slopes were 0.70, 0.40, 0.24 ng and -0.09, -0.06, -0.05 ng/ml/month, respectively. The PSA slope for SBRT was greater than CF-EBRT (p < 0.05) at 2 and 3 years following RT, although similar during the first year. Similarly, PSA nadir was significantly lower for SBRT when compared to EBRT for years 2 and 3 (p < 0.005). Patients treated with SBRT experienced a lower PSA nadir and greater rate of decline in PSA 2 and 3 years following completion of RT than with CF-EBRT, consistent

  11. Prostatic biopsy in the prostate specific antigen gray zone; La biopsia prostatica multipla nalla zona grigia dei valori dell'antigene prostatico specifico

    Energy Technology Data Exchange (ETDEWEB)

    Drudi, F. M.; Ricci, P.; Iannicelli, E.; Di Nardo, R.; Novelli, L.; Laghi, A.; Passariello, R. [Rome Univ. La Sapienza, Rome (Italy). Ist. di Radiologia II Cattedra; Perugia, G. [Rome Univ. La Sapienza, Rome (Italy). Dipt. di Urologia U. Bracci

    2000-02-01

    The main purpose of this study was to identify cases of undetected prostatic cancer in patients with normal findings at digital examination and transrectal US, and prostate specific antigen (PSA) values ranging 4-10 ng/mL. 290 patients were submitted to transrectal US and random bilateral prostatic biopsy; 3 samples were collected from each side of the gland using 16-Gauge thru-cut needles. Of the 290 patients who gave full informed consent, 34 people were selected whose age range was between 56 to 76 years (mean: 64). Inclusion criteria were PSA 4-10 ng/mL, PSAD cut-off 0.15, free/total PSA ratio 15-25%, and normal findings at digital examination and transrectal US. PSA velocity was calculated collecting 3 blood samples every 30 days for 2 months. 5 of the 34 selected patients (15%) had prostatic cancer, and 2 (6%) Pin (1 Pin 1 and 1 Pin 2). As for the other 27 patients, biopsy demonstrated 4 (12%) cases of prostatitis and 23 (62%) cases of BPH. PSA values increased in all patients with positive histology, versus only 6 (22%) of those with negative histology. Our findings confirm that prostatic biopsy can detect tumors also in areas which appear normal at transrectal US and digital examination, and that PSA rate increases in patients with positive histology. Finally, the actual clinical role of prostatic biopsy relative to all other diagnostic imaging techniques remains to be defined. [Italian] Si intende qui dimostrare la percentuale di neoplasie prostatiche sfuggite all'esplorazione rettale e all'ecografia transrettale nei pazienti convalori di antigene prostatico specifico tra 4 e 10 ng/ml. 290 pazienti sono stati sottoposti a ecografia transrettale e biopsia multipla (6 prelievi, ago da 16 Gauge) dopo consenso informato. Di questi sono stati selezionati 34: eta' tra 56 e 76 anni, eta' media 64 anni. Parametri di selezione: antigene prostatico specifico con valori tra 4 e 10ng/ml; densita' dell'antigene prostatico specifico con

  12. Level 1 PSA study of Mochovce unit 1 NPP (SM AA 10 and 08)

    International Nuclear Information System (INIS)

    This paper presents genesis of Level 1 PSA project preparation for all operational modes of Mochovce NPP unit 1 including the description of its' main objectives, scope and working method. The PSA study which includes full power (FPSA) as well as shutdown and low power conditions (SPSA) Level 1 PSA has to support the nuclear safety improvements of the unit. They evaluate the basic design and the benefits of all improvements, which were found necessary to be incorporated before the start-up of the unit. The study includes internal events (transients and under-loss of coolant accident, LOCAs), internal hazards as fires and floods and selected external hazards as earthquake, influence of external industry, extreme meteorological conditions and aircraft crash.The PSA (both FPSA and SPSA) models is developed using the RISK SPECTRUM PSA code. (author)

  13. The clinical value of serum PSA and PAP determinations in prostate cancer patients

    International Nuclear Information System (INIS)

    Objective: To investigate the clinical value of serum PSA and PAP determinations in diagnosis of prostate cancer patients. Methods: The serum PSA and PAP levels of 98 prostate cancer patients, 45 prostate benign disease patients and 40 normal subjects were tested by IRMA. Results: The serum PSA and PAP levels of prostate cancer patients were significantly higher than those in prostate benign disease patients and normal controls (P < 0.01). The diagnostic sensitivity and specificity of serum PSA for prostate cancer were 93.9% and 93.3% respectively. The diagnostic sensitivity and specificity of serum PAP for prostate cancer were 71.4% and 91.1% respectively. Conclusion: The determination of serum PSA and PAP was of high clinical value for diagnosis of early prostate cancer. It could be used as an important reference parameter for the clinical staging, follow-up of treatment result and prediction of prognosis

  14. Production of a panel of monoclonal antibodies, specific for PSA, for the diagnosis of prostate cancer using IRMA or RIA

    International Nuclear Information System (INIS)

    Immunoradiometric assay and Enzyme linked immunosorbent assay were developed for measurement of total-PSA in human serum. Similar assays for free-PSA are also under final optimization and validation. In order to develop in-house assays monoclonal antibodies were raised against PSA at our laboratory, screened and selected. MAbs with good specificity and suitability for use in both total and free PSA IRMAs could be identified. The developed assays exhibited equimolar response towards the different forms of PSA and compared well with commercial t-PSA kits. Using one of our in-house MAbs, immunopurification of PSA from seminal plasma could be achieved and PSA of ∼91% purity could be obtained. (author)

  15. Lessons learnt from PSA for new and advanced reactors in Russia

    International Nuclear Information System (INIS)

    Customer requirements to probabilistic safety targets are usually stronger than existing Regulatory or IAEA ones. It appears that industry takes the lead over regulation in this case and forces the designer to find and implement appropriate means to enhance safety, which sometimes have no reference to practical experience. On the other hand, regulatory documents and the existing PSA methodology are mainly oriented to operating plants. This creates problems when developing a PSA as well as performing regulatory reviews. The scope of the PSA may be different depending on a design stage such as the development conceptual, basic or detailed design. In addition, the base case PSA is usually performed for NPP in design. However, a customer may require additional PSA applications to consider, for instance, risk monitoring. In this case the scope of the PSA should be extended to implement special attributes of the application needed that often requires specific information not available at the design stage. Lack of design information affecting PSA development may be associated with incompleteness of the design that is typical for interim design stages and communication problems caused by the involvement of many different companies in the deign activity. To deal with this issue bounding technologies and the iterative PSA development are used. However this sometimes contradicts to the ''best estimate'' approach recommended by regulatory guides. PSA development for advanced NPPs has raised some issues originated from unknown new components, processes and technologies incorporated into the design of an advanced plant. The paper addresses some issues resolved while carrying out PSAs for advanced NPPs. Some PSA results for new advanced VVER plants under construction and the first lessons learnt from the Fukushima accident are also discussed. (orig.)

  16. Mass screening of prostate cancer in a Chinese population:the relationship between pathological features of prostate cancer and serum prostate specific antigen

    Institute of Scientific and Technical Information of China (English)

    Hong-Wen Gao; Masaaki Kuwahara; Xue-Jian Zhao; Yu-Lin Li; Shan Wu; Yi-Shu Wang; Hai-Feng Zhang; Yu-Zhuo Pan; Ling Zhang; Hiroo Tateno; Ikuro Sato

    2005-01-01

    Aim: To investigate the pathological features of the prostate biopsy through mass screening for prostate cancer in a Chinese cohort and their association with serum prostate specific antigen (PSA). Methods: A total of 12 027 Chinese men in Changchun were screened for prostate cancer by means of the serum total prostate specific antigen (tPSA) test (oy Elisa assay). Transrectal ultrasound-guided systematic six-sextant biopsies were performed on those whose serum tPSA value was >4.0 ng/mL and those who had obstructive symptoms (despite their tPSA value) and were subject to subsequent pathological analysis with the aid of the statistic software SPSS 10.0 (SPSS. Inc., Chicago. USA). Results: Of the 12 027 cases, 158 (including 137 patients whose serum tPSA values were >4.0 ng/mL and 21 patients [serum tPSA <4.0 ng/mL] who had obstructive symptoms) undertook prostate biopsy. Of the 158 biopsies, 41 cases of prostatic carcinoma were found (25.9 %, 41/158). The moderately differentiated carcinoma and poorly differentiated carcinoma accounted for 61% and 34%, respectively. A significant linear positive correlation between the serum tPSA and the Gleason scores in the 41 cases of prostatic carcinoma (r = 0.312, P < 0.01) was established. A significant linear positive correlation between the serum tPSA value of the 41 prostatic carcinoma and the positive counts of carcinoma in sextant biopsies was established (r = 0.406, P < 0.01), indicating a significant linear relationship between serum tPSA and the size of tumor.Conclusion: This study was the first to conduct mass screening for prostate cancer by testing for serum tPSA values and the first to investigate the pathological features of prostate cancer in a cohort of Chinese men. Our results reveal that the moderately differentiated carcinoma is the most common type of prostate cancer. This study also has shown that the serum tPSA value in prostate cancer is associated with the Gleason score and the size of tumor.

  17. Post treatment PSA nadirs support continuing dose escalation study in patients with pretreatment PSA levels >10 ng/ml, but not in those with PSA <10 NG/ML

    International Nuclear Information System (INIS)

    Purpose: We have recently shown that ICRU reporting point radiation doses above 71 Gy are not associated with improved bNED survival in prostate cancer patients with pretreatment PSA level 20 ng/ml we found a strong correlation between dose and nadir values < 1.0 ng/ml (p=.003) as well as for nadir's < 0.5 ng/ml (p=.04). This dose/nadir effect held at several dose levels, but 74 Gy for nadir values < 1.0 ng/ml and 72 Gy for nadir's < 0.5 ng/ml remained the most significant. 32% of these patients achieved a nadir < 1.0ng/ml and 15% < 0.5ng/ml. Conclusions: This analysis provides strong additional support that patients with pretreatment PSA values of < 10 ng/ml do not benefit from dose escalation beyond an ICRU reporting point dose of 71 Gy. For patients with pretreatment PSA's of 10-19.9 ng/ml there is no dose/nadir response evaluated at a nadir of 1.0 ng/ml; however, there is a borderline effect observed at a nadir of 0.5 ng/ml. Patients with pretreatment PSA's of 20 ng/ml or greater clearly benefit from higher doses as evaluated by PSA nadirs of 1.0 ng/ml, and 0.5 ng/ml. These studies support the continued investigation of dose escalation in treating patients with PSA levels over 10 ng/ml, they do not support continued investigation of dose escalation beyond 71 Gy in patients with pretreatment PSA levels < 10 ng/ml. The failure to demonstrate any dose response for the low PSA group and the finding of only a borderline effect for the intermediate PSA group may be influenced by the relatively small number of patients in our series treated to doses < 70 Gy and the fact that none of our patients were treated to doses below 65.98 Gy. The lower limit of acceptible dose has yet to be defined

  18. Flooding risk reduction for the ASCO NPP PSA

    International Nuclear Information System (INIS)

    Developed within the framework of the UTE (INITEC-INYPSA-Empresarios Agrupados), the Probabilistic Safety Analysis (PSA) of the Asco Nuclear Power Plant has served both as a basic tool in reducing the risk of potential internal flooding at the plant, and as a guideline for studying the optimization and feasibility of necessary plant design modifications and changes to procedures. During execution of the work, and in view of the results, a series of improvements were proposed which gave rise to design modification studies. The paper seeks to describe the effect of these modifications on reducing core damage frequency, it also includes a general description of the methodology used. Finally, it compares the results obtained in the context of similar studies performed in other PSAs. (author)

  19. Hybrid membrane--PSA system for separating oxygen from air

    Science.gov (United States)

    Staiger, Chad L.; Vaughn, Mark R.; Miller, A. Keith; Cornelius, Christopher J.

    2011-01-25

    A portable, non-cryogenic, oxygen generation system capable of delivering oxygen gas at purities greater than 98% and flow rates of 15 L/min or more is described. The system consists of two major components. The first component is a high efficiency membrane capable of separating argon and a portion of the nitrogen content from air, yielding an oxygen-enriched permeate flow. This is then fed to the second component, a pressure swing adsorption (PSA) unit utilizing a commercially available, but specifically formulated zeolite compound to remove the remainder of the nitrogen from the flow. The system is a unique gas separation system that can operate at ambient temperatures, for producing high purity oxygen for various applications (medical, refining, chemical production, enhanced combustion, fuel cells, etc . . . ) and represents a significant advance compared to current technologies.

  20. The influence of seasonal characteristics in the level-3 PSA

    International Nuclear Information System (INIS)

    The variation of health effects and economic consequences resulting from the severe accidents of the YGN 3 and 4 nuclear power plants was examined for various combinations of source term release parameters and meteorological data. The release parameters and meteorological data considered in making basic scenarios are release height, heat content, release time, warning time, wind speed, rainfall rate, and atmospheric stability class. The seasonal scenarios were also made in order to estimate the seasonal variation of health effects and economic consequences by considering seasonal characteristics of Korea. According to the results, there are large differences in health effects and economic consequences from scenario to scenario although an equal amount of radioactive materials is released to the atmosphere. Also, there are large differences in health effects and economic consequences from season to season due to distinct seasonal characteristics of Korea. Therefore, it is necessary to consider seasonal characteristics in Level-3 PSA

  1. Outcomes after radical prostatectomy in the PSA era

    International Nuclear Information System (INIS)

    This year 317,000 men will be diagnosed with prostate cancer and 41,400 will die of this disease. Prostate cancer will kill nearly 1 million men alive today who are now over 50 years old. Since the mortality rate from prostate cancer increases more rapidly with age than any other cancer, and the most rapidly growing segment of the population is those > 80 years old, and mortality from other causes is declining, the number of deaths from prostate cancer is expected to increase inexorably for many years. Among the clinical prognostic factors that have been established as important predictors of the natural history of prostate cancer in conservatively treated patients, none is more important than the grade of the tumor. A similar influence of grade has been reported in patients treated surgically. At Baylor we assessed a variety of clinical prognostic factors in 728 men treated with radical prostatectomy and followed with serial PSA levels with no other therapy before proven recurrence of the cancer. While a variety of factors were significant in univariate analyses, in multivariate analysis only grade and serum PSA levels were significant clinical prognostic factors. Once the prostate was removed and pathologic information was available, however, pathologic stage became the most important factor (especially seminal vesicle or lymph node involvement), but Gleason grade was also a powerful independent factor. Surgical margin status and the presence of extracapsular extension were also independent predictors of recurrence, but total tumor volume added little additional information. Once the pathological information is available, none of the prognostic factors known before the operation, including PSA, PSA density, and clinical, have any independent power to predict prognosis. While radical prostatectomy may carry greater risk of complications than radiotherapy, its major advantage is the high probability that the cancer can be completely eradicated, especially if it is

  2. In vitro evaluation of a soluble Leishmania promastigote surface antigen as a potential vaccine candidate against human leishmaniasis.

    Directory of Open Access Journals (Sweden)

    Rym Chamakh-Ayari

    Full Text Available PSA (Promastigote Surface Antigen belongs to a family of membrane-bound and secreted proteins present in several Leishmania (L. species. PSA is recognized by human Th1 cells and provides a high degree of protection in vaccinated mice. We evaluated humoral and cellular immune responses induced by a L. amazonensis PSA protein (LaPSA-38S produced in a L. tarentolae expression system. This was done in individuals cured of cutaneous leishmaniasis due to L. major (CCLm or L. braziliensis (CCLb or visceral leishmaniasis due to L. donovani (CVLd and in healthy individuals. Healthy individuals were subdivided into immune (HHR-Lm and HHR-Li: Healthy High Responders living in an endemic area for L. major or L. infantum infection or non immune/naive individuals (HLR: Healthy Low Responders, depending on whether they produce high or low levels of IFN-γ in response to Leishmania soluble antigen. Low levels of total IgG antibodies to LaPSA-38S were detected in sera from the studied groups. Interestingly, LaPSA-38S induced specific and significant levels of IFN-γ, granzyme B and IL-10 in CCLm, HHR-Lm and HHR-Li groups, with HHR-Li group producing TNF-α in more. No significant cytokine response was observed in individuals immune to L. braziliensis or L. donovani infection. Phenotypic analysis showed a significant increase in CD4+ T cells producing IFN-γ after LaPSA-38S stimulation, in CCLm. A high positive correlation was observed between the percentage of IFN-γ-producing CD4+ T cells and the released IFN-γ. We showed that the LaPSA-38S protein was able to induce a mixed Th1 and Th2/Treg cytokine response in individuals with immunity to L. major or L. infantum infection indicating that it may be exploited as a vaccine candidate. We also showed, to our knowledge for the first time, the capacity of Leishmania PSA protein to induce granzyme B production in humans with immunity to L. major and L. infantum infection.

  3. Application of fire PSA in enhancing NPP safety: a case study with Indian PHWRS

    International Nuclear Information System (INIS)

    Fire PSA (Probabilistic Safety Assessment) is the probabilistic analysis of fire events and their potential impact on the safety of a Nuclear Power Plant (NPP). Using probabilistic models, the fire PSA takes into account the possibility of a fire at specific plant locations and its propagation, detection and suppression of the fire; and also helps to assess the effect of the fire on safety related cables and equipment. Typically, Fire PSA involves five stages of analysis: Screening Analysis, Fire Hazard Analysis, Fire Frequency Analysis, Fire Propagation Analysis and System analysis. The probabilistic criteria used in fire PSA are based on the risk concept. Core damage frequency is a typical criterion used for PSA Level 1. Fire PSA relies on the plant response model developed for the internal initiating events. The availability of a plant model that logically examines the contributions to core damage is a prerequisite for a fire PSA. It should be pointed out that extending an internal event PSA to a fire PSA requires a considerable amount of plant specific data, such as the location of cable routes in plant compartments, fire barriers etc. The detailed fire PSA analyses was carried out for a typical Indian Nuclear Power Plant. Fire fighting system for the NPP under consideration was designed based on the prevailing standards for fire safety design. These provisions were critically analysed (after appropriate screening of fire critical areas) by using codes such as COMPBRN IIIe and Fire Dynamics Simulator (FDS). Based on the results of these studies, activities such as installation of fire barriers at critical locations, re-routing of redundant safety related cables, etc. were carried out for reducing the fire contribution to CDF. Also, suitable provisions were identified to prevent occurrence of possible core damage scenario as pointed in Fire PSA study. After retrofitting, fire PSA was re-done to quantify and ensure the reduction in the contribution of the CDF

  4. Improvement of Level-1 PSA computer code package -A study for nuclear safety improvement-

    International Nuclear Information System (INIS)

    This year is the second year of the Government-sponsored Mid- and Long-Term Nuclear Power Technology Development Project. The scope of this subproject titled on 'The Improvement of Level-1 PSA Computer Codes' is divided into three main activities : (1) Methodology development on the under-developed fields such as risk assessment technology for plant shutdown and external events, (2) Computer code package development for Level-1 PSA, (3) Applications of new technologies to reactor safety assessment. At first, in the area of PSA methodology development, foreign PSA reports on shutdown and external events have been reviewed and various PSA methodologies have been compared. Level-1 PSA code KIRAP and CCF analysis code COCOA are converted from KOS to Windows. Human reliability database has been also established in this year. In the area of new technology applications, fuzzy set theory and entropy theory are used to estimate component life and to develop a new measure of uncertainty importance. Finally, in the field of application study of PSA technique to reactor regulation, a strategic study to develop a dynamic risk management tool PEPSI and the determination of inspection and test priority of motor operated valves based on risk importance worths have been studied. (Author)

  5. Localization and functional characterization of the human NKCC2 isoforms

    DEFF Research Database (Denmark)

    Carota, I; Theilig, F; Oppermann, M;

    2010-01-01

    inhibited by bumetanide than by furosemide. A sequence analysis of the amino acids encoded by exon 4 variants revealed high similarities between human and rodent NKCC2 isoforms, suggesting that differences in ion transport characteristics between species may be related to sequence variations outside the...... isoforms have specific localizations and transport characteristics, as assessed for rabbit, rat and mouse. In the present study, we aimed to address the localization and transport characteristics of the human NKCC2 isoforms. METHODS: RT-PCR, in situ hybridization and uptake studies in Xenopus oocytes were...... performed to characterize human NKCC2 isoforms. RESULTS: All three classical NKCC2 isoforms were detected in the human kidney; in addition, we found splice variants with tandem duplicates of the variable exon 4. Contrary to rodents, in which NKCC2F is the most abundant NKCC2 isoform, NKCC2A was the dominant...

  6. Tumorigenic properties of alternative osteopontin isoforms in mesothelioma

    Energy Technology Data Exchange (ETDEWEB)

    Ivanov, Sergey V., E-mail: Sergey.Ivanov@med.nyu.edu [Thoracic Surgery Laboratory, Cardiothoracic Surgery Department, NYU Langone Medical Center, 462 First Ave., Bellevue Hospital, Room 15N20, NY 10016 (United States); Ivanova, Alla V.; Goparaju, Chandra M.V.; Chen, Yuanbin; Beck, Amanda; Pass, Harvey I. [Thoracic Surgery Laboratory, Cardiothoracic Surgery Department, NYU Langone Medical Center, 462 First Ave., Bellevue Hospital, Room 15N20, NY 10016 (United States)

    2009-05-08

    Osteopontin (SPP1) is an inflammatory cytokine that we previously characterized as a diagnostic marker in patients with asbestos-induced malignant mesothelioma (MM). While SPP1 shows both pro- and anti-tumorigenic biological effects, little is known about the molecular basis of these activities. In this study, we demonstrate that while healthy pleura possesses all three differentially spliced SPP1 isoforms (A-C), in clinical MM specimens isoform A is markedly up-regulated and predominant. To provide a clue to possible functions of the SPP1 isoforms we next performed their functional evaluation via transient expression in MM cell lines. As a result, we report that isoforms A-C demonstrate different activities in cell proliferation, wound closure, and invasion assays. These findings suggest different functions for SPP1 isoforms and underline pro-tumorigenic properties of isoforms A and B.

  7. A novel functional rabbit IL- 7 isoform

    OpenAIRE

    Siewe, Basile T.; Kalis, Susan L.; Esteves, Pedro J; Zhou, Tong; Knight, Katherine L.

    2010-01-01

    IL-7 is required for B cell development in mouse and is a key regulator of T cell development and peripheral T cell homeostasis in mouse and human. Recently, we found that IL-7 is expressed in rabbit bone marrow and in vitro, is required for differentiation of lymphoid progenitors to B and T lineage cells. Herein, we report the identification of a novel rabbit IL-7 isoform, IL-7II. Recombinant IL-7II (rIL-7II) binds lymphocytes via the IL-7R and induces phosphorylation of STAT5. Further, rIL-...

  8. Electrochemical immunosensor for the prostate specific antigen detection based on carbon nanotube and gold nanoparticle amplification strategy

    International Nuclear Information System (INIS)

    We describe a highly sensitive electrochemical sandwich-type immunosensor for the prostate specific antigen (PSA), a biomarker related to prostate cancer. A glassy carbon electrode was covalently modified with multi-walled carbon nanotubes to which the anti-PSA was immobilized. Following addition of a sample containing PSA, a secondary antibody is added that consists of gold nanoparticles modified with secondary antibody and 6-ferrocenyl hexanethiol acting as the signal molecule. This approach represents a multiple signal amplification strategy in that the functionalized carbon nanotubes improve the electron transfer on the surface of the electrode, while the gold nanoparticles act as carriers for capturing large quantities of Ab2 and ferrocene. The modifying processes were characterized by cyclic voltammetry and electrochemical impedance spectroscopy. Under the optimal conditions, the differential pulse voltammetric signals (acquired at a typical potential of 0.31 V vs. SCE) is linearly related to the concentration of PSA in the 10 pg.mL−1 to 100 ng.mL−1 range. The detection limit is 5.4 pg.mL−1. When applied to the determination of PSA in spiked human serum, the recoveries were between 92.4 and 120.0 %. We perceive that this immunosensor holds great promise in the field of clinical screening for cancer biomarkers. (author)

  9. Androgen receptor isoforms in human and rat prostate

    Institute of Scientific and Technical Information of China (English)

    Shu-JieXIA; Gang-YaoHAO; Xiao-DaTANG

    2000-01-01

    Aim: To investigate the androgen receptor (AR) isoforms and its variability of expression in human and rat prostatic tissues. Methods: Human benign prostatic hyperplasia (BPH) and prostatic cancer tissues were obtained from patients undergoing prostatectomy, and rat ventral prostate was incised 3 days after castration. Forty-one AR-positive BPH specimens, 3 prostatic cancer specimens, and 6 rat prostates were used. After processing at 4℃, the tissues were examined by means of high resolution isoelectric focusing (IEF) technique to determine their AR isoforms. Results:From the prostatic specimens, 3 types of AR isoforms were detected with pI values at 6.5, 6.0, and 5.3. In human BPH tissues, 15/41 (36.6%) specimens showed all the three types of isoforms, while 19/41 (46.3%) showed 2 isoforms at various combinations and 7/41(17.1%), 1 isoform. For the 3 prostatic cancer specimens, one showed 3 isoforms, one, 2 isoforms, and the other failed to show any isoform. All rat prostatic tissues showed 2 isoforms at different combinations. Binding of 3H-dihydrotestosterone (DHT) to the isoforms was inhibited by the addition of 100-fold excess of DHT or testosterone, but not progesterone, oestradiol or diethylstilboestrol. Conclusion: AR isoforms are different in different patients. Although their genesis is not clear, the therapeutic implication of the present observation appears to be interesting, that may help clarifying the individual differences in the response to hormonal therapy.(Asian J Androl 2000 Dec;2:307-310)

  10. A Review of PSA Technology Applications according to the Development of Sodium-cooled Fast Reactors in the World

    International Nuclear Information System (INIS)

    The international nuclear societies request to perform Probabilistic Safety Assessment (PSA) according to the development of Gen IV Sodium-cooled Fast Reactors (SFR). One of the major tasks of the PSA is to identify various sequences of events which could lead to the release of radioactivity. However, due to the limited operating and SFR PSA experiences, it will be difficult to derive and to quantify core damage frequency for SFR under development in Korea, so called KALIMER. Hence, in this report, the foreign PSA results, such as USA and Japan, are analyzed based on the obtained documents. Finally an approach on how to perform PSA for KALIMER is suggested

  11. Association between PSA kinetics and cancer-specific mortality in patients with localised prostate cancer

    DEFF Research Database (Denmark)

    Thomsen, F B; Brasso, K; Berg, K D;

    2016-01-01

    with localised PCa managed on watchful waiting. PATIENTS AND METHODS: Patients with clinically localised PCa managed observationally, who were randomised to and remained on placebo for minimum 18 months in the SPCG-6 study, were included. All patients survived at least 2 years and had a minimum of...... three PSA determinations available. The prognostic value of PSA kinetics was analysed and patients were stratified according to their PSA at consent: ≤10, 10.1-25, and >25 ng/ml. Cumulative incidences of PCa-specific mortality were estimated with the Aalen-Johansen method. RESULTS: Two hundred and sixty...

  12. A Bayesian belief nets based quantification method of qualitative software reliability assessment for PSA

    International Nuclear Information System (INIS)

    Current reliability assessments of safety critical software embedded in the digital systems in nuclear power plants are based on the rule-based qualtitative assessment methods. But practical needs require the quantitative features of software reliability for Probabilistic Safety Assessment (PSA) that is one of important methods being used in assessing the whole safety of nuclear power plant. This paper discusses a Bayesian Belief Nets(BBN) based quantification method that models current qualitative software assessment in formal way and produces quantitative results required for PSA. Commercial Off-The-Shelf(COTS) software dedication process was applied to the discussed BBN based method for evaluating the plausibility of the method in PSA

  13. Key Characteristics of Combined Accident including TLOFW accident for PSA Modeling

    Energy Technology Data Exchange (ETDEWEB)

    Kim, Bo Gyung; Kang, Hyun Gook [KAIST, Daejeon (Korea, Republic of); Yoon, Ho Joon [Khalifa University of Science, Technology and Research, Abu Dhabi (United Arab Emirates)

    2015-05-15

    The conventional PSA techniques cannot adequately evaluate all events. The conventional PSA models usually focus on single internal events such as DBAs, the external hazards such as fire, seismic. However, the Fukushima accident of Japan in 2011 reveals that very rare event is necessary to be considered in the PSA model to prevent the radioactive release to environment caused by poor treatment based on lack of the information, and to improve the emergency operation procedure. Especially, the results from PSA can be used to decision making for regulators. Moreover, designers can consider the weakness of plant safety based on the quantified results and understand accident sequence based on human actions and system availability. This study is for PSA modeling of combined accidents including total loss of feedwater (TLOFW) accident. The TLOFW accident is a representative accident involving the failure of cooling through secondary side. If the amount of heat transfer is not enough due to the failure of secondary side, the heat will be accumulated to the primary side by continuous core decay heat. Transients with loss of feedwater include total loss of feedwater accident, loss of condenser vacuum accident, and closure of all MSIVs. When residual heat removal by the secondary side is terminated, the safety injection into the RCS with direct primary depressurization would provide alternative heat removal. This operation is called feed and bleed (F and B) operation. Combined accidents including TLOFW accident are very rare event and partially considered in conventional PSA model. Since the necessity of F and B operation is related to plant conditions, the PSA modeling for combined accidents including TLOFW accident is necessary to identify the design and operational vulnerabilities.The PSA is significant to assess the risk of NPPs, and to identify the design and operational vulnerabilities. Even though the combined accident is very rare event, the consequence of combined

  14. Why is the Markov method not used as a standard technique in PSA?

    International Nuclear Information System (INIS)

    This paper reviews the current applications in PSA, and discusses the perspectives in the various subdomains of PSA, like Markov vs. fault trees in system analysis and Markov vs. event trees in event sequence quantification, in both of which it is deemed that combined use of Markov and fault trees or event trees, respectively, would produce more effective (and also more efficient) modelling; or the capability of the method to deal with special topics, f.i., human reliability analysis and modelling of certain time-dependent phenomena. Finally, the paper attempts at defining under what specifications can the Markov method be made a standard guideline in PSA. (orig./DG)

  15. 延边地区1627例前列腺相关疾病患者t-PSA检测分析%ANALYSIS ON T-PSA DETECTION OF 1 627 CASES OF PROSTATE RELATED DISEASES IN YANBIAN

    Institute of Scientific and Technical Information of China (English)

    李忠吉; 李素香; 朴英花

    2012-01-01

    [Objective] To investigate the early diagnosis and the predictive value of prostate disease by screening serum prostate specific antigen (t-PSA) of 1 627 male cases. [Methods] Chemiluminescence was used in detection of serum prostate specific antigen. [Results] In 1 627 cases, 27 cases (1.7%) were proved as prostate cancer, 68 cases (4.2%) were proved as prostatic hyperplasia, 51 cases (3.1%) as prostatitis. [Conclusion] Serum t-PSA is not only a diagnosis which has a higher value of tumor markers in detecting prostate cancer, but also valuable in diagnosis of benign proatatic hyperplasia, prostatitis and other prostate disease. At the same time, a preliminary understanding has done on whether the occurrence of the prostate disease is related to different ethnic groups, namely the relation of diet and lifestyle.%[目的]通过对1 627例男性血清前列腺特异抗原(t-PSA)的筛查,探讨其对前列腺疾病的早期诊断及预测价值.[方法]采用化学发光法测定血清前列腺特异抗原(t-PSA).[结果]1 627例通过血清(t-PSA)筛查发现前列腺癌27例(1.7%),前列腺增生68例(4.2%),前列腺炎51例(3.1%).[结论]男性血清(t-PSA)不仅诊断前列腺癌(Pca)有较高价值的肿瘤标志物,而且对前列腺增生.前列腺炎等前列腺疾病的诊断也有价值.与此同时初步的了解和统计了延边地区前列腺疾病与不同民族,即饮食结构与生活习惯是否有一定的关系,为今后大量普查工作做了初步的探讨.

  16. Detection of prostate-specific antigen with biomolecule-gated AlGaN/GaN high electron mobility transistors

    International Nuclear Information System (INIS)

    In order to improve the sensitivity of AlGaN/GaN high electron mobility transistor (HEMT) biosensors, a simple biomolecule-gated AlGaN/GaN HEMT structure was designed and successfully fabricated for prostate specific antigen (PSA) detection. UV/ozone was used to oxidize the GaN surface and then a 3-aminopropyl trimethoxysilane (APTES) self-assembled monolayer was bound to the sensing region. This monolayer serves as a binding layer for attachment of the prostate specific antibody (anti-PSA). The biomolecule-gated AlGaN/GaN HEMT sensor shows a rapid and sensitive response when the target prostate-specific antigen in buffer solution was added to the antibody-immobilized sensing area. The current change showed a logarithm relationship against the PSA concentration from 0.1 pg/ml to 0.993 ng/ml. The sensitivity of 0.215% is determined for 0.1 pg/ml PSA solution. The above experimental result of the biomolecule-gated AlGaN/GaN HEMT biosensor suggested that this biosensor might be a useful tool for prostate cancer screening. (paper)

  17. Identification of a novel TDRD7 isoforms

    Directory of Open Access Journals (Sweden)

    Filonenko V. V.

    2011-12-01

    Full Text Available The aim of our study was to investigate the tudor domain-containing protein 7 (TDRD7 subcellular localization, which could be linked to diverse functions of this protein within the cell. Methods. In this study we employed cell imaging technique for detecting TDRD7 subcellular localization, Western blot analysis of HEK293 cell fractions with anti-TDRD7 monoclonal antibodies and bioinformatical search of possible TDRD7 isoforms in Uniprot, Ensemble, UCSC databases. Results. We have observed specific TDRD7-containing structures in cytoplasm as well as in the nucleus in HEK293 cells. The Western blot analysis of subcellular fractions (cytoplasm, mitochondria, nucleus allowed us to detect three lower immunoreactive bands, with the aproximate molecular weight of 130, 110 and 60 kDa (we termed them as TDRD7, TDRD7 and TDRD7 and specific subcellular localization. The bioinformatical analysis of TDRD7 primary structure allowed us to determine two alternative transcripts from TDRD7 gene coding for proteins with calculated molecular weight of 130 and 60 kDa. Conclusion. The presented data demonstrate the existence at protein level of potential TDRD7 isoforms: TDRD7, TDRD7 and TDRD7. The expression profile of these splice variants and their role in cells remains to be elucidated.

  18. Impact of pathological tumor stage for salvage radiotherapy after radical prostatectomy in patients with prostate-specific antigen < 1.0 ng/ml

    International Nuclear Information System (INIS)

    To evaluate prognostic factors in salvage radiotherapy (RT) for patients with pre-RT prostate-specific antigen (PSA) < 1.0 ng/ml. Between January 2000 and December 2009, 102 patients underwent salvage RT for biochemical failure after radical prostatectomy (RP). Re-failure of PSA after salvage RT was defined as a serum PSA value of 0.2 ng/ml or more above the postradiotherapy nadir followed by another higher value, a continued rise in serum PSA despite salvage RT, or initiation of systemic therapy after completion of salvage RT. Biochemical relapse-free survival (bRFS) was estimated using the Kaplan-Meier method. Multivariate analysis was performed using the Cox proportional hazards regression model. The median follow-up period was 44 months (range, 11-103 months). Forty-three patients experienced PSA re-failure after salvage RT. The 4-year bRFS was 50.9% (95% confidence interval [95% CI]: 39.4-62.5%). In the log-rank test, pT3-4 (p < 0.001) and preoperative PSA (p = 0.037) were selected as significant factors. In multivariate analysis, only pT3-4 was a prognostic factor (hazard ratio: 3.512 [95% CI: 1.535-8.037], p = 0.001). The 4-year bRFS rates for pT1-2 and pT3-4 were 79.2% (95% CI: 66.0-92.3%) and 31.7% (95% CI: 17.0-46.4%), respectively. In patients who have received salvage RT after RP with PSA < 1.0 ng/ml, pT stage and preoperative PSA were prognostic factors of bRFS. In particular, pT3-4 had a high risk for biochemical recurrence after salvage RT

  19. Prostate-specific antigen nadir after high-dose-rate brachytherapy predicts long-term survival outcomes in high-risk prostate cancer

    Science.gov (United States)

    Satoh, Takefumi; Ishiyama, Hiromichi; Tabata, Ken-ichi; Komori, Shouko; Sekiguchi, Akane; Ikeda, Masaomi; Kurosaka, Shinji; Fujita, Tetsuo; Kitano, Masashi; Hayakawa, Kazushige; Iwamura, Masatsugu

    2016-01-01

    Purpose To evaluate the prognostic value of prostate-specific antigen nadir (nPSA) after high-dose-rate (HDR) brachytherapy in clinically non-metastatic high-risk prostate cancer patients. Material and methods Data from 216 patients with high-risk or locally advanced prostate cancer who underwent HDR brachytherapy and external beam radiation therapy with long-term androgen deprivation therapy (ADT) between 2003 and 2008 were analyzed. The median prostate-specific antigen (PSA) level at diagnosis was 24 ng/ml (range: 3-338 ng/ml). The clinical stage was T1c-2a in 55 cases (26%), T2b-2c in 48 (22%), T3a in 75 (35%), and T3b-4 in 38 (17%). The mean dose to 90% of the planning target volume was 6.3 Gy/fraction of HDR brachytherapy. After 5 fractions, external beam radiation therapy with 10 fractions of 3 Gy was administered. All patients initially underwent neoadjuvant ADT for at least 6 months, and adjuvant ADT was continued for 36 months. The median follow-up was 7 years from the start of radiotherapy. Results The 7-year PSA relapse-free rate among patients with a post-radiotherapy nPSA level of ≤ 0.02 ng/ml was 94%, compared with 23% for patients with higher nPSA values (HR = 28.57; 95% CI: 12.04-66.66; p < 0.001). Multivariate analysis revealed that the nPSA value after radiotherapy was a significant independent predictor of biochemical failure, whereas pretreatment predictive values for worse biochemical control including higher level of initial PSA, Gleason score ≥ 8, positive biopsy core rate ≥ 67%, and T3b-T4, failed to reach independent predictor status. The 7-year cancer-specific survival rate among patients with a post-radiotherapy nPSA level of ≤ 0.02 ng/ml was 99%, compared with 82% for patients with higher nPSA values (HR = 32.25; 95% CI: 3.401-333.3; p = 0.002). Conclusions A post-radiotherapy nPSA value of ≤ 0.02 ng/ml was associated with better long-term biochemical tumor control even if patients had pretreatment predictive values for worse

  20. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone

    OpenAIRE

    SALIDO-GUADARRAMA, ALBERTO IVAN; MORALES-MONTOR, JORGE GUSTAVO; Rangel-Escareño, Claudia; Langley, Elizabeth; Peralta-Zaragoza, Oscar; COLIN, JOSE LUIS CRUZ; Rodriguez-dorantes, Mauricio

    2016-01-01

    At present, prostate-specific antigen (PSA) is used as a clinical biomarker for prostate cancer (PCa) diagnosis; however, a large number of patients with benign prostate hyperplasia (BPH) with PSA levels in the ʻgray areaʼ (4–10 ng/ml) are currently subjected to unnecessary biopsy due to overdiagnosis. Certain microRNAs (miRs) have been proven to be useful biomarkers, several of which are detectable in bodily fluids. The present study identified and validated a urinary miR-based signature to ...

  1. Lesson learned from PSA in the design improvement program of KSNP+

    International Nuclear Information System (INIS)

    KOPEC (Korea Power Engineering Co.) in conjunction with the client KEPCO (Korea Electric Power Corp.) has been developing a highly competitive Improved Korean Standard Nuclear Power Plant named KSNP+. From the beginning of Design Improvement Program, PSA was carried out to assure that the safety level of KSNP+ is maintained or improved in comparison with that of KSNP, the Korean Standard NPP. To achieve the safety goal of KSNP+, PSA team reviewed all design changes that might affect the plant safety. Design vulnerabilities were identified from the PSA results and safety improvement items were recommended to the system designers. Through the Design Improvement Program, KSNP+ became more reliable, safer and economically competitive than KSNP. This was achieved by systematic approach for design optimization and effective use of PSA technology based on past experience and expertise of nuclear power plant. (author)

  2. A computer tool for systems configuration management based on PSA models and techniques

    International Nuclear Information System (INIS)

    In the frame of the IAEA coordinated research programme for expert systems development, in the Institute for Nuclear Research, a PSA based computer tool for systems configuration management is in progress. The system is designed to be integrated in the future ''living PSA'' system under development now. The design of the system is mainly based on the PSA model for Cernavoda NPP and the risk-based configuration management methods, taking into account the user requirements. The system will be developed taking into account the expert systems techniques, specific PSA methods (MCS and path-sets generation, etc.) and friendly user interface features. The work done up to now for the system mainly consist of the users requirements identification, development techniques choosing and top-level system design. (author). 4 refs, 1 fig

  3. The evaluation of clinical application for measurement of serum PSA and PAP

    International Nuclear Information System (INIS)

    The serum PSA and PAP were measured in 23 cases of prostatic carcinoma, 42 cases of benign prostatic hypertrophy and 21 cases of non-prostatic disease. Significant differences were found between prostatic carcinoma and benign prostatic hypertrophy or control group. According to the Decision Matrix for general clinical evaluation, the diagnostic index and availability of serum PSA and PAP were 135.8%, 138.3% and 0.36, 0.40, respectively. The study showed that the measurement of the serum PSA and PAP should be complementary each other for the diagnosis and differential diagnosis of prostatic carcinoma. Finally, it was considered that the measurement of the serum PSA is superior to that of PAP for therapeutic follow-up in patients with prostatic carcinoma

  4. COS Imaging TA and Spectroscopic WCA-PSA/BOA offset verifications

    Science.gov (United States)

    Penton, Steven

    2013-10-01

    This program builds upon the monitoring and calibration of the FGSs (13616 - HST Cycle 21 Focal Plane Calibration (SI-FGS Alignment)). HST 13616 performs back-to-back PSA/MIRRORA & PSA/MIRRORB ACQ/IMAGES, from which all the results herein are bootstrapped.The list of proposals, cycles, and the order in which the alignment is checked is given below. 11878->12399->12781->13171->13616 C17->C18 ->C19->C20->C21 STIS->WFC3->ACS->COSThis program will be repeated every cycle and we will once again use it's COS exposures as the baseline for this program.This program performs a PSA/MIRRORA ACQ/IMAGE on a target that should already be centered in the aperture. This verifies the COS NUV PSA aperture position in the SIAF. After this PSA+MIRRORA ACQ/IMAGE, a PSA+MIRRORB ACQ/IMAGE is then performed. This exposure bootstraps the PSA+MIRRORB centering to the PSA+MIRROR SIAF verification. This allows us to monitor the properties of the PSA+MIRRORB image in a controlled way on a centered target. No spectra are taken in 13616 due to time constraints.This program extends the SIAF verification of 13616 to the other two ACQ/IMAGE combinations (BOA+MIRRORA & BOA+MIRRORB) by bootstraping from the PSA+MIRRORB verification of 13616.Visit 1 of this program begins with a PSA+MIRRORB NUV ACQ/IMAGE followed by a BOA+MIRRORA ACQ/IMAGE. Both observations are high S/N to get the most accurate centering information possible. The program then takes a PSA+MIRRORB IMAGE to ensure that we are still properly centered. We prefer that Visit 01 of this program executes within 45 days of Visit 02 of 13616, to ensure that no long term instrument or telescope focus changes impart our results.After the Imaging verification , Visit 1 of this program will obtain a S/N > 60 NUV spectrum using the most popular NUV grating (G230L, G185M, & G285M), and FUV Spectra using G130M/1309 and G140L/1280. This allows the direct verification of the NUV and FUV WCA-to-PSA cross-dispersion offsets used by ACQ/PEAKXD.Visit 02 of

  5. Cysteine-rich secretory protein 3 plays a role in prostate cancer cell invasion and affects expression of PSA and ANXA1.

    Science.gov (United States)

    Pathak, Bhakti R; Breed, Ananya A; Apte, Snehal; Acharya, Kshitish; Mahale, Smita D

    2016-01-01

    Cysteine-rich secretory protein 3 (CRISP-3) is upregulated in prostate cancer as compared to the normal prostate tissue. Higher expression of CRISP-3 has been linked to poor prognosis and hence it has been thought to act as a prognostic marker for prostate cancer. It is proposed to have a role in innate immunity but its role in prostate cancer is still unknown. In order to understand its function, its expression was stably knocked down in LNCaP cells. CRISP-3 knockdown did not affect cell viability but resulted in reduced invasiveness. Global gene expression changes upon CRISP-3 knockdown were identified by microarray analysis. Microarray data were quantitatively validated by evaluating the expression of seven candidate genes in three independent stable clones. Functional annotation of the differentially expressed genes identified cell adhesion, cell motility, and ion transport to be affected among other biological processes. Prostate-specific antigen (PSA, also known as Kallikrein 3) was the top most downregulated gene whose expression was also validated at protein level. Interestingly, expression of Annexin A1 (ANXA1), a known anti-inflammatory protein, was upregulated upon CRISP-3 knockdown. Re-introduction of CRISP-3 into the knockdown clone reversed the effect on invasiveness and also led to increased PSA expression. These results suggest that overexpression of CRISP-3 in prostate tumor may maintain higher PSA expression and lower ANXA1 expression. Our data also indicate that poor prognosis associated with higher CRISP-3 expression could be due to its role in cell invasion. PMID:26369530

  6. EuroTrough collector prototype under testing at PSA

    Energy Technology Data Exchange (ETDEWEB)

    Luepfert, E.; Geyer, M. [German Aerospace Center (DLR), Platforma Solar de Almeria (PSA) (Spain); Schiel, W. [Schlaich Bergermann und Partner (SBP), Stuttgart (Germany); Esteban, A.; Osuna, R. [INABENSA, Div. Taller, Sevilla (Spain); Zarza, E.; Rojas, E. [CIEMAT-PSA, Plataforma Solar de Almeria (Spain); Nava, P. [Flabeg Solar International, Cologne (Germany); Brakmann, G. [Fichtner Solar, Stuttgart (Germany); Kotsaki, E. [CRES, Athens (Greece)

    2001-07-01

    In international project collaboration a parabolic trough collector has been developed for various applications in the 200-400 C temperature range in solar fields up to the hundreds Megawatts range. The design of a new support structure of the collector included concept studies, wind tunnel measurements, finite elements method (FEM) analyses and resulted in a structure with a central framework element. This torque box design has lower weight and less deformation of the collector structure than the other designs considered. It will be possible in future to connect more collector elements on one drive which results in reduced total number of drives and interconnecting pipes, thus reducing the installation cost and thermal losses. In terms of the degree of material usage further weight reduction will be possible. The presented design has a significant potential for cost reduction, the most important goal of the EuroTrough project. The prototype has been set-up and is under testing at PSA (Plataforma Solar de Almeria) for its thermal and mechanical properties. (orig.)

  7. PSA application for the scram system of Romanian TRIGA Reactor

    International Nuclear Information System (INIS)

    The paper is dedicated to the fault tree analysis of the scram system in TRIGA-INR Pitesti reactor. It is a brief description of the scram system which involves instrumentation, mechanical, electrical,and control devices. The failure criteria considered is fail to drop 5 of 8 control rods. Fault tree was developed using immediate cause principle. The reliability data base used is developed in INR Pitesti based on the IAEA data available. The fault tree was analyzed by an original PC code developed for Romanian PSA program. The dominant for this fault tree appeared to be the human errors. This deserves a sensitivity analysis. If we do not consider the CCF errors contribution, the system computed unavailability is: A = 1.25 · 10-7. The failure rate is 1.087 · 10-2 eV/1000 yr. The mean time between failures is 105 years. Taking in the account roads stuck common cause failure, unavailability will increase by two magnitude orders, A = 3.02 · 10-5. We considered this number still provides a reassuring mean time between failures. This value is within the limits accepted by similar scram system studies, but is higher than the value obtained in a similar way for the TRIGA reactor of University of Texas. The reason was the taking into account in our case the human error and CCF

  8. Benchmark exercise on expert judgment techniques in PSA Level 2

    International Nuclear Information System (INIS)

    This article summarizes objectives and aims of the concerted action 'Benchmark Exercise on Expert Judgment Techniques in PSA Level 2' and the results obtained within the project. The project was organized in three phases, namely a survey phase (pre-phase), a first phase devoted to parameter estimation assessment and a second phase devoted to benchmarking expert judgment methods on a scenario development case. The paper is focused on the first phase and on the results obtained by the application of five structured Expert Judgment (EJ) methodologies to the problem at hand. The results of the comparison of EJ methodologies are also provided; they are based on the use of some metrics suitably designed during the project. The context of Phase 2 and the issue to be tackled in this phase are briefly described; since this phase has been carried out only at a preliminary level (mainly after the end of the project), the results obtained are not reported here in detail but are only briefly commented on

  9. 美国三级 PSA 发展过程及研究进展%The Developing Process and Study Trends of Level 3 PSA in USA

    Institute of Scientific and Technical Information of China (English)

    王建华; 陈鹏; 杨杰; 苏永杰

    2015-01-01

    Public risk is an important index of Nuclear Power Plant (NPP) safety .WASH-740 ,which was is-sued in 1957 ,started introducing the concept of reactor risk analysis .In 1972 ,WASH-1400 accomplished systematically a Level 3 PSA for the first time ,and gave rise to the development of CRAC series codes .Fur-thermore ,NUREG-1550 was published in 1990 ,which indicated PSA application matured .NRC established the current framework for risk-informed regulation by issuing a PRA Policy Statement in 1995 .In 2007 ,The SOARCA project was initiated to develop best estimates of the offsite radiological health consequences for po -tential severe reactor accidents for Peach Bottom Atomic Power Station and Surry Power Station .In 2011 ,NRC proposed to perform a new full-scope comprehensive Level 3 PSA which addressed additional considerations such as multi-unit site effects and other on-site radiological sources .%公众风险是验证核电厂安全性能的重要指标。美国1957年发布的 WASH-740中开始引入反应堆风险分析的概念;1972年,WASH-1400第一次系统性地完成了三级 PSA ,并开发了 CRAC 系列分析程序;1990年,NRC 发布NUREG-1150,标志着 PSA 应用进入成熟期;1995年,正式在法规层面上确定了 PSA 地位;始于2007年的 SOARCA 研究计划在 SARP 研究基础上,结合最新研究进展利用改进的三级 PSA 工具对两个核电厂重新进行了评估;2011年,考虑最新的技术进步和福岛事故影响,计划重新启动完整三级 PSA 研究,以考虑如乏燃料水池工况、群堆工况、外部事件等新的认识。

  10. A design-phase PSA of anuclear-powered hydrogen plant

    OpenAIRE

    Flores Flores, Alain

    2007-01-01

    A probabilistic safety assessment (PSA) is being developed for a steam-methane reforming hydrogenproduction plant linked to a high-temperature gas-cooled nuclear reactor (HTGR). This work is based on the Japan Atomic Energy Research Institute's (JAERI) High Temperature Engineering Test Reactor (HTTR) prototype in Japan. The objective of this paper is to show how the PSA can be used for improving the design of the coupled plants. A simplified HAZOP study was performed to identify initiating ev...

  11. Determining the Quality of Probabilistic Safety Assessment (PSA) for Applications in Nuclear Power Plants

    OpenAIRE

    KIRCHSTEIGER Christian; KUBANYI Jozef

    2006-01-01

    Probabilistic safety assessment (PSA) of nuclear power plants (NPPs) complements the traditional deterministic analysis and is widely recognized as a comprehensive, structured approach to identifying accident scenarios and deriving numerical estimates of risks dealing with NPP operation and associated plant vulnerabilities. Increasingly, during the last years, PSA has been broadly applied to support numerous applications and risk-informed decisions on various operational and regulatory mat...

  12. Lessons learned in applying PSA technology to diverse risk management applications

    International Nuclear Information System (INIS)

    Brief overview of various PSAs performed by PLG, Inc., during the last two decades is given. Selected case studies in PSA applications are presented. Broad number of specific applications are described. Information related to PSA scope and modelling requirements is also given. The use of dynamic decision aids for plant operators is pointed out as one of the most promising new developments. (author). 17 refs, 6 figs, 3 tabs

  13. The association of general practitioners’ risk attitudes, level of empathy and burnout status with PSA testing

    DEFF Research Database (Denmark)

    Pedersen, Anette Fischer; Carlsen, Anders Helles; Vedsted, Peter

    2015-01-01

    Når alment praktiserende læger sammenlignes, finder man ofte stor variation i raten af PSA-tests foretaget på mandlige patienter. Dette studie viser, at lægens risikovillighed influerer på raten af PSA-tests. Således har patienter, som er registreret hos en læge, som har mange bekymringer for fej...

  14. Role of HLA class I antigens in the development of psoriatic arthritis and its clinical presentation

    Directory of Open Access Journals (Sweden)

    Irina Aleksandrovna Troshkina

    2012-01-01

    Full Text Available Objective: to investigate the association of HLA Class I antigens with the predisposition to psoriatic arthritis (PsA and the severity and types of articular syndrome in PsA. Subjects and methods. The investigation enrolled 99 patients (56 females and 43 males aged 43.5+13 years with PA with a median duration of 2 (range 0.8-10 years. An oligoarthritic type was observed in 28 patients, polyarthritic, distal, and spondyloarthritic types were present in 28, 39, and 10 patients, respectively. Two patient groups were formed according to the age at onset of psoriasis: 1 71 patients aged less than 40 years and 2 23 patients aged over 40 years. Results. As compared with the control group, the patients with PsA were found to have a higher frequency of HLA-B13 (odds ratio [OR] 2.72; p < 0.004, HLA-В16 (OR 3.95; p < 0.0001, and HLA-B27 (OR 3.2; p < 0.003. There was an association of the types of joint injury with HLA antigens: the distal type with HLA-B13 (OR 3.38; p < 0.02 and HLA-В16 (OR 3.95; p < 0.01, the polyarthritic type with HLA-В16 (OR 5.90; p < 0.0001 and HLA-B27 (OR 3.26; p < 0.01, and the spondyloarthritic type with HLA-B27 (OR 6.32; p < 0.001. The young onset of psoriasis was associated with HLA-B13 (OR 3.29; p < 0.001. The detection rate of the B38 antigen (the subtype of HLA-B16 was higher in all X-ray stages of PsA and was 16.4% in Stages I-IIA, 25% in Stage IIB, and 40.9% in Stages III-IV versus 8.7% in the control group, the magnitude of the association being increased with the higher degree of joint destruction. Conclusion. The detailed analysis of the investigation revealed that HLA system antigens were differently involved in the development of PsA and clinical types of articular syndrome.

  15. Spinach pyruvate kinase isoforms: partial purification and regulatory properties

    Energy Technology Data Exchange (ETDEWEB)

    Baysdorfer, C.; Bassham, J.A.

    1984-02-01

    Pyruvate kinase from spinach (Spinacea oleracea L.) leaves consists of two isoforms, separable by blue agarose chromatography. Both isoforms share similar pH profiles and substrate and alternate nucleotide K/sub m/ values. In addition, both isoforms are inhibited by oxalate and ATP and activated by AMP. The isoforms differ in their response to three key metabolites; citrate, aspartate, and glutamate. The first isoform is similar to previously reported plant pyruvate kinases in its sensitivity to citrate inhibition. The K/sub i/ for this inhibition is 1.2 millimolar citrate. The second isoform is not affected by citrate but is regulated by aspartate and glutamate. Aspartate is an activator with a K/sub a/ of 0.05 millimolar, and glutamate is an inhibitor with a K/sub i/ of 0.68 millimolar. A pyruvate kinase with these properties has not been previously reported. Based on these considerations, the authors suggest that the activity of the first isoform is regulated by respiratory metabolism. The second isoform, in contrast, may be regulated by the demand for carbon skeletons for use in ammonia assimilation.

  16. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer

    DEFF Research Database (Denmark)

    Martínez-Piñeiro, Luis; Schalken, Jack A; Cabri, Patrick;

    2014-01-01

    OBJECTIVE: To assess prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG scores in patients with advanced and metastatic prostate cancer at baseline and after 6 months of treatment with triptorelin 22.5 mg, and analyse these scores in patient-groups defined by different disease characteristics...... change at 6 months, according to baseline variables. Other outcome measures included urinary PCA3 and TMPRSS2-ERG scores and statuses, and serum testosterone and prostate-specific antigen (PSA) levels at baseline and at 1, 3 and 6 months after initiation of ADT. Safety was assessed by recording adverse...... metastasis or unknown metastasis status. TMPRSS2-ERG scores ≥35 were considered positive (n = 149 [51.6%]). Age, presence of metastasis, PSA level and Gleason score at baseline were not associated with a significant difference in the proportion of TMPRSS2-ERG-positive scores. The median serum PSA levels...

  17. Survey on Prognostics Techniques for Updating Initiating Event Frequency in PSA

    International Nuclear Information System (INIS)

    One of the applications using PSA is a risk monito. The risk monitoring is real-time analysis tool to decide real-time risk based on real state of components and systems. In order to utilize more effective, the methodologies that manipulate the data from Prognostics was suggested. Generally, Prognostic comprehensively includes not only prognostic but also monitoring and diagnostic. The prognostic method must need condition monitoring. In case of applying PHM to a PSA model, the latest condition of NPPs can be identified more clearly. For reducing the conservatism and uncertainties, we suggested the concept that updates the initiating event frequency in a PSA model by using Bayesian approach which is one of the prognostics techniques before. From previous research, the possibility that PSA is updated by using data more correctly was found. In reliability theory, the Bathtub curve divides three parts (infant failure, constant and random failure, wareout failure). In this paper, in order to investigate the applicability of prognostic methods in updating quantitative data in a PSA model, the OLM acceptance criteria from NUREG, the concept of how to using prognostic in PSA, and the enabling prognostic techniques are suggested. The prognostic has the motivation that improved the predictive capabilities using existing monitoring systems, data, and information will enable more accurate equipment risk assessment for improved decision-making

  18. Development of a Base Frame for the New Fire PSA Training, and Lessons Learned

    Energy Technology Data Exchange (ETDEWEB)

    Kim, Kilyoo; Kang, DaeIl; Kim, Wee Kyoung [Korea Atomic Energy Research Institute, Daejeon (Korea, Republic of)

    2014-10-15

    US NRC/EPRI issued a new fire PSA method represented by NUREG/CR 6850, and since it is about time to introduce the new fire PSA method as a regulatory requirement for the fire protection in Korea, a simple and easy-understandable base model for the fire PSA training is required, and thus KAERI-KINS jointly prepared a base model for the new fire PSA training last year. In this year, as a base frame development, fire ignition frequencies and severity factors, which were assumed in developing of the base model, are calculated. The fire modeling is performed to get the severity factor. This paper describes how the base frame is developed. Using an imaginary simple NPP, a base frame of fire PSA following the new fire PSA method was developed, and with which two days training course was provided twice for the plant engineers and regulators. Several lessons learned from the training are described. The two methods in quantification, i.e., CCDP method and initiator method are described.

  19. Survey on Prognostics Techniques for Updating Initiating Event Frequency in PSA

    Energy Technology Data Exchange (ETDEWEB)

    Kim, Hyeonmin; Heo, Gyunyoung [Kyung Hee University, Yongin (Korea, Republic of)

    2015-05-15

    One of the applications using PSA is a risk monito. The risk monitoring is real-time analysis tool to decide real-time risk based on real state of components and systems. In order to utilize more effective, the methodologies that manipulate the data from Prognostics was suggested. Generally, Prognostic comprehensively includes not only prognostic but also monitoring and diagnostic. The prognostic method must need condition monitoring. In case of applying PHM to a PSA model, the latest condition of NPPs can be identified more clearly. For reducing the conservatism and uncertainties, we suggested the concept that updates the initiating event frequency in a PSA model by using Bayesian approach which is one of the prognostics techniques before. From previous research, the possibility that PSA is updated by using data more correctly was found. In reliability theory, the Bathtub curve divides three parts (infant failure, constant and random failure, wareout failure). In this paper, in order to investigate the applicability of prognostic methods in updating quantitative data in a PSA model, the OLM acceptance criteria from NUREG, the concept of how to using prognostic in PSA, and the enabling prognostic techniques are suggested. The prognostic has the motivation that improved the predictive capabilities using existing monitoring systems, data, and information will enable more accurate equipment risk assessment for improved decision-making.

  20. Development of a Base Frame for the New Fire PSA Training, and Lessons Learned

    International Nuclear Information System (INIS)

    US NRC/EPRI issued a new fire PSA method represented by NUREG/CR 6850, and since it is about time to introduce the new fire PSA method as a regulatory requirement for the fire protection in Korea, a simple and easy-understandable base model for the fire PSA training is required, and thus KAERI-KINS jointly prepared a base model for the new fire PSA training last year. In this year, as a base frame development, fire ignition frequencies and severity factors, which were assumed in developing of the base model, are calculated. The fire modeling is performed to get the severity factor. This paper describes how the base frame is developed. Using an imaginary simple NPP, a base frame of fire PSA following the new fire PSA method was developed, and with which two days training course was provided twice for the plant engineers and regulators. Several lessons learned from the training are described. The two methods in quantification, i.e., CCDP method and initiator method are described

  1. Abnormal antigens in breast cancer tissues and production of monoclonal antibodies against one of these antigens

    International Nuclear Information System (INIS)

    Breast cancer is associated with up regulation, down regulation of normal antigens or abnormal antigens. These antigens are very useful candidates as targets for the different breast cancer therapies and for vaccination trials. This study was done to characterize abnormal antigens, extract one of them and to produce monoclonal antibodies against the extracted antigen. One hundred and twenty Sudanese female patients were included in this study after informed consent. The mean age was 47. 2 years (16-80). Two tissue samples were obtained from each patient and they were confirmed as normal and cancerous breast tissues microscopically. 2D PAGE was used to analyze the protein content of samples. LC/MS and nr. fast a database search were used for separation and indentification of the abnormal proteins. Three different patterns of 2D Page results were obtained, the first pattern involved detection of four abnormal proteins in 26.7% of the patient cancerous tissues while they were undetected in the normal tissues of the same patients. In the second 2D PAGE result pattern the cancerous and the normal tissues of 67.5% patients were identical and they did not contain the four abnormal proteins while the third 2D PAGE pattern involved the presence of two abnormal antigens (from the four) in the cancerous tissues of 5.8% of the patients and they were absent from the normal tissues of the same patients. The four abnormal proteins were identified as, human Thioredoxin (D60nmutant), x-ray crystal structure of human galectin-1, retrocopy of tropomyosin 3(rc TPM3) and beta-tropomyosin (isoform 2). The primary and the secondary structures were obtained from the SWISSPROT and the PDB databases. Beta tropomyosin spot was extracted and used as antigen for monoclonal antibody production. Monoclonal antibody against beta- tropomyosin with a concentration of 0.35 mg/ml and a G11 anti beta-tropomyosin hybridoma cell line were produced. The monoclonal antibody was with single bad and

  2. Monitoring of prostate cancer growth and metastasis using a PSA luciferase report plasmid in a mouse model

    Institute of Scientific and Technical Information of China (English)

    Qi-Qi; Mao; Yi-Wei; Lin; Hong; Chen; Kai; Yang; De-Bo; Kong; Hai; Jiang

    2014-01-01

    Objective:To construct a PSA luciferase report plasmid and monitor the growth and metastasis of prostate cancer after emasculation in SCID mice.Methods:PSA promoter sequence and luciferase gene were amplified by PCR and subsequently inserted into pZsCreen1-1 vector to construct pPSA-FL-Luc vector.LNCaP cells that were stably transfected with pPSA-FL-Luc were used to establish a SCID mouse xenograft model.Then,the growth and metastasis of prostate cancer were monitored via living imaging.Results:We successfully constructed a PSA luciferase piasmid,pPSA-FL-Luc.DHT enhanced lucifcrase activity in a concentration-dependent manner in 293 T cells with pPSA-FL-Luc transfection.Prostate cancer SCID mouse model was established with pPSA-FL-Luc transfected LNCaP cells.In tumor bearing mice with or without emasculation,pPSA-FL-Lue piasmid was applied to monitored tumor growth and metastasis based on bioluminescence imaging.Conclusions:We construct a pPSA-FL-Luc piasmid,which stably expresses luciferase and can be applied to monitor tumor development in a prostate SCID mouse model.

  3. Evaluating the Impact of PSA as a Selection Criteria for Nerve Sparing Radical Prostatectomy in a Screened Cohort

    Directory of Open Access Journals (Sweden)

    Shyam K. Tanguturi

    2014-01-01

    Full Text Available Purpose. We investigated whether NS-RP increased risk of PSA failure and whether PSA should be included as a selection criterion for NS. Methods. We evaluated 357 consecutive men with screen-detected PC who underwent open RP without adjuvant radiotherapy between 9/11/2001 and 12/30/2008. Criteria for NS included Gleason score ≤3 + 4, percentage of positive biopsies (PPB ≤50%, percentage of core involvement ≤50%, nonapical location, no perineural invasion, and no palpable disease on pre- or intraoperative exam but did not include a PSA threshold. Cox multivariable regression assessed whether increasing PSA or unilateral- or bilateral-NS versus non-NS-RP was associated with PSA failure adjusting for prognostic factors. Results. After a median follow-up of 3.96 years, 34 men sustained PSA failure (9.5%. Increasing PSA was significantly associated with increased risk of PSA failure in the interaction model (adjusted hazard ratio (AHR: 1.09 [95% CI: 1.03–1.16]; P=0.005, whereas unilateral (AHR: 1.24 [95% CI: 0.36–4.34]; P=0.73 or bilateral NS (AHR: 0.41 [95% CI: 0.06–2.59]; P=0.34 versus non-NS RP was not. Conclusion. NS-RP in a screened cohort did not increase risk of PSA failure using NS criteria not including PSA.

  4. Prostate-specific antigen levels are higher in African-American than in white patients in a multicenter registration study: Results of RTOG 94-12

    International Nuclear Information System (INIS)

    Purpose: To compare serum prostate-specific antigen (PSA) levels in a national sample of African-American and white men with prostate cancer, and to attempt to explain any differences by using self-reported individual-level socioeconomic status adjustments. Methods and Materials: During 4((1)/(2)) months in 1994-95, 709 patients with nonmetastatic prostate cancer were enrolled in this prospective study; 17.5% were African-American and 82.5% were white. Information about clinical stage, tumor grade, pretreatment PSA, type of insurance, and educational and income status was obtained. Serum PSA levels were measured and racial differences were found; how the differences were influenced by other patient- or tumor-related factors and if the differences could be explained by socioeconomic status disparities were determined. In univariate analyses, factors associated with the mean PSA levels were studied; log-converted values were used to yield a normal distribution. Multivariate analyses were done on log-linear models for description of association patterns among various categorical variables; a perfectly fitted model should have a correlation value (CV) of 1.0. Results: The mean PSA level was higher in African-Americans (14.68 ng/ml) than in whites (9.82 ng/ml) (p = 0.001). Clinical stage (p = 0.001), Gleason sum tumor grade (p = 0.0001), educational level (p = 0.001), and household income (p = 0.03) were also associated with mean PSA levels; age, type of biopsy, and insurance status were not. Disease stage (p = 0.0001), grade (p 0.0001), education (p = 0.07), and income (p = 0.02) were all associated with PSA levels for whites, but none of these factors were important for African-Americans (all p values > 0.1). The best fitted log-linear model (CV = 0.99) contained PSA ( 20), Gleason sum grade (2-5, 6-7, and 8-10), race, and two interactions: PSA by race (p = 0.0012) and PSA by Gleason sum (p = 0.0001). Models replacing race for either income (CV = 0.82) or education

  5. Guidance to Risk-Informed Evaluation of Technical Specifications using PSA

    International Nuclear Information System (INIS)

    This report presents guidance for evaluation of Technical Specification conditions with PSA. It covers quality in PSA, how to verify that the PSA model is sufficiently robust and sufficiently complete and general requirements on methods. Acceptance criteria for evaluation of changes in the TS conditions are presented. As the probabilistic safety assessment (PSA) has developed over the years, it has demonstrated to constitute a useful tool for evaluating many aspects of the TS from a risk point of view. and in that way making the PSAs as well as the decision tools better. This also means that it will be possible to take credit for safety system overcapacity as well as inherent safety features and strength of non-safety classed systems. However, PSA is only one of the tools that shall be used in an evaluation process of TS changes (strengthening/relaxation). PSA is an excellent tool to be used to verify the importance, and thereby possibly relaxation, of TS requirements. But, since PSA is only one tool in the evaluation, it is not sufficient in itself for defining which equipment that shall or shall not have TS requirements. The purpose of this guidance document is to provide general requirements, requirements on methods and acceptance criteria on risk-informed evaluation of TS changes based on PSA. The purpose is not to provide a single solution. As part of the review of the TS conditions this guidance specify requirements on: - Quality verification of the PSA model; - Verification that the PSA model is sufficiently robust with regard to SSCs for which requirements both are and are not defined by the TS; - Verification that the SSCs, for which TS demands are to be evaluated, are modelled in a sufficient manner; - Methods for performing the evaluation; - Which evaluation criteria that shall be used (and how that is verified to be correct); - Acceptance criteria: This guidance also briefly discusses the documentation of the analysis of the TS changes. This guidance

  6. Development of computing code system for level 3 PSA

    Energy Technology Data Exchange (ETDEWEB)

    Jeong, Jong Tae; Yu, Dong Han; Kim, Seung Hwan

    1997-07-01

    Among the various research areas of the level 3 PSA, the effect of terrain on the transport of radioactive material was investigated through wind tunnel experiment. These results will give a physical insight in the development of a new dispersion model. Because there are some discrepancies between the results from Gaussian plume model and those from field test, the effect of terrain on the atmospheric dispersion was investigated by using CTDMPLUS code. Through this study we find that the model which can treat terrain effect is essential in the atmospheric dispersion of radioactive materials and the CTDMPLUS model can be used as a useful tool. And it is suggested that modification of a model and experimental study should be made through the continuous effort. The health effect assessment near the Yonggwang site by using IPE (Individual plant examination) results and its site data was performed. The health effect assessment is an important part of consequence analysis of a nuclear power plant site. The MACCS was used in the assessment. Based on the calculation of CCDF for each risk measure, it is shown that CCDF has a slow slope and thus wide probability distribution in cases of early fatality, early injury, total early fatality risk, and total weighted early fatality risk. And in cases of cancer fatality and population dose within 48km and 80km, the CCDF curve have a steep slope and thus narrow probability distribution. The establishment of methodologies for necessary models for consequence analysis resulting form a server accident in the nuclear power plant was made and a program for consequence analysis was developed. The models include atmospheric transport and diffusion, calculation of exposure doses for various pathways, and assessment of health effects and associated risks. Finally, the economic impact resulting form an accident in a nuclear power plant was investigated. In this study, estimation models for each cost terms that considered in economic

  7. Automated installation for gas separation and purification using the Pressure Swing Adsorption (PSA) process; Instalacao automatizada para separacao e purificacao de gases por PSA

    Energy Technology Data Exchange (ETDEWEB)

    Neves, Celia F. Cordeiro; Schvartzman, Monica M.A.M. [Centro de Desenvolvimento da Tecnologia Nuclear (CDTN), Belo Horizonte, MG (Brazil); Jordao, Elizabete [Universidade Estadual de Campinas, SP (Brazil). Dept. de Engenharia de Sistemas Quimicos e Informatica

    1999-11-01

    This paper describes the first laboratorial PSA (Pressure Swing Adsorption) unit designed and built in Brazil for gas separation by adsorption process. It consists of a stainless steel column, which was filled with zeolite 5A molecular sieve. Six solenoid valves located at the feed., product, countercurrent and high-pressure air lines were used to regulate the flow directions of different streams. Pressure and flowrate transducers and thermocouples were used to record respectively the pressure, flowrate of both feed and product stream and temperature history of the process. These instruments and the solenoid valves were joined to a programmable logic controller. By the use of a computer the unit can be automatically operated to simulate all steps in the PSA cycle and data can be easily acquired and recorded. The unit will be used to study basic parameters of PSA processes and to separate several gas mixtures. As a first goal the unit will be operated to produce oxygen-enriched air using synthetic zeolites. This PSA laboratory unit is an important step in CDTN`s objective of consolidating a research group in gas separation by adsorption processes. (author) 7 refs., 8 figs., 2 tabs.

  8. Expression, purification and enzymatic characterization of the catalytic domains of human tryptophan hydroxylase isoforms

    DEFF Research Database (Denmark)

    Windahl, Michael Skovbo; Boesen, Jane; Karlsen, Pernille Efferbach; Christensen, Hans Erik Mølager

    Tryptophan hydroxylase exists in two isoforms: Isoform 1 catalyses the first and rate-limiting step in the synthesis of serotonin in the peripheral parts of the body while isoform 2 catalyses this step in the brain. The catalytic domains of human tryptophan hydroxylase 1 and 2 have been expressed......, purified and the kinetic properties have been studied and are compared. Substrate inhibition by tryptophan is observed for isoform 1 but not for isoform 2. Large differences are observed in the K m,tetrahydrobiopterin values for the two isoforms, being >10 times larger for isoform 1 compared to isoform 2....

  9. Prevalence and Risk Factors of Prostate Cancer in Chinese Men with PSA 4–10 ng/mL Who Underwent TRUS-Guided Prostate Biopsy: The Utilization of PAMD Score

    Science.gov (United States)

    Fang, Dong; Ren, Da; Zhao, Chenglin; Li, Xuesong; Yu, Wei; Wang, Rui; Wang, Huihui; Xi, Chenguang; He, Qun; Wang, Xiaoying; Xin, Zhongcheng; Zhou, Liqun

    2015-01-01

    Purpose. To elucidate the characteristics and risk factors for positive biopsy outcomes in Chinese patients with prostate specific antigen (PSA) 4–10 ng/mL and develop a risk-stratification score model. Methods. The data of 345 patients who underwent transrectal ultrasound-guided prostate biopsy between 2011 and 2013 was retrospectively analyzed. Digital rectal examination (DRE), prostate volume (PV), magnetic resonance imaging (MRI), and smoking status were also collected. Positive biopsy outcomes were defined as prostate cancer (PCa) and high grade PCa (HGPCa, Gleason Score ≥ 7). Results. The median PSA was 7.15 (IQR 5.91–8.45) ng/mL. Overall 138 patients (40.0%) were shown to have PCa, including 100 patients (29.0%) with HGPCa. Smaller PV, elder age, MRI results, and positive DRE were proved to be predictive factors for positive biopsy outcomes in both univariate and multivariate analysis. We developed a “PAMD” score which combined the four factors to categorize patients into three risk groups, and the model performed good predictive sensitivity and specificity. Conclusion. The prevalence of prostate cancer in Chinese patients with PSA 4–10 ng/mL was 40%, including 29% patients with high grade disease. DRE, age, MRI, and PV were predictive factors for positive biopsy outcomes, and the PAMD score model could be utilized for risk-stratification and decision-making. PMID:26557679

  10. Prevalence and Risk Factors of Prostate Cancer in Chinese Men with PSA 4–10 ng/mL Who Underwent TRUS-Guided Prostate Biopsy: The Utilization of PAMD Score

    Directory of Open Access Journals (Sweden)

    Dong Fang

    2015-01-01

    Full Text Available Purpose. To elucidate the characteristics and risk factors for positive biopsy outcomes in Chinese patients with prostate specific antigen (PSA 4–10 ng/mL and develop a risk-stratification score model. Methods. The data of 345 patients who underwent transrectal ultrasound-guided prostate biopsy between 2011 and 2013 was retrospectively analyzed. Digital rectal examination (DRE, prostate volume (PV, magnetic resonance imaging (MRI, and smoking status were also collected. Positive biopsy outcomes were defined as prostate cancer (PCa and high grade PCa (HGPCa, Gleason Score≥7. Results. The median PSA was 7.15 (IQR 5.91–8.45 ng/mL. Overall 138 patients (40.0% were shown to have PCa, including 100 patients (29.0% with HGPCa. Smaller PV, elder age, MRI results, and positive DRE were proved to be predictive factors for positive biopsy outcomes in both univariate and multivariate analysis. We developed a “PAMD” score which combined the four factors to categorize patients into three risk groups, and the model performed good predictive sensitivity and specificity. Conclusion. The prevalence of prostate cancer in Chinese patients with PSA 4–10 ng/mL was 40%, including 29% patients with high grade disease. DRE, age, MRI, and PV were predictive factors for positive biopsy outcomes, and the PAMD score model could be utilized for risk-stratification and decision-making.

  11. Establishment of Infrastructure for Domestic-Specific Level 3 PSA based on MACCS2

    International Nuclear Information System (INIS)

    Research activities related to the Level 3 PSA have naturally disappeared since the use of risk surrogates. Recently, Level 3 PSA was only performed to the extent of the purpose of operating license for the plant under construction. Since the Fukushima accident, concern about a comprehensive site-specific Level 3 PSA has been raised for some compelling reasons, especially the evaluation of the domestic multi-unit site risk effect including other site radiological sources (e.g., spent fuel pool, multi-units). Unfortunately, there are no domestic-specific consequence analysis code and input database required to perform a site-specific Level 3 PSA. The paper focuses on the development of the input data management system for domestic-specific Level 3 PSA based MACCS2 (MELCOR Accident Consequence Code System). The authors call it KOSCA-MACCS2 (Korea Off-Site Consequence Analysis based in MACCS2). It serves as an integrated platform for a domestic-specific Level 3 PSA. Also, it provides the pre-processing modules to automatically generate MACCS2 input from diverse types of the domestic-specific data including numerical map data, e.g., meteorological data, numerical population map, digital land use map, economic statistics and so on. Note that some functions should be still developed and added on it, e.g., post-processing module to convert MACCS2 outputs to graphic report forms, and so on. Henceforth, it is necessary to develop a Korean-specific Level 3 PSA code as a substitution for the foreign software, MACCS2

  12. MiR-614 Inhibited Lung Cancer Cell Invasion and Proliferation via Targeting PSA

    Directory of Open Access Journals (Sweden)

    Fang LV

    2014-10-01

    Full Text Available Background and objective MicroRNAs (miRNAs is a group of non-coding small RNA molecules, which play important roles in the development of tumor. The mechanisms of various kinds of miRNAs in lung cancer still need to be further elucidated. This study investigated the function of miR-614 on lung cancer cell invasion and proliferation. Methods Real-time quantitative PCR was used to detect the expression of miR-614 in lung cancer cell PGCL3 and PGLH7. Transwell assay was used to test the role of miR-614 on regulating invasion and migration of cells. CCK8 assay and BrdU incorporation assay was used to assess the role of miR-614 on cell proliferation. Bioinformatics software predicted the potential target genes of miR-614 and dual luciferase reporter gene was used to analyze the binding between miR-614 and 3’UTR of puromycin-sensitive aminopeptidase (PSA. Western blot detected the PSA protein levels. Results The expression of miR-614 in PGCL3 cells with high metastasis potential was significantly lower than that in PGLH7 cells with low metastasis potential. Furthermore, altered expression of miR-614 by transfection of pre-miR-614 mimics and inhibitor significantly affected the ability of invasion and proliferation of lung cancer cells. Bioinformatics analysis predicted that PSA was one of the potential target genes of miR-614. Altered expression of miR-614 markedly down-regulated the PSA protein levels of lung cancer cells. In addition, dual luciferase reporter gene assay indicated that miR-614 regulated PSA expression by binding to the 3’UTR of PSA mRNA. Conclusion MiR-614 inhibited cell invasion and proliferationa targeting PSA in lung cancer cells, PGCL3.

  13. Analytical and clinical performances of immunoradiometric assay of total and free PSA developed locally

    International Nuclear Information System (INIS)

    A specific assay was developed for total and free PSA (PSAt, PSAf). Both assay use a two site IRMA with polyclonal anti PSA antibodies coated on tubes. Polyclonal antibodies were obtained after rabbit's immunisation using an under skin injection of pure PSA in multiple site. For quantification, two monoclonal antibodies were selected, the first highly specific to free PSA and the second recognising both free and bound PSA. A correlation study was performed comparatively with two commercial kits from CIS Bio and Immunotech. For that purpose, 464 serums samples ranging from 0.5 ng/ml to 3399 ng/ml were used to characterise the analytical performance of the new test. The analytical detection limit of the new test was equal to 0.05 ng/ml for the total PSA and 0.02ng/ml for the free PSA. The within run and between-day coefficients of variation were to 20 ng/ml. For BPH, no significant difference was found between the three test for the ratio PSAf/PSAt using a cut off of 14% (all were>to 14%). For the 120 patients with PC, all PSAt were > to 2 ng/ml. However the mean value of PSAt was higher for the commercial kits (14.74 ng/ml against 12.48ng/ml for the new test) but all ratio of PSAf/PSAt for the 120 newly diagnosed cancer were <14%. In conclusion, our immunoradiometric assay developed locally has a good analytical performance and its outputs are well correlated to clinical findings in prostate disease. Furthermore, a cut off of 14% for the ratio PSAf/PSAt appears to be the most accurate tools to depict a prostate cancer

  14. Use of simplified PSA studies in support of the ASTRID design process

    International Nuclear Information System (INIS)

    In the framework of the French Act of 28 June 2006 about nuclear materials and waste management, a GEN IV and actinides incineration demonstration prototype is to be commissioned in the 2020 decade. In this objective a prototype called ASTRID (Advanced Sodium Technological Reactor for Industrial Demonstration) is proposed to demonstrate the progress made in SFR technology at an industrial scale by qualifying innovative options, some of which still remain open in the areas requiring improvements, especially safety and operability. More specifically, we aim for a level of safety that is at least equivalent to that of the EPR (third generation), with improvements made in SFR-specific fields. The integration of safety issues in the early phase of the design of ASTRID is necessarily expected. For this purpose, CEA and its partners AREVA and EDF have planned to perform a level-1 PSA to support and orientate the preliminary design of ASTRID reactor. This paper presents the PSA approach and current studies for the assessment of safety systems and the future work to be done for the 2012-2014 period. The preliminary preparation of PSA studies is presented: objectives and scope of the early design phase PSA, definition of core damage states, selection and grouping of initiating events, assessment of safety functions and related systems. Work under progress is also presented: modelling of event trees, construction of fault trees of safety systems, transient calculations of accident sequences with the CATHARE2 code and reliability data assessment. Main objectives of a level-1 PSA performed at conceptual design stage are an early assessment of the safety architecture of the reactor and findings about the most effective areas for improvement, but also the identification of dominant accident sequences and comparison with alternative designs. After the elaboration of a simplified level-1 PSA model for nominal state and main internal initiators, various design alternatives will be

  15. Distinctive PSA-NCAM and NCAM Hallmarks in Glutamate-Induced Dendritic Atrophy and Synaptic Disassembly

    Science.gov (United States)

    Podestá, María Fernanda; Yam, Patricia; Codagnone, Martín Gabriel; Uccelli, Nonthué Alejandra; Colman, David; Reinés, Analía

    2014-01-01

    Dendritic and synapse remodeling are forms of structural plasticity that play a critical role in normal hippocampal function. Neural cell adhesion molecule (NCAM) and its polysialylated form (PSA-NCAM) participate in neurite outgrowth and synapse formation and plasticity. However, it remains unclear whether they contribute to dendritic retraction and synaptic disassembly. Cultured hippocampal neurons exposed to glutamate (5 µM) showed a reduced MAP-2 (+) area in the absence of neuronal death 24 h after the insult. Concomitantly, synapse loss, revealed by decreased synaptophysin and post-synaptic density-95 cluster number and area, together with changes in NCAM and PSA-NCAM levels were found. Dendritic atrophy and PSA-NCAM reduction proved NMDA-receptor dependent. Live-imaging experiments evidenced dendritic atrophy 4 h after the insult; this effect was preceded by smaller NCAM clusters (1 h) and decreased surface and total PSA-NCAM levels (3 h). Simultaneously, total NCAM cluster number and area remained unchanged. The subsequent synapse disassembly (6 h) was accompanied by reductions in total NCAM cluster number and area. A PSA mimetic peptide prevented both the dendritic atrophy and the subsequent synaptic changes (6 h) but had no effect on the earliest synaptic remodeling (3 h). Thus, NCAM-synaptic reorganization and PSA-NCAM level decrease precede glutamate-induced dendritic atrophy, whereas the NCAM level reduction is a delayed event related to synapse loss. Consequently, distinctive stages in PSA-NCAM/NCAM balance seem to accompany glutamate-induced dendritic atrophy and synapse loss. PMID:25279838

  16. Serum PSA and cure perspective for prostate cancer in males with nonpalpable tumor

    Directory of Open Access Journals (Sweden)

    Marcos F. Dall'Oglio

    2005-10-01

    Full Text Available INTRODUCTION: Many studies have shown the association between PSA levels and the subsequent detection of prostate cancer. In the present trial, we have studied the relationship between preoperative PSA levels and clinical outcome following radical prostatectomy in men with clinical stage T1c. MATERIALS AND METHODS: 257 individuals with clinical stage T1c undergoing retropubic radical prostatectomy were selected in the period from 1991 to 2000. Following surgery, biochemical recurrence-free survival curves were constructed according to PSA levels between 0-4; 4.1-10; 10.1-20 and > 20 ng/mL. RESULTS: Of the total of 257 selected patients, 206 (80% had Gleason scores from 2 to 6 and 51 (20%, presented Gleason scores 7 and 8, as defined by the pathological report from prostate biopsy. There was no biochemical recurrence of disease when the PSA was lower than 4, regardless of Gleason score. Biochemical recurrence-free survival according to PSA between 0-4; 4.1-10; 10.1-20 and > 20 was 100%, 87.6%, 79% and 68.8% for Gleason scores 2-6 and 100%; 79.4%; 40% and 100% for Gleason scores 7-8 respectively. When all individuals were grouped, regardless of their Gleason scores, the probability of biochemical recurrence-free survival was 100%, 65.1%, 53.4% and 72.2% according to PSA between 0-4; 4.1-10; 10.1-20 and > 20 ng/mL respectively. CONCLUSION: Non-palpable prostate cancer presents higher chances of cure when the PSA is inferior to 4 ng/mL.

  17. Fire propagation equation for the explicit identification of fire scenarios in a fire PSA

    International Nuclear Information System (INIS)

    When performing fire PSA in a nuclear power plant, an event mapping method, using an internal event PSA model, is widely used to reduce the resources used by fire PSA model development. Feasible initiating events and component failure events due to fire are identified to transform the fault tree (FT) for an internal event PSA into one for a fire PSA using the event mapping method. A surrogate event or damage term method is used to condition the FT of the internal PSA. The surrogate event or the damage term plays the role of flagging whether the system/component in a fire compartment is damaged or not, depending on the fire being initiated from a specified compartment. These methods usually require explicit states of all compartments to be modeled in a fire area. Fire event scenarios, when using explicit identification, such as surrogate or damage terms, have two problems: there is no consideration of multiple fire propagation beyond a single propagation to an adjacent compartment, and there is no consideration of simultaneous fire propagations in which an initiating fire event is propagated to multiple paths simultaneously. The present paper suggests a fire propagation equation to identify all possible fire event scenarios for an explicitly treated fire event scenario in the fire PSA. Also, a method for separating fire events was developed to make all fire events a set of mutually exclusive events, which can facilitate arithmetic summation in fire risk quantification. A simple example is given to confirm the applicability of the present method for a 2x3 rectangular fire area. Also, a feasible asymptotic approach is discussed to reduce the computational burden for fire risk quantification

  18. Establishment of Infrastructure for Domestic-Specific Level 3 PSA based on MACCS2

    Energy Technology Data Exchange (ETDEWEB)

    Jang, Seung-Cheol; Han, Seok-Jung; Choi, Sun-Yeong; Lee, Seung-Jun [KAERI, Daejeon (Korea, Republic of); Kim, Wan-Seob [Korea Reliability Technology and System, Daejeon (Korea, Republic of)

    2015-05-15

    Research activities related to the Level 3 PSA have naturally disappeared since the use of risk surrogates. Recently, Level 3 PSA was only performed to the extent of the purpose of operating license for the plant under construction. Since the Fukushima accident, concern about a comprehensive site-specific Level 3 PSA has been raised for some compelling reasons, especially the evaluation of the domestic multi-unit site risk effect including other site radiological sources (e.g., spent fuel pool, multi-units). Unfortunately, there are no domestic-specific consequence analysis code and input database required to perform a site-specific Level 3 PSA. The paper focuses on the development of the input data management system for domestic-specific Level 3 PSA based MACCS2 (MELCOR Accident Consequence Code System). The authors call it KOSCA-MACCS2 (Korea Off-Site Consequence Analysis based in MACCS2). It serves as an integrated platform for a domestic-specific Level 3 PSA. Also, it provides the pre-processing modules to automatically generate MACCS2 input from diverse types of the domestic-specific data including numerical map data, e.g., meteorological data, numerical population map, digital land use map, economic statistics and so on. Note that some functions should be still developed and added on it, e.g., post-processing module to convert MACCS2 outputs to graphic report forms, and so on. Henceforth, it is necessary to develop a Korean-specific Level 3 PSA code as a substitution for the foreign software, MACCS2.

  19. p53 Family: Role of Protein Isoforms in Human Cancer

    Directory of Open Access Journals (Sweden)

    Jinxiong Wei

    2012-01-01

    Full Text Available TP53, TP63, and TP73 genes comprise the p53 family. Each gene produces protein isoforms through multiple mechanisms including extensive alternative mRNA splicing. Accumulating evidence shows that these isoforms play a critical role in the regulation of many biological processes in normal cells. Their abnormal expression contributes to tumorigenesis and has a profound effect on tumor response to curative therapy. This paper is an overview of isoform diversity in the p53 family and its role in cancer.

  20. 无症状炎症性前列腺炎与血清 PSA 水平的关系--防城港地区男性健康大型横断面调查%The relationship between asymptomatic inflammatory prostatitis and serum PSA level-A large prevalence survey of Fangchenggang area male health

    Institute of Scientific and Technical Information of China (English)

    张志甫; 吴春磊; 陆铮; 莫曾南

    2014-01-01

    Objective To investigate the relationship between asymptomatic inflammatory prostatitis (AIP)and serum prostate specific antigen (PSA). Methods Data collection was conducted in the Medical Examination Centre of Fangchenggang First People's Hospital.During the physical examination,trained physi-cians administered a standard questionnaire,basic data including National Institutes of Health Chronic Prostati-tis Symptom Index (NIH-CPSI),demographic information (age,education,occupation,etc),history of dis-ease,and lifestyle risk factors (smoking,alcohol consumption,and physical activity),and health status were collected using a standardized questionnaire.A trained profession conducted the anthtopometric parameters measurements for the participants.8 h-fasting vein blood was drawn and then the biochemical indexes [PSA, triglyceride (TG),high density cholesterol-cholesterol (HDL-C),and fasting blood glucose]were meas-ured.The expressed prostatic secretions (EPS)were collected and then were smeared on a glass slide for counting the mean WBC count of EPS.According to the NIH-CPSI score,and presence of inflammation,the participants were divided into a NIH-IV prostatitis group and a healthy group. Results The mean value of serum PSA in the healthy group and the NIH-IV prostatitis group were 0.91 ng/ml and 1.27 ng/ml,the standard deviation was 0.79 ng/ml,and 1.52 ng/ml,there were statistically significant differences (P <0.001).In NIH-IV prostatitis group,the scores of age,TG,diastolic blood pressure (DBP),systolic blood pressure (SBP),hypertension,education status,physical activity were higher than those in the healthy group. NIH-IV prostatitis (WBC≥3+)group compared to healthy group,along with the elevated PSA the OR value was also increased,the OR value was 1.078,3.589,4.406,respectively.In PSAQ4,with the elevation of in-flammation the OR value also increased.Respectively in age,education status,dyslipidemia,diabetes,high blood pressure

  1. PSA e medidas antropométricas em índios da Amazônia: avaliação da comunidade Parkatejê PSA and anthropometric measurements among Amazon Indians: an evaluation of the Parkatejê community

    Directory of Open Access Journals (Sweden)

    Homero Oliveira de Arruda

    2003-10-01

    Full Text Available OBJETIVO: O rastreamento com o PSA (antígeno prostático específico para detecção precoce de câncer de próstata em uma comunidade nativa tem grande importância epidemiológica. Assim, realizou-se estudo com objetivo de verificar a ocorrência do câncer da próstata em uma tribo indígena da Amazônia e uma possível relação entre o aculturamento, a presença de sobrepeso (índice de massa corporal e o aparecimento da doença. MÉTODOS: Foi realizado um levantamento dos hábitos e medidas antropométricas em 22 homens com idade presumida maior de 50 anos, de uma tribo isolada de 363 índios, autodenominados Parkatejê e Kikatêjê, vivendo na região Amazônica (Pará. Além dos exames físico e hematológicos, foram realizadas dosagens de PSA total e PSA livre. RESULTADO: Os níveis séricos de PSA total variaram de 0,35 a 25,8 ng/ml. Três nativos apresentaram PSA maior que 4,0 ng/ml e outros dois evidenciaram PSA entre 2,5 e 4,0 ng/ml. Biopsia prostática em dois nativos revelou a presença de adenocarcinoma de próstata em um e neoplasia intraepitelial em outro. Sobrepeso com índice de massa corporal >25 Kg/m² e relação cintura-quadril >0,9 foram observados em 68,1% e 72,7% do grupo estudado. CONCLUSÕES: Mudanças nutricionais decorrentes do contato com a civilização, como substituição da caça e fibras vegetais por alimentos mais calóricos, estão aumentando a freqüência de sobrepeso na comunidade indígena. Devido à associação entre incidência de câncer de próstata, dieta gordurosa e menor atividade física, pode-se presumir que o futuro testemunhará mais casos da neoplasia prostática, visto que vários de seus membros já evidenciaram altos níveis séricos de PSA.OBJECTIVE: PSA (prostate-specific antigen screening for early detection of prostate cancer in a native community is of great epidemiological importance. The study was conducted with the objective of verifying the occurrence of prostate cancer among

  2. Development of regulatory guidance on safety reviews of nuclear power plants in Germany. A survey on accomplished and current PSA activities

    International Nuclear Information System (INIS)

    The paper describes the key points of the accomplished and current regulatory activities in order to revise PSA guide and the corresponding technical documents in Germany. The regulatory German PSA guide covers the fundamental requirements concerning the performance of PSAs in the frame of comprehensive safety reviews. The technical details regarding the performance of PSA are set out in two technical documents (PSA Methods and PSA Data) that have been developed by a working group of PSA experts (FAK PSA). Based on the experiences from the first series of PSRs, international experiences and the fact that PSR is mandatory since April 2002 revisions of all guides are underway. The first guide to be updated is the PSA guide together with the corresponding technical documents. The working programme and the revision process of FAK PSA was finished at the end of 2004 and the technical documents have recently been republished. (author)

  3. Comprehensive evaluation of new probabilistic safety analyses (PSA) for nuclear power stations outside Germany and status report on safety engineering

    International Nuclear Information System (INIS)

    This report was prepared on behalf of the Minister of Environment, Nature Conservation and Nuclear Safety. It summarizes the results of an analysis of the state of the art of foreign Probabilistic Safety Assessments (PSA) for nuclear power plants. Main features of selected PSA documents, characterizing methods and their application within the framework of operational safety assessment, are presented as well as insights gained from discussions with utilities and an authority. German examples of PSA were compared to the foreign analyses using experiences of the TUeV Nord e.V. from reviewing PSA. This comparison covers PSA of level 1. It was found that German PSA methods are generally comparable to the foreign approaches. Nevertheless differences were found with respect to the scope of operational states covered by the analyses, the details down to which human error analyses were performed as well as some special issues. The foreign examples demonstrate an extended application of PSA within the operational safety management. Experiences that were gained within this process over years form an appropriate basis for the establishment of probabilistic safety criteria as well as procedures for incorporating PSA into the operational safety evaluation process. A procedure is proposed for further performing and evaluating PSA and their results in Germany. (orig.)

  4. Risk evaluations of aging: Procedures guide for an age-dependent PSA with emphasis on prioritization and sensitivity studies

    International Nuclear Information System (INIS)

    Based on the previous work which has been performed in the project, a procedures guide is being developed for carrying out an age-dependent probabilistic safety assessment (PSA) for evaluating the core damage frequency with aging effects explicitly treated. A PSA is basically a Level 1 Probabilistic Risk Assessment (PRA). The emphasis of the guide is on prioritization and sensitivity studies. Focus is also on active components although consideration of aging effects in passive components is also treated. The guide is intended to become a NUREG/CR and is the first of three volumes which are being developed. The following topics with demonstrations and applications are described in the presentation: (1) the age-dependent PSA versus the standard PSA; (2) component reliability models used in an age-dependent PSA; (3) approaches for transforming a PSA into an age-dependent PSA; (4) application of an age-dependent PSA; (5) using a PSA to evaluate the risk effects from aging passive components; (6) evaluation of the risk importance of passive components; (7) prioritizations of aging contributors; (8) evaluations of test and maintenance effectiveness; and (9) sensitivity studies and uncertainty analyses of aging effects

  5. The use of living PSA for on-line risk management by plant operators

    International Nuclear Information System (INIS)

    The concept of Living Probabilistic Safety Assessment (LPSA) has existed for several years and reflects the desire to utilise the knowledge gained in producing PSAs for nuclear power plants. In most countries the regulator requires that PSA are performed on all new nuclear power plants in order to demonstrate that the design and operation of the plant will meet the required safety standards. In the past, having satisfied the regulator, these PSAs were then regarded as having served their purpose and 'put on the shelf'. In the course of time all plants undergo modification, operational procedures change and develop, and plant specific reliability data becomes available throughout the lifetime of the plant. The original plant specific PSA will therefore rapidly become outdated and need revision. The concept of LPSA is therefore to provide a vehicle for evaluating the effect of plant changes throughout the plant's lifetime. Within the framework of LPSA 'living' can mean anything from updating the PSA infrequently, e.g. as and when major design changes are implemented, to updating the PSA in real time as plant is made unavailable due to maintenance or failure. Constructing and analysing plant specific PSA takes man years of effort in analysing all safety related systems. The result is a very detailed model of the interactions between systems and how they can fail. In order to gain the maximum benefit from this extensive and detailed knowledge base. Nuclear Electric has been involved in the development of PSA codes which enable rapid assessment of PSA. The development of such a code, the Essential Systems Status Monitor (ESSM), has allowed interactive use of the PSA and has maximised the benefit of the knowledge held in the PSA to plan and manage low risk maintenance strategies. The paper describes how the emphasis in the development of the ESSM has been to provide the operator with an interactive LPSA facility to maximise the use and benefits of the original PSA model

  6. Use of PSA in the regulatory process. Report of the specialist's meeting. Working material

    International Nuclear Information System (INIS)

    The objective of this meeting was to focus on the role of the regulator in relation to PSA, to give a picture of the present status, and near term plans, of the requirements placed on licensees and of the uses, formal and informal, made of PSA in regulatory decision making. One such use, in which there is currently much interest, is known as Risk-Based Regulation. This term has various connotations but essentially refers to a more flexible and efficient application of Technical Specifications in the interests of gains in both economy and safety. The position in many countries is one of change in the use of PSA by regulators, and hence any report can only give a snapshot in time. It has to be noted that a number of countries, with important nuclear power programmes, were not represented at the meeting, and so the overall picture is not as comprehensive as might have been hoped. The field of the discussion in the meeting was divided into three areas, progressed in three working groups, namely: Regulatory requirements related to PSA, Regulatory uses of PSA, and Risk-Based Regulation. The outcomes are covered in the next three sections. The fifth section of this report gives the overall conclusions of the meeting and the final section makes some recommendations for future IAEA activities in these areas. Refs, figs, tabs

  7. Application of PSA methodology to design improvement of JAERI Passive Safety Reactor (JPSR)

    International Nuclear Information System (INIS)

    A probabilistic safety assessment (PSA) technique was applied to the design of JAERI Passive Safety Reactor (JPSR). A PSA was performed to clarify safety features and identify vulnerabilities of the original design. Based on the PSA results and considering thermal-hydraulic analyses and experiments, the JPSR design was improved to enhance plant safety. The improved design was re-evaluated with the PSA. Initiating events selected in this study were: large-break LOCA, medium- and small-break LOCAs, SGTR, main steam line break, loss of offsite power, loss of feed water, and other transients. Fault tree analyses were used to evaluate the system unavailabilities. The total core damage frequency due to internal events was estimated to be less than 10-7/RY. The contribution of high frequency non-LOCA events could be significantly reduced by the design modification. The dominant initiating event was the small break LOCA and the dominant sequence was the failure of residual heat removal system. The present study indicated that the improved JPSR design has sufficient safety margin and the PSA methodology is very effective to improve reactor safety systems in a conceptual design phase. (author)

  8. A quantitative study on important factors of the PSA of safety-critical digital systems

    International Nuclear Information System (INIS)

    This paper quantitatively presents the effects of important factors of the probabilistic safety assessment (PSA) of safety-critical digital systems. The result which is quantified using fault tree analysis methodology shows that these factors remarkably affect the system safety. In this paper we list the factors which should be represented by the model for PSA. Based on the PSA experience, we select three important factors which are expected to dominate the system unavailability. They are the avoidance of common cause failure, the coverage of fault tolerant mechanisms and software failure probability. We quantitatively demonstrate the effect of these three factors. The broader usage of digital equipment in nuclear power plants gives rise to the safety problems. Even though conventional PSA methods are immature for applying to microprocessor-based digital systems, practical needs force us to apply it because the result of PSA plays an important role in proving the safety of a designed system. We expect the analysis result to provide valuable feedback to the designers of digital safety-critical systems

  9. Research on the improvement of nuclear safety -Improvement of level 1 PSA computer code package-

    Energy Technology Data Exchange (ETDEWEB)

    Park, Chang Kyoo; Kim, Tae Woon; Kim, Kil Yoo; Han, Sang Hoon; Jung, Won Dae; Jang, Seung Chul; Yang, Joon Un; Choi, Yung; Sung, Tae Yong; Son, Yung Suk; Park, Won Suk; Jung, Kwang Sub; Kang Dae Il; Park, Jin Heui; Hwang, Mi Jung; Hah, Jae Joo [Korea Atomic Energy Research Institute, Taejon (Korea, Republic of)

    1995-07-01

    This year is the third year of the Government-sponsored mid- and long-term nuclear power technology development project. The scope of this sub project titled on `The improvement of level-1 PSA computer codes` is divided into three main activities : (1) Methodology development on the underdeveloped fields such as risk assessment technology for plant shutdown and low power situations, (2) Computer code package development for level-1 PSA, (3) Applications of new technologies to reactor safety assessment. At first, in this area of shutdown risk assessment technology development, plant outage experiences of domestic plants are reviewed and plant operating states (POS) are decided. A sample core damage frequency is estimated for over draining event in RCS low water inventory i.e. mid-loop operation. Human reliability analysis and thermal hydraulic support analysis are identified to be needed to reduce uncertainty. Two design improvement alternatives are evaluated using PSA technique for mid-loop operation situation: one is use of containment spray system as backup of shutdown cooling system and the other is installation of two independent level indication system. Procedure change is identified more preferable option to hardware modification in the core damage frequency point of view. Next, level-1 PSA code KIRAP is converted to PC-windows environment. For the improvement of efficiency in performing PSA, the fast cutest generation algorithm and an analytical technique for handling logical loop in fault tree modeling are developed. 48 figs, 15 tabs, 59 refs. (Author).

  10. The potential role of prebiopsy magnetic resonance imaging combined with prostate-specific antigen density in the detection of prostate cancer

    International Nuclear Information System (INIS)

    Two-thirds of patients with a gray-zone prostate-specific antigen (PSA) level undergo unnecessary biopsy. Sensitivity is not yet sufficient to permit the use of modified PSA parameters or magnetic resonance (MR) imaging alone for prostate cancer screening. Thus, we evaluated the combination of MR imaging and PSA density (PSAD) for specificity and sensitivity. During the period April 2004 through March 2006, 185 patients with a PSA level of 4.0-10.0 ng/mL underwent MR imaging and transrectal ultrasonography-guided 8-core biopsy (systemic sextant biopsy of the peripheral zone plus two cores of transition zone). All MR images were interpreted prospectively by two radiologists. An image was considered positive for prostate cancer if any feature indicated a cancerous lesion. Receiver operating characteristic (ROC) curves were used to compare the usefulness of the PSA level, PSAD and PSA transitional zone density (PSATZ) for the detection of prostate cancer. Of the 185 patients, 62 had prostate cancer. Sensitivity and specificity of the axial T2-weighted MR imaging findings for cancer detection were 79.0% and 59.4%, respectively. The area under the ROC curve was 0.590 for the PSA level, 0.718 for PSAD and 0.695 for PSATZ. MR imaging findings and PSAD were shown by multivariate analysis to be statistically significant independent predictors of prostate cancer (P<0.001). With a PSAD cut-off value of 0.111, sensitivity was 96.8%, but specificity was 19.5%. Combining MR imaging findings with PSAD increased the specificity to 40% and retained 95% sensitivity. MR imaging findings combined with PSAD provide high sensitivity and improve the specificity for the early detection of prostate cancer. (author)

  11. An antibody to de-N-acetyl sialic acid containing-polysialic acid identifies an intracellular antigen and induces apoptosis in human cancer cell lines.

    Directory of Open Access Journals (Sweden)

    Lindsay M Steirer

    Full Text Available Polysialic acid (PSA, an α2,8-linked homopolymer of N-acetylneuraminic acid (Neu5Ac, is developmentally regulated and its expression is thought to be restricted to a few tissues in adults. Recently, we showed that two human pathogens expressed a derivative of PSA containing de-N-acetyl sialic acid residues (NeuPSA. Here we show that an epitope identified by the anti-NeuPSA monoclonal antibody, SEAM 3 (SEAM 3-reactive antigen or S3RA, is expressed in human melanomas, and also intracellularly in a human melanoma cell line (SK-MEL-28, a human T cell leukemia cell line (Jurkat, and two neuroblastoma cell lines (CHP-134 and SH-SY5Y. SEAM 3 binding induced apoptosis in the four cell lines tested. The unusual intracellular distribution of S3RA was similar to that described for the PSA polysialyltransferases, STX and PST, which are also expressed in the four cell lines used here. Interestingly, suppression of PST mRNA expression by transfection of SK-MEL-28 cells with PST-specific short interfering RNA (siRNA resulted in decreased SEAM 3 binding. The results suggest further studies of the utility of antibodies such as SEAM 3 as therapeutic agents for certain malignancies.

  12. Prostate cancer detection upon transrectal ultrasound-guided biopsy in relation to digital rectal examination and prostate-specific antigen level: what to expect in the Chinese population?

    Directory of Open Access Journals (Sweden)

    Jeremy YC Teoh

    2015-01-01

    Full Text Available We investigated the prostate cancer detection rates upon transrectal ultrasound (TRUS-guided biopsy in relation to digital rectal examination (DRE and prostate-specific antigen (PSA, and risk factors of prostate cancer detection in the Chinese population. Data from all consecutive Chinese men who underwent first TRUS-guided prostate biopsy from year 2000 to 2013 was retrieved from our database. The prostate cancer detection rates with reference to DRE finding and PSA level of 50 ng ml−1 were investigated. Multivariate logistic regression analyses were performed to investigate for potential risk factors of prostate cancer detection. A total of 2606 Chinese men were included. In patients with normal DRE, the cancer detection rates were 8.6%, 13.4%, 21.8%, 41.7% and 85.2% in patients with PSA 50 ng ml−1 respectively. In patients with abnormal DRE, the cancer detection rates were 12.4%, 30.2%, 52.7%, 80.6% and 96.4% in patients with PSA 50 ng ml−1 respectively. Older age, smaller prostate volume, larger number of biopsy cores, presence of abnormal DRE finding and higher PSA level were associated with increased risk of prostate cancer detection upon multivariate logistic regression analyses (P < 0.001. Chinese men appeared to have lower prostate cancer detection rates when compared to the Western population. Taking the different risk factors into account, an individualized approach to the decision of TRUS-guided biopsy can be adopted.

  13. Complete Biochemical (Prostate-specific Antigen) Response to Sipuleucel-T With Enzalutamide in Castration-resistant Prostate Cancer: A Case Report With Implications for Future Research

    Science.gov (United States)

    Graff, Julie N.; Drake, Charles G.; Beer, Tomasz M.

    2016-01-01

    OBJECTIVE To describe the case of a patient with castration-resistant, metastatic prostate cancer who achieved a complete and durable biochemical response after treatment with sipuleucel-T while continuing with enzalutamide and to explore the immunologic basis for such a response. MATERIALS AND METHODS We obtained serial prostate-specific antigen (PSA) measurements and bone scans to assess the patient’s response to enzalutamide followed by the addition of sipuleucel-T. Using preclinical and clinical data, we describe his response through known immunobiologic mechanisms. RESULTS This patient’s PSA level became undetectable during treatment with enzalutamide and began to increase again after 14 months. He opted for treatment with sipuleucel-T, while continuing with the enzalutamide. This resulted in another complete PSA response 6 months after exposure to sipuleucel-T. CONCLUSION Sipuleucel-T typically does not produce significant PSA reductions, and, to the best of our knowledge, only 1 previous report of a durable complete PSA response in a patient with metastatic disease has been published. The timing of this response supports an immune mechanism. The biologic rationale for the combination, coupled with the clinical result observed in our patient, provides a basis for studies of the combination of sipuleucel-T and enzalutamide. PMID:23374810

  14. Twelve-Month Prostate-Specific Antigen Values and Perineural Invasion as Strong Independent Prognostic Variables of Long-Term Biochemical Outcome After Prostate Seed Brachytherapy

    International Nuclear Information System (INIS)

    Purpose: To determine whether post-treatment prostate-specific antigen (ptPSA) values at 12 months and other clinical parameters predict long-term PSA relapse-free survival (PRFS) following prostate seed brachytherapy. Methods and Materials: Records of 204 hormone-naïve patients with localized adenocarcinoma of the prostate treated at St. Mary’s Regional Medical Center in Reno, NV, and at Carson Tahoe Regional Medical Center in Carson City, NV, between 1998 and 2003, using I-125 or Pd-103 seed brachytherapy, were retrospectively analyzed. Treatment planning was done using a preplanned, modified peripheral loading technique. A total of 185 of 204 patients had PSA records at 12 months after implant. Variables included were age, initial pretreatment PSA, Gleason score, T stage, National Comprehensive Cancer Network (NCCN) risk group (RG), perineural invasion (PNI), external beam boost, dose, and ptPSA levels at 12 months with cutpoints at ≤1, 1.01 to 2.00, 2.01 to 3.00, and >3.00 ng/ml. Results: Median follow-up was 80 months, and median age was 69 years. The numbers of patients stratified by NCCN low, intermediate, and high RG were 110:65:10, respectively. Monotherapy and boost prescription doses were 145 Gy and 110 Gy for I-125, and 125 Gy and 100 Gy for Pd-103 seeds, respectively. The median dose (D90) was 95.4% of the prescribed dose. The 5-year PRFS at the 12-months ptPSA levels of ≤1, 1.01 to 2.00, 2.01 to 3.00, and >3.00 ng/ml were 98.5%, 85.7%, 61.5%, and 22.2%, respectively. The 10-year PRFS at the 12-months ptPSA levels of ≤1 and 1.01 to 2.00 ng/ml were 90.5% and 85.7%, respectively. In multivariate analysis, both ptPSA and PNI were significant independent predictors of PRFS. Hazard ratios (HR) for ptPSA levels at ≤1, 1.01 to 2.00, 2.01 to 3.00, and >3.00 ng/ml at 12 months were 1, 4.96, 27.57, and 65.10, respectively. PNI had an HR of 6.1 (p = 0.009). Conclusions: Presence of PNI and ptPSA values at 12 months are strong prognostic variables for

  15. Specific regulation of NRG1 isoform expression by neuronal activity

    OpenAIRE

    Liu, Xihui; Bates, Ryan; Wang, Fay; Su, Nan; Kirov, Sergei A.; Luo, Yuling; Wang, Jian-Zhi; Xiong, Wen-Cheng; Mei, Lin

    2011-01-01

    Neuregulin 1 (NRG1) is a trophic factor that has been implicated in neural development, neurotransmission and synaptic plasticity. NRG1 has multiple isoforms that are generated by usage of different promoters and alternative splicing of a single gene. However, little is known about NRG1 isoform composition profile, whether it changes during development or the underlying mechanisms. We found that each of the six types of NRG1 has a distinct expression pattern in the brain at different ages, re...

  16. Correlating PSA, bone scan and Gleason score in prostate cancer patients

    International Nuclear Information System (INIS)

    The hypothesis was that Gleason Score was more important than PSA in predicting bone metastases in prostate cancer patients. The objective of the work was to identify a group of low risk in which bone scan could be omitted. Clinical records of 165 patients with recently diagnosed prostate cancer, who had had, between January of 1993 and December of 1995, bone scans, PSA and Gleason determinations, were reviewed. 5,5% had well differentiated cancer. 49,7% had a negative bone scan. The risk of bone metastases in spite of levels of PSA < 10-20 ng / mL is not worthless in patients with prostate cancer Gleason Score 7-9. (author)

  17. Application of probabilistic safety analysis (PSA) approach to structuring accident mitigation systems of a PWR

    International Nuclear Information System (INIS)

    The safety evaluation technology of PWRs has already been improved substantially because of large-scale safety verification tests and improvement of accuracy in analyses. However, for structuring accident mitigation systems (AMS), the selection of appropriate systems from various AMS candidates mainly depends on engineering judgements by design engineers. So systematic designing process should be established. Reliability of each AMS forms the basis for reliability of safety plant design as a whole. Therefore, explicitly understanding characteristics of each AMS's reliability is very important for safety design. Based on these facts as a background, the limitation of improving reliability by strengthening redundancy of AMS mainly consisting of active components was clarified by applying PSA. At the same time, reliability and other characteristics of AMS mainly consisting of passive components were also clarified with PSA. Through these studies, it is proved that the application of PSA for structuring AMS is effective. (author)

  18. Application of PSA to Assess the Safety Level of Nuclear Power Plants

    International Nuclear Information System (INIS)

    This paper reviews the application of PSA in German nuclear power plant regulation. From a fundamental point of view, it has to be mentioned that as stipulated in the corresponding requirements, regulatory decision making in Germany is primarily based on deterministic analyses and evaluations. Therefore, PSA is not used as a stand alone but as a supplementary basis. In this context PSA has developed a valuable tool with continuously growing importance. Level 1+ PSAs are now elaborated for all German nuclear power plants in operation, most of them are already reviewed by the competent supervisory authority and its experts. Current research activities on the federal level primarily concentrate on the further development of the methodology in the areas human factor, common cause failures, accident management measures and reduction of uncertainties in methods and data. (author)

  19. Study of possibility using LANL PSA-methodology for accident probability RBMK researches

    International Nuclear Information System (INIS)

    The reactor facility probabilistic safety analysis methodologies are considered which are used at U.S. LANL and RF NIKIET. The methodologies are compared in order to reveal their similarity and differences, determine possibilities of using the LANL technique for RBMK type reactor safety analysis. It is found that at the PSA-1 level the methodologies practically do not differ. At LANL the PHA, HAZOP hazards analysis methods are used for more complete specification of the accounted initial event list which can be also useful at performance of PSA for RBMK. Exchange of information regarding the methodology of detection of dependent faults and consideration of human factor impact on reactor safety is reasonable. It is accepted as useful to make a comparative study result analysis for test problems or PSA fragments using various computer programs employed at NIKIET and LANL

  20. Data analysis treatment in the Juragua Nuclear Power Plant preoperational PSA

    International Nuclear Information System (INIS)

    Data Analysis is an important task within Probabilistic safety Assessment,. which usually determines the level of detail of the analysis, being the way to feed the PSA with the operational experience of the Nuclear Power Plant analysed. In this paper the role of the Data Analysis Task as part of the PSA process and the different kinds of data to be estimated are explained. A description is presented of the organization of the data Analysis in the Juragua NPP Preoperational PSA, the information sources and the criteria handled for the estimation of the different kinds of Data. The Generic Data Base adopted for equipment failures and the state of the generic data issue for VVER reactors and its prospects are also dealt with. The paper concludes with suggestions for the further development of Juragua NPP generic Data Base